



# **STIC Search Report**

## **EIC 1700**

**STIC Database Tracking Number: 176724**

**TO: Ben Sackey**  
**Location: REM 5B31**  
**Art Unit : 1626**  
**January 25, 2006**

**Case Serial Number: 10/654112**

**From: Ross Shipe**  
**Location: EIC 1700**  
**REMSEN 4B31**  
**Phone: 571/272-6018**  
**Ross.Shipe@uspto.gov**

### **Search Notes**

Examiner Sackey:

Please review the attached search results.

If you have any questions or if you would like to refine the search query, please feel free to contact me at any time.

Thanks you for using EIC 1700 search services!

Ross Shipe (ASRC)  
Technical Information Specialist



FOR OFFICIAL USE ONLY

ACCESS DB # 176724  
PLEASE PRINT CLEARLY

Scientific and Technical Information Center

# SEARCH REQUEST FORM

Requester's Full Name: BEN SACKETT Examiner #: 73489 Date: 1/14/06  
Art Unit: 1626 Phone Number: 2-0704 Serial Number: 101654112  
Location (Bldg/Room#): REM 5631 (Mailbox #): \_\_\_\_\_ Results Format Preferred (circle) PAPER DISK  
\*\*\*\*\*

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following:

Title of Invention: Modulation of CCR4 function  
Inventors (please provide full names): Jessie Collins et al.

Earliest Priority Date: 5/23/01

## Search Topic:

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.

\*For Sequence Searches Only\* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

A method of treating a CCR4-mediated disease in a subject comprising the administration of a compound of

formula (I) <sup>claim 1</sup> Ar<sup>1</sup> - X - Ar<sup>2</sup> wherein:

Ar<sup>1</sup> is phenyl and naphthyl

X is -N(R)- or -C(O)S-

Ar<sup>2</sup> is substituted thiophenyl

formula (I) of claim 80 wherein

N is naphthyl, Y is NH, Z is -N; X is -S,

Thanks

R<sup>1</sup> is C<sub>1</sub>-8 alkyl, H, halogen, CN, CO<sub>2</sub>R', CONR'R'',

R<sup>2</sup> ✓ ✓ ✓ ✓ ✓ ✓ ✓

## STAFF USE ONLY

Searcher: ROS

Searcher Phone #: \_\_\_\_\_

Searcher Location: \_\_\_\_\_

Date Searcher Picked Up: \_\_\_\_\_

Date Completed: 1/25/06

Searcher Prep & Review Time: 30

Online Time: 180

## Type of Search

\_\_\_\_ NA Sequence (#)

\_\_\_\_ AA Sequence (#)

2 Structure (#)

\_\_\_\_ Bibliographic

\_\_\_\_ Litigation

\_\_\_\_ Fulltext

\_\_\_\_ Other

## Vendors and cost where applicable

✓ STN \_\_\_\_\_ Dialog

\_\_\_\_ Questel/Orbit \_\_\_\_\_ Lexis/Nexis

\_\_\_\_ Westlaw \_\_\_\_\_ WWW/Internet

\_\_\_\_ In-house sequence systems

\_\_\_\_ Commercial

\_\_\_\_ Interference

\_\_\_\_ Other (specify)

\_\_\_\_ Oligomer

\_\_\_\_ SPDI

\_\_\_\_ Score/Length

\_\_\_\_ Encode/Transl

=> d his full

FILE 'REGISTRY' ENTERED AT 09:25:17 ON 25 JAN 2006

```

      ACT SAC112/A
L1      STR
L2      SCR 1839
L3      SCR 1842
L4      SCR 2043
L5      SCR 1918
L6      STR
L7 (    341980) SEA SSS FUL L6 AND L2 NOT (L3 OR L4 OR L5)
L8      28391 SEA SUB=L7 SSS FUL L1

```

FILE 'HCAPLUS' ENTERED AT 09:25:47 ON 25 JAN 2006

```

L9      1532 SEA ABB=ON PLU=ON L8
L10     762 SEA ABB=ON PLU=ON CCR4
L11     435105 SEA ABB=ON PLU=ON TREAT? (L) (CONDITION# OR DISEASE#)
L12     561 SEA ABB=ON PLU=ON CCR4 (L) CHEMOKINE (L) RECEPTOR#
L13     41743 SEA ABB=ON PLU=ON PSORIAS## OR DERMATAT? OR ASTHMA?
L14      3 SEA ABB=ON PLU=ON L9 AND L10
L15      2 SEA ABB=ON PLU=ON L9 AND L11 AND L12
L16     149 SEA ABB=ON PLU=ON L9 AND L11
L17      28 SEA ABB=ON PLU=ON L9 AND L11 AND L13
L18     13027 SEA ABB=ON PLU=ON CHEMOKINE (L) RECEPTOR#
L19      3 SEA ABB=ON PLU=ON L9 AND L11 AND L18
L20      2 SEA ABB=ON PLU=ON L9 AND L18 AND L13
L21      5 SEA ABB=ON PLU=ON L9 AND L18
L22     552 SEA ABB=ON PLU=ON L9 AND (BSU OR BIOL OR PAC OR
      THU)/RL
L23      5 SEA ABB=ON PLU=ON L9 AND (BSU OR BIOL OR PAC OR
      THU)/RL AND L18
L24     39 SEA ABB=ON PLU=ON L9 AND (BSU OR BIOL OR PAC OR
      THU)/RL AND L13
L25      5 SEA ABB=ON PLU=ON L14 OR L15 OR L19 OR L20 OR L21 OR
      L23
L26     37 SEA ABB=ON PLU=ON (L17 OR L24) NOT L25
L27     13651 SEA ABB=ON PLU=ON RECEPTOR (L) MODULATOR#
L28     77983 SEA ABB=ON PLU=ON INFLAMMAT? (L) (CONDITION# OR
      DISEASE#)
L29     12 SEA ABB=ON PLU=ON L9 AND L27
L30     19 SEA ABB=ON PLU=ON (L17 OR L24) AND (L28 OR L27) NOT
      L25
L31     10 SEA ABB=ON PLU=ON L29 NOT (L19 OR L25)
L32     24 SEA ABB=ON PLU=ON L30 OR L25

```

FILE 'CAOLD' ENTERED AT 09:56:29 ON 25 JAN 2006

```

L33     127 SEA ABB=ON PLU=ON L8
L34      0 SEA ABB=ON PLU=ON L33 AND CCR4
L35      0 SEA ABB=ON PLU=ON L33 AND CHEMOKINE AND RECEPTOR#
L36      0 SEA ABB=ON PLU=ON L33 AND PHARMAC?/SC,SX
L37      0 SEA ABB=ON PLU=ON L33 AND TREAT?/TI
L38      0 SEA ABB=ON PLU=ON L33 AND CCR4/TI
L39      0 SEA ABB=ON PLU=ON L33 AND CHEMOKINE/TI

```


=> file reg

FILE 'REGISTRY' ENTERED AT 10:21:46 ON 25 JAN 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

=> d 132 que stat  
L1 STR



VAR G1=22/19-3 20-13/20-3 19-13

VAR G2=18/14/16

VAR G3=H/AK

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC 14

NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE


L2 SCR 1839

L3 SCR 1842

L4 SCR 2043

L5 SCR 1918

L6 STR



REP G1=(0-3) A

VAR G2=18/14/16

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC 14

NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE

L7 ( 341980) SEA FILE=REGISTRY SSS FUL L6 AND L2 NOT (L3 OR L4 OR L5)

L8 28391 SEA FILE=REGISTRY SUB=L7 SSS FUL L1

L9 1532 SEA FILE=HCAPLUS ABB=ON PLU=ON L8

L10 762 SEA FILE=HCAPLUS ABB=ON PLU=ON CCR4

L11 435105 SEA FILE=HCAPLUS ABB=ON PLU=ON TREAT? (L) (CONDITION# OR DISEASE#)

L12 561 SEA FILE=HCAPLUS ABB=ON PLU=ON CCR4 (L) CHEMOKINE (L) RECEPTOR#

L13 41743 SEA FILE=HCAPLUS ABB=ON PLU=ON PSORIAS## OR DERMATAT? OR ASTHMA?



L14 3 SEA FILE=HCAPLUS ABB=ON PLU=ON L9 AND L10  
 L15 2 SEA FILE=HCAPLUS ABB=ON PLU=ON L9 AND L11 AND L12  
 L17 28 SEA FILE=HCAPLUS ABB=ON PLU=ON L9 AND L11 AND L13  
 L18 13027 SEA FILE=HCAPLUS ABB=ON PLU=ON CHEMOKINE (L) RECEPTOR#  
  
 L19 3 SEA FILE=HCAPLUS ABB=ON PLU=ON L9 AND L11 AND L18  
 L20 2 SEA FILE=HCAPLUS ABB=ON PLU=ON L9 AND L18 AND L13  
 L21 5 SEA FILE=HCAPLUS ABB=ON PLU=ON L9 AND L18  
 L23 5 SEA FILE=HCAPLUS ABB=ON PLU=ON L9 AND (BSU OR BIOL OR  
 PAC OR THU)/RL AND L18  
 L24 39 SEA FILE=HCAPLUS ABB=ON PLU=ON L9 AND (BSU OR BIOL OR  
 PAC OR THU)/RL AND L13  
 L25 5 SEA FILE=HCAPLUS ABB=ON PLU=ON L14 OR L15 OR L19 OR  
 L20 OR L21 OR L23  
 L27 13651 SEA FILE=HCAPLUS ABB=ON PLU=ON RECEPTOR (L) MODULATOR#  
  
 L28 77983 SEA FILE=HCAPLUS ABB=ON PLU=ON INFLAMMAT? (L) (CONDITIO  
 N# OR DISEASE#)  
 L30 19 SEA FILE=HCAPLUS ABB=ON PLU=ON (L17 OR L24) AND (L28  
 OR L27) NOT L25  
 L32 24 SEA FILE=HCAPLUS ABB=ON PLU=ON L30 OR L25

=> file hcaplus  
 FILE 'HCAPLUS' ENTERED AT 10:22:26 ON 25 JAN 2006  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> d l32 1-24 ibib abs hitstr hitind

L32 ANSWER 1 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2005:1265299 HCAPLUS  
 DOCUMENT NUMBER: 144:22939  
 TITLE: Preparation of bicyclic heterocycles,  
 particularly pyrimido[2,1-c][1,4]oxazine-2-  
 carboxamides, as HIV integrase inhibitors  
 INVENTOR(S): Naidu, B. Narasimhulu; Banville, Jacques;  
 Beaulieu, Francis; Connolly, Timothy P.;  
 Krystal, Mark R.; Matiskella, John D.; Ouellet,  
 Carl; Plamondon, Serge; Remillard, Roger;  
 Sorenson, Margaret E.; Ueda, Yasutsugu; Walker,  
 Michael A.  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 156 pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	
US 2005267105	A1	20051201	US 2005-126891	200505 11
WO 2005118593	A1	20051215	WO 2005-US16473	200505 12

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA,

CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
 GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM,  
 KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,  
 MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU,  
 SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA,  
 UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,  
 AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ,  
 DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC,  
 NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA,  
 GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005267132 A1 20051201 US 2005-138726

200505  
26

US 2005267131 A1 20051201 US 2005-138773

200505  
26

WO 2005118589 A1 20051215 WO 2005-US18567

200505  
27

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA,  
 CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
 GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM,  
 KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,  
 MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU,  
 SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA,  
 UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,  
 AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ,  
 DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC,  
 NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA,  
 GN, GQ, GW, ML, MR, NE, SN, TD, TG

WO 2005118590 A1 20051215 WO 2005-US18568

200505  
27

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA,  
 CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
 GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM,  
 KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,  
 MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU,  
 SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA,  
 UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,  
 AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ,  
 DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC,  
 NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA,  
 GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 2004-575513P

P

200405  
28

US 2004-603371P

P

200408  
20

US 2005-126891

A

200505  
11

US 2005-138726

A

200505  
26




US 2005-138773

A

200505

26

GI



AB The invention is related to the prepn. of title compds. I [R1 = C1-6(Ar1)alkyl, C1-6(Ar1)oxyalkyl, C1-6(Ar1)hydroxyalkyl, etc.; R2 = H, alkyl, OH, alkyloxy; Ar1 = (un)substituted Ph, naphthyl, benzothiophenyl, etc.; X-Y-Z = C(R3)2OC(R3)2, C(R3)2OC(R3)2C(R3)2, C(R3)2C(R3)2C(R3)2C(R3)2; R3 = H, alkyl], and their pharmaceutically acceptable salts or solvates which inhibit HIV integrase and prevent viral integration into human DNA. The invention is also related to the pharmaceutical compns. comprising pyrimidinones I, and methods of using them for treating HIV infection and AIDS. Thus, reacting ester II (prepn. given) with 4-fluorobenzylamine in DMF/ethanol in the presence of TEA at 90° gave amide III in 82% yield.

Selected I displayed IC50 values in the range of 0.002-0.1  $\mu$ M for the inhibition of HIV integrase activity. II demonstrated synergistic or additive-synergistic HIV antiviral activity when used in combination with other antiviral agents, e.g., zidovudine, indinavir, T-20, etc.


IT **870560-23-9P**, N-[[4-Fluoro-2-[(2-thiazolyl)amino]phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide

RL: **PAC** (Pharmacological activity); **SPN** (Synthetic preparation); **THU** (Therapeutic use); **BIOL** (Biological study); **PREP** (Preparation); **USES** (Uses)


(drug candidate; prepn. of bicyclic heterocycles as HIV integrase inhibitors)

RN 870560-23-9 HCAPLUS

CN Pyrimido[2,1-c][1,4]oxazine-2-carboxamide, N-[[4-fluoro-2-(2-thiazolylamino)phenyl]methyl]-4,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo- (9CI) (CA INDEX NAME)



IT 870562-87-1P, 4-Fluoro-2-[(thiazol-2-yl)amino]benzonitrile  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);  
 RACT (Reactant or reagent)  
 (intermediate; prepn. of bicyclic heterocycles as HIV integrase  
 inhibitors)  
 RN 870562-87-1 HCAPLUS  
 CN Benzonitrile, 4-fluoro-2-(2-thiazolylamino)- (9CI) (CA INDEX NAME)



IC ICM A61K031-538  
 ICS C07D491-04  
 INCL 514230500; 544105000  
 CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))  
 Section cross-reference(s): 1, 63  
 IT Chemokine receptors  
 RL: BSU (Biological study, unclassified); BIOL  
 (Biological study)  
 (CCR5, CCR5 inhibitors and HIV attachment inhibitors; combination  
 therapy agents; prepn. of bicyclic heterocycles for use in  
 combination therapy for treating HIV infection)  
 IT Chemokine receptors  
 RL: BSU (Biological study, unclassified); BIOL  
 (Biological study)  
 (CXCR4, CXCR4 inhibitors and HIV budding or maturation  
 inhibitors; combination therapy agents; prepn. of bicyclic  
 heterocycles for use in combination therapy for treating HIV  
 infection)  
 IT 3056-17-5, Stavudine 7481-89-2, Zalcitabine 30516-87-1,  
 Zidovudine 69655-05-6, Didanosine 127779-20-8, Saquinavir  
 129618-40-2, Nevirapine 134678-17-4, Lamivudine 136470-78-5,  
 Abacavir 136817-59-9, Delavirdine 143491-57-0, Emtricitabine  
 147127-20-6, Tenofovir 150378-17-9, Indinavir 154598-52-4,  
 Efavirenz 155213-67-5, Ritonavir 159519-65-0, Enfuvirtide  
 159989-64-7, Nelfinavir 161814-49-9, Amprenavir 192725-17-0,  
 Lopinavir 198904-31-3, Atazanavir  
 RL: THU (Therapeutic use); BIOL (Biological study)  
 ; USES (Uses)  
 (combination therapy agent; prepn. of bicyclic heterocycles for  
 use in combination therapy for treating HIV infection)

IT 870559-67-4P, N-[[2-[3-[(Dimethylamino)carbonyl]-1H-1,2,4-triazol-1-yl]-4-fluorophenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-68-5P, N-[[4-Fluoro-2-[3-[(methylsulfonyl)amino]carbonyl]-1H-1,2,4-triazol-1-yl]phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-69-6P, 870559-71-0P, N-[[2-[3-[(4-Acetyl-1-piperazinyl)carbonyl]-1H-1,2,4-triazol-1-yl]-4-fluorophenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-73-2P, N-[[4-Fluoro-2-[3-[(2-hydroxyethyl)(methyl)amino]carbonyl]-1H-1,2,4-triazol-1-yl]phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-74-3P, N-[[4-Fluoro-2-[3-[[[(4-fluorophenyl)sulfonyl]amino]carbonyl]-1H-1,2,4-triazol-1-yl]phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-75-4P, N-[[4-Fluoro-2-[3-[(4-methyl-1-piperazinyl)carbonyl]-1H-1,2,4-triazol-1-yl]phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-76-5P, N-[[2-[3-[[[2-(Dimethylamino)ethyl]amino]carbonyl]-1H-1,2,4-triazol-1-yl]-4-fluorophenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-77-6P, N-[[2-[3-[[[2-(Dimethylamino)ethyl](methyl)amino]carbonyl]-1H-1,2,4-triazol-1-yl]-4-fluorophenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-78-7P, N-[[4-Fluoro-2-[3-[(2-hydroxyethyl)amino]carbonyl]-1H-1,2,4-triazol-1-yl]phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-79-8P, N-[[4-Fluoro-2-iodophenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-80-1P, N-[[5-Fluoro[1,1'-biphenyl]-2-yl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-81-2P, N-[[4-Fluoro-2-(3-pyridinyl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-82-3P, N-[[4-Fluoro-2-(2-methoxy-3-pyridinyl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-83-4P, N-[[4-Fluoro-2-(6-methoxy-3-pyridinyl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-84-5P, N-[[2-(1,2-Dihydro-2-oxo-3-pyridinyl)-4-fluorophenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-85-6P, N-[[2-(1,6-Dihydro-6-oxo-3-pyridinyl)-4-fluorophenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-86-7P, N-[[2-(1,6-Dihydro-6-oxo-2-pyridinyl)-4-fluorophenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-87-8P, N-[[4-Fluoro-2-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-88-9P, N-[[4-Fluoro-2-(5-methyl-1H-1,2,4-triazol-1-yl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-89-0P, N-[[2-Fluoro-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-90-3P, N-[[4-Fluoro-2-(1,2,3-thiadiazol-4-yl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-91-4P, N-[[4-Fluoro-2-(1H-pyrazol-3-yl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-92-5P, N-[[4-Fluoro-2-(5-methyl-2-oxazolyl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-

carboxamide 870559-93-6P, N-[[2-(Ethylamino)-4-fluorophenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-94-7P, N-[[2-Ethynyl-4-fluorophenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-95-8P, N-[[4-Fluoro-2-(3-hydroxy-1-propynyl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-96-9P, N-[[4-Fluoro-2-[3-[(methylsulfonyl)oxy]-1-propynyl]phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-98-1P 870559-99-2P, N-[[4-Fluoro-2-[3-(methylsulfonyl)-1-propynyl]phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-00-2P, N-[[4-Fluoro-2-[3-(tetrahydro-1,1-dioxido-2H-1,2-thiazin-2-yl)-1-propynyl]phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-01-3P 870560-02-4P, N-[[4-Fluoro-2-hydroxyphenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; prepn. of bicyclic heterocycles)

IT 870558-24-0P, N-[[4-Fluorophenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; prepn. of bicyclic heterocycles as HIV integrase inhibitors)

IT 870560-07-9P, N-[[4-Fluoro-2-(methylthio)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-20-6P, 3-Hydroxy-9,9-dimethyl-N-[[2-(methylthio)phenyl]methyl]-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-55-7P, N-[[2-Bromophenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870561-16-3P, N-[[4-Fluorophenyl]methyl]-3-hydroxy-9-[2-(methylthio)ethyl]-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; prepn. of bicyclic heterocycles as HIV integrase inhibitors)

IT 870557-73-6P, N-[[4-Fluorophenyl]methyl]-3-hydroxy-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870557-76-9P, N-[[4-Fluoro-3-methylphenyl]methyl]-3-hydroxy-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870557-80-5P, N-[[4-Fluoro-2-[(methylamino)carbonyl]phenyl]methyl]-3-hydroxy-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870557-83-8P, N-[[4-Fluorophenyl]methyl]-3-hydroxy-9-methyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870557-87-2P, N-[[4-Fluoro-3-methylphenyl]methyl]-3-hydroxy-9-methyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870557-90-7P, N-[[3,4-Dichlorophenyl]methyl]-3-hydroxy-9-methyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870557-95-2P, N-[[3-Chloro-4-fluorophenyl]methyl]-3-hydroxy-9-methyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870557-98-5P, N-[[3,4-Dimethylphenyl]methyl]-3-hydroxy-9-methyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide



870558-02-4P, N-[[4-Fluoro-2-[(methylamino)carbonyl]phenyl]methyl]-3-hydroxy-9-methyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-05-7P, 9-Ethyl-N-[(4-fluorophenyl)methyl]-3-hydroxy-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-08-0P, 9-Ethyl-N-[(4-fluoro-3-methylphenyl)methyl]-3-hydroxy-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-09-1P, N-[(3,4-Dichlorophenyl)methyl]-9-ethyl-3-hydroxy-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-10-4P, N-[(3,4-Dimethylphenyl)methyl]-9-ethyl-3-hydroxy-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-12-6P, N-[(3-Chloro-4-fluorophenyl)methyl]-9-ethyl-3-hydroxy-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-14-8P, 9-Ethyl-N-[[4-fluoro-2-[(methylamino)carbonyl]phenyl]methyl]-3-hydroxy-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-16-0P, 9-Ethyl-N-[[4-fluoro-2-(1H-1,2,4-triazol-1-yl)phenyl]methyl]-3-hydroxy-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-19-3P, N-[(4-Fluorophenyl)methyl]-3-hydroxy-9-(1-methylethyl)-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-22-8P, N-[(4-Fluoro-3-methylphenyl)methyl]-3-hydroxy-9-(1-methylethyl)-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-27-3P, N-[(4-Fluoro-3-methylphenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-30-8P, N-[[4-Fluoro-2-(1H-1,2,4-triazol-1-yl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-33-1P, N-[[2-Fluoro-4-(1H-1,2,4-triazol-1-yl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-36-4P, N-[[4-Fluoro-2-(4-morpholinyl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-39-7P, N-[[2-Fluoro-4-(4-morpholinyl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-42-2P, N-[3-(3,4-Dichlorophenyl)propyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-45-5P, N-[3-(4-Fluorophenyl)propyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-49-9P, N-[[4-Fluoro-2-(tetrahydro-1,1-dioxido-2H-1,2-thiazin-2-yl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-51-3P, N-[(3,5-Difluoro-2-pyridinyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-54-6P, N-[(5-Chloropyridin-2-yl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-56-8P, N-[(3-Bromo-4-fluorophenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-59-1P, N-[(3,4-Dimethylphenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-62-6P, N-[(3-Chloro-4-fluorophenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-65-9P, N-[(3,4-Difluorophenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-68-2P, N-[(4-Chlorophenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-73-9P, N-[(2,4-Difluorophenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-79-5P, N-[(2-Chloro-4-fluorophenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-83-1P, N-[(2,4-Dimethylphenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-



carboxamide 870558-87-5P, N-[(3,5-Dimethylphenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-90-0P, N-[(4-Fluoro-2-methylphenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-94-4P, N-[(4-Fluoro-1-naphthalenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870558-98-8P, N-[(4-Fluoro-2-methoxyphenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-01-6P, 9,9-Diethyl-N-[(4-fluorophenyl)methyl]-3-hydroxy-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-04-9P, 9,9-Diethyl-N-[(4-fluoro-3-methylphenyl)methyl]-3-hydroxy-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-07-2P, N-[(4-Fluorophenyl)methyl]-4,7,8,10-tetrahydro-3-hydroxy-10,10-dimethyl-4-oxo-6H-pyrimido[2,1-c][1,4]oxazepine-2-carboxamide 870559-10-7P, N-[(4-Fluoro-3-methylphenyl)methyl]-4,7,8,10-tetrahydro-3-hydroxy-10,10-dimethyl-4-oxo-6H-pyrimido[2,1-c][1,4]oxazepine-2-carboxamide 870559-14-1P, N-[[4-Fluoro-2-[2-(4-morpholinyl)-2-oxoethoxy]phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-18-5P, 5-Fluoro-2-[[[(3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazin-2-yl)carbonyl]amino]methyl]benzoic acid methyl ester 870559-23-2P, 5-Fluoro-2-[[[(3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazin-2-yl)carbonyl]amino]methyl]benzoic acid 870559-27-6P, N-[[4-Fluoro-2-[(methylamino)carbonyl]phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-31-2P, N-[[2-[(Cyclopropylamino)carbonyl]-4-fluorophenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-35-6P, N-[[4-Fluoro-2-[[2-(2-hydroxyethyl)amino]carbonyl]phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-39-0P, N-[[4-Fluoro-2-[(4-morpholinyl)carbonyl]phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-44-7P, N-[[4-Fluoro-2-(1H-imidazol-1-yl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-48-1P, N-[[5-Fluoro-2-(1H-1,2,4-triazol-1-yl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-52-7P, N-[[3-Fluoro-2-(tetrahydro-1,1-dioxido-2H-1,2-thiazin-2-yl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-54-9P, N-[[3-Fluoro-2-(1H-1,2,4-triazol-1-yl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-56-1P, N-[[4-Fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-58-3P, N-[[2-Fluoro-4-(2H-1,2,3-triazol-2-yl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-60-7P, N-[(2-Bromo-4-fluorophenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870559-62-9P, 1H-1,2,4-Triazole-3-carboxylic acid 1-[5-fluoro-2-[[[(3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazin-2-yl)carbonyl]amino]methyl]phenyl]methyl ester 870559-64-1P, 1-[5-Fluoro-2-[[[(3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazin-2-yl)carbonyl]amino]methyl]phenyl]-1H-1,2,4-Triazole-3-carboxylic acid 870559-65-2P, N-[[4-Fluoro-2-[3-[(4-morpholinyl)carbonyl]-1H-1,2,4-triazol-1-yl]phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-

tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-03-5P,  
N,N-Dimethylcarbamic acid 5-fluoro-2-[[[(3-hydroxy-9,9-dimethyl-4-  
oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazin-2-  
yl)carbonyl]amino]methyl]phenyl ester 870560-04-6P,  
N-[[4-Fluoro-2-[2-(methylamino)-2-oxoethoxy]phenyl]methyl]-3-hydroxy-  
9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-  
carboxamide 870560-05-7P, N-[[2-[2-(Dimethylamino)-2-oxoethoxy]-4-  
fluorophenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-  
tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-06-8P,  
4-Morpholinecarboxylic acid 5-fluoro-2-[[[(3-hydroxy-9,9-dimethyl-4-  
oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazin-2-  
yl)carbonyl]amino]methyl]phenyl ester 870560-08-0P,  
N-[[4-Fluoro-2-(methylsulfonyl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-  
4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide  
870560-09-1P, N-[[4-Fluoro-2-(methylsulfinyl)phenyl]methyl]-3-  
hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-  
c][1,4]oxazine-2-carboxamide 870560-11-5P 870560-12-6P,  
3-Hydroxy-9,9-dimethyl-4-oxo-N-[[3-[3-(trifluoromethyl)-3-  
diaziridinyl]phenyl]methyl]-4,6,7,9-tetrahydropyrimido[2,1-  
c][1,4]oxazine-2-carboxamide 870560-13-7P, 3-Hydroxy-9,9-dimethyl-  
4-oxo-N-[[3-[3-(trifluoromethyl)-3H-diazirin-3-yl]phenyl]methyl]-  
4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide  
870560-14-8P, N-[[4-Fluoro-2-(2-methyl-2H-tetrazol-5-  
yl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-  
tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-15-9P,  
N-[[4-Fluoro-2-(1-methyl-1H-tetrazol-5-yl)phenyl]methyl]-3-hydroxy-  
9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-  
carboxamide 870560-16-0P, N-[[2-[(Dimethylamino)sulfonyl]-4-  
fluorophenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-  
tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-17-1P,  
N-[[4-Fluoro-2-[(methylamino)sulfonyl]phenyl]methyl]-3-hydroxy-9,9-  
dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-  
carboxamide 870560-18-2P, N-[[2-(Aminosulfonyl)-4-  
fluorophenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-  
tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-19-3P,  
N-[[2-[(1-Azetidinyl)sulfonyl]-4-fluorophenyl]methyl]-3-hydroxy-9,9-  
dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-  
carboxamide 870560-21-7P, 3-Hydroxy-9,9-dimethyl-N-[[2-  
(methylsulfinyl)phenyl]methyl]-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-  
c][1,4]oxazine-2-carboxamide 870560-22-8P, 3-Hydroxy-9,9-dimethyl-  
N-[[2-(methylsulfonyl)phenyl]methyl]-4-oxo-4,6,7,9-  
tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide  
870560-23-9P, N-[[4-Fluoro-2-[(2-  
thiazolyl)amino]phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-  
tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-24-0P,  
N-[[4-Fluoro-2-[(5-methyl-1,3,4-thiadiazol-2-yl)amino]phenyl]methyl]-  
3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-  
c][1,4]oxazine-2-carboxamide 870560-25-1P, N-[[4-Fluoro-2-(1H-  
1,2,4-triazol-1-yl)phenyl]methyl]-4,7,8,10-tetrahydro-3-hydroxy-  
10,10-dimethyl-4-oxo-6H-pyrimido[2,1-c][1,4]oxazepine-2-carboxamide  
870560-26-2P, N-[[4-Fluoro-2-[(methylamino)carbonyl]phenyl]methyl]-  
4,7,8,10-tetrahydro-3-hydroxy-10,10-dimethyl-4-oxo-6H-pyrimido[2,1-  
c][1,4]oxazepine-2-carboxamide 870560-27-3P, 9,9-Diethyl-N-[[4-  
fluoro-2-(1H-1,2,4-triazol-1-yl)phenyl]methyl]-3-hydroxy-4-oxo-  
4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide  
870560-28-4P, 9,9-Diethyl-N-[[4-fluoro-2-  
[(methylamino)carbonyl]phenyl]methyl]-3-hydroxy-4-oxo-4,6,7,9-  
tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-29-5P,  
N-[[4-Fluoro-2-(2-oxo-1-piperidinyl)phenyl]methyl]-3-hydroxy-9,9-  
dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-  
carboxamide 870560-30-8P, 3-Hydroxy-9,9-dimethyl-4-oxo-N-[[2-(2-  
oxo-3-oxazolidinyl)phenyl]methyl]-4,6,7,9-tetrahydropyrimido[2,1-

c) [1,4]oxazine-2-carboxamide 870560-31-9P, 3-Hydroxy-9,9-dimethyl-4-oxo-N-[[2-(2-oxo-1-azetidinyl)phenyl]methyl]-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-32-0P, N-[[4-Fluoro-2-(2-oxo-1-pyrrolidinyl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-33-1P, N-[[4-Fluoro-2-(hexahydro-2-oxo-1H-azepin-1-yl)phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-34-2P, N-[4-Fluoro-2-(2-oxoazetidin-1-yl)benzyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-35-3P, N-[4-Fluoro-2-(2-oxooxazolidin-3-yl)benzyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-36-4P, N-[[4-Fluoro-2-[(2R)-2-(hydroxymethyl)-5-oxo-1-pyrrolidinyl]phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-37-5P, N-[[2-[(2R)-2-(Acetyloxy)methyl]-5-oxo-1-pyrrolidinyl]-4-fluorophenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-38-6P, N-[[4-Fluoro-2-[(2S)-2-(hydroxymethyl)-5-oxo-1-pyrrolidinyl]phenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-39-7P, (R)-N-[2-[2-[(Dimethylamino)methyl]-5-oxopyrrolidin-1-yl]-4-fluorobenzyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-40-0P, (R)-N-[2-[2-(Azidomethyl)-5-oxopyrrolidin-1-yl]-4-fluorobenzyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-41-1P, (R)-N-[2-[2-(Aminomethyl)-5-oxopyrrolidin-1-yl]-4-fluorobenzyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-42-2P, N-[(2-Amino-4-fluorophenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-43-3P, N-[[2-(Acetylamin)-4-fluorophenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-44-4P, N-[[2-[(Acetyl)(methyl)amino]-4-fluorophenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-45-5P, N-[2-(2,5-Dioxo-2H-pyrrol-1(5H)-yl)benzyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-46-6P, N-[(Benzo[b]thien-7-yl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-47-7P, N-[(1,1-Dioxidobenzo[b]thien-7-yl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-48-8P, N-[(2,3-Dihydro-1,1-dioxidobenzo[b]thien-7-yl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870560-49-9P 870560-50-2P 870560-51-3P 870560-52-4P 870560-53-5P 870560-54-6P 870560-56-8P 870560-57-9P 870560-58-0P 870560-59-1P 870560-60-4P 870560-61-5P 870560-62-6P 870560-63-7P 870560-64-8P 870560-65-9P 870560-66-0P 870560-67-1P 870560-68-2P 870560-69-3P 870560-70-6P 870560-71-7P 870560-72-8P 870560-73-9P 870560-74-0P 870560-75-1P 870560-76-2P 870560-77-3P 870560-78-4P 870560-79-5P 870560-80-8P 870560-81-9P 870560-82-0P 870560-83-1P 870560-84-2P 870560-85-3P 870560-86-4P 870560-87-5P 870560-88-6P 870560-89-7P 870560-90-0P 870560-91-1P 870560-92-2P 870560-93-3P 870560-94-4P 870560-95-5P 870560-96-6P 870560-97-7P 870560-98-8P 870560-99-9P 870561-00-5P 870561-01-6P 870561-02-7P 870561-03-8P 870561-04-9P 870561-05-0P 870561-06-1P 870561-07-2P 870561-08-3P 870561-09-4P, N-[(4-Fluoro-2,5-dibromophenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-

tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870561-10-7P,  
 N-[[4-Fluoro-2-(methylsulfonyl)phenyl]methyl]-4,7,8,10-tetrahydro-3-  
 hydroxy-10,10-dimethyl-4-oxo-6H-Pyrimido[2,1-c][1,4]oxazepine-2-  
 carboxamide 870561-11-8P, 9,9-Diethyl-N-[[4-fluoro-2-  
 (methylsulfonyl)phenyl]methyl]-3-hydroxy-4-oxo-4,6,7,9-  
 tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870561-12-9P,  
 N-[[2-[(Dimethylamino)sulfonyl]-4-fluorophenyl]methyl]-4,7,8,10-  
 tetrahydro-3-hydroxy-10,10-dimethyl-4-oxo-6H-pyrimido[2,1-  
 c][1,4]oxazepine-2-carboxamide 870561-13-0P, N-[[2-  
 [(Dimethylamino)sulfonyl]-4-fluorophenyl]methyl]-9,9-diethyl-3-  
 hydroxy-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-  
 carboxamide 870561-14-1P, 4,7,8,10-Tetrahydro-3-hydroxy-10,10-  
 dimethyl-4-oxo-N-[[2-(tetrahydro-1,1-dioxido-2H-1,2-thiazin-2-  
 yl)phenyl]methyl]-6H-pyrimido[2,1-c][1,4]oxazepine-2-carboxamide  
 870561-15-2P, 3-Hydroxy-9,9-diethyl-4-oxo-N-[[2-(tetrahydro-1,1-  
 dioxido-2H-1,2-thiazin-2-yl)phenyl]methyl]-4,6,7,9-  
 tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870561-17-4P,  
 N-[[4-Fluorophenyl]methyl]-3-hydroxy-9-[2-(methylsulfonyl)ethyl]-4-  
 oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide  
 870561-18-5P, N-[[4-Fluoro-2-(3-methyl-5-isoxazolyl)phenyl]methyl]-3-  
 hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-  
 c][1,4]oxazine-2-carboxamide 870561-19-6P, N-[[2-((2Z)-3-Amino-1-  
 oxo-2-butenyl)-4-fluorophenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-  
 4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide  
 870561-20-9P, N-[[2-(3-Bromo-5-isoxazolyl)-4-fluorophenyl]methyl]-3-  
 hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-  
 c][1,4]oxazine-2-carboxamide 870561-21-0P, [5-Fluoro-2-[[[(3-  
 hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-  
 c][1,4]oxazin-2-yl)carbonyl]amino]methyl]phenyl]phosphonic acid  
 diethyl ester 870561-22-1P, N-[[4-Fluorophenyl]methyl]-3-hydroxy-N-  
 methoxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-  
 c][1,4]oxazine-2-carboxamide 870561-23-2P, 3-Hydroxy-9,9-dimethyl-  
 4-oxo-N-[[2-(tetrahydro-1,1-dioxido-2H-1,2-thiazin-2-  
 yl)phenyl]methyl]-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-  
 carboxamide 870561-24-3P, 3-Hydroxy-9,9-dimethyl-4-oxo-N-[[2-(1H-  
 1,2,4-triazol-1-yl)phenyl]methyl]-4,6,7,9-tetrahydropyrimido[2,1-  
 c][1,4]oxazine-2-carboxamide 870561-25-4P, 3-Hydroxy-9,9-dimethyl-  
 4-oxo-N-(3-phenylpropyl)-4,6,7,9-tetrahydropyrimido[2,1-  
 c][1,4]oxazine-2-carboxamide 870561-26-5P 870561-27-6P  
 870561-28-7P 870561-29-8P 870561-30-1P 870561-31-2P  
 870561-32-3P 870561-33-4P 870561-34-5P 870561-35-6P  
 870561-36-7P 870561-37-8P 870561-38-9P 870561-39-0P  
 870561-40-3P 870561-41-4P 870561-42-5P 870561-43-6P  
 870561-44-7P 870561-45-8P 870561-46-9P 870561-47-0P  
 870561-48-1P 870561-49-2P 870561-50-5P 870561-51-6P  
 870561-52-7P 870561-53-8P 870561-54-9P 870561-55-0P  
 870561-56-1P 870561-57-2P 870561-58-3P 870561-59-4P  
 870561-60-7P 870561-61-8P 870561-62-9P 870561-63-0P  
 870561-64-1P 870561-65-2P 870561-66-3P 870561-67-4P  
 870561-68-5P, 3-Hydroxy-9,9-dimethyl-N-[[2-(4-  
 morpholinyl)phenyl]methyl]-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-  
 c][1,4]oxazine-2-carboxamide 870561-69-6P, 4-[2-[[[(3-Hydroxy-9,9-  
 dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazin-2-  
 yl)carbonyl]amino]methyl]phenyl]-1-piperazinecarboxylic acid  
 1,1-dimethylethyl ester 870561-70-9P, 3-Hydroxy-9,9-dimethyl-N-[[2-  
 (1-methylethoxy)phenyl]methyl]-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-  
 c][1,4]oxazine-2-carboxamide 870561-71-0P, 3-Hydroxy-9,9-dimethyl-  
 N-[[3-(1-methylethoxy)phenyl]methyl]-4-oxo-4,6,7,9-  
 tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870561-72-1P,  
 3-[[[(3-Hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-  
 c][1,4]oxazin-2-yl)carbonyl]amino]methyl]benzoic acid methyl ester  
 870561-73-2P, N-[[4-Cyanophenyl]methyl]-3-hydroxy-9,9-dimethyl-4-oxo-



4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide  
 870561-74-3P, N-[(3-Chloro-2-fluorophenyl)methyl]-3-hydroxy-9,9-  
 dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-  
 carboxamide 870561-75-4P, N-[(2,3-Dihydro-1,4-benzodioxin-5-  
 yl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-  
 tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870561-76-5P,  
 N-[(3,4-Dihydro-2H-1,5-benzodioxepin-6-yl)methyl]-3-hydroxy-9,9-  
 dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-  
 carboxamide 870561-77-6P, N-[(2,5-Dimethylphenyl)methyl]-3-hydroxy-  
 9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-  
 carboxamide 870561-78-7P, N-[(5-Chloro-2-fluorophenyl)methyl]-3-  
 hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-  
 c][1,4]oxazine-2-carboxamide 870561-79-8P, N-[(2,4-  
 Dichlorophenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-  
 tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870561-80-1P,  
 N-[(4-Chloro-2-methylphenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-  
 4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide  
 RL: PAC (Pharmacological activity); SPN (Synthetic  
 preparation); THU (Therapeutic use); BIOL (Biological  
 study); PREP (Preparation); USES (Uses)

(drug candidate; prepn. of bicyclic heterocycles as HIV integrase  
 inhibitors)

IT 870561-81-2P, N-[(2-Chloro-6-fluorophenyl)methyl]-3-hydroxy-9,9-  
 dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-  
 carboxamide 870561-82-3P, N-[(6-Chloro-2-fluoro-3-  
 methylphenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-  
 tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870561-83-4P,  
 N-[(2,6-Difluoro-3-methylphenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-  
 4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide  
 870561-84-5P, N-[(2,3-Difluoro-4-methylphenyl)methyl]-3-hydroxy-9,9-  
 dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-  
 carboxamide 870561-85-6P, N-[(4-Chloro-2-fluorophenyl)methyl]-3-  
 hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-  
 c][1,4]oxazine-2-carboxamide 870561-86-7P, N-[(2-Chloro-6-fluoro-3-  
 methylphenyl)methyl]-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-  
 tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870561-87-8P,  
 3-Hydroxy-9,9-dimethyl-N-[(1-methyl-1H-indol-4-yl)methyl]-4-oxo-  
 4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide  
 870561-88-9P, N-[[4-Fluoro-2-(2-oxo-1-azetidiny)phenyl]methyl]-  
 4,7,8,10-tetrahydro-3-hydroxy-10,10-dimethyl-4-oxo-6H-pyrimido[2,1-  
 c][1,4]oxazepine-2-carboxamide 870561-89-0P, [5-Fluoro-2-[[[(3-  
 hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-  
 c][1,4]oxazin-2-yl)carbonyl]amino]methyl]phenyl]phosphonic acid  
 dimethyl ester 870561-90-3P, [5-Fluoro-2-[[[(3-hydroxy-9,9-  
 dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazin-2-  
 yl)carbonyl]amino]methyl]phenyl]phosphonic acid monoethyl ester  
 RL: PAC (Pharmacological activity); SPN (Synthetic  
 preparation); THU (Therapeutic use); BIOL (Biological  
 study); PREP (Preparation); USES (Uses)

(drug candidate; prepn. of bicyclic heterocycles as HIV integrase  
 inhibitors)

IT 450-88-4P, 1-Bromo-4-fluoro-2-methoxybenzene 2339-57-3P,  
 5-Fluoro-2-methylbenzenesulfonamide 10133-24-1P,  
 7-(Bromomethyl)benzo[b]thiophene 14315-15-2P, 7-  
 Methylbenzo[b]thiophene 16630-62-9P, 2-[2-(Methylthio)ethyl]-1,3-  
 dioxolane 25699-87-0P, 2-(1H-1,2,4-Triazol-1-yl)benzonitrile  
 34451-66-6P, 2-Ethyl-2-hydroxybutanenitrile 67938-76-5P,  
 (5-Chloropyridin-2-yl)methanamine 91905-69-0P,  
 (2,2-Diethoxyethyl)(o-tolyl)sulfane 162845-02-5P,  
 3-(3-Bromomethylphenyl)-3-trifluoromethyl-3H-diazirine  
 186590-01-2P, 4-Fluoro-2-hydroxybenzonitrile 190198-07-3P,  
 4-Fluoro-2-(imidazol-1-yl)benzonitrile 191014-55-8P,

4-Fluoro-2-methoxybenzonitrile 217661-27-3P, 2-(Bromomethyl)-5-fluorobenzonitrile 353265-76-6P, 2-(2-Oxooxazolidin-3-yl)benzonitrile 410545-49-2P, (4-Fluoro-2-methylsulfanylbenzyl)amine 410545-71-0P, 5-Fluoro-2-methyl-N,N-dimethylbenzenesulfonamide 410545-72-1P, 2-Bromomethyl-5-fluoro-N,N-dimethylbenzenesulfonamide 410545-73-2P, 2-Azidomethyl-5-fluoro-N,N-dimethylbenzenesulfonamide 410545-74-3P, 2-(Aminomethyl)-5-fluoro-N,N-dimethylbenzenesulfonamide 449758-80-9P, 5-Fluoro-2-(1H-1,2,4-triazol-1-yl)benzonitrile 503293-06-9P, 2-(Benzyloxy)-4-fluorobenzonitrile 554448-62-3P, 4-Morpholino-2-fluorobenzonitrile 791071-00-6P, 2-(1,1-Dioxo-[1,2]thiazinan-2-yl)benzonitrile 864054-89-7P, (5-Fluoro-2-methylphenyl)(morpholino)methanone 869591-69-5P, 4-Fluoro-2-(1H-1,2,4-triazol-1-yl)benzonitrile 869591-70-8P, 4-(1H-1,2,4-Triazol-1-yl)-2-fluorobenzonitrile 869591-76-4P, 4-Fluoro-2-(2H-1,2,3-triazol-2-yl)benzonitrile 869591-78-6P, [2-(1,1-Dioxo-[1,2]thiazinan-2-yl)benzyl]amine hydrochloride 869591-79-7P, 4-Fluoro-2-(1,1-dioxo-[1,2]thiazinan-2-yl)benzonitrile 869591-80-0P, [4-Fluoro-2-(1,1-dioxo-[1,2]thiazinan-2-yl)phenyl]methanamine hydrochloride 869591-84-4P, 4-Fluoro-2-(3-methyl-1H-1,2,4-triazol-1-yl)benzonitrile 869591-85-5P, 4-Fluoro-2-(5-methyl-1H-1,2,4-triazol-1-yl)benzonitrile 869591-92-4P, [3-Fluoro-2-(1H-1,2,4-triazol-1-yl)phenyl]methanamine 870561-91-4P, 2-(Azidomethyl)-5-fluorobenzenesulfonamide 870561-93-6P, 2-[2-(Methylthio)ethoxy]acetic acid 870561-94-7P, Methyl 2-[2-(methylthio)ethoxy]acetate 870561-95-8P, 2-[2-(Methylthio)ethoxy]acetamide hydrochloride 870561-96-9P, Ethyl 5-benzyloxy-2-[[2-(methylthio)ethoxy]methyl]-6-oxo-1,6-dihydropyrimidine-4-carboxylate 870561-97-0P, Ethyl 5-benzyloxy-2-[[2-(dimethylsulfonium)ethoxy]methyl]-6-oxo-1,6-dihydropyrimidine-4-carboxylate iodide 870561-98-1P, Ethyl 3-benzyloxy-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxylate 870561-99-2P, 3-(Benzyloxy)-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxylic acid 870562-00-8P, Ethyl 3-hydroxy-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxylate 870562-01-9P, 2-[2-(Methylthio)ethoxy]propanoic acid 870562-02-0P, Methyl 2-[2-(methylthio)ethoxy]propanoate 870562-03-1P, 2-[2-(Methylthio)ethoxy]propanamide hydrochloride 870562-04-2P, Ethyl 5-benzyloxy-2-[1-[2-(methylthio)ethoxy]ethyl]-6-oxo-1,6-dihydropyrimidine-4-carboxylate 870562-05-3P, Ethyl 5-benzyloxy-2-[1-[2-(dimethylsulfonium)ethoxy]ethyl]-6-oxo-1,6-dihydropyrimidine-4-carboxylate iodide 870562-06-4P, Ethyl 3-(benzyloxy)-9-methyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxylate 870562-07-5P, Ethyl 3-hydroxy-9-methyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxylate 870562-08-6P, 3-Benzyloxy-9-methyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxylic acid 870562-09-7P, 4-(Methylthio)-2-[2-[(trimethylsilyl)oxy]ethoxy]butane nitrile 870562-10-0P 870562-11-1P, Ethyl 5-(benzyloxy)-2-[1-(2-hydroxyethoxy)-3-(methylthio)propyl]-6-oxo-1,6-dihydropyrimidine-4-carboxylate 870562-12-2P, Ethyl 3-(benzyloxy)-9-[2-(methylthio)ethyl]-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxylate 870562-13-3P, 3-(Benzyloxy)-9-[2-(methylthio)ethyl]-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxylic acid 870562-14-4P, 2-(2-Chloroethoxy)-2-methylpropanenitrile 870562-15-5P, Ethyl 2-(2-ethoxy-2-oxoethyl)-8,8-dimethyl-2,5,6,8-tetrahydro-[1,2,4]oxadiazolo[3,2-c][1,4]oxazine-2-carboxylate 870562-16-6P, Ethyl 3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxylate 870562-17-7P, Ethyl

3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxylate 870562-18-8P, 3-(Benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxylic acid 870562-19-9P, 2-(2-Chloroethoxy)-2-ethylbutanenitrile 870562-20-2P 870562-21-3P, Ethyl 9,9-diethyl-3-hydroxy-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxylate 870562-22-4P, 2-(3-Chloropropoxy)-2-methylpropanenitrile 870562-23-5P, Ethyl 2-[2-(3-chloropropoxy)propan-2-yl]-5-hydroxy-6-oxo-1,6-dihydropyrimidine-4-carboxylate 870562-24-6P, 3-(Benzyloxy)-10,10-dimethyl-4-oxo-6,7,8,10-tetrahydro-4H-pyrimido[2,1-c][1,4]oxazepine-2-carboxylic acid 870562-25-7P, Ethyl 3-hydroxy-10,10-dimethyl-4-oxo-6,7,8,10-tetrahydro-4H-pyrimido[2,1-c][1,4]oxazepine-2-carboxylate 870562-26-8P, (4-Fluoronaphthalen-1-yl)methanamine hydrochloride 870562-27-9P, Methyl 2-(aminomethyl)-5-fluorobenzoate trifluoroacetate 870562-29-1P, 2-Aminomethyl-5-fluoro-N-methylbenzamide trifluoroacetate 870562-30-4P, 2-(Aminomethyl)-N-cyclopropyl-5-fluorobenzamide trifluoroacetate 870562-31-5P, [2-(Bromomethyl)-5-fluorophenyl](morpholino)methanone 870562-32-6P, [2-(Azidomethyl)-5-fluorophenyl](morpholino)methanone 870562-33-7P, [2-(Aminomethyl)-5-fluorophenyl](morpholino)methanone hydrochloride 870562-34-8P, 5-Fluoro-2-methyl-N-methylbenzenesulfonamide 870562-35-9P, 2-Bromomethyl-5-fluoro-N-methylbenzenesulfonamide 870562-36-0P, 2-Azidomethyl-5-fluoro-N-methylbenzenesulfonamide 870562-37-1P, 2-(Aminomethyl)-5-fluoro-N-methylbenzenesulfonamide hydrochloride 870562-38-2P, 2-Bromomethyl-5-fluorobenzenesulfonamide 870562-39-3P, 2-(Aminomethyl)-5-fluorobenzenesulfonamide hydrochloride 870562-40-6P, 5-(2-Bromo-5-fluorophenyl)-2-methyl-2H-tetrazole 870562-42-8P, 4-Fluoro-2-(2-methyl-2H-tetrazol-5-yl)benzonitrile 870562-43-9P 870562-44-0P, 3-(m-Tolyl)-3-trifluoromethyl-3H-diazirine 870562-46-2P 870562-47-3P 870562-48-4P 870562-49-5P 870562-50-8P, 4-Fluoro-2-morpholinobenzonitrile 870562-51-9P 870562-52-0P 870562-53-1P, 2-Fluoro-4-(2H-1,2,3-triazol-2-yl)benzylamine 870562-54-2P 870562-55-3P, 2-Fluoro-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzonitrile 870562-56-4P, 2-Fluoro-4-(5-methyl-1H-1,2,4-triazol-1-yl)benzonitrile 870562-57-5P 870562-58-6P 870562-59-7P 870562-60-0P, [4-Fluoro-2-(1H-imidazol-1-yl)phenyl]methanamine hydrochloride 870562-61-1P, 1-(2-Cyano-5-fluorophenyl)-1H-1,2,4-triazole-3-carboxylic acid methyl ester 870562-62-2P, Methyl 1-[2-(aminomethyl)-5-fluorophenyl]-1H-1,2,4-triazole-3-carboxylate 870562-63-3P, 3-Fluoro-2-(1,1-dioxo-[1,2]thiazinan-2-yl)benzonitrile 870562-64-4P, [3-Fluoro-2-(1,1-dioxo-[1,2]thiazinan-2-yl)benzyl]amine hydrochloride 870562-65-5P, 3-Fluoro-2-(1,2,4-triazol-1-yl)benzonitrile 870562-66-6P 870562-67-7P 870562-68-8P, (3,5-Difluoropyridin-2-yl)methanamine hydrochloride 870562-69-9P, 2-[(1,3-Dioxoisindolin-2-yl)methyl]-5-fluorobenzonitrile 870562-70-2P, tert-Butyl (2-cyano-4-fluorobenzyl)carbamate 870562-72-4P, 2-(Aminomethyl)-5-fluorobenzonitrile trifluoroacetate 870562-73-5P, (2,5-Dibromo-4-fluorophenyl)methanamine 870562-74-6P, 2-(Aminomethyl)-5-fluorobenzenamine hydrochloride 870562-75-7P, 4-Fluoro-2-(2-oxopyrrolidin-1-yl)benzonitrile 870562-76-8P 870562-77-9P, 4-Fluoro-2-(2-oxopiperidin-1-yl)benzonitrile 870562-78-0P, 4-Fluoro-2-(2-oxoazepan-1-yl)benzonitrile 870562-79-1P, N-(2-Cyano-5-fluorophenyl)-N-methylacetamide 870562-80-4P, 2-(2-Oxoazetidin-1-yl)benzonitrile 870562-81-5P, 4-Fluoro-2-(2-oxooxazolidin-3-yl)benzonitrile 870562-82-6P, 3-[2-(Aminomethyl)-5-fluorophenyl]oxazolidin-2-one hydrochloride 870562-83-7P, 4-Fluoro-2-(2-oxoazetidin-1-yl)benzonitrile 870562-84-8P, 1-[2-(Aminomethyl)-5-fluorophenyl]azetidin-2-one



hydrochloride 870562-85-9P, (R)-2-[2-[[[tert-Butyldimethylsilyl)oxy)methyl]-5-oxopyrrolidin-1-yl]-4-fluorobenzonitrile 870562-86-0P, (S)-2-[2-[[[tert-Butyldimethylsilyl)oxy)methyl]-5-oxopyrrolidin-1-yl]-4-fluorobenzonitrile 870562-87-1P, 4-Fluoro-2-[(thiazol-2-yl)amino]benzonitrile 870562-88-2P, 4-Fluoro-2-[(5-methyl-1,3,4-thiadiazol-2-yl)amino]benzonitrile 870562-89-3P, 1-[2-(Aminomethyl)-5-fluorophenyl]piperidin-2-one hydrochloride 870562-90-6P, (4-Fluoro-2-methoxybenzyl)amine hydrochloride 870562-91-7P, 4-Fluoro-2-[2-(morpholino)-2-oxoethoxy]benzonitrile 870562-92-8P, 2-[2-(Aminomethyl)-5-fluorophenoxy]-1-morpholinoethanone hydrochloride 870562-93-9P, Dimethylcarbamic acid 2-cyano-5-fluorophenyl ester 870562-94-0P, Dimethylcarbamic acid 2-aminomethyl-5-fluorophenyl ester hydrochloride 870562-95-1P, (2-Hydroxy-4-fluorobenzyl)amine hydrochloride 870562-96-2P, Benzo[b]thiophen-7-ylmethanamine hydrochloride 870562-97-3P, N-[4-Fluoro-2-(methylcarbamoyl)benzyl]-3-benzyloxy-9-methyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870562-98-4P, N-(4-Fluorobenzyl)-3-(benzyloxy)-9-[2-(methylthio)ethyl]-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870562-99-5P, 3-(Benzyloxy)-2-[(6-fluoro-1-oxoisindolin-2-yl)carbonyl]-9,9-dimethyl-6,7-dihydropyrimido[2,1-c][1,4]oxazin-4(9H)-one 870563-00-1P, N-[4-Fluoro-2-(methylcarbamoyl)benzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-01-2P, N-(4-Fluoro-2-hydroxybenzyl)-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-02-3P 870563-03-4P, N-[4-Fluoro-2-(2-oxoazetidin-1-yl)benzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-04-5P, N-[(Benzo[b]thiophen-7-yl)methyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-05-6P, N-[4-Fluoro-2-(methylcarbamoyl)benzyl]-3-(benzyloxy)-10,10-dimethyl-4-oxo-6,7,8,10-tetrahydro-4H-pyrimido[2,1-c][1,4]oxazepine-2-carboxamide 870563-06-7P, N-(4-Fluorobenzyl)-3-(benzyloxy)-9-methyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-07-8P, N-[4-Fluoro-2-(methylcarbamoyl)benzyl]-3-(benzyloxy)-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-08-9P, N-[4-Fluoro-2-(1H-1,2,4-triazol-1-yl)benzyl]-3-(benzyloxy)-9-ethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-10-3P, N-[4-Fluoro-2-(3-methyl-1H-1,2,4-triazol-1-yl)benzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-11-4P, N-[2-Fluoro-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-12-5P 870563-13-6P, N-[2-(Cyclopropylcarbamoyl)-4-fluorobenzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-14-7P, N-[4-Fluoro-2-(morpholine-4-carbonyl)benzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-15-8P, N-[4-Fluoro-2-[2-(morpholino)-2-oxoethoxy]benzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-16-9P, Dimethylcarbamic acid 2-[[[(3-benzyloxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazin-2-yl)carbonyl]amino)methyl]-5-fluorophenyl ester 870563-17-0P, N-[4-Fluoro-2-(2-oxopyrrolidin-1-yl)benzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-18-1P, N-[4-Fluoro-2-(2-oxoazepan-1-yl)benzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-19-2P, N-[2-(2-Oxooxazolidin-3-yl)benzyl]-3-(benzyloxy)-9,9-

dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-20-5P, N-[2-(2-Oxoazetidin-1-yl)benzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-21-6P, N-[4-Fluoro-2-[(thiazol-2-yl)amino]benzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-22-7P, N-[4-Fluoro-2-[(5-methyl-1,3,4-thiadiazol-2-yl)amino]benzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-23-8P, N-[4-Fluoro-2-(2-oxooxazolidin-3-yl)benzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-24-9P, (R)-N-[2-[2-[[[(tert-Butyldimethylsilyl)oxy]methyl]-5-oxopyrrolidin-1-yl]-4-fluorobenzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-25-0P, (S)-N-[2-[2-[[[(tert-Butyldimethylsilyl)oxy]methyl]-5-oxopyrrolidin-1-yl]-4-fluorobenzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-26-1P, N-[4-Fluoro-2-(N-methylacetamido)benzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-27-2P, N-(2-Amino-4-fluorobenzyl)-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-28-3P, N-[2-(Ethylamino)-4-fluorobenzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-30-7P, N-(4-Fluorobenzyl)-3-(benzyloxy)-N-methoxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-31-8P, N-[4-Fluoro-2-(1,2,3-thiadiazol-4-yl)benzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-33-0P, N-[4-Fluoro-2-(5-methyloxazol-2-yl)benzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-35-2P, N-(4-Fluoro-2-iodobenzyl)-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-36-3P, N-[4-Fluoro-2-(2-methoxypyridin-3-yl)benzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-37-4P, N-(4-Fluoro-2-phenylbenzyl)-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-38-5P, N-[4-Fluoro-2-(1H-pyrazol-3-yl)benzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-39-6P, N-[4-Fluoro-2-[2-(trimethylsilyl)ethynyl]benzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-40-9P, N-(2-Ethynyl-4-fluorobenzyl)-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-41-0P, N-[4-Fluoro-2-(3-methylisoxazol-5-yl)benzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-42-1P, N-[2-(3-Bromoisoxazol-5-yl)-4-fluorobenzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-43-2P, N-[4-Fluoro-2-(3-hydroxyprop-1-ynyl)benzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-44-3P, 3-[2-[[[3-(Benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazin-2-yl]carbonyl]amino]methyl]-5-fluorophenyl]prop-2-ynyl methanesulfonate 870563-45-4P, N-[2-[3-(Dimethylamino)prop-1-ynyl]-4-fluorobenzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-46-5P, N-[4-Fluoro-2-[3-(methylthio)prop-1-ynyl]benzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-47-6P, N-[4-Fluoro-2-[3-(methylsulfonyl)prop-1-ynyl]benzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-48-7P,

Diethyl [2-[[[3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazin-2-yl]carbonyl]amino]methyl]-5-fluorophenyl]phosphonate 870563-49-8P, Ethyl hydrogen [2-[[[3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazin-2-yl]carbonyl]amino]methyl]-5-fluorophenyl]phosphonate 870563-50-1P, N-(2-Acetamido-4-fluorobenzyl)-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-51-2P, 2-[[[3-(Benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazin-2-yl]carbonyl]amino]methyl]-5-fluorobenzoic acid 870563-52-3P, N-[2-[(2-Hydroxyethyl)carbonyl]-4-fluorobenzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-53-4P, (R)-N-[4-Fluoro-2-[2-(hydroxymethyl)-5-oxopyrrolidin-1-yl]benzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-54-5P, (R)-[1-[2-[[[3-(Benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazin-2-yl]carbonyl]amino]methyl]-5-fluorophenyl]-5-oxopyrrolidin-2-yl]methyl acetate 870563-55-6P, (R)-[1-[2-[[[3-(Benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazin-2-yl]carbonyl]amino]methyl]-5-fluorophenyl]-5-oxopyrrolidin-2-yl]methyl methanesulfonate 870563-56-7P, (R)-N-[2-[2-(Azidomethyl)-5-oxopyrrolidin-1-yl]-4-fluorobenzyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-57-8P, N-[(1,1-DioxoBenzo[b]thiophen-7-yl)methyl]-3-(benzyloxy)-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydropyrimido[2,1-c][1,4]oxazine-2-carboxamide 870563-63-6P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(intermediate; prepn. of bicyclic heterocycles as HIV integrase inhibitors)  
IT 9068-38-6  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(non/nucleoside HIV reverse transcriptase inhibitors; combination therapy agents; prepn. of bicyclic heterocycles for use in combination therapy for treating HIV infection)  
IT 52350-85-3, HIV integrase  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(of HIV inhibitors; prepn. of bicyclic heterocycles as HIV integrase inhibitors)

L32 ANSWER 2 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1242755 HCAPLUS

DOCUMENT NUMBER: 143:472565

TITLE: Methods of **treating conditions** associated with an Edg-7 receptor

INVENTOR(S): Solow-Cordero, David; Shankar, Geetha; Spencer, Juliet V.; Gluchowski, Charles

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 33 pp., Cont.-in-part of U.S. Ser. No. 352,579.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

-----  
 US 2005261298 A1 20051124 US 2003-390428 200303  
 14  
 WO 2003062392 A2 20030731 WO 2003-US1881 200301  
 21  
 WO 2003062392 A3 20050120  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,  
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD,  
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,  
 LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,  
 NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ,  
 TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,  
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI,  
 SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
 SN, TD, TG  
 PRIORITY APPLN. INFO.: US 2002-350446P P 200201  
 18  
 WO 2003-US1881 A1 200301  
 21  
 US 2003-352579 B2 200301  
 27  
 US 2002-350445P P 200201  
 18  
 US 2002-350447P P 200201  
 18  
 US 2002-350448P P 200201  
 18


AB In one aspect, the present invention provides a method for  
 modulating an Edg-7 **receptor** mediated biol. activity in a  
 cell. A cell expressing the Edg-7 **receptor** is contacted  
 with a **modulator** of the Edg-7 **receptor** which is  
 capable of modulating an Edg-7 **receptor** mediated biol.  
 activity. In another aspect, the present invention provides a  
 method for modulating an Edg-7 **receptor** mediated biol.  
 activity in a subject. A therapeutically effective amt. of a  
**modulator** of the Edg-7 **receptor** is administered to  
 the subject.

IT 353771-45-6P

RL: PAC (Pharmacological activity); SPN (Synthetic  
 preparation); THU (Therapeutic use); BIOL (Biological  
 study); PREP (Preparation); USES (Uses)  
 (Edg-7 modulators for treating  
 conditions assocd. with Edg-7 receptor)

RN 353771-45-6 HCAPLUS

CN Acetic acid, [4-bromo-2-[[2-[(4-chlorophenyl)amino]-4-oxo-5(4H)-  
 thiazolylidene]methyl]phenoxy]- (9CI) (CA INDEX NAME)




IT 569656-05-9

RL: RCT (Reactant); RACT (Reactant or reagent)  
 (Edg-7 modulators for treating  
 conditions assocd. with Edg-7 receptor)

RN 569656-05-9 HCAPLUS

CN Acetic acid, [4-bromo-2-[[2-[(4-chlorophenyl)amino]-4-oxo-5(4H)-  
 thiazolylidene]methyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



IC ICM A61K031-498

ICS A61K031-4709; A61K031-455; A61K031-426; A61K031-382;  
 A61K031-165

INCL 514249000; 514355000; 514310000; 514309000; 514437000; 514622000;  
 514443000; 514369000

CC 1-6 (Pharmacology)

Section cross-reference(s): 28

ST antitumor Edg7 receptor modulator prepn  
 inflammation lung disease therapy; phenoxyacetate  
 deriv prepn Edg7 modulator asthma heart  
 disease therapy

IT Animal cell line

(A431; Edg-7 modulators for treating  
 conditions assocd. with Edg-7 receptor)

IT Dopamine receptors

RL: BSU (Biological study, unclassified); BIOL  
 (Biological study)  
 (D2(long); Edg-7 modulators for treating  
 conditions assocd. with Edg-7 receptor)

IT G protein-coupled receptors

RL: BSU (Biological study, unclassified); BIOL  
 (Biological study)  
 (EDG (endothelial differentiation gene); Edg-7 modulators  
 for treating conditions assocd. with Edg-7  
 receptor)

IT G protein-coupled receptors

RL: BSU (Biological study, unclassified); BIOL

(Biological study)  
 (EDG-1 (endothelial differentiation gene 1); Edg-7  
 modulators for treating conditions  
 assocd. with Edg-7 receptor)

IT G protein-coupled receptors  
 RL: BSU (Biological study, unclassified); BIOL  
 (Biological study)  
 (EDG-2 (endothelial differentiation gene 2); Edg-7  
 modulators for treating conditions  
 assocd. with Edg-7 receptor)

IT G protein-coupled receptors  
 RL: BSU (Biological study, unclassified); BIOL  
 (Biological study)  
 (EDG-3 (endothelial differentiation gene 3); Edg-7  
 modulators for treating conditions  
 assocd. with Edg-7 receptor)

IT G protein-coupled receptors  
 RL: BSU (Biological study, unclassified); BIOL  
 (Biological study)  
 (EDG-4 (endothelial differentiation gene 4); Edg-7  
 modulators for treating conditions  
 assocd. with Edg-7 receptor)

IT G protein-coupled receptors  
 RL: BSU (Biological study, unclassified); BIOL  
 (Biological study)  
 (EDG-5 (endothelial differentiation gene 5); Edg-7  
 modulators for treating conditions  
 assocd. with Edg-7 receptor)

IT G protein-coupled receptors  
 RL: BSU (Biological study, unclassified); BIOL  
 (Biological study)  
 (EDG-6 (endothelial differentiation gene 6); Edg-7  
 modulators for treating conditions  
 assocd. with Edg-7 receptor)

IT G protein-coupled receptors  
 RL: BSU (Biological study, unclassified); BIOL  
 (Biological study)  
 (EDG-7 (endothelial differentiation gene 7); Edg-7  
 modulators for treating conditions  
 assocd. with Edg-7 receptor)

IT G protein-coupled receptors  
 RL: BSU (Biological study, unclassified); BIOL  
 (Biological study)  
 (EDG-8 (endothelial differentiation gene 8); Edg-7  
 modulators for treating conditions  
 assocd. with Edg-7 receptor)

IT Angiogenesis  
 Anti-inflammatory agents  
 Anti-ischemic agents  
 Antiasthmatics  
 Antitumor agents  
 Apoptosis  
 Asthma  
 Cardiovascular agents  
 Cardiovascular system, disease  
 Cell migration  
 Cell proliferation  
 Combination chemotherapy  
 Cytotoxic agents  
 Fibroblast  
 Human  
 Inflammation



Ischemia  
 Kidney, neoplasm  
 Lung, **disease**  
 Lung, neoplasm  
 Mammary gland, neoplasm  
 Myoblast  
 Neuron  
 Ovary, neoplasm  
 Pancreas, neoplasm  
 Peritoneum, neoplasm  
 Platelet (blood)  
 Platelet activation  
 Prostate gland, neoplasm  
 Stomach, neoplasm  
 Thyroid gland, neoplasm  
 Uterus, neoplasm  
 Wound healing  
     (Edg-7 modulators for treating  
     conditions assocd. with Edg-7 receptor)  
 IT Muscarinic receptors  
 RL: BSU (Biological study, unclassified); BIOL  
     (Biological study)  
     (Edg-7 modulators for treating  
     conditions assocd. with Edg-7 receptor)  
 IT Carbohydrates, biological studies  
 Nucleic acids  
 Organic compounds, biological studies  
 Proteins  
 RL: PAC (Pharmacological activity); THU (Therapeutic  
 use); BIOL (Biological study); USES (Uses)  
     (Edg-7 modulators for treating  
     conditions assocd. with Edg-7 receptor)  
 IT Animal cell line  
     (HT-1080; Edg-7 modulators for treating  
     conditions assocd. with Edg-7 receptor)  
 IT Animal cell line  
     (HTC; Edg-7 modulators for treating  
     conditions assocd. with Edg-7 receptor)  
 IT Animal cell line  
     (HUVEC; Edg-7 modulators for treating  
     conditions assocd. with Edg-7 receptor)  
 IT Histamine receptors  
 RL: BSU (Biological study, unclassified); BIOL  
     (Biological study)  
     (H1; Edg-7 modulators for treating  
     conditions assocd. with Edg-7 receptor)  
 IT Calcium channel  
 RL: BSU (Biological study, unclassified); BIOL  
     (Biological study)  
     (L-type; Edg-7 modulators for treating  
     conditions assocd. with Edg-7 receptor)  
 IT Animal cell line  
     (MDA-MB-231; Edg-7 modulators for treating  
     conditions assocd. with Edg-7 receptor)  
 IT Animal cell line  
     (OV202, CAOV-3, MDA-MB-453; Edg-7 modulators for  
     treating conditions assocd. with Edg-7  
     receptor)  
 IT Respiratory distress syndrome  
     (adult; Edg-7 modulators for treating  
     conditions assocd. with Edg-7 receptor)  
 IT Antiarteriosclerotics



(antiatherosclerotics; Edg-7 modulators for treating conditions assocd. with Edg-7 receptor)

IT Atherosclerosis  
(atherogenesis; Edg-7 modulators for treating conditions assocd. with Edg-7 receptor)

IT Immune system  
(autoimmune response; Edg-7 modulators for treating conditions assocd. with Edg-7 receptor)

IT Biological transport  
(calcium; Edg-7 modulators for treating conditions assocd. with Edg-7 receptor)

IT Lysophosphatidic acids  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(cell proliferation stimulated by; Edg-7 modulators for treating conditions assocd. with Edg-7 receptor)

IT Carcinoma  
Pheochromocytoma  
(cell; Edg-7 modulators for treating conditions assocd. with Edg-7 receptor)

IT Uterus, neoplasm  
(cervix; Edg-7 modulators for treating conditions assocd. with Edg-7 receptor)

IT Intestine, neoplasm  
(colon; Edg-7 modulators for treating conditions assocd. with Edg-7 receptor)

IT Intestine, neoplasm  
(colorectal; Edg-7 modulators for treating conditions assocd. with Edg-7 receptor)

IT Eye  
(cornea, transcorneal freezing; Edg-7 modulators for treating conditions assocd. with Edg-7 receptor)

IT Burn  
(cutaneous; Edg-7 modulators for treating conditions assocd. with Edg-7 receptor)

IT Uterus, neoplasm  
(endometrium; Edg-7 modulators for treating conditions assocd. with Edg-7 receptor)

IT Epithelium  
(epithelial cell; Edg-7 modulators for treating conditions assocd. with Edg-7 receptor)

IT Sarcoma  
(fibrosarcoma, cell; Edg-7 modulators for treating conditions assocd. with Edg-7 receptor)

IT Carcinoma  
(hepatocellular, cell; Edg-7 modulators for treating conditions assocd. with Edg-7 receptor)

IT Liver, neoplasm  
(hepatoma, cell; Edg-7 modulators for treating conditions assocd. with Edg-7 receptor)

IT Phosphatidylinositols  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(hydrolysis; Edg-7 modulators for treating conditions assocd. with Edg-7 receptor)

IT Neoplasm

(invasiveness; Edg-7 modulators for treating conditions assocd. with Edg-7 receptor)

IT Neoplasm  
(metastasis; Edg-7 modulators for treating conditions assocd. with Edg-7 receptor)

IT Ovary  
(ovarian cell; Edg-7 modulators for treating conditions assocd. with Edg-7 receptor)

IT Actins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(polymn.; Edg-7 modulators for treating conditions assocd. with Edg-7 receptor)

IT Intestine, neoplasm  
(small; Edg-7 modulators for treating conditions assocd. with Edg-7 receptor)

IT Interleukin 8  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(synthesis; Edg-7 modulators for treating conditions assocd. with Edg-7 receptor)

IT 5-HT receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(type 5-HT1; Edg-7 modulators for treating conditions assocd. with Edg-7 receptor)

IT Angiotensin receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(type AT2; Edg-7 modulators for treating conditions assocd. with Edg-7 receptor)

IT Endothelin receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(type ETA; Edg-7 modulators for treating conditions assocd. with Edg-7 receptor)

IT Adrenoceptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
( $\alpha$ 1; Edg-7 modulators for treating conditions assocd. with Edg-7 receptor)

IT Adrenoceptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
( $\alpha$ 2; Edg-7 modulators for treating conditions assocd. with Edg-7 receptor)

IT Adrenoceptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
( $\beta$ -; Edg-7 modulators for treating conditions assocd. with Edg-7 receptor)

IT 60-92-4, CAMP 127464-60-2, VEGF  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(Edg-7 modulators for treating conditions assocd. with Edg-7 receptor)

IT 40622-01-3P, 2,3-Bis(4-Methoxyphenyl)quinoxaline-6-carboxylic acid  
66085-59-4P 306764-68-1P 312501-62-5P 331945-22-3P  
353771-45-6P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Edg-7 modulators for treating conditions assocd. with Edg-7 receptor)

IT 91-56-5, 1H-Indole-2,3-dione 108-31-6, Maleic anhydride, reactions 108-38-3, 1,3-Dimethylbenzene, reactions 119-80-2 619-05-6, 3,4-Diaminobenzoic acid 1226-42-2, 4,4'-Dimethoxybenzil 4506-71-2, Ethyl 2-amino-4,5,6,7-tetrahydrobenzo[B]thiophene-3-carboxylate 5242-26-2 64900-65-8, 2-Chlorobenzenesulfonyl isocyanate 82799-44-8 569656-05-9 569656-06-0  
RL: RCT (Reactant); RACT (Reactant or reagent)

(Edg-7 modulators for treating conditions assocd. with Edg-7 receptor)

IT 7741-54-0P 76293-13-5P, 2,4-Dimethylthioxanthen-9-one 569656-29-7P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(Edg-7 modulators for treating conditions assocd. with Edg-7 receptor)

IT 7440-70-2, Calcium, biological studies  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(transport; Edg-7 modulators for treating conditions assocd. with Edg-7 receptor)

L32 ANSWER 3 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1016895 HCAPLUS

DOCUMENT NUMBER: 143:415586

TITLE: G-Protein-Coupled Receptor Affinity Prediction Based on the Use of a Profiling Dataset: QSAR Design, Synthesis, and Experimental Validation  
AUTHOR(S): Rolland, Catherine; Gozalbes, Rafael; Nicolaie, Eric; Paugam, Marie-France; Coussy, Laurent; Barbosa, Frederique; Horvath, Dragos; Revah, Frederic

CORPORATE SOURCE: Cerep, Rueil-Malmaison, 92500, Fr.

SOURCE: Journal of Medicinal Chemistry (2005), 48(21), 6563-6574

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A QSAR model accounting for "av." G-protein-coupled receptor (GPCR) binding was built from a large set of exptl. standardized binding data (1939 compds. systematically tested over 40 different GPCRs) and applied to the design of a library of "GPCR-predicted" compds. Three hundred and sixty of these compds. were randomly selected and tested in 21 GPCR binding assays. Positives were defined by their ability to inhibit by more than 70% the binding of ref. compds. at 10  $\mu$ M. A 5.5-fold enrichment in positives was obsd. when comparing the "GPCR-predicted" compds. with 600 randomly selected compds. predicted as "non-GPCR" from a general collection. The model was efficient in predicting strongest binders, since enrichment was greater for higher cutoffs. Significant enrichment was also obsd. for peptidic GPCRs and receptors not included to develop the QSAR model, suggesting the usefulness of the model to design ligands binding with newly identified GPCRs, including orphan ones.

IT 412008-22-1


RL: PAC (Pharmacological activity); PRP (Properties);

THU (Therapeutic use); BIOL (Biological study);

USES (Uses)

(QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a

profiling dataset)  
 RN 412008-22-1 HCAPLUS  
 CN 2-Thiazolamine, N-(4-chloro-1-naphthalenyl)-4-(1,1-dimethylethyl)-  
 (9CI) (CA INDEX NAME)



CC 1-3 (Pharmacology)  
 Section cross-reference(s): 27, 28  
 IT Adenosine receptors  
 RL: BSU (Biological study, unclassified); BIOL  
 (Biological study)  
 (A1, ligands; QSAR design, synthesis, and exptl. validation of  
 G-protein-coupled receptor affinity prediction based on use of a  
 profiling dataset)  
 IT Adenosine receptors  
 RL: BSU (Biological study, unclassified); BIOL  
 (Biological study)  
 (A2A, ligands; QSAR design, synthesis, and exptl. validation of  
 G-protein-coupled receptor affinity prediction based on use of a  
 profiling dataset)  
 IT Bradykinin receptors  
 RL: BSU (Biological study, unclassified); BIOL  
 (Biological study)  
 (B2, ligands; QSAR design, synthesis, and exptl. validation of  
 G-protein-coupled receptor affinity prediction based on use of a  
 profiling dataset)  
 IT Cholecystokinin receptors  
 RL: BSU (Biological study, unclassified); BIOL  
 (Biological study)  
 (CCKA, ligands; QSAR design, synthesis, and exptl. validation of  
 G-protein-coupled receptor affinity prediction based on use of a  
 profiling dataset)  
 IT Chemokine receptors  
 RL: BSU (Biological study, unclassified); BIOL  
 (Biological study)  
 (CCR1, ligands; QSAR design, synthesis, and exptl. validation of  
 G-protein-coupled receptor affinity prediction based on  
 use of a profiling dataset)  
 IT Chemokine receptors  
 RL: BSU (Biological study, unclassified); BIOL  
 (Biological study)  
 (CCR2, ligands; QSAR design, synthesis, and exptl. validation of  
 G-protein-coupled receptor affinity prediction based on  
 use of a profiling dataset)  
 IT Chemokine receptors  
 RL: BSU (Biological study, unclassified); BIOL  
 (Biological study)

(CCR3, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Chemokine receptors  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(CCR4, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Chemokine receptors  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(CCR5, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Chemokine receptors  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(CXCR1, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Chemokine receptors  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(CXCR2, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Dopamine receptors  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(D1, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Dopamine receptors  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(D1A, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Dopamine receptors  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(D2, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Dopamine receptors  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(D2(short), ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Dopamine receptors  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(D3, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Dopamine receptors  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(D4, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a

profiling dataset)

IT GABA receptors  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(GABAB, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT G protein-coupled receptors  
Hormone receptors  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(GHS-R (growth hormone secretagogue receptor), ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Histamine receptors  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(H1, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Histamine receptors  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(H2, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT G protein-coupled receptors  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(MCH-1R (melanin concg. hormone receptor 1), ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Muscarinic receptors  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(M1, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Muscarinic receptors  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(M2, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Muscarinic receptors  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(M3, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT G protein-coupled receptors  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Vasopressin receptors  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(V1a, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)



IT Neuropeptide Y receptors  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(Y1, ligands; QSAR design, synthesis, and exptl. validation of  
G-protein-coupled receptor affinity prediction based on use of a  
profiling dataset)

IT Calcitonin gene-related peptide receptors  
Somatostatin receptors  
VIP receptors  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(ligands; QSAR design, synthesis, and exptl. validation of  
G-protein-coupled receptor affinity prediction based on use of a  
profiling dataset)

IT Pituitary hormone receptors  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(melanocortin receptor 1, ligands; QSAR design, synthesis, and  
exptl. validation of G-protein-coupled receptor affinity  
prediction based on use of a profiling dataset)

IT Pituitary hormone receptors  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(melanocortin receptor 3, ligands; QSAR design, synthesis, and  
exptl. validation of G-protein-coupled receptor affinity  
prediction based on use of a profiling dataset)

IT Pituitary hormone receptors  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(melanocortin receptor 4, ligands; QSAR design, synthesis, and  
exptl. validation of G-protein-coupled receptor affinity  
prediction based on use of a profiling dataset)

IT 5-HT receptors  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(type 5-HT1A, ligands; QSAR design, synthesis, and exptl.  
validation of G-protein-coupled receptor affinity prediction  
based on use of a profiling dataset)

IT 5-HT receptors  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(type 5-HT1B, ligands; QSAR design, synthesis, and exptl.  
validation of G-protein-coupled receptor affinity prediction  
based on use of a profiling dataset)

IT 5-HT receptors  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(type 5-HT1D, ligands; QSAR design, synthesis, and exptl.  
validation of G-protein-coupled receptor affinity prediction  
based on use of a profiling dataset)

IT 5-HT receptors  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(type 5-HT2A, ligands; QSAR design, synthesis, and exptl.  
validation of G-protein-coupled receptor affinity prediction  
based on use of a profiling dataset)

IT 5-HT receptors  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(type 5-HT2B, ligands; QSAR design, synthesis, and exptl.  
validation of G-protein-coupled receptor affinity prediction  
based on use of a profiling dataset)



IT 5-HT receptors  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(type 5-HT2C, ligands; QSAR design, synthesis, and exptl.  
validation of G-protein-coupled receptor affinity prediction  
based on use of a profiling dataset)

IT 5-HT receptors  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(type 5-HT4, ligands; QSAR design, synthesis, and exptl.  
validation of G-protein-coupled receptor affinity prediction  
based on use of a profiling dataset)

IT 5-HT receptors  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(type 5-HT6, ligands; QSAR design, synthesis, and exptl.  
validation of G-protein-coupled receptor affinity prediction  
based on use of a profiling dataset)

IT 5-HT receptors  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(type 5-HT7, ligands; QSAR design, synthesis, and exptl.  
validation of G-protein-coupled receptor affinity prediction  
based on use of a profiling dataset)

IT Angiotensin receptors  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(type AT1, ligands; QSAR design, synthesis, and exptl. validation  
of G-protein-coupled receptor affinity prediction based on use of  
a profiling dataset)

IT Cannabinoid receptors  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(type CB1, ligands; QSAR design, synthesis, and exptl. validation  
of G-protein-coupled receptor affinity prediction based on use of  
a profiling dataset)

IT Endothelin receptors  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(type ETB, ligands; QSAR design, synthesis, and exptl. validation  
of G-protein-coupled receptor affinity prediction based on use of  
a profiling dataset)

IT Tachykinin receptors  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(type NK1, ligands; QSAR design, synthesis, and exptl. validation  
of G-protein-coupled receptor affinity prediction based on use of  
a profiling dataset)

IT Tachykinin receptors  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(type NK2, ligands; QSAR design, synthesis, and exptl. validation  
of G-protein-coupled receptor affinity prediction based on use of  
a profiling dataset)

IT Receptors  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(urotensin II, ligands; QSAR design, synthesis, and exptl.  
validation of G-protein-coupled receptor affinity prediction  
based on use of a profiling dataset)

IT Opioid receptors  
RL: BSU (Biological study, unclassified); BIOL

(Biological study)  
 ( $\kappa$ -opioid, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Interleukin 8 receptors  
 RL: BSU (Biological study, unclassified); BIOL  
 (Biological study)  
 ( $\alpha$ , ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Adrenoceptors  
 RL: BSU (Biological study, unclassified); BIOL  
 (Biological study)  
 ( $\alpha$ 1A, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Adrenoceptors  
 RL: BSU (Biological study, unclassified); BIOL  
 (Biological study)  
 ( $\alpha$ 2, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Adrenoceptors  
 RL: BSU (Biological study, unclassified); BIOL  
 (Biological study)  
 ( $\alpha$ 2A, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Interleukin 8 receptors  
 RL: BSU (Biological study, unclassified); BIOL  
 (Biological study)  
 ( $\beta$ , ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Adrenoceptors  
 RL: BSU (Biological study, unclassified); BIOL  
 (Biological study)  
 ( $\beta$ 1, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Adrenoceptors  
 RL: BSU (Biological study, unclassified); BIOL  
 (Biological study)  
 ( $\beta$ 2, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Opioid receptors  
 RL: BSU (Biological study, unclassified); BIOL  
 (Biological study)  
 ( $\delta$ -opioid, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT Opioid receptors  
 RL: BSU (Biological study, unclassified); BIOL  
 (Biological study)  
 ( $\mu$ -opioid, ligands; QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

IT 217645-38-0 219866-03-2 302347-94-0 325823-79-8 331756-51-5  
 342636-04-8 357612-05-6 365513-78-6 367506-61-4 373380-99-5  
 387825-78-7 387876-41-7 395679-53-5 412008-22-1  
 423722-34-3 444045-28-7 444683-11-8 457893-92-4 460047-71-6

485391-80-8 500013-54-7 515141-51-2 532994-25-5 538342-73-3  
 540765-44-4 562102-64-1 582325-54-0 583867-53-2 620610-83-5  
 626208-21-7 630052-65-2 642049-63-6 642443-00-3 643746-94-5  
 644974-13-0 645399-82-2 648884-40-6 652979-01-6 654010-68-1  
 758682-52-9 765887-47-6 782445-88-9 868056-59-1 868056-61-5  
 868056-63-7 868056-65-9 868056-67-1 868056-69-3 868056-71-7  
 868056-72-8 868056-73-9 868056-74-0 868056-75-1 868056-76-2  
 868056-77-3 868056-78-4 868056-80-8 868056-81-9 868056-83-1  
 868056-84-2 868056-86-4 868056-87-5 868056-89-7 868056-90-0  
 868056-91-1 868056-93-3 868056-94-4 868056-95-5 868056-96-6  
 868056-97-7 868056-98-8 868056-99-9 868057-00-5 868057-02-7  
 868057-06-1 868057-07-2 868057-08-3 868057-09-4 868057-11-8  
 868057-16-3 868057-21-0 868057-23-2 868057-25-4 868057-29-8  
 868057-32-3 868057-35-6 868057-37-8 868057-40-3 868057-41-4  
 868057-42-5

RL: PAC (Pharmacological activity); PRP (Properties);

THU (Therapeutic use); BIOL (Biological study);

USES (Uses)

(QSAR design, synthesis, and exptl. validation of

G-protein-coupled receptor affinity prediction based on use of a  
 profiling dataset)

REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE  
 FOR THIS RECORD. ALL CITATIONS AVAILABLE  
 IN THE RE FORMAT

L32 ANSWER 4 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1004737 HCAPLUS

DOCUMENT NUMBER: 143:286695

TITLE: Preparation of peptides as caspase inhibitors

INVENTOR(S): Charrier, Jean-Damien; Durrant, Steven;  
 Mortimore, Michael; O'Donnell, Michael;  
 Rutherford, Alistair; Ramaya, Sharn; Studley,  
 John R.; Trudeau, Martin; Looker, Adam

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA

SOURCE: PCT Int. Appl., 177 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005085236	A2	20050915	WO 2005-US6540	20050228
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2005233979	A1	20051020	US 2005-69895	20050228

## PRIORITY APPLN. INFO.:

US 2004-548610P	P	200402 27
US 2004-629661P	P	200411 19
US 2004-629743P	P	200411 19

OTHER SOURCE(S): MARPAT 143:286695  
GI



AB The invention provides compds. I [Y is CH(CHO)CH<sub>2</sub>CO<sub>2</sub>H or 2-hydroxy-5-oxotetrahydro-3-furanyl or their ethers; ring A is 2-pyrrolidine or 2-piperidine or their cyclopropano or bicyclic derivs.; R is HCO, R<sub>3</sub>CO, R<sub>3</sub>SO<sub>2</sub>, R<sub>3</sub>O<sub>2</sub>C, R<sub>3</sub>2NCO, etc., where R<sub>3</sub> is alkyl, cycloalkyl, aryl, heterocyclyl, etc.; R<sub>2</sub> is (un)substituted alkyl, aryl, heteroaryl or cycloalkyl] that are useful as caspase inhibitors, including processes for their prepn. and pharmaceutical compns. contg. these compds. for the **treatment of diseases** and disorders related to caspase-mediated **conditions**. Thus, peptide aldehyde II was prepd. via amidation reactions and showed K<sub>i</sub> < 10 nM for inhibition of caspase-1 or caspase-8.


IT 864166-92-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of peptides as caspase inhibitors)

RN 864166-92-7 HCAPLUS

CN L-Prolinamide, N-[2-chloro-4-(2-thiazolylamino)benzoyl]-L-valyl-N-[(2R,3S)-2-ethoxytetrahydro-5-oxo-3-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IC ICM C07D405-00  
 CC 34-3 (Amino Acids, Peptides, and Proteins)  
 Section cross-reference(s): 1, 63  
 IT **Inflammation**  
 (Crohn's disease; prepn. of peptides as caspase inhibitors)  
 IT Interleukin 1  
 RL: BSU (Biological study, unclassified); BIOL  
 (Biological study)  
 (disease mediated by; prepn. of peptides as caspase inhibitors)  
 IT Intestine, disease  
 (inflammatory; prepn. of peptides as caspase inhibitors)  
 IT Inflammation  
 Peritoneum, disease  
 (peritonitis, inflammatory; prepn. of peptides as caspase inhibitors)  
 IT Aging, animal  
 Alcoholism  
 Alopecia  
 Alzheimer's disease  
 Anti-Alzheimer's agents  
 Anti-infective agents  
 Anti-inflammatory agents  
 Antiarthritics  
 Antiasthmatics  
 Antidiabetic agents  
 Antiparkinsonian agents  
 Antirheumatic agents  
 Antiviral agents  
 Apoptosis  
**Asthma**  
 Atherosclerosis  
 Autoimmune disease  
 Bone, disease  
 Cell death  
 Diabetes mellitus  
 Encephalitis  
 Epilepsy  
 Graves' disease  
 Heart, disease  
 Hepatitis GB virus C/G  
 Human immunodeficiency virus  
 Infection  
 Inflammation  
 Kidney, disease  
 Leukemia  
 Liver, disease  
 Meningitis  
 Multiple myeloma



Multiple sclerosis  
 Myasthenia gravis  
 Myelodysplastic syndromes  
 Osteoarthritis  
 Osteoporosis  
 Parkinson's disease  
 Prion diseases  
     **Psoriasis**  
 Rheumatoid arthritis  
 Sepsis  
 Spinal muscular atrophy  
 Tuberculosis  
     (prepn. of peptides as caspase inhibitors)  
 IT Peptides, preparation  
     RL: **PAC (Pharmacological activity)**; RCT (Reactant); SPN  
     (Synthetic preparation); **THU (Therapeutic use)**; **BIOL**  
     (**Biological study**); PREP (Preparation); RACT (Reactant or  
     reagent); USES (Uses)  
     (prepn. of peptides as caspase inhibitors)  
 IT 122191-40-6, Caspase-1 179241-78-2, Caspase-8  
     RL: **BSU (Biological study, unclassified)**; **BIOL**  
     (**Biological study**)  
     (prepn. of peptides as caspase inhibitors)  
 IT 864166-40-5P 864166-98-3P  
     RL: **PAC (Pharmacological activity)**; RCT (Reactant); SPN  
     (Synthetic preparation); **THU (Therapeutic use)**; **BIOL**  
     (**Biological study**); PREP (Preparation); RACT (Reactant or  
     reagent); USES (Uses)  
     (prepn. of peptides as caspase inhibitors)  
 IT 864166-41-6P 864166-42-7P 864166-43-8P 864166-44-9P  
     864166-45-0P 864166-46-1P 864166-47-2P 864166-48-3P  
     864166-49-4P 864166-50-7P 864166-51-8P 864166-52-9P  
     864166-53-0P 864166-54-1P 864166-55-2P 864166-56-3P  
     864166-57-4P 864166-58-5P 864166-59-6P 864166-60-9P  
     864166-61-0P 864166-62-1P 864166-63-2P 864166-64-3P  
     864166-65-4P 864166-66-5P 864166-67-6P 864166-68-7P  
     864166-69-8P 864166-70-1P 864166-71-2P 864166-72-3P  
     864166-73-4P 864166-74-5P 864166-75-6P 864166-76-7P  
     864166-77-8P 864166-78-9P 864166-79-0P 864166-80-3P  
     864166-81-4P 864166-82-5P 864166-83-6P 864166-84-7P  
     864166-85-8P 864166-86-9P 864166-87-0P 864166-88-1P  
     864166-89-2P 864166-90-5P 864166-91-6P **864166-92-7P**  
     864166-93-8P 864166-94-9P 864166-95-0P 864166-96-1P  
     864166-97-2P 864166-99-4P 864167-00-0P 864167-01-1P  
     864167-02-2P 864167-03-3P 864167-04-4P 864167-05-5P  
     864167-06-6P 864167-07-7P 864167-08-8P 864167-09-9P  
     864167-10-2P 864167-11-3P 864167-12-4P 864167-33-9P  
     864167-34-0P 864167-35-1P 864167-36-2P 864167-37-3P  
     864167-38-4P 864167-39-5P 864167-40-8P 864167-41-9P  
     864167-42-0P 864167-43-1P 864167-44-2P 864167-46-4P  
     864167-48-6P 864167-50-0P 864167-51-1P 864167-53-3P  
     864167-54-4P 864167-56-6P 864167-58-8P 864167-59-9P  
     864167-60-2P 864167-61-3P 864167-62-4P 864167-63-5P  
     864167-64-6P 864167-65-7P 864167-66-8P 864167-67-9P  
     864167-68-0P 864167-69-1P 864167-70-4P 864167-71-5P  
     864167-72-6P 864167-73-7P 864167-74-8P 864167-75-9P  
     864167-76-0P 864167-77-1P 864167-78-2P 864167-79-3P  
     864167-80-6P 864167-81-7P 864167-82-8P 864167-83-9P  
     864167-84-0P 864167-85-1P 864167-86-2P 864167-87-3P  
     864167-88-4P 864167-89-5P 864167-90-8P 864167-91-9P  
     864167-92-0P 864167-93-1P 864167-94-2P 864167-95-3P  
     864167-96-4P 864167-97-5P 864167-98-6P 864167-99-7P

864168-00-3P 864168-01-4P 864168-02-5P 864168-03-6P  
864168-04-7P

RL: PAC (Pharmacological activity); SPN (Synthetic  
preparation); THU (Therapeutic use); BIOL (Biological  
study); PREP (Preparation); USES (Uses)  
(prepn. of peptides as caspase inhibitors)

L32 ANSWER 5 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:673279 HCAPLUS

DOCUMENT NUMBER: 143:172865

TITLE: Preparation of thiazole derivatives as  
modulators of the phosphoinositide 3-kinases  
(PI3Ks)

INVENTOR(S): Quattropiani, Anna; Rueckle, Thomas; Schwarz,  
Matthias; Dorbais, Jerome; Sauer, Wolfgang;  
Cleva, Christophe; Desforages, Gwenaelle

PATENT ASSIGNEE(S): Applied Research Systems ARS Holding N. V.,  
Neth. Antilles

SOURCE: PCT Int. Appl., 212 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005068444	A2	20050728	WO 2005-EP50102	20050111
WO 2005068444	A3	20050909		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPLN. INFO.:		EP 2004-100083	A	20040112

OTHER SOURCE(S): MARPAT 143:172865  
GI




AB The title compds. I [R1 = NR5R6; R2, R3, R5 = H, alkyl, alkenyl, alkynyl; R4 = H, alkyl, alkenyl, alkynyl, NR8R9 (wherein R8, R9 = H, alkyl, alkenyl, etc.); R6 = alkyl, aryl, heteroaryl, etc.], useful in particular for the **treatment** and/or prophylaxis of autoimmune disorders and/or **inflammatory diseases**, cardiovascular **diseases**, neurodegenerative **diseases**, bacterial or viral infections, kidney **diseases**, platelet aggregation, cancer, transplantation, graft rejection or lung injuries, were prepd. and formulated. Thus, reacting 3-[(aminocarbonothioyl)amino]benzoic acid with N-[5-(bromoacetyl)-4-methyl-1,3-thiazol-2-yl]acetamide (prepn. given) afforded II.HBr which showed IC50 of 10 nM against PI3Ky.

IT 860619-22-3P 860619-39-2P 860619-75-6P  
860620-37-7P 860620-38-8P 860620-39-9P  
860620-40-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(prepn. of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

RN 860619-22-3 HCAPLUS


CN Benzoic acid, 3-[[2'-(acetylamino)-4'-methyl[4,5'-bithiazol]-2-yl]amino]-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr


RN 860619-39-2 HCAPLUS

CN Acetamide, N-[2-[(4-cyanophenyl)amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)




RN 860619-75-6 HCAPLUS

CN Benzamide, 3-[[2'-(acetylamino)-4'-methyl[4,5'-bithiazol]-2-yl]amino]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 860620-37-7 HCAPLUS

CN Benzeneacetic acid, 4-[[2'-(acetylamino)-4'-methyl[4,5'-bithiazol]-2-yl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 860620-38-8 HCAPLUS

CN  $\beta$ -Alanine, N-[4-[[2'-(acetylamino)-4'-methyl[4,5'-bithiazol]-2-yl]amino]benzoyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 860620-39-9 HCAPLUS

CN Glycine, N-[4-[[2'-(acetylamino)-4'-methyl[4,5'-bithiazol]-2-yl]amino]benzoyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 860620-40-2 HCAPLUS  
 CN Benzenepropanoic acid, 3-[[2'-(acetylamino)-4'-methyl[4,5'-bithiazol]-2-yl]amino]-, methyl ester (9CI) (CA INDEX NAME)




IT 307343-36-8P 315704-54-2P 315705-71-6P  
 315705-72-7P 315705-74-9P 315705-75-0P  
 315705-76-1P 315705-77-2P 315705-78-3P  
 315705-79-4P 315705-80-7P 315705-81-8P  
 315705-82-9P 315705-86-3P 315705-87-4P  
 315705-90-9P 315705-91-0P 315705-92-1P  
 315705-94-3P 315705-95-4P 333746-64-8P  
 333746-84-2P 421580-61-2P 428836-20-8P  
 443747-65-7P 472980-88-4P 860619-26-7P  
 860619-40-5P 860619-41-6P 860619-50-7P  
 860619-51-8P 860619-52-9P 860619-63-2P  
 860619-65-4P 860619-68-7P 860619-69-8P  
 860619-77-8P 860619-78-9P 860619-79-0P  
 860619-80-3P 860619-81-4P 860619-82-5P  
 860619-83-6P 860619-84-7P 860619-85-8P  
 860619-87-0P 860619-89-2P 860620-05-9P  
 860620-08-2P 860620-09-3P 860620-10-6P  
 860620-12-8P 860620-13-9P 860620-18-4P  
 860620-20-8P 860620-29-7P 860620-30-0P  
 860620-34-4P 860620-36-6P 860620-41-3P  
 860620-43-5P 860620-47-9P 860620-48-0P  
 860620-50-4P 860620-51-5P 860620-52-6P  
 860620-53-7P 860620-75-3P 860620-78-6P  
 860620-89-9P 860621-21-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

RN 307343-36-8 HCAPLUS  
 CN Acetamide, N-[2-[[4-(aminosulfonyl)phenyl]amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)







RN 315704-54-2 HCAPLUS  
 CN Propanamide, N-[4'-methyl-2-[[4-[(5-methyl-3-isoxazolyl)amino]sulfonyl]phenyl]amino][4,5'-bithiazol]-2'-yl]-(9CI) (CA INDEX NAME)




RN 315705-71-6 HCAPLUS  
 CN Acetamide, N-[4'-methyl-2-(phenylamino)[4,5'-bithiazol]-2'-yl]-(9CI) (CA INDEX NAME)




RN 315705-72-7 HCAPLUS  
 CN Acetamide, N-[2-[(4-chlorophenyl)amino]-4'-methyl[4,5'-bithiazol]-2'-yl]-(9CI) (CA INDEX NAME)




RN 315705-74-9 HCAPLUS  
 CN Acetamide, N-[2-[(4-bromophenyl)amino]-4'-methyl[4,5'-bithiazol]-2'-yl]-(9CI) (CA INDEX NAME)




RN 315705-75-0 HCAPLUS  
CN Acetamide, N-[2-[(2-methoxyphenyl)amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)




RN 315705-76-1 HCAPLUS  
CN Acetamide, N-[2-[(4-methoxyphenyl)amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 315705-77-2 HCAPLUS  
CN Acetamide, N-[2-[(3-hydroxyphenyl)amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)




RN 315705-78-3 HCAPLUS  
CN Acetamide, N-[2-[(4-hydroxyphenyl)amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)




RN 315705-79-4 HCAPLUS  
CN Acetamide, N-[2-[(4-ethoxyphenyl)amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)

yl]- (9CI) (CA INDEX NAME)




RN 315705-80-7 HCAPLUS

CN Acetamide, N-[2-[(3-acetylphenyl)amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)




RN 315705-81-8 HCAPLUS

CN Benzoic acid, 3-[[2'-(acetylamino)-4'-methyl[4,5'-bithiazol]-2'-yl]amino]- (9CI) (CA INDEX NAME)




RN 315705-82-9 HCAPLUS

CN Benzoic acid, 4-[[2'-(acetylamino)-4'-methyl[4,5'-bithiazol]-2'-yl]amino]- (9CI) (CA INDEX NAME)




RN 315705-86-3 HCAPLUS

CN Acetamide, N-[2-[(4-aminophenyl)amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)




RN 315705-87-4 HCAPLUS

CN Acetamide, N-[2-[[4-(dimethylamino)phenyl]amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)




RN 315705-90-9 HCAPLUS

CN Acetamide, N-[2-[[4-[[[(4,6-dimethyl-2-pyrimidinyl)amino]sulfonyl]phenyl]amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)




RN 315705-91-0 HCAPLUS

CN Acetamide, N-[2-[[4-[[[(2,6-dimethoxy-4-pyrimidinyl)amino]sulfonyl]phenyl]amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)




RN 315705-92-1 HCAPLUS

CN Acetamide, N-[4'-methyl-2-[[4-[[[(5-methyl-3-isoxazolyl)amino]sulfonyl]phenyl]amino][4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)




RN 315705-94-3 HCAPLUS


CN Acetamide, N-[4'-methyl-2-[(2-methylphenyl)amino][4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)




RN 315705-95-4 HCAPLUS  
CN Acetamide, N-[4'-methyl-2-[(4-methylphenyl)amino][4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 333746-64-8 HCAPLUS  
CN Acetamide, N-[2-[(2-ethylphenyl)amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)




RN 333746-84-2 HCAPLUS  
CN Acetamide, N-[2-[(2,5-dimethoxyphenyl)amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)




RN 421580-61-2 HCAPLUS  
CN Acetamide, N-[4'-methyl-2-[(3-nitrophenyl)amino][4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)







RN 428836-20-8 HCAPLUS  
 CN Acetamide, N-[4'-(4-nitrophenyl)amino][4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 443747-65-7 HCAPLUS  
 CN Propanamide, N-[2-[[4-[[[(4,6-dimethyl-2-pyrimidinyl)amino]sulfonyl]phenyl]amino]-4'-methyl[4,5'-bithiazol]-2'-yl]]- (9CI) (CA INDEX NAME)




RN 472980-88-4 HCAPLUS  
 CN Benzoic acid, 4-[[2'-(acetylamino)-4'-methyl[4,5'-bithiazol]-2-yl]amino]-, monohydrobromide (9CI) (CA INDEX NAME)




● HBr

RN 860619-26-7 HCAPLUS  
 CN Benzoic acid, 4-[[2'-(acetylamino)-4'-methyl[4,5'-bithiazol]-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 860619-40-5 HCAPLUS

CN Acetamide, N-[2-[(2-chlorophenyl)amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)




RN 860619-41-6 HCAPLUS

CN Acetamide, N-[2-[(3-chlorophenyl)amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 860619-50-7 HCAPLUS

CN Acetamide, N-[2-(5-benzofuranyl)amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)




RN 860619-51-8 HCAPLUS

CN Acetamide, N-[2-(5-benzofuranyl)amino]-4'-methyl[4,5'-bithiazol]-2'-yl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 860619-50-7


CMF C17 H14 N4 O2 S2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 860619-52-9 HCAPLUS

CN Acetamide, N-[2-[(3-cyanophenyl)amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)




RN 860619-63-2 HCAPLUS

CN Acetamide, N-[4'-methyl-2-[[3-(5-oxazolyl)phenyl]amino][4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)




RN 860619-65-4 HCAPLUS

CN Acetamide, N-[4'-methyl-2-[[4-(1H-tetrazol-5-yl)phenyl]amino][4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 860619-68-7 HCAPLUS

CN Acetamide, N-[2-[[3-(5-amino-1,3,4-thiadiazol-2-yl)phenyl]amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)




RN 860619-69-8 HCAPLUS

CN Acetamide, N-[2-[[3-(5-amino-1,3,4-thiadiazol-2-yl)phenyl]amino]-4'-methyl[4,5'-bithiazol]-2'-yl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 860619-68-7


CMF C17 H15 N7 O S3



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 860619-77-8 HCAPLUS

CN Acetamide, N-[2-[[3-[(Z)-(2,4-dioxo-5-thiazolidinylidene)methyl]phenyl]amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 860619-78-9 HCAPLUS

CN Acetamide, N-[2-[[3-[(Z)-(2,4-dioxo-5-thiazolidinylidene)methyl]phenyl]amino]-4'-methyl[4,5'-bithiazol]-2'-yl]-, monoacetate (9CI) (CA INDEX NAME)


INDEX NAME)

CM 1

CRN 860619-77-8

CMF C19 H15 N5 O3 S3


Double bond geometry as shown.



CM 2


CRN 64-19-7

CMF C2 H4 O2




RN 860619-79-0 HCAPLUS

CN Acetamide, N-[4'-methyl-2-[[4-[(2-pyridinylamino)sulfonyl]phenyl]amino][4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 860619-80-3 HCAPLUS


CN Acetamide, N-[2-[[2-(2-hydroxyethyl)phenyl]amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 860619-81-4 HCAPLUS


CN Acetamide, N-[2-[[3-(hydroxymethyl)phenyl]amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)






RN 860619-82-5 HCAPLUS

CN Acetamide, N-[2-[[4-(2-hydroxyethyl)phenyl]amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)




RN 860619-83-6 HCAPLUS

CN Acetamide, N-[2-[[3-[(2-hydroxyethyl)sulfonyl]phenyl]amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)




RN 860619-84-7 HCAPLUS

CN Acetamide, N-[2-[[4-[(dimethylamino)sulfonyl]phenyl]amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)




RN 860619-85-8 HCAPLUS

CN Acetamide, N-[2-[[3-(aminosulfonyl)phenyl]amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)




RN 860619-87-0 HCAPLUS

CN Acetamide, N-[4'-(methylamino)sulfonylphenyl]amino]-4-methyl[4,5'-bithiazol]-2'-yl- (9CI) (CA INDEX NAME)




RN 860619-89-2 HCAPLUS

CN Acetamide, N-[2-[(2,3-dihydro-5-benzofuranyl)amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)




RN 860620-05-9 HCAPLUS

CN Acetamide, N-[2-[(2-hydroxyphenyl)amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)




RN 860620-08-2 HCAPLUS

CN Acetamide, N-[2-[(3-methoxyphenyl)amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)




RN 860620-09-3 HCAPLUS

CN Benzamide, 3-[[2'-(acetylamino)-4'-methyl[4,5'-bithiazol]-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 860620-10-6 HCAPLUS

CN Acetamide, N-[4'-methyl-2-[(2-nitrophenyl)amino][4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)




RN 860620-12-8 HCAPLUS

CN Acetamide, N-[4'-methyl-2-(5-quinolinylamino)[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)




RN 860620-13-9 HCAPLUS


CN Acetamide, N-[4'-methyl-2-(6-quinolinylamino)[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)




RN 860620-18-4 HCAPLUS  
 CN Acetamide, N-[4'-methyl-2-[[3-(methylsulfonyl)phenyl]amino][4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)




RN 860620-20-8 HCAPLUS  
 CN Acetamide, N-[2-[(1,1-dioxidobenzo[b]thien-6-yl)amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)




RN 860620-29-7 HCAPLUS  
 CN Acetamide, N-[4'-methyl-2-[[4-(4-morpholinylsulfonyl)phenyl]amino][4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 860620-30-0 HCAPLUS  
 CN Acetamide, N-[2-[[3-[(butylamino)sulfonyl]phenyl]amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)




RN 860620-34-4 HCAPLUS  
 CN Acetamide, N-[4'-methyl-2-[[2-(methylsulfonyl)phenyl]amino][4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)




RN 860620-36-6 HCAPLUS

CN Acetamide, N-[2-[[3-(1-hydroxyethyl)phenyl]amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)




RN 860620-41-3 HCAPLUS

CN Benzenepropanoic acid, 4-[[2'-(acetylamino)-4'-methyl[4,5'-bithiazol]-2-yl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 860620-43-5 HCAPLUS

CN Benzeneacetic acid, 3-[[2'-(acetylamino)-4'-methyl[4,5'-bithiazol]-2-yl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 860620-47-9 HCAPLUS

CN Urea, [4'-methyl-2-(phenylamino)[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)




RN 860620-48-0 HCAPLUS

CN Urea, [2-[(4-hydroxyphenyl)amino]-4'-methyl[4,5'-bithiazol]-2'-yl]-  
(9CI) (CA INDEX NAME)


RN 860620-50-4 HCAPLUS

CN Benzeneacetic acid, 4-[[2'-(acetylamino)-4'-methyl[4,5'-bithiazol]-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 860620-51-5 HCAPLUS


CN beta-Alanine, N-[4-[[2'-(acetylamino)-4'-methyl[4,5'-bithiazol]-2-yl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 860620-52-6 HCAPLUS


CN Glycine, N-[4-[[2'-(acetylamino)-4'-methyl[4,5'-bithiazol]-2-yl]amino]benzoyl]- (9CI) (CA INDEX NAME)






RN 860620-53-7 HCAPLUS

CN Benzenepropanoic acid, 3-[[2'-(acetylamino)-4'-methyl[4,5'-bithiazol]-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 860620-75-3 HCAPLUS

CN Acetamide, N-[4'-methyl-2-[[3-(1H-tetrazol-5-yl)phenyl]amino][4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)




RN 860620-78-6 HCAPLUS

CN Acetamide, N-[2-[[3-(4,5-dihydro-5-oxo-1,3,4-oxadiazol-2-yl)phenyl]amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)




RN 860620-89-9 HCAPLUS


CN Acetamide, N-[2-[[3-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)phenyl]amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



RN 860621-21-2 HCAPLUS  
 CN Acetamide, N-[4-[[2'-(acetylamino)-5-methyl[4,5'-bithiazol]-2-yl]amino]phenyl]- (9CI) (CA INDEX NAME)



IT 860620-90-2P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);  
 RACT (Reactant or reagent)  
 (prepn. of thiazole derivs. as modulators of the phosphoinositide  
 3-kinases (PI3Ks))  
 RN 860620-90-2 HCAPLUS  
 CN Acetamide, N-[2-[[3-(1,3-dioxolan-2-yl)phenyl]amino]-4'-methyl[4,5'-  
 bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



IC ICM C07D277-46  
 CC 28-7 (Heterocyclic Compounds (More Than One Hetero Atom))  
 Section cross-reference(s): 1, 63  
 IT Nervous system, **disease**  
 (Huntington's chorea, **treating** or preventing; prepn. of  
 thiazole derivs. as modulators of the phosphoinositide 3-kinases  
 (PI3Ks))  
 IT Muscle, **disease**  
 (atrophy, **treating** or preventing skeletal muscle  
 atrophy; prepn. of thiazole derivs. as modulators of the  
 phosphoinositide 3-kinases (PI3Ks))  
 IT Lung, **disease**  
 (chronic obstructive pulmonary **disease**,  
**treating** or preventing; prepn. of thiazole derivs. as  
 modulators of the phosphoinositide 3-kinases (PI3Ks))  
 IT Nervous system, **disease**  
 (degeneration, **treating** or preventing; prepn. of  
 thiazole derivs. as modulators of the phosphoinositide 3-kinases  
 (PI3Ks))  
 IT Kidney, **disease**  
 (fibrosis, **treating** or preventing progressive renal

fibrosis; prepn. of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Inflammation  
Kidney, **disease**  
(glomerulonephritis, **treating** or preventing; prepn. of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Kidney, **disease**  
(glomerulosclerosis, **treating** or preventing; prepn. of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Muscle, **disease**  
(hypertrophy, **treating** or preventing skeletal muscle atrophy/hypertrophy; prepn. of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Heart, **disease**  
(hypertrophy, **treating** or preventing; prepn. of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Brain, **disease**  
(infection, **treating** or preventing; prepn. of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Intestine, **disease**  
(**inflammatory**, **treating** or preventing; prepn. of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Lung, **disease**  
Reperfusion  
(injury, **treating** or preventing; prepn. of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Inflammation  
Lung, **disease**  
(pneumonitis, **treating** or preventing; prepn. of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Brain, **disease**  
(stroke, **treating** or preventing; prepn. of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Central nervous system, **disease**  
(trauma, **treating** or preventing; prepn. of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Allergy  
Alzheimer's **disease**  
Anaphylaxis  
Angiogenesis  
**Asthma**  
Atherosclerosis  
Autoimmune **disease**  
Cardiovascular system, **disease**  
Encephalitis  
Fibrosis  
Hypertension  
Inflammation  
Ischemia  
Kidney, **disease**  
Melanoma  
Meningitis  
Multiple sclerosis  
Neoplasm  
Platelet aggregation  
**Psoriasis**  
Rheumatoid arthritis

Sepsis

Thrombosis

Transplant and Transplantation

Transplant rejection

Vasoconstriction

(treating or preventing; prepn. of thiazole derivs. as  
modulators of the phosphoinositide 3-kinases (PI3Ks))

IT 115926-52-8

RL: BSU (Biological study, unclassified); BIOL  
(Biological study)(prepn. of thiazole derivs. as modulators of the phosphoinositide  
3-kinases (PI3Ks))

IT 860619-22-3P 860619-39-2P 860619-58-5P

860619-75-6P 860620-37-7P 860620-38-8P

860620-39-9P 860620-40-2P 860620-42-4P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN

(Synthetic preparation); THU (Therapeutic use); BIOL

(Biological study); PREP (Preparation); RACT (Reactant or  
reagent); USES (Uses)(prepn. of thiazole derivs. as modulators of the phosphoinositide  
3-kinases (PI3Ks))

IT 32558-17-1P 307343-36-8P 315704-54-2P

315705-71-6P 315705-72-7P 315705-74-9P

315705-75-0P 315705-76-1P 315705-77-2P

315705-78-3P 315705-79-4P 315705-80-7P

315705-81-8P 315705-82-9P 315705-83-0P

315705-86-3P 315705-87-4P 315705-90-9P

315705-91-0P 315705-92-1P 315705-94-3P

315705-95-4P 333746-52-4P 333746-55-7P 333746-64-8

P 333746-84-2P 412919-76-7P 421580-61-2P

428836-20-8P 443747-65-7P 472980-88-4P

860619-23-4P 860619-24-5P 860619-25-6P 860619-26-7P

860619-27-8P 860619-28-9P 860619-29-0P 860619-30-3P

860619-31-4P 860619-32-5P 860619-33-6P 860619-34-7P

860619-35-8P 860619-36-9P 860619-37-0P 860619-38-1P

860619-40-5P 860619-41-6P 860619-42-7P

860619-43-8P 860619-44-9P 860619-45-0P 860619-46-1P

860619-47-2P 860619-48-3P 860619-49-4P 860619-50-7P

860619-51-8P 860619-52-9P 860619-53-0P

860619-54-1P 860619-55-2P 860619-56-3P 860619-57-4P

860619-59-6P 860619-60-9P 860619-61-0P 860619-62-1P

860619-63-2P 860619-64-3P 860619-65-4P

860619-66-5P 860619-67-6P 860619-68-7P

860619-69-8P 860619-70-1P 860619-71-2P 860619-72-3P

860619-73-4P 860619-74-5P 860619-76-7P 860619-77-8P

860619-78-9P 860619-79-0P 860619-80-3P

860619-81-4P 860619-82-5P 860619-83-6P

860619-84-7P 860619-85-8P 860619-86-9P

860619-87-0P 860619-88-1P 860619-89-2P

860619-90-5P 860619-91-6P 860619-92-7P 860619-93-8P

860619-94-9P 860619-95-0P 860619-96-1P 860619-98-3P

860620-00-4P 860620-02-6P 860620-03-7P 860620-04-8P

860620-05-9P 860620-06-0P 860620-07-1P

860620-08-2P 860620-09-3P 860620-10-6P

860620-11-7P 860620-12-8P 860620-13-9P

860620-14-0P 860620-15-1P 860620-16-2P 860620-17-3P

860620-18-4P 860620-19-5P 860620-20-8P

860620-21-9P 860620-22-0P 860620-23-1P 860620-24-2P

860620-25-3P 860620-26-4P 860620-27-5P 860620-28-6P

860620-29-7P 860620-30-0P 860620-31-1P

860620-32-2P 860620-33-3P 860620-34-4P 860620-35-5P

860620-36-6P 860620-41-3P 860620-43-5P

860620-44-6P 860620-45-7P 860620-46-8P 860620-47-9P  
 860620-48-0P 860620-49-1P 860620-50-4P  
 860620-51-5P 860620-52-6P 860620-53-7P  
 860620-70-8P 860620-75-3P 860620-76-4P 860620-77-5P  
 860620-78-6P 860620-83-3P 860620-84-4P 860620-86-6P  
 860620-87-7P 860620-88-8P 860620-89-9P 860621-18-7P  
 860621-19-8P 860621-20-1P 860621-21-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT 618-95-1P, Methyl 3-nitrobenzoate 926-59-0P 3043-28-5P,  
 3-Bromo-2,4-pentanedione 4138-35-6P, Methyl 3-aminopropanoate  
 14062-34-1P 32519-72-5P 32519-75-8P 39884-12-3P 53159-71-0P,  
 1-(2-Amino-1,3-thiazol-5-yl)ethanone 83725-80-8P,  
 5-(3-Nitrophenyl)-1,3,4-oxadiazol-2-ol 87005-15-0P 94284-63-6P,  
 Ethyl 5-acetyl-2-amino-1,3-thiazole-4-carboxylate 115082-05-8P  
 167405-28-9P, 1-[2-Amino-4-(trifluoromethyl)-1,3-thiazol-5-  
 yl]ethanone 191399-17-4P, 1-(2-Amino-4-methyl-1,3-oxazol-5-  
 yl)ethanone 299441-33-1P, 5-(3-Aminophenyl)-1,3,4-thiadiazol-2-  
 amine 440087-89-8P 696629-98-8P 860615-87-8P 860620-54-8P  
 860620-55-9P, N-(5-Acetyl-4-methyl-1,3-oxazol-2-yl)acetamide  
 860620-56-0P 860620-57-1P, N-(5-Acetyl-1,3-thiazol-2-yl)acetamide  
 860620-58-2P 860620-59-3P, N-[5-Acetyl-4-(trifluoromethyl)-1,3-  
 thiazol-2-yl]acetamide 860620-60-6P 860620-61-7P, Ethyl  
 5-acetyl-2-(acetylamino)-1,3-thiazole-4-carboxylate 860620-62-8P  
 860620-63-9P 860620-64-0P, N-[3-(5-Amino-[1,3,4]thiadiazol-2-  
 yl)phenyl]-2,2,2-trifluoro-acetamide 860620-81-1P 860620-82-2P  
 860620-85-5P 860620-90-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

L32 ANSWER 6 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:395267 HCAPLUS

DOCUMENT NUMBER: 142:463596

TITLE: Preparation of indole derivatives as PGD2 antagonists

INVENTOR(S): Middlemiss, David; Ashton, Mark Richard; Boyd, Edward Andrew; Brookfield, Frederick Arthur; Armer, Richard Edward

PATENT ASSIGNEE(S): Oxagen Limited, UK

SOURCE: PCT Int. Appl., 131 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	
WO 2005040112	A1	20050506	WO 2004-GB4337	20041013

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD,

SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,  
 VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,  
 AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ,  
 DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL,  
 PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
 GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

GB 2003-24083

A

200310  
14

GB 2004-3334

A

200402  
14

GB 2004-6963

A

200403  
27

OTHER SOURCE(S):

MARPAT 142:463596

GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*


AB Title compds. I [R1, R2, R3, and R4 independently = H, halo, alkyl, etc.; R5 and R6 independently = H, alkyl or R5 and R6 together with carbon atom to which they are attached 3-7-membered cycloalkyl; R7 = H, alkyl; R8 = alkyl, alkenyl, alkynyl, etc.; R9 = H, alkyl, aryl, etc.] and their pharmaceutically acceptable salts, are prepd. and disclosed as PGD2 antagonists. Thus, e.g., II was prepd. by sulfonylation of (5-fluoro-1H-indol-3-yl)-acetic acid Et ester with 4-fluorobenzene sulfonyl chloride and subsequent hydrolysis of the Et ester. The activity of I towards CRTH2 receptors was evaluated in radioligand binding assays and it revealed that selected compds. of the invention displayed Ki values in the range of 15 up to 3050 nM. I as PGD2 antagonists should prove useful in the **treatment of allergic diseases** such as **asthma**, allergic rhinitis and atopic dermatitis. Pharmaceutical compns. comprising I are disclosed.

IT 851448-72-1P 851449-21-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of indole derivs. as PGD antagonists)


RN 851448-72-1 HCAPLUS

CN 1H-Indole-3-acetic acid, 5-fluoro-2-methyl-1-[[4-(2-thiazolylamino)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 851449-21-3 HCAPLUS

CN 1H-Indole-3-acetic acid, 5-fluoro-2-methyl-1-[[4-(methyl-2-thiazolylamino)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



IC ICM C07D209-18  
ICS A61K031-404; A61P043-00; C07D403-12

CC 27-11 (Heterocyclic Compounds (One Hetero Atom))  
Section cross-reference(s): 1, 63

IT **Inflammation**  
(Crohn's disease; prepn. of indole derivs. as PGD antagonists)

IT Antibodies and Immunoglobulins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(IgE, hyper syndrome; prepn. of indole derivs. as PGD antagonists)

IT Allergy  
(allergic asthma; prepn. of indole derivs. as PGD antagonists)

IT **Asthma**  
(allergic; prepn. of indole derivs. as PGD antagonists)

IT Intestine, disease  
(inflammatory; prepn. of indole derivs. as PGD antagonists)

IT Acne  
Antiasthmatics  
Antirheumatic agents  
Antitumor agents  
Autoimmune disease  
Combination chemotherapy  
Food allergy  
Human  
Multiple sclerosis  
Osteoarthritis  
**Psoriasis**  
Rheumatoid arthritis  
(prepn. of indole derivs. as PGD antagonists)

IT Prostanoid receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(type DP2; prepn. of indole derivs. as PGD antagonists)

IT Prostanoid receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(type DP; prepn. of indole derivs. as PGD antagonists)

IT 6990-06-3, Fusidic acid 23593-75-1, Clotrimazole 79794-75-5, Loratidine 89365-50-4, Salmeterol 90566-53-3, Fluticasone 104987-11-3, Tacrolimus 111406-87-2, Zileuton 122320-73-4, Rosiglitazone 137071-32-0, Pimecrolimus 158966-92-8, Montelukast 242138-07-4, Omalizumab  
RL: THU (Therapeutic use); BIOL (Biological study)  
; USES (Uses)  
(claimed co-drugs; prepn. of indole derivs. as PGD antagonists)



IT 851447-47-7P 851447-48-8P 851447-49-9P 851447-50-2P  
851447-51-3P 851447-52-4P 851447-53-5P 851447-54-6P  
851447-55-7P 851447-56-8P 851447-57-9P 851447-58-0P  
851447-59-1P 851447-60-4P 851447-61-5P 851447-62-6P  
851447-63-7P 851447-64-8P 851447-65-9P 851447-66-0P  
851447-67-1P 851447-68-2P 851447-69-3P 851447-70-6P  
851447-71-7P 851447-72-8P 851447-73-9P 851447-74-0P  
851447-75-1P 851447-76-2P 851447-77-3P 851447-78-4P  
851447-79-5P 851447-80-8P 851447-81-9P 851447-82-0P  
851447-83-1P 851447-84-2P 851447-85-3P 851447-86-4P  
851447-87-5P 851447-88-6P 851447-89-7P 851447-90-0P  
851447-91-1P 851447-92-2P 851447-93-3P 851447-94-4P  
851447-95-5P 851447-96-6P 851447-97-7P 851447-98-8P  
851447-99-9P 851448-00-5P 851448-01-6P 851448-02-7P  
851448-03-8P 851448-04-9P 851448-05-0P 851448-06-1P  
851448-07-2P 851448-08-3P 851448-09-4P 851448-10-7P  
851448-11-8P 851448-14-1P 851448-15-2P 851448-16-3P  
851448-17-4P 851448-18-5P 851448-19-6P 851448-20-9P  
851448-21-0P 851448-22-1P 851448-23-2P 851448-24-3P  
851448-25-4P 851448-26-5P 851448-27-6P 851448-28-7P  
851448-29-8P 851448-30-1P 851448-31-2P 851448-32-3P  
851448-33-4P 851448-34-5P 851448-35-6P 851448-36-7P  
851448-37-8P 851448-38-9P 851448-39-0P 851448-40-3P  
851448-41-4P 851448-42-5P 851448-43-6P 851448-44-7P  
851448-45-8P 851448-46-9P 851448-47-0P 851448-48-1P  
851448-49-2P 851448-50-5P 851448-51-6P 851448-52-7P  
851448-53-8P 851448-54-9P 851448-55-0P 851448-56-1P  
851448-57-2P 851448-58-3P 851448-59-4P 851448-60-7P  
851448-61-8P 851448-62-9P 851448-63-0P 851448-64-1P  
851448-65-2P 851448-66-3P 851448-67-4P 851448-68-5P  
851448-69-6P 851448-70-9P 851448-71-0P 851448-72-1P  
851448-73-2P 851448-74-3P 851448-75-4P 851448-76-5P  
851448-77-6P 851448-78-7P 851448-79-8P 851448-80-1P  
851448-81-2P 851448-82-3P 851448-83-4P 851448-84-5P  
851448-85-6P 851448-86-7P 851448-87-8P 851448-88-9P  
851448-89-0P 851448-90-3P 851448-91-4P 851448-92-5P  
851448-93-6P 851448-94-7P 851448-95-8P 851448-96-9P  
851448-97-0P 851448-98-1P 851448-99-2P 851449-00-8P  
851449-01-9P 851449-02-0P 851449-03-1P 851449-04-2P  
851449-05-3P 851449-06-4P 851449-07-5P 851449-08-6P  
851449-09-7P 851449-10-0P 851449-11-1P 851449-12-2P  
851449-13-3P 851449-14-4P 851449-15-5P 851449-16-6P  
851449-17-7P 851449-18-8P 851449-19-9P 851449-20-2P  
851449-21-3P 851449-22-4P 851449-23-5P 851449-24-6P  
851449-25-7P 851449-26-8P 851449-27-9P 851449-28-0P  
851449-29-1P 851449-30-4P 851449-31-5P 851449-32-6P  
851449-33-7P 851449-34-8P 851449-35-9P 851449-36-0P  
851449-37-1P 851449-38-2P 851449-39-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of indole derivs. as PGD antagonists)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR  
THIS RECORD. ALL CITATIONS AVAILABLE IN  
THE RE FORMAT

L32 ANSWER 7 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2005:369133 HCAPLUS  
DOCUMENT NUMBER: 142:435774  
TITLE: Compositions treatment of chronic  
inflammatory diseases  
INVENTOR(S): Shapiro, Howard K.

PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 44 pp., Cont.-in-part of  
 U.S. Ser. No. 610,073, abandoned.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 4  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005090553	A1	20050428	US 2004-924945	20040824
PRIORITY APPLN. INFO.:			US 1992-906909	B2 19920630
			US 1994-241603	B2 19940511
			US 1997-814291	B2 19970310
			US 2000-610073	B2 20000705

OTHER SOURCE(S): MARPAT 142:435774


AB This invention defines novel compns. that can be used for clin. **treatment** of a class of chronic **inflammatory diseases**. Increased generation of carbonyl substances, aldehydes and ketones, occurs at sites of chronic **inflammation** and is common to the etiologies of all of the clin. disorders addressed herein. Such carbonyl substances are cytotoxic and addnl. serve to perpetuate and disseminate the **inflammatory** process. This invention defines use of compns., the orally administered required primary agents of which are primary amine derivs. of benzoic acid capable of reacting with the carbonyl substances. P-Aminobenzoic acid (or PABA) is an example of the required primary agent of the present invention. PABA has a small mol. wt., is water sol., has a primary amine group which reacts with carbonyl-contg. substances and is tolerated by the body in relatively high dosages for extended periods. The method of the present invention includes administration of a compn. comprising: (1) an orally consumed primary agent; (2) a previously known medicament co-agent recognized as effective to **treat** a chronic **inflammatory disease** addressed herein administered to the mammalian subject via the oral route, other systemic routes of administration or via the topical route; and (3) optionally 1 or more addnl. orally consumed co-agent selected from the group consisting of antioxidants, vitamins, metabolites at risk of depletion, sulfhydryl co-agents, co-agents which may facilitate glutathione activity and nonabsorbable primary amine polymeric co-agents, so as to produce an additive or synergistic physiol. effect of an anti-**inflammatory** nature.

IT **110952-54-0**, 2-(2-Hydroxy-4-methylphenyl)aminothiazole hydrochloride  
 RL: THU (Therapeutic use); BIOL (Biological study)

; USES (Uses)  
 (compns. treatment of chronic inflammatory diseases)

RN 110952-54-0 HCAPLUS

CN Phenol, 5-methyl-2-(2-thiazolylamino)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IC ICM A61K031-195

INCL 514565000; 514567000

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1

ST chronic inflammatory disease

IT Inflammation

(Crohn's disease; compns. treatment of chronic inflammatory diseases)

IT Intestine, disease

(Crohn's; compns. treatment of chronic inflammatory diseases)

IT Carbohydrates, biological studies

RL: THU (Therapeutic use); BIOL (Biological study)

; USES (Uses)

(amino sugars; compns. treatment of chronic inflammatory diseases)

IT Polysaccharides, biological studies

RL: THU (Therapeutic use); BIOL (Biological study)

; USES (Uses)

(aminodeoxy; compns. treatment of chronic inflammatory diseases)

IT Inflammation

Spinal column, disease

(ankylosing spondylitis; compns. treatment of chronic inflammatory diseases)

IT Autoimmune disease

Inflammation

Stomach, disease

(autoimmune gastritis, chronic; compns. treatment of chronic inflammatory diseases)

IT Lung, disease

(chronic obstructive pulmonary disease; compns. treatment of chronic inflammatory diseases)

IT Inflammation

(chronic; compns. treatment of chronic inflammatory diseases)

IT Inflammation

Intestine, disease

(colitis; compns. treatment of chronic inflammatory diseases)

IT Antioxidants

Arthritis  
Edema  
Epilepsy  
Human  
Ischemia  
Multiple sclerosis  
Myasthenia gravis  
Myositis  
Osteoarthritis  
Pneumoconiosis  
    **Psoriasis**  
Quillaja  
Reperfusion  
Rheumatoid arthritis  
    (compns. treatment of chronic inflammatory  
    diseases)  
IT Coal dust  
RL: ADV (Adverse effect, including toxicity); BIOL (Biological  
study)  
    (compns. treatment of chronic inflammatory  
    diseases)  
IT Coal tar  
RL: THU (Therapeutic use); BIOL (Biological study)  
; USES (Uses)  
    (compns. treatment of chronic inflammatory  
    diseases)  
IT Collagens, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study)  
; USES (Uses)  
    (compns. treatment of chronic inflammatory  
    diseases)  
IT Ginsenosides  
RL: THU (Therapeutic use); BIOL (Biological study)  
; USES (Uses)  
    (compns. treatment of chronic inflammatory  
    diseases)  
IT Macrolides  
RL: THU (Therapeutic use); BIOL (Biological study)  
; USES (Uses)  
    (compns. treatment of chronic inflammatory  
    diseases)  
IT Polysaccharides, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study)  
; USES (Uses)  
    (compns. treatment of chronic inflammatory  
    diseases)  
IT Saponins  
RL: THU (Therapeutic use); BIOL (Biological study)  
; USES (Uses)  
    (compns. treatment of chronic inflammatory  
    diseases)  
IT Thiols, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study)  
; USES (Uses)  
    (compns. treatment of chronic inflammatory  
    diseases)  
IT Ubiquinones  
RL: THU (Therapeutic use); BIOL (Biological study)  
; USES (Uses)  
    (compns. treatment of chronic inflammatory  
    diseases)  
IT Vitamins

RL: THU (Therapeutic use); BIOL (Biological study)  
 ; USES (Uses)  
 (compns. treatment of chronic inflammatory diseases)

IT Bladder, disease  
 Inflammation  
 (cystitis, interstitial; compns. treatment of chronic inflammatory diseases)

IT Tendon  
 (disease, tendinitis; compns. treatment of chronic inflammatory diseases)

IT Tendon  
 (disease, tenosynovitis; compns. treatment of chronic inflammatory diseases)

IT Mandevilla velutina  
 (exts.; compns. treatment of chronic inflammatory diseases)

IT Drug delivery systems  
 (gels; compns. treatment of chronic inflammatory diseases)

IT Gingiva, disease  
 Inflammation  
 (gingivitis, chronic; compns. treatment of chronic inflammatory diseases)

IT Inflammation  
 Intestine, disease  
 (ileitis; compns. treatment of chronic inflammatory diseases)

IT Heart, disease  
 (infarction; compns. treatment of chronic inflammatory diseases)

IT Intestine, disease  
 (inflammatory; compns. treatment of chronic inflammatory diseases)

IT Drug delivery systems  
 (injections, i.m.; compns. treatment of chronic inflammatory diseases)

IT Drug delivery systems  
 (injections, i.v.; compns. treatment of chronic inflammatory diseases)

IT Kidney, disease  
 (ischemia; compns. treatment of chronic inflammatory diseases)

IT Drug delivery systems  
 (lotions; compns. treatment of chronic inflammatory diseases)

IT Streptomyces tsukubaensis  
 (macrolide from; compns. treatment of chronic inflammatory diseases)

IT Nerve, disease  
 (neuropathy, inflammatory; compns. treatment of chronic inflammatory diseases)

IT Natural products, pharmaceutical  
 RL: THU (Therapeutic use); BIOL (Biological study)  
 ; USES (Uses)  
 (opium; compns. treatment of chronic inflammatory diseases)

IT Drug delivery systems  
 (oral; compns. treatment of chronic inflammatory diseases)

IT Inflammation  
 Periodontium, disease

(periodontitis, chronic; compns. treatment of chronic inflammatory diseases)

IT Nerve, disease  
(peripheral nerve injury, carpal tunnel syndrome; compns. treatment of chronic inflammatory diseases)

IT Injury  
(peripheral nerve, carpal tunnel syndrome; compns. treatment of chronic inflammatory diseases)

IT Ischemia  
(renal; compns. treatment of chronic inflammatory diseases)

IT Brain, disease  
(stroke; compns. treatment of chronic inflammatory diseases)

IT Lupus erythematosus  
(systemic; compns. treatment of chronic inflammatory diseases)

IT Drug delivery systems  
(tablets; compns. treatment of chronic inflammatory diseases)

IT Inflammation  
(tendinitis; compns. treatment of chronic inflammatory diseases)

IT Inflammation  
(tenosynovitis; compns. treatment of chronic inflammatory diseases)

IT Drug delivery systems  
(topical; compns. treatment of chronic inflammatory diseases)

IT Central nervous system, disease  
(trauma, acute; compns. treatment of chronic inflammatory diseases)

IT Injury  
Spinal cord, disease  
(trauma; compns. treatment of chronic inflammatory diseases)

IT Interferons  
RL: THU (Therapeutic use); BIOL (Biological study)  
; USES (Uses)  
( $\alpha$ -2a; compns. treatment of chronic inflammatory diseases)

IT Interferons  
RL: THU (Therapeutic use); BIOL (Biological study)  
; USES (Uses)  
( $\alpha$ -2b; compns. treatment of chronic inflammatory diseases)

IT Interferons  
RL: THU (Therapeutic use); BIOL (Biological study)  
; USES (Uses)  
( $\alpha$ -N3; compns. treatment of chronic inflammatory diseases)

IT Interferons  
RL: THU (Therapeutic use); BIOL (Biological study)  
; USES (Uses)  
( $\beta$ ; compns. treatment of chronic inflammatory diseases)

IT 24967-94-0, Dermatan sulfate  
RL: THU (Therapeutic use); BIOL (Biological study)  
; USES (Uses)  
(complex with heparinoids; compns. treatment of chronic

**inflammatory diseases)**

IT 7782-42-5, Graphite, biological studies 14807-96-6, Talc, biological studies

RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)

(compns. treatment of chronic inflammatory diseases)

IT 50-02-2, Dexamethasone 50-03-3, Hydrocortisone acetate 50-06-6, Phenobarbital, biological studies 50-14-6, Vitamin D2 50-18-0, Cyclophosphamide 50-23-7, Hydrocortisone 50-24-8, Prednisolone 50-33-9, Phenylbutazone, biological studies 50-34-0, Propantheline bromide 50-44-2, 6-Mercaptopurine 50-48-6, Amitriptyline 50-49-7, Imipramine 50-53-3, Chlorpromazine, biological studies 51-06-9, Procainamide 51-34-3, Scopolamine 51-83-2, Carbachol 52-53-9, Verapamil 52-67-5, D-Penicillamine 52-90-4, L-Cysteine, biological studies 53-03-2, Prednisone 53-06-5, Cortisone 53-33-8, Paramethasone 53-36-1, Methylprednisolone acetate 53-86-1, Indomethacin 54-05-7, Chloroquine 54-21-7, Sodium salicylate 54-35-3, Penicillin G procaine 54-47-7, Pyridoxal 5-phosphate 54-85-3, Isoniazid 54-96-6, 3,4-Diaminopyridine 55-63-0, Trinitroglycerin 56-40-6, Glycine, biological studies 57-00-1, Creatine 57-41-0, Phenytoin 57-50-1D, Sucrose, esters with fatty acids 57-96-5, Sulfinpyrazone 58-05-9, Folinic acid 58-25-3, Chlordiazepoxide 58-32-2, Dipyridamole 58-73-1, Diphenhydramine 58-85-5, Vitamin H 58-95-7, (+)- $\alpha$ -Tocopheryl acetate 59-02-9,  $\alpha$ -Tocopherol 59-05-2, Methotrexate 59-30-3, Folic acid, biological studies 59-43-8, Vitamin B1, biological studies 59-43-8D, Thiamine, salts 59-58-5, Thiamine propyl disulfide 59-66-5, Acetazolamide 59-67-6, Nicotinic acid, biological studies 59-96-1, Phenoxybenzamine 60-23-1, Cysteamine 60-54-8, Tetracycline 61-68-7, Mefenamic acid 63-68-3, L-Methionine, biological studies 65-22-5, Pyridoxal hydrochloride 66-72-8, Pyridoxal 67-16-3, Thiamine disulfide 67-73-2, Fluocinolone acetonide 67-78-7, Triamcinolone diacetate 67-97-0, Vitamin D3 68-19-9, Vitamin B12 68-26-8, Retinol 69-46-5, Calcium acetylsalicylate 69-72-7, Salicylic acid, biological studies 70-18-8, Glutathione, biological studies 74-31-7, N,N'-Diphenyl-p-phenylenediamine 76-25-5, Triamcinolone acetonide 76-57-3, Codeine 77-37-2, Procyclidine 77-67-8, Ethosuximide 77-92-9, Citric acid, biological studies 79-83-4, Pantothenic acid 80-08-0, Dapsone 81-81-2, Warfarin 83-43-2, Methylprednisolone 83-68-1, Vitamin K6 83-69-2, Vitamin K7 83-70-5, Vitamin K5 83-88-5, Vitamin B2; biological studies 83-89-6, Quinacrine 85-87-0, Pyridoxamine 86-42-0, Amodiaquine 87-33-2, Isosorbide dinitrate 89-57-6, 5-Aminosalicylic acid 91-53-2, Ethoxyquin 91-86-1,  $\eta$ -Tocopherol 92-43-3, Phenidone 98-92-0, Niacinamide 99-66-1, Valproic acid 107-35-7, Taurine 113-98-4, Penicillin G potassium 114-07-8, Erythromycin 116-31-4, Vitamin A aldehyde 117-39-5, Quercetin 118-42-3, Hydroxychloroquine 118-92-3, Vitamin L1 119-13-1,  $\delta$ -Tocopherol 121-79-9, Propyl gallate 124-94-7, Triamcinolone 125-33-7, Primidone 127-47-9, Retinyl acetate 128-37-0, Butylated hydroxytoluene, biological studies 129-03-3, Cyproheptadine 129-20-4, Oxyphenbutazone 130-24-5, Vitamin K5 hydrochloride 130-40-5, Riboflavin 5'-phosphate ester monosodium salt 132-17-2, Benztropine mesylate 132-98-9, Penicillin V potassium 137-08-6, Pantothenic acid calcium salt 137-58-6, Lidocaine 138-14-7, Deferoxamine mesylate 144-11-6, Trihexyphenidyl 148-03-8,  $\beta$ -Tocopherol 153-18-4, Rutin 298-46-4, Carbamazepine 298-50-0, Propantheline 298-81-7, Methoxsalen 302-79-4, Vitamin A acid 305-03-3, Chlorambucil 309-36-4, Methohexital sodium 315-30-0, Allopurinol 317-34-0,



Aminophylline 327-97-9, Chlorogenic acid 352-97-6,  
 Guanidinoacetic acid 356-12-7, Fluocinonide 378-44-9,  
 Betamethasone 404-86-4, Capsaicin 432-70-2,  $\alpha$ -Carotene  
 439-14-5, Diazepam 443-48-1, Metronidazole 444-27-9, Timonacic  
 446-72-0, Genistein 446-86-6, Azathioprine 458-37-7, Curcumin  
 462-20-4, Dihydrolipoic acid 472-93-5,  $\gamma$ -Carotene  
 476-66-4, Ellagic acid 480-16-0, Morin 480-17-1, Leucocyanidol  
 480-19-3, Isorhamnetin 481-46-9, Ginkgetin 489-35-0, Gossypetin  
 490-23-3,  $\epsilon$ -Tocopherol 493-35-6,  $\zeta$ 2-Tocopherol  
 498-02-2, Apocynin 500-38-9, Nordihydroguaiaretic acid 501-30-4,  
 Kojic acid 502-65-8,  $\psi$ -, $\psi$ -Carotene 504-24-5,  
 4-Aminopyridine 511-28-4, Vitamin D4 514-65-8, Biperiden  
 520-18-3, Kaempferol 520-36-5, Apigenin 521-32-4, Bilobetin  
 522-00-9, Ethopropazine 523-68-2, N-Acetyl vitamin K5 524-36-7,  
 Pyridoxamine dihydrochloride 525-66-6, Propranolol 528-48-3,  
 Fisetin 529-96-4, Pyridoxamine phosphate 530-78-9, Flufenamic  
 acid 532-11-6, Sulfarlem 532-40-1, Thiamine phosphate ester  
 chloride 532-43-4, Thiamine mononitrate 533-31-3, Sesamol  
 534-13-4, N,N'-Dimethylthiourea 540-05-6 541-15-1, L-Carnitine  
 548-19-6, Isoginkgetin 548-75-4, Quercetagetin-7-glucoside  
 552-66-9, Daidzin 552-94-3, Salsalate 564-25-0, Doxycycline  
 578-36-9, Potassium salicylate 599-79-1, Sulfasalazine 604-87-5  
 616-91-1, N-Acetylcysteine 635-97-2, Thiamine phosphoric acid  
 ester phosphate salt 637-07-0, Clofibrate 638-23-3,  
 S-Carboxymethylcysteine 644-62-2, Meclofenamic acid 644-62-2D,  
 Meclofenamic acid, salts 652-78-8, Gossypin 674-38-4,  
 Bethanechol 752-56-7, Riboflavin tetrabutyrates 768-94-5,  
 Amantadine 841-73-6, Bucolome 846-49-1, Lorazepam 867-81-2,  
 Pantothenic acid sodium salt 915-30-0, Diphenoxylate 992-46-1,  
 Thiamine disulfide phosphate 1077-28-7, Thioctic acid 1115-84-0,  
 Vitamin U 1134-47-0, Baclofen 1143-38-0, Anthralin 1166-52-5,  
 Dodecylgallate 1398-61-4D, Chitin, derivs. 1424-27-7,  
 Acetazolamide sodium 1505-95-9, Naphthypramide 1508-65-2,  
 Oxybutynin chloride 1524-88-5, Flurandrenolide 1538-09-6  
 1553-60-2, Ibuprofen 1562-74-9, 5-Thiopyridoxine 1597-82-6,  
 Paramethasone 21-acetate 1622-61-3, Clonazepam 1721-51-3,  
 $\zeta$ 1-Tocopherol 1948-33-0, tert-Butylhydroquinone 1953-02-2,  
 Tiopronin 2016-36-6, Choline salicylate, biological studies  
 2055-44-9, Perisoxal 2124-57-4, Vitamin K2(35) 2145-14-4,  
 Paramethasone disodium phosphate 2152-44-5, Betamethasone valerate  
 2319-84-8, Thioctic acid sodium salt 2447-54-3, Sanguinarine  
 2457-80-9, Vitamin L2 2487-39-0, Vitamin K-S(II) 2766-51-0,  
 Methylmethioninesulfonium bromide 3040-38-8, Acetyl-L-carnitine  
 3211-76-5, L-Selenomethionine 3286-46-2, Thiamine disulfide  
 O,O-di-isobutyrate 3380-34-5, Triclosan 3416-24-8, Glucosamine  
 3475-65-8, Thiamine triphosphoric acid ester 3570-15-8, Nicotinic  
 acid monoethanolamine salt 3930-20-9, Sotalol 4345-03-3  
 4394-00-7, Niflumic acid 4759-48-2, Isotretinoin 5003-48-5,  
 Benorylate 5011-34-7, Trimetazidine 5034-76-4, Indoxole  
 5104-49-4, Flurbiprofen 5355-16-8, Diaveridine 5593-20-4,  
 Betamethasone 17,21-dipropionate

RL: THU (Therapeutic use); BIOL (Biological study)  
 ; USES (Uses)

(compns. treatment of chronic inflammatory  
 diseases)

IT 5633-20-5, Oxybutynin 5728-52-9, Felbinac 5913-70-2, Pyridoxal  
 5-phosphate calcium salt 5934-23-6, Vitamin K2(30) dihydro  
 diacetate 5934-25-8, Vitamin K6 dihydrochloride 5934-26-9,  
 Vitamin K7 hydrochloride 5949-29-1, Citric acid monohydrate  
 6020-87-7, Creatine monohydrate 6027-13-0, Homocysteine  
 6035-45-6, Folinic acid calcium salt pentahydrate 6054-98-4,  
 Disodium azodisalicylate 6100-05-6 6223-35-4, Sodium

guaiiazulene-3-sulfonate 6452-71-7, Oxprenolol 6493-05-6,  
Pentoxifylline 7085-45-2, Biperiden lactate 7235-40-7,  
β-Carotene 7512-17-6, N-AcetylGlucosamine 7616-22-0,  
γ-Tocopherol 7683-59-2, Isoproterenol 7782-49-2, Selenium,  
biological studies 8059-24-3, Vitamin B6 8069-87-2 9001-90-5D,  
Plasmin, streptokinase complex, acylated 9002-01-1, Streptokinase  
9002-01-1D, Streptokinase, plasmin complex, acylated 9002-60-2,  
Corticotropin, biological studies 9002-89-5D, Poly(vinyl alcohol),  
derivs. 9003-39-8, Polyvinylpyrrolidone 9003-53-6D, Polystyrene,  
derivs. 9003-70-7D, Divinylbenzene-styrene copolymer, derivs.  
9004-34-6D, Cellulose, derivs. 9004-57-3, Ethyl cellulose  
9005-49-6, Heparin, biological studies 9014-67-9, Aloxiprin  
9039-53-6D, Urokinase, acylated 9041-08-1, Heparin sodium  
10118-90-8, Minocycline 10236-58-5, L-Selenocysteine 11032-49-8,  
Vitamin K2 11104-38-4, Vitamin K1 12192-57-3, Aurothioglucose  
12244-57-4, Gold sodium thiomalate 13345-51-2D, Prostaglandin B1,  
oligomers 13422-55-4, Methyl vitamin B12 13523-86-9, Pindolol  
13539-59-8, Azapropazone 13655-52-2, Alprenolol 13710-19-5,  
Tolfenamic acid 13739-02-1, Diacetylrhein 13993-65-2, Metiazinic  
acid 14402-89-2, Sodium nitroprusside 15307-86-5, Diclofenac  
15475-56-6, Methotrexate sodium 15686-51-8, Clemastine  
15687-27-1, Ibuprofen 15722-48-2, Olsalazine 16051-77-7,  
Isosorbide 5-mononitrate 17969-20-9, Fenclozic acid 18471-20-0,  
Ditazol 18472-51-0, Chlorhexidine gluconate 18642-10-9, Thiamine  
disulfide hydrochloride 18694-40-1, Epirizole 18917-89-0,  
Magnesium salicylate 19771-63-2, L-2-Oxothiazolidine-4-carboxylic  
acid 19982-08-2, Memantine 20168-99-4, Cinmetacin 20554-84-1,  
Parthenolide 21256-18-8, Oxaprozin 21829-25-4, Nifedipine  
22071-15-4, Ketoprofen 22204-53-1, Naproxen 22494-42-4,  
Diflunisal 22760-18-5, Proquazone 23288-49-5, Probuco  
23981-47-7, 6-Methoxy-2-naphthylacetic acid 24237-54-5, Tinoridine  
25013-16-5, Butylated hydroxyanisole 25122-46-7, Clobetasol  
propionate 25451-15-4, Felbamate 25486-55-9, Vitamin K1 oxide  
26171-23-3, Tolmetin 26589-39-9, Eudragit S 26787-78-0,  
Amoxicillin 26839-75-8, Timolol 27035-30-9, Oxametacin  
27470-51-5, Suxibuzone 27686-36-8, Hypolaetin-8-glucoside  
27696-41-9, Hypolaetin 28704-27-0, L-Alanine-L-glutamic  
acid-L-lysine-L-tyrosine copolymer 28841-62-5,  
D-myo-Inositol-1.2.6-trisphosphate 29031-19-4, Glucosamine sulfate  
29098-15-5, Etoclofene 29122-68-7, Atenolol 29679-58-1,  
Fenoprofen 29908-03-0, S-Adenosylmethionine 30011-11-1,  
Bimetopyrol 30748-29-9, Feprazone 31793-07-4, Pirprofen  
31842-01-0, Indoprofen 32808-51-8, Bucloxic acid 32839-30-8,  
Eicosapentaenoic acid 33005-95-7, Tiaprofenic acid 34031-32-8,  
Auranofin 34042-85-8, Sudoxicam 34148-01-1, Clidanac  
34334-69-5, Cirsiliol 34461-73-9, Bumadizone calcium 34552-84-6,  
Isoxicam 34645-84-6, Fenclofenac 36322-90-4, Piroxicam  
36330-85-5, Fenbufen 36364-49-5, Imidazole salicylate  
36616-52-1, Fenclorac 36740-73-5, Flumizole 36894-69-6,  
Labetalol 36994-25-9, 2-(p-Bromophenyl)-9-dimethylaminopropyl-9H-  
imidazo[1,2-a]benzimidazole 37270-89-6, Heparin calcium  
37517-30-9, Acebutolol 38194-50-2, Sulindac 38363-40-5,  
Penbutolol 38957-41-4, Emorfazone 40828-46-4, Suprofen  
41340-25-4, Etodolac 42200-33-9, Nadolol 42399-41-7, Diltiazem  
42924-53-8, Nabumetone 50270-32-1, 1-Isobutyl-3,4-diphenylpyrazole-  
5-acetic acid 50270-33-2, Isofezolac 51059-44-0, Oroxindin  
51234-28-7, Benoxaprofen 51322-75-9, Tizanidine 51384-51-1,  
Metoprolol 51484-40-3, Difenpiramide 51579-82-9, Amfenac  
51781-06-7, Carteolol 51803-78-2, Nimesulide 52263-84-0,  
(S)-(+)-Carprofen 52443-21-7, Glucametacin 53123-88-9, Rapamycin  
53179-11-6D, Loperamide, diazo derivs. 53527-28-9, Scalaradial  
53597-27-6, Fendosal 53716-49-7, Carprofen 54350-48-0,

Etretinate 55142-85-3, Ticlopidine 55242-55-2, Propentophylline  
 55366-56-8, Hibifolin 55453-87-7, Isoxepac 55837-18-8, Butibufen  
 55985-32-5, Nicardipine 56824-20-5, Amiprilose 57132-53-3,  
 Proglumetacin 58433-11-7, Tilomisol 58456-91-0,  
 2-Aminomethyl-4-tert-butyl-6-iodophenol 59122-46-2, Misoprostol  
 59804-37-4, Tenoxicam 59865-13-3, Cyclosporin A 59937-28-9,  
 Malotilate 60142-96-3, Gabapentin 60940-34-3, Ebselen  
 61941-57-9, Ethyl 2-amino-3-benzoylphenylacetate 62571-86-2,  
 Captopril 63329-53-3, Lobenzarit 63659-18-7, Betaxolol  
 64217-16-9, Phenytoin-phenobarbital mixt. 64224-21-1, Oltipraz  
 64294-95-7, Setastine 64425-90-7, Choline magnesium trisalicylate,  
 biological studies 65277-42-1, Ketoconazole 65666-07-1,  
 Silymarin 66734-13-2, Alclometasone dipropionate 66934-18-7,  
 Flunoxaprofen 68291-97-4, Zonisamide 68506-86-5, Vigabatrin  
 68767-14-6, Loxoprofen 69425-13-4, 2,6-Di-tert-butyl-4-[2'-  
 thenoyl]-phenol 70360-12-2, Sideritoflavone 71125-38-7,  
 Meloxicam 71320-77-9, Moclobemide 72509-76-3, Felodipine  
 74103-06-3, Ketorolac 74103-07-4, Ketorolac tromethamine  
 74469-00-4, Amoxicillin-clavulanate potassium mixt. 75060-92-3  
 75364-47-5 75695-93-1, Isradipine 75706-12-6, Leflunomide  
 75821-71-5, Lonazolac calcium 75847-73-3, Enalapril 76420-72-9,  
 Enalaprilat 76547-98-3, Lisinopril 76584-70-8, Divalproex sodium  
 76990-56-2, Milacemide 77086-21-6, Dizocilpine 77699-47-9,  
 Herbimycin 80474-14-2, Fluticasone propionate 80937-31-1,  
 6-(2,4-Difluorophenoxy)-5-methylsulfonylamino-1-indanone  
 81147-92-4, Esmolol 83919-23-7, Mometasone 17-(2-furoate)  
 84057-84-1, Lamotrigine 85441-61-8, Quinapril 86541-75-5,  
 Benazepril 87333-19-5, Ramipril 88150-42-9, Amlodipine  
 89149-10-0, 15-Deoxyspergualin 89796-99-6, Aceclofenac  
 90101-16-9, Droxicam 91418-71-2, Diacetylsplenopentin  
 98048-97-6, Fosinopril 98320-39-9, (10-Methoxy-4H-  
 benzo[4,5]cyclohepta[1,2-b]thiophene-4-ylidene)acetic acid  
 100827-28-9, Erbstatin 103475-41-8, Tepoxalin 110101-67-2,  
 Tirilazad mesylate 110952-54-0, 2-(2-Hydroxy-4-  
 methylphenyl)aminothiazole hydrochloride 111406-87-2, Zileuton  
 117279-73-9 120072-59-5, 7-[3-(4-Acetyl-3-methoxy-2-propylphenoxy)-  
 propoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid  
 120210-48-2, Tenidap 122726-03-8, Vitamin K2(35) dihydro diacetate  
 125697-92-9, Lavendustin A 129424-08-4 131420-91-2,  
 (Z)-3-[4-(Acetyloxy)-5-ethyl-3-methoxy-1-naphthalenyl]-2-methyl-2-  
 propenoic acid 132392-39-3, 5-[[3,5-Bis(1,1-dimethylethyl)-4-  
 hydroxyphenyl]methylene]-3-(dimethylamino)-4-thiazolidinone  
 132392-65-5, 5-[[3,5-Bis(1,1-dimethylethyl)-4-  
 hydroxyphenyl]methylene]-3-(methylamino)-4-thiazolidinone  
 133332-08-8, DL-2-(4-Hexyloxyphenyl)glycine octyl ester  
 133763-16-3, 1-p-Chlorobenzyl-2-dimethylaminomethyl-1,2-cyclohexene  
 135872-94-5, 1-[(4-Chlorophenyl)methyl]-2-methyl-5-  
 (quinolinylmethoxy)-1H-indole-3-acetic acid 136449-85-9  
 139639-23-9, Tissue plasminogen activator 143090-92-0, Anakinra  
 150977-36-9, Bromelain 151035-57-3, Quinapril-hydrochlorothiazide  
 mixt. 226721-96-6, Sodium 2-[4-(2-oxocyclopentylmethyl)phenyl]prop  
 ionate dihydrate 354124-52-0, Thiocetic acid ethylenediamine  
 700346-94-7, Nicotinic acid sodium salt sesquihydrate 762210-30-0,  
 DL-2-[4-(5,5-Dimethylhexyloxy)phenyl]glycine octyl ester  
 RL: THU (Therapeutic use); BIOL (Biological study)  
 ; USES (Uses)

(compns. treatment of chronic inflammatory  
 diseases)

IT 850785-97-6, Diphenoxylate-atropine sulfate mixt. 850785-98-7

RL: THU (Therapeutic use); BIOL (Biological study)

; USES (Uses)

(compns. treatment of chronic inflammatory

diseases)

L32 ANSWER 8 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:703129 HCAPLUS

DOCUMENT NUMBER: 141:218996

TITLE: Methods using Edg-7 modulators for  
treating conditions associated  
with an Edg-7 receptorINVENTOR(S): Solow-Cordero, David; Shankar, Geetha; Spencer,  
Juliet V.; Gluchowski, Charles

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 27 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	
-----				
US 2004167192	A1	20040826	US 2004-760002	200401 16
PRIORITY APPLN. INFO.:			US 2003-440321P	P 200301 16
			US 2003-454881P	P 200303 13

OTHER SOURCE(S): MARPAT 141:218996


AB The invention provides a method for modulating an Edg-7  
**receptor** mediated biol. activity in a cell. A cell  
expressing the Edg-7 **receptor** is contacted with a  
**modulator** of the Edg-7 **receptor** which is capable  
of modulating an Edg-7 **receptor**-mediated biol. activity.  
The invention also provides a method for modulating an Edg-7  
**receptor**-mediated biol. activity in a subject. A  
therapeutically effective amt. of a **modulator** of the Edg-7  
**receptor** is administered to the subject. Prepn. of e.g.  
4-Bromo-2-[2-(4-chlorophenylamino)-4-oxothiazolidin-5-  
ylidenemethyl]phenoxyacetic acid is described.

IT 353771-45-6P


RL: PAC (Pharmacological activity); SPN (Synthetic  
preparation); THU (Therapeutic use); BIOL (Biological  
study); PREP (Preparation); USES (Uses)(Edg-7 modulators for treating  
conditions assocd. with an Edg-7 receptor)

RN 353771-45-6 HCAPLUS


CN Acetic acid, [4-bromo-2-[[2-[(4-chlorophenyl)amino]-4-oxo-5(4H)-  
thiazolylidene]methyl]phenoxy]- (9CI) (CA INDEX NAME)



IT 352694-02-1  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (Edg-7 modulators for treating conditions assocd. with an Edg-7 receptor)  
 RN 352694-02-1 HCAPLUS  
 CN Acetic acid, [2-[[2-[(4-bromophenyl)amino]-4-oxo-5(4H)-thiazolylidene]methyl]phenoxy]- (9CI) (CA INDEX NAME)



IT 569656-05-9  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (Edg-7 modulators for treating conditions assocd. with an Edg-7 receptor)  
 RN 569656-05-9 HCAPLUS  
 CN Acetic acid, [4-bromo-2-[[2-[(4-chlorophenyl)amino]-4-oxo-5(4H)-thiazolylidene]methyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



IC ICM A61K031-4196  
 ICS A61K031-4172; A61K031-415; A61K031-41  
 INCL 514381000; 514383000; 514398000  
 CC 1-12 (Pharmacology)  
 Section cross-reference(s): 28

IT Animal cell line  
(A431; Edg-7 modulators for treating  
conditions assocd. with an Edg-7 receptor)

IT Animal cell line  
(CAOV-3; Edg-7 modulators for treating  
conditions assocd. with an Edg-7 receptor)

IT G protein-coupled receptors  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(EDG (endothelial differentiation gene); Edg-7 modulators  
for treating conditions assocd. with an Edg-7  
receptor)

IT G protein-coupled receptors  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(EDG-1 (endothelial differentiation gene 1); Edg-7  
modulators for treating conditions  
assocd. with an Edg-7 receptor)

IT G protein-coupled receptors  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(EDG-2 (endothelial differentiation gene 2); Edg-7  
modulators for treating conditions  
assocd. with an Edg-7 receptor)

IT G protein-coupled receptors  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(EDG-3 (endothelial differentiation gene 3); Edg-7  
modulators for treating conditions  
assocd. with an Edg-7 receptor)

IT G protein-coupled receptors  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(EDG-4 (endothelial differentiation gene 4); Edg-7  
modulators for treating conditions  
assocd. with an Edg-7 receptor)

IT G protein-coupled receptors  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(EDG-5 (endothelial differentiation gene 5); Edg-7  
modulators for treating conditions  
assocd. with an Edg-7 receptor)

IT G protein-coupled receptors  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(EDG-6 (endothelial differentiation gene 6); Edg-7  
modulators for treating conditions  
assocd. with an Edg-7 receptor)

IT G protein-coupled receptors  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(EDG-7 (endothelial differentiation gene 7); Edg-7  
modulators for treating conditions  
assocd. with an Edg-7 receptor)

IT G protein-coupled receptors  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(EDG-8 (endothelial differentiation gene 8); Edg-7  
modulators for treating conditions  
assocd. with an Edg-7 receptor)

IT Angiogenesis  
Anti-inflammatory agents



Anti-ischemic agents  
 Antiasthmatics  
 Antitumor agents  
 Apoptosis  
   **Asthma**  
 Cardiovascular agents  
 Cardiovascular system, **disease**  
 Cell migration  
 Cell proliferation  
 Combination chemotherapy  
 Cytotoxic agents  
 Fibroblast  
 Human  
   **Inflammation**  
 Ischemia  
 Kidney, neoplasm  
 Lung, **disease**  
 Lung, neoplasm  
 Mammary gland, neoplasm  
 Myoblast  
 Neuron  
 Ovary, neoplasm  
 Pancreas, neoplasm  
 Peritoneum, neoplasm  
 Platelet (blood)  
 Platelet activation  
 Platelet activation  
 Prostate gland, neoplasm  
 Stomach, neoplasm  
 Thyroid gland, neoplasm  
 Uterus, neoplasm  
 Wound healing  
   (Edg-7 modulators for treating  
   **conditions** assocd. with an Edg-7 receptor)  
 IT Carbohydrates, biological studies  
 Nucleic acids  
 Organic compounds, biological studies  
 Proteins  
 RL: PAC (Pharmacological activity); THU (Therapeutic  
 use); BIOL (Biological study); USES (Uses)  
   (Edg-7 modulators for treating  
   **conditions** assocd. with an Edg-7 receptor)  
 IT Animal cell line  
   (HT-1080; Edg-7 modulators for treating  
   **conditions** assocd. with an Edg-7 receptor)  
 IT Animal cell line  
   (HTC; Edg-7 modulators for treating  
   **conditions** assocd. with an Edg-7 receptor)  
 IT Animal cell line  
   (HUVEC; Edg-7 modulators for treating  
   **conditions** assocd. with an Edg-7 receptor)  
 IT Animal cell line  
   (MDA-MB-231; Edg-7 modulators for treating  
   **conditions** assocd. with an Edg-7 receptor)  
 IT Animal cell line  
   (MDA-MB-453; Edg-7 modulators for treating  
   **conditions** assocd. with an Edg-7 receptor)  
 IT Animal cell line  
   (OV202; Edg-7 modulators for treating  
   **conditions** assocd. with an Edg-7 receptor)  
 IT Respiratory distress syndrome  
   (adult; Edg-7 modulators for treating



conditions assocd. with an Edg-7 receptor)

IT Antiarteriosclerotics  
(antiatherosclerotics; Edg-7 modulators for treating conditions assocd. with an Edg-7 receptor)

IT Atherosclerosis  
(atherogenesis; Edg-7 modulators for treating conditions assocd. with an Edg-7 receptor)

IT Immune system  
(autoimmune response; Edg-7 modulators for treating conditions assocd. with an Edg-7 receptor)

IT Lysophosphatidic acids  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(cell proliferation stimulated by; Edg-7 modulators for treating conditions assocd. with an Edg-7 receptor)

IT Carcinoma  
Pheochromocytoma  
(cell; Edg-7 modulators for treating conditions assocd. with an Edg-7 receptor)

IT Uterus, neoplasm  
(cervix; Edg-7 modulators for treating conditions assocd. with an Edg-7 receptor)

IT Intestine, neoplasm  
(colon; Edg-7 modulators for treating conditions assocd. with an Edg-7 receptor)

IT Intestine, neoplasm  
(colorectal; Edg-7 modulators for treating conditions assocd. with an Edg-7 receptor)

IT Eye  
(cornea, transcorneal freezing; Edg-7 modulators for treating conditions assocd. with an Edg-7 receptor)

IT Burn  
(cutaneous; Edg-7 modulators for treating conditions assocd. with an Edg-7 receptor)

IT Uterus, neoplasm  
(endometrium; Edg-7 modulators for treating conditions assocd. with an Edg-7 receptor)

IT Epithelium  
(epithelial cell; Edg-7 modulators for treating conditions assocd. with an Edg-7 receptor)

IT Sarcoma  
(fibrosarcoma, cell; Edg-7 modulators for treating conditions assocd. with an Edg-7 receptor)

IT Carcinoma  
(hepatocellular, cell; Edg-7 modulators for treating conditions assocd. with an Edg-7 receptor)

IT Liver, neoplasm  
(hepatoma, cell; Edg-7 modulators for treating conditions assocd. with an Edg-7 receptor)




IT Phosphatidylinositols  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(hydrolysis; Edg-7 modulators for treating conditions assocd. with an Edg-7 receptor)

IT Neoplasm  
(invasiveness; Edg-7 modulators for treating

- conditions assocd. with an Edg-7 receptor)
- IT Ovary  
(ovarian cell; Edg-7 modulators for treating conditions assocd. with an Edg-7 receptor)
- IT Actins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(polymn.; Edg-7 modulators for treating conditions assocd. with an Edg-7 receptor)
- IT Intestine, neoplasm  
(small; Edg-7 modulators for treating conditions assocd. with an Edg-7 receptor)
- IT Epithelium  
(surface epithelial cell injury; Edg-7 modulators for treating conditions assocd. with an Edg-7 receptor)
- IT Interleukin 8  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(synthesis; Edg-7 modulators for treating conditions assocd. with an Edg-7 receptor)
- IT 26993-30-6, Sphingosine-1-phosphate  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(Edg-7 modulators for treating conditions assocd. with an Edg-7 receptor)
- IT 312501-62-5P 331945-22-3P 353771-45-6P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(Edg-7 modulators for treating conditions assocd. with an Edg-7 receptor)
- IT 49581-16-0 333772-21-7 352444-98-5 352683-56-8  
352694-02-1 744198-30-9  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(Edg-7 modulators for treating conditions assocd. with an Edg-7 receptor)
- IT 91-56-5, 1H-Indole-2,3-dione 108-31-6, Maleic anhydride, reactions  
5242-26-2 569656-05-9 569656-06-0  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(Edg-7 modulators for treating conditions assocd. with an Edg-7 receptor)
- IT 60-92-4, Cyclic AMP  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(formation, inhibition; Edg-7 modulators for treating conditions assocd. with an Edg-7 receptor)
- IT 7440-70-2, Calcium, biological studies  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(mobilization; Edg-7 modulators for treating conditions assocd. with an Edg-7 receptor)
- IT 127464-60-2, Vascular endothelial growth factor  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(synthesis; Edg-7 modulators for treating conditions assocd. with an Edg-7 receptor)

DOCUMENT NUMBER: 141:190788  
 TITLE: A preparation of N-containing heterocyclic compounds, useful as vanilloid receptor ligands  
 INVENTOR(S): Doherty, Elizabeth M.; Fotsch, Christopher H.; Han, Nianhe; Hungate, Randall W.; Liu, Qingyian; Norman, Mark H.; Xi, Ning; Xu, Shimin  
 PATENT ASSIGNEE(S): Amgen Inc., USA  
 SOURCE: U.S. Pat. Appl. Publ., 38 pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004157845	A1	20040812	US 2004-775980	20040209
CA 2515215	AA	20040826	CA 2004-2515215	20040209
WO 2004072068	A1	20040826	WO 2004-US3908	20040209
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG EP 1603905 A1 20051214 EP 2004-709532 20040209				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK PRIORITY APPLN. INFO.: US 2003-446511P P 20030210 WO 2004-US3908 W 20040209				
OTHER SOURCE(S): MARPAT 141:190788 GI				



AB The invention relates to a prepn. of N-contg. heterocyclic compds. of formula I [wherein: Q1, Q2, Q3, and Q4 are independently selected from N or C(R2); L is a substituted ethylene-1,2-diyl; X is NH, S, S(:O), SO2, or O; Y is NH, O, S, S(:O), or C(:O), etc.; R1 is halo, (halo)alkyl, -NH-alkyl, , or alkoxy, etc.; R2 is H, F, alkyl, or haloalkyl, etc.], useful as vanilloid receptor ligands (no biol. data). Compds. of formula I are useful for the **treatment** of **diseases** such as cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general **inflammation**, arthritis, rheumatic **diseases**, or osteoarthritis, etc. For instance, (pyridinylamino)thiazole deriv. II was prepd. via heterocyclization of 2-Cl-C6H4CH2C(:S)NH2 with Et bromopyruvate, hydrolysis of the obtained ester III (R3 = CO2Et), chlorination of the obtained acid III (R3 = CO2H), and subsequent amination of the obtained thiazole deriv. III [R3 = C(:O)Cl] by 3-amino-6-(trifluoromethyl)pyridine (example 1).


IT 736971-02-1P 736971-63-4P 736971-67-8P  
736971-83-8P 736972-70-6P 736972-72-8P  
736972-73-9P 736972-75-1P 736972-76-2P  
736972-78-4P 736972-80-8P 736972-82-0P  
736972-83-1P 736972-84-2P 736972-86-4P  
736972-87-5P 736972-89-7P 736972-91-1P  
736972-93-3P 736972-94-4P 736972-96-6P  
736972-98-8P 736973-00-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of heterocyclic compds., useful as vanilloid receptor ligands)


RN 736971-02-1 HCAPLUS

CN 4-Thiazolecarboxamide, 2-[(2,6-dimethylphenyl)amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 736971-63-4 HCAPLUS

CN 4-Thiazolecarboxamide, 5-bromo-2-[(2,6-dichlorophenyl)amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 736971-67-8 HCAPLUS

CN 2-Thiazolamine, N-(2,6-dichlorophenyl)-4-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 736971-83-8 HCAPLUS

CN 2-Thiazolamine, 4-(5,6-dichloro-1H-benzimidazol-2-yl)-N-(2,6-dichlorophenyl)- (9CI) (CA INDEX NAME)




RN 736972-70-6 HCAPLUS

CN 4-Thiazolecarboxamide, 2-[(2-fluorophenyl)amino]-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 736972-72-8 HCAPLUS

CN 4-Thiazolecarboxamide, N-(4-bromophenyl)-2-[(2-fluorophenyl)amino]-  
(9CI) (CA INDEX NAME)


RN 736972-73-9 HCAPLUS

CN 4-Thiazolecarboxamide, N-(4-bromophenyl)-2-[(2,6-dichlorophenyl)amino]- (9CI) (CA INDEX NAME)




RN 736972-75-1 HCAPLUS

CN 4-Thiazolecarboxamide, 2-[(2,6-dichlorophenyl)amino]-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 736972-76-2 HCAPLUS


CN 4-Thiazolecarboxamide, 2-[(2-fluorophenyl)amino]-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 736972-78-4 HCAPLUS  
CN 4-Thiazolecarboxamide, 2-[(2,6-dichlorophenyl)amino]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 736972-80-8 HCAPLUS  
CN 4-Thiazolecarboxamide, N-(6-bromo-3-pyridinyl)-2-[(2-chlorophenyl)amino]- (9CI) (CA INDEX NAME)



RN 736972-82-0 HCAPLUS  
CN 4-Thiazolecarboxamide, 2-[(2-chlorophenyl)amino]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 736972-83-1 HCAPLUS  
CN 4-Thiazolecarboxamide, 2-[(2,6-dimethylphenyl)amino]-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 736972-84-2 HCAPLUS  
CN 4-Thiazolecarboxamide, N-(4-bromophenyl)-2-[(2,6-dimethylphenyl)amino]- (9CI) (CA INDEX NAME)






RN 736972-86-4 HCAPLUS

CN 4-Thiazolecarboxamide, N-[4-(trifluoromethyl)phenyl]-2-[[2-(trifluoromethyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 736972-87-5 HCAPLUS

CN 4-Thiazolecarboxamide, N-[4-(1-methylethyl)phenyl]-2-[[2-(trifluoromethyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 736972-89-7 HCAPLUS

CN 4-Thiazolecarboxamide, N-(4-bromophenyl)-2-[[2-(trifluoromethyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 736972-91-1 HCAPLUS

CN 4-Thiazolecarboxamide, N-(4-bromophenyl)-2-[[2-chloro-6-(trifluoromethyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 736972-93-3 HCAPLUS

CN 4-Thiazolecarboxamide, 2-[[2-chloro-6-(trifluoromethyl)phenyl]amino]-  
N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 736972-94-4 HCAPLUS

CN 4-Thiazolecarboxamide, 2-[[2-chloro-6-(trifluoromethyl)phenyl]amino]-  
N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 736972-96-6 HCAPLUS

CN 2-Thiazolamine, 4-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]-N-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 736972-98-8 HCAPLUS

CN 2-Thiazolamine, N-[2-chloro-6-(trifluoromethyl)phenyl]-4-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 736973-00-5 HCAPLUS


CN 2-Thiazolamine, 4-(5-bromo-1H-benzimidazol-2-yl)-N-(2,6-dichlorophenyl)- (9CI) (CA INDEX NAME)




IT 736971-65-6 736971-74-7  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (prepn. of heterocyclic compds., useful as vanilloid receptor  
 ligands)  
 RN 736971-65-6 HCAPLUS  
 CN 4-Thiazolecarboxamide, 2-[(2,6-dichlorophenyl)amino]-N-[4-  
 (trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 736971-74-7 HCAPLUS  
 CN 4-Thiazolecarboxylic acid, 2-[(2,6-dichlorophenyl)amino]- (9CI) (CA  
 INDEX NAME)



IT 736970-97-1P 736971-00-9P 736971-05-4P  
 736971-07-6P 736971-69-0P 736971-71-4P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);  
 RACT (Reactant or reagent)  
 (prepn. of heterocyclic compds., useful as vanilloid receptor  
 ligands)  
 RN 736970-97-1 HCAPLUS  
 CN 4-Thiazolecarboxylic acid, 2-[(2,6-dimethylphenyl)amino]-, ethyl  
 ester (9CI) (CA INDEX NAME)




RN 736971-00-9 HCAPLUS  
 CN 4-Thiazolecarboxylic acid, 2-[(2,6-dimethylphenyl)amino]- (9CI) (CA  
 INDEX NAME)




RN 736971-05-4 HCAPLUS

CN 4-Thiazolecarboxamide, N-[2-amino-4-(trifluoromethyl)phenyl]-2-[(2,6-dimethylphenyl)amino]-(9CI) (CA INDEX NAME)




RN 736971-07-6 HCAPLUS

CN 4-Thiazolecarboxamide, N-[2-amino-5-(trifluoromethyl)phenyl]-2-[(2,6-dimethylphenyl)amino]-(9CI) (CA INDEX NAME)




RN 736971-69-0 HCAPLUS

CN 4-Thiazolecarboxamide, N-[2-amino-5-(trifluoromethyl)phenyl]-2-[(2,6-dichlorophenyl)amino]-(9CI) (CA INDEX NAME)



RN 736971-71-4 HCAPLUS

CN 4-Thiazolecarboxamide, N-[2-amino-5-(trifluoromethyl)phenyl]-2-[(2,6-dichlorophenyl)amino]-(9CI) (CA INDEX NAME)



IC ICM A61K031-53  
ICS A61K031-52; A61K031-506  
INCL 514242000; 514255050; 514252020; 514263200; 544182000; 544238000;  
544277000; 544295000  
CC 28-9 (Heterocyclic Compounds (More Than One Hetero Atom))  
Section cross-reference(s): 1, 63  
IT Allergy  
Inflammation  
Nose, **disease**  
(allergic rhinitis, **treatment** of; prepn. of  
heterocyclic compds., useful as vanilloid receptor ligands)  
IT Pain  
Skin, **disease**  
(allodynia, **treatment** of; prepn. of heterocyclic  
compds., useful as vanilloid receptor ligands)  
IT Bladder, **disease**  
Intestine, **disease**  
(inflammatory, **treatment** of; prepn. of  
heterocyclic compds., useful as vanilloid receptor ligands)  
IT Stomach, **disease**  
(lesion, induced by necrotizing agent, **treatment** of;  
prepn. of heterocyclic compds., useful as vanilloid receptor  
ligands)  
IT Capsaicin receptors  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(ligand; prepn. of heterocyclic compds., useful as vanilloid  
receptor ligands)  
IT Eye, **disease**  
Inflammation  
(ophthalmitis, **treatment** of; prepn. of heterocyclic  
compds., useful as vanilloid receptor ligands)  
IT Arthritis  
Asthma  
Bronchi, **disease**  
Burn  
Diarrhea  
Digestive tract, **disease**  
Headache  
Human herpesvirus  
Inflammation  
Osteoarthritis  
Pruritus  
Psoriasis  
Rheumatic **diseases**  
Vitiligo  
Wound  
(**treatment** of; prepn. of heterocyclic compds., useful  
as vanilloid receptor ligands)  
IT 736970-85-7P 736970-94-8P 736971-02-1P 736971-09-8P  
736971-16-7P 736971-23-6P 736971-31-6P 736971-39-4P  
736971-41-8P 736971-47-4P 736971-48-5P 736971-59-8P  
736971-61-2P 736971-63-4P 736971-67-8P

736971-76-9P 736971-80-5P 736971-83-8P 736971-88-3P  
 736971-98-5P 736972-05-7P 736972-11-5P 736972-13-7P  
 736972-15-9P 736972-17-1P 736972-19-3P 736972-21-7P  
 736972-23-9P 736972-25-1P 736972-27-3P 736972-29-5P  
 736972-31-9P 736972-32-0P 736972-34-2P 736972-37-5P  
 736972-39-7P 736972-40-0P 736972-42-2P 736972-43-3P  
 736972-45-5P 736972-47-7P 736972-49-9P 736972-51-3P  
 736972-53-5P 736972-56-8P 736972-58-0P 736972-60-4P  
 736972-62-6P 736972-64-8P 736972-65-9P 736972-66-0P  
 736972-68-2P 736972-70-6P 736972-72-8P  
 736972-73-9P 736972-75-1P 736972-76-2P  
 736972-78-4P 736972-80-8P 736972-82-0P  
 736972-83-1P 736972-84-2P 736972-86-4P  
 736972-87-5P 736972-89-7P 736972-91-1P  
 736972-93-3P 736972-94-4P 736972-96-6P  
 736972-98-8P 736973-00-5P 736973-02-7P  
 736973-04-9P 736973-06-1P 736973-08-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of heterocyclic compds., useful as vanilloid receptor ligands)

IT 62-56-6, Thiourea, reactions 70-23-5, Ethyl bromopyruvate  
 95-76-1, 3,4-Dichloroaniline 99-88-7, 4-Isopropylaniline  
 105-39-5, Ethyl chloroacetate 106-40-1, 4-Bromoaniline 368-71-8,  
 4-(Trifluoromethyl)-1,2-phenylenediamine 455-14-1,  
 4-Trifluoromethylaniline 532-55-8, Benzoyl isothiocyanate  
 2104-89-4 2402-77-9, 2,3-Dichloropyridine 2856-63-5,  
 2-Chlorobenzyl cyanide 3215-64-3, 2,6-Dichlorophenylacetonitrile  
 3863-11-4 4755-81-1, Methyl 2-chloroacetoacetate 5348-42-5  
 6396-76-5 17518-49-9 22889-78-7, 4-Amino-3,5-dichloropyridine  
 54897-59-5 106877-33-2, 3-Amino-6-(trifluoromethyl)pyridine  
 263157-83-1 736971-27-0 736971-65-6 736971-74-7

RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of heterocyclic compds., useful as vanilloid receptor ligands)

IT 109-94-4P, Ethyl formate 5398-36-7P 5922-20-3P 6059-44-5P  
 263157-86-4P 673476-96-5P 736970-78-8P 736970-80-2P  
 736970-83-5P 736970-88-0P 736970-90-4P 736970-92-6P  
 736970-97-1P 736971-00-9P 736971-05-4P  
 736971-07-6P 736971-13-4P 736971-14-5P 736971-18-9P  
 736971-20-3P 736971-25-8P 736971-29-2P 736971-33-8P  
 736971-37-2P 736971-43-0P 736971-46-3P 736971-53-2P  
 736971-55-4P 736971-57-6P 736971-69-0P  
 736971-71-4P 736971-85-0P 736971-91-8P 736971-94-1P  
 736971-96-3P 736972-00-2P 736972-02-4P 736972-07-9P  
 736972-08-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of heterocyclic compds., useful as vanilloid receptor ligands)

L32 ANSWER 10 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:648516 HCAPLUS

DOCUMENT NUMBER: 141:190785


TITLE: Preparation of thiazole derivatives as VAP-1 inhibitors for treatment of macular edema and other VAP-1 associated diseases

INVENTOR(S): Inoue, Takayuki; Tojo, Takashi; Morita, Masataka; Ohkubo, Mitsuru; Yoshihara, Kousei; Nagashima, Akira

PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 268 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004067521	A1	20040812	WO 2004-JP708	20040127
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
CA 2514573	AA	20040812	CA 2004-2514573	20040127
US 2004259923	A1	20041223	US 2004-764529	20040127
EP 1587800	A1	20051026	EP 2004-705519	20040127
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.:		US 2003-442509P	P	20030127
		US 2003-458369P	P	20030331
		US 2003-517377P	P	20031106
		WO 2004-JP708	W	20040127


OTHER SOURCE(S): MARPAT 141:190785  
 GI



II




- AB Title compds. of formula R1NHXYZ [I; wherein R1 = acyl; X = a bivalent (un)substituted thiazole; Y = a bond, alkylene, alkenylene, COHN; Z = 2-aminobenzimidazolyl, C6H4-R2; R2 = ABDE; A = a bond, alkylene, NH, SO2; B = a bond, alkylene, CO, O; D = a bond, alkylene, NH, CH2NH; E = (un)protected amino, N=CH2, dihydrothiazol-2-yl, dihydroimidazol-2-yl, C(=NH)R3; R3 = H, alkyl(thio), NHR4; R4 = H, NH2, alkyl; and pharmaceutically acceptable salts thereof] were prepd. as vascular adhesion protein-1 (VAP-1) inhibitors. For example, cycloaddn. of 3-chloro-2-oxopropyl acetate and thiourea in EtOH gave (2-amino-1,3-thiazol-4-yl)methyl acetate•HCl, which was amidated with acetyl chloride using pyridine in CH2Cl2. Deprotection of [2-(acetylamino)thiazol-4-yl]methyl acetate using K2CO3 in MeOH, followed by reaction of the resulting alc. with MnO2 in MeOH/CHCl3 provided N-(4-formylthiazol-2-yl)acetamide. Coupling of the aldehyde with 1-(bromomethyl)-4-nitrobenzene in the presence of PPh3 and t-BuOH in DMF gave N-[4-[(Z)-2-(4-nitrophenyl)ethenyl]thiazol-2-yl]acetamide, which was reduced to the amine with Pd/C in MeOH/THF/AcOH. Finally, coupling of the amine with cyanamide in the presence of HCl in EtOH/EtOAc afforded II. The latter inhibited VAP-1 enzyme (SSAO) activity in both human and rat plasma (IC50 = 0.15 µM and 0.012 µM, resp.), but not the enzyme activities of other amine oxidases (IC50 >100µM), such as human platelet monoamine oxidase (MAO) and cloned diamine oxidase (DAO, histaminase). **Treatment** of diabetic rats daily with II (10 mg/kg/ s.c. u.i.d.) improved their ocular permeability in comparison with the diabetic control group (vitreal/plasma ratio of fluorescein concns. = 5.39 ± 0.73 x10<sup>-3</sup> and 8.93 ± 1.14 x10<sup>-3</sup>, resp.). Thus, I and their pharmaceutical compns. are useful for preventing or **treating** VAP-1 assocd. **diseases**, esp. macular edema (no data).
- IT **183365-33-5P**, N-[4-[2-[4-(4,5-Dihydrothiazol-2-ylamino)phenyl]ethyl]thiazol-2-yl]acetamide **737822-89-8P**, N-[4-[(E)-2-[4-(4,5-Dihydrothiazol-2-ylamino)phenyl]ethenyl]thiazol-2-yl]acetamide **737824-82-7P**, N-[4-[2-[4-(4,5-Dihydrothiazol-2-ylamino)phenyl]ethyl]-5-[4-(methylsulfonyl)benzyl]thiazol-2-yl]acetamide  
 RL: **PAC (Pharmacological activity)**; **SPN (Synthetic preparation)**; **THU (Therapeutic use)**; **BIOL (Biological study)**; **PREP (Preparation)**; **USES (Uses)**  
 (VAP-1 inhibitor; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)
- RN **183365-33-5** HCAPLUS  
 CN Acetamide, N-[4-[2-[4-[(4,5-dihydro-2-thiazolyl)amino]phenyl]ethyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




- RN **737822-89-8** HCAPLUS  
 CN Acetamide, N-[4-[(1E)-2-[4-[(4,5-dihydro-2-thiazolyl)amino]phenyl]ethenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 737824-82-7 HCAPLUS  
 CN Acetamide, N-[4-[2-[4-[(4,5-dihydro-2-thiazolyl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]-2-thiazolyl]-(9CI) (CA INDEX NAME)



IC ICM C07D277-46  
 ICS C07D277-48; C07D277-56; C07D417-12; C07D417-06; A61K031-426;  
 A61K031-427; A61K031-4439; A61K031-454; A61P027-02  
 CC 28-7 (Heterocyclic Compounds (More Than One Hetero Atom))  
 Section cross-reference(s): 1, 63  
 IT **Inflammation**  
 (Crohn's disease; prepn. of thiazole derivs. as VAP-1  
 inhibitors for treatment of macular edema and other  
 VAP-1 assocd. diseases)  
 IT Intestine, disease  
 (Crohn's; prepn. of thiazole derivs. as VAP-1 inhibitors for  
 treatment of macular edema and other VAP-1 assocd.  
 diseases)  
 IT Blood vessel, disease  
 (Raynaud's phenomenon; prepn. of thiazole derivs. as VAP-1  
 inhibitors for treatment of macular edema and other  
 VAP-1 assocd. diseases)  
 IT Arthritis  
 (Reiter's syndrome; prepn. of thiazole derivs. as VAP-1  
 inhibitors for treatment of macular edema and other  
 VAP-1 assocd. diseases)  
 IT Cell adhesion molecules  
 RL: BSU (Biological study, unclassified); BIOL  
 (Biological study)  
 (VAP-1 (vascular adhesion protein-1); prepn. of thiazole derivs.  
 as VAP-1 inhibitors for treatment of macular edema and  
 other VAP-1 assocd. diseases)  
 IT Granulomatous disease  
 (Wegener's granulomatosis; prepn. of thiazole derivs. as VAP-1

inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)

IT Cell differentiation  
(adipocyte cell differation aberrations, **diseases**; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)

IT Adipose tissue  
(adipocyte, adipocyte cell differation aberrations, **diseases**; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)

IT Respiratory distress syndrome  
(adult; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)

IT Heart, **disease**  
(angina pectoris; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)

IT Inflammation  
Spinal column, **disease**  
(ankylosing spondylitis; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)

IT Antiartherosclerotics  
(antiatherosclerotics; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)

IT Inflammation  
Mouth, **disease**  
(aphthous stomatitis; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)

IT Artery, **disease**  
Inflammation  
(arteritis, temporal; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)

IT Dermatitis  
(atopic; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)

IT Ischemia  
(cardiac; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)

IT Inflammation  
(central nervous system; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)

IT Lung, **disease**  
(chronic obstructive pulmonary **disease**; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)

IT Arthritis  
(chronic; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other VAP-1 assocd. **diseases**)

IT Intestine, **disease**  
(colon, spastic colon; prepn. of thiazole derivs. as VAP-1 inhibitors for **treatment** of macular edema and other

VAP-1 assocd. **diseases**)

IT Dermatitis  
(contact; prepn. of thiazole derivs. as VAP-1 inhibitors for  
**treatment** of macular edema and other VAP-1 assocd.  
**diseases**)

IT Ulcer  
(cutaneous, foot; prepn. of thiazole derivs. as VAP-1 inhibitors  
for **treatment** of macular edema and other VAP-1 assocd.  
**diseases**)

IT Eye, **disease**  
(diabetic macular edema; prepn. of thiazole derivs. as VAP-1  
inhibitors for **treatment** of macular edema and other  
VAP-1 assocd. **diseases**)

IT Lupus erythematosus  
(discoid; prepn. of thiazole derivs. as VAP-1 inhibitors for  
**treatment** of macular edema and other VAP-1 assocd.  
**diseases**)

IT Joint, anatomical  
(**disease**, degeneration; prepn. of thiazole derivs. as  
VAP-1 inhibitors for **treatment** of macular edema and  
other VAP-1 assocd. **diseases**)

IT Metabolism, animal  
(disorder, carbohydrate metab.; prepn. of thiazole derivs. as  
VAP-1 inhibitors for **treatment** of macular edema and  
other VAP-1 assocd. **diseases**)

IT Blood vessel, **disease**  
(endothelium; prepn. of thiazole derivs. as VAP-1 inhibitors for  
**treatment** of macular edema and other VAP-1 assocd.  
**diseases**)

IT Connective tissue, **disease**  
**Inflammation**  
(eosinophilic fasciitis; prepn. of thiazole derivs. as VAP-1  
inhibitors for **treatment** of macular edema and other  
VAP-1 assocd. **diseases**)

IT Kidney, **disease**  
(failure; prepn. of thiazole derivs. as VAP-1 inhibitors for  
**treatment** of macular edema and other VAP-1 assocd.  
**diseases**)

IT Liver, **disease**  
(fibrosis; prepn. of thiazole derivs. as VAP-1 inhibitors for  
**treatment** of macular edema and other VAP-1 assocd.  
**diseases**)

IT Fibrosis  
(hepatic; prepn. of thiazole derivs. as VAP-1 inhibitors for  
**treatment** of macular edema and other VAP-1 assocd.  
**diseases**)

IT Heart, **disease**  
(infarction; prepn. of thiazole derivs. as VAP-1 inhibitors for  
**treatment** of macular edema and other VAP-1 assocd.  
**diseases**)

IT Central nervous system, **disease**  
Connective tissue, **disease**  
(**inflammation**; prepn. of thiazole derivs. as VAP-1  
inhibitors for **treatment** of macular edema and other  
VAP-1 assocd. **diseases**)

IT Intestine, **disease**  
(**inflammatory**; prepn. of thiazole derivs. as VAP-1  
inhibitors for **treatment** of macular edema and other  
VAP-1 assocd. **diseases**)

IT Reperfusion  
(injury; prepn. of thiazole derivs. as VAP-1 inhibitors for  
**treatment** of macular edema and other VAP-1 assocd.)

diseases)

IT Autoimmune disease  
(insulin-dependent diabetes mellitus; prepn. of thiazole derivs.  
as VAP-1 inhibitors for **treatment** of macular edema and  
other VAP-1 assocd. **diseases**)

IT Diabetes mellitus  
(insulin-dependent; prepn. of thiazole derivs. as VAP-1  
inhibitors for **treatment** of macular edema and other  
VAP-1 assocd. **diseases**)

IT Intestine, disease  
(irritable bowel syndrome; prepn. of thiazole derivs. as VAP-1  
inhibitors for **treatment** of macular edema and other  
VAP-1 assocd. **diseases**)

IT Heart, disease  
(ischemia; prepn. of thiazole derivs. as VAP-1 inhibitors for  
**treatment** of macular edema and other VAP-1 assocd.  
**diseases**)

IT Disease, animal  
(joint degeneration; prepn. of thiazole derivs. as VAP-1  
inhibitors for **treatment** of macular edema and other  
VAP-1 assocd. **diseases**)

IT Rheumatoid arthritis  
(juvenile; prepn. of thiazole derivs. as VAP-1 inhibitors for  
**treatment** of macular edema and other VAP-1 assocd.  
**diseases**)

IT Skin, disease  
(lesion, allergic; prepn. of thiazole derivs. as VAP-1 inhibitors  
for **treatment** of macular edema and other VAP-1 assocd.  
**diseases**)

IT Skin, disease  
(lichen planus; prepn. of thiazole derivs. as VAP-1 inhibitors  
for **treatment** of macular edema and other VAP-1 assocd.  
**diseases**)

IT Carbohydrates, biological studies  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(metab.; prepn. of thiazole derivs. as VAP-1 inhibitors for  
**treatment** of macular edema and other VAP-1 assocd.  
**diseases**)

IT Connective tissue, disease  
(mixed connective tissue **disease**; prepn. of thiazole  
derivs. as VAP-1 inhibitors for **treatment** of macular  
edema and other VAP-1 assocd. **diseases**)

IT Kidney, disease  
(nephrotic syndrome; prepn. of thiazole derivs. as VAP-1  
inhibitors for **treatment** of macular edema and other  
VAP-1 assocd. **diseases**)

IT Nerve, disease  
(neuropathy; prepn. of thiazole derivs. as VAP-1 inhibitors for  
**treatment** of macular edema and other VAP-1 assocd.  
**diseases**)

IT Eye, disease  
(non-diabetic macular edema; prepn. of thiazole derivs. as VAP-1  
inhibitors for **treatment** of macular edema and other  
VAP-1 assocd. **diseases**)

IT Artery, disease  
**Inflammation**  
(periarteritis nodosa; prepn. of thiazole derivs. as VAP-1  
inhibitors for **treatment** of macular edema and other  
VAP-1 assocd. **diseases**)

IT Artery, disease  
(peripheral, occlusion; prepn. of thiazole derivs. as VAP-1

inhibitors for treatment of macular edema and other VAP-1 assocd. diseases)

IT Skin, **disease**  
(pityriasis versicolor; prepn. of thiazole derivs. as VAP-1 inhibitors for treatment of macular edema and other VAP-1 assocd. diseases)

IT **Inflammation**  
Lung, **disease**  
(pneumonitis; prepn. of thiazole derivs. as VAP-1 inhibitors for treatment of macular edema and other VAP-1 assocd. diseases)

IT Bone, **disease**  
**Inflammation**  
(polychondritis; prepn. of thiazole derivs. as VAP-1 inhibitors for treatment of macular edema and other VAP-1 assocd. diseases)

IT Muscle, **disease**  
(polymyalgia rheumatica; prepn. of thiazole derivs. as VAP-1 inhibitors for treatment of macular edema and other VAP-1 assocd. diseases)

IT Myositis  
(polymyositis; prepn. of thiazole derivs. as VAP-1 inhibitors for treatment of macular edema and other VAP-1 assocd. diseases)

IT Alzheimer's **disease**  
Analgesics  
Anti-Alzheimer's agents  
Anti-inflammatory agents  
Antianginal agents  
Antiarthritics  
Antiasthmatics  
Antidiabetic agents  
Antihypertensives  
Antiobesity agents  
Antirheumatic agents  
Arthritis  
**Asthma**  
Atherosclerosis  
Behcet's syndrome  
Blindness  
Blood vessel, **disease**  
Cardiovascular agents  
Cardiovascular system, **disease**  
Dermatitis  
Dermatomyositis  
Diabetes mellitus  
Drug delivery systems  
Gout  
Human  
Hypertension  
Kidney, **disease**  
Multiple sclerosis  
Obesity  
Osteoarthritis  
Pain  
**Psoriasis**  
Rheumatoid arthritis  
Sjogren's syndrome  
Skin, **disease**  
(prepn. of thiazole derivs. as VAP-1 inhibitors for treatment of macular edema and other VAP-1 assocd. diseases)

- IT Biliary tract, disease  
(primary biliary cirrhosis; prepn. of thiazole derivs. as VAP-1 inhibitors for treatment of macular edema and other VAP-1 assocd. diseases)
- IT Arthritis  
(psoriatic arthritis; prepn. of thiazole derivs. as VAP-1 inhibitors for treatment of macular edema and other VAP-1 assocd. diseases)
- IT Injury  
(reperfusion; prepn. of thiazole derivs. as VAP-1 inhibitors for treatment of macular edema and other VAP-1 assocd. diseases)
- IT Eye, disease  
(retinopathy; prepn. of thiazole derivs. as VAP-1 inhibitors for treatment of macular edema and other VAP-1 assocd. diseases)
- IT Connective tissue, disease  
(scleroderma; prepn. of thiazole derivs. as VAP-1 inhibitors for treatment of macular edema and other VAP-1 assocd. diseases)
- IT Inflammation  
Mouth, disease  
(stomatitis; prepn. of thiazole derivs. as VAP-1 inhibitors for treatment of macular edema and other VAP-1 assocd. diseases)
- IT Brain, disease  
Brain, disease  
(stroke; prepn. of thiazole derivs. as VAP-1 inhibitors for treatment of macular edema and other VAP-1 assocd. diseases)
- IT Lupus erythematosus  
(systemic; prepn. of thiazole derivs. as VAP-1 inhibitors for treatment of macular edema and other VAP-1 assocd. diseases)
- IT Thrombosis  
(thromboangiitis obliterans; prepn. of thiazole derivs. as VAP-1 inhibitors for treatment of macular edema and other VAP-1 assocd. diseases)
- IT Skin, disease  
(ulcer, foot; prepn. of thiazole derivs. as VAP-1 inhibitors for treatment of macular edema and other VAP-1 assocd. diseases)
- IT Inflammation  
Intestine, disease  
(ulcerative colitis; prepn. of thiazole derivs. as VAP-1 inhibitors for treatment of macular edema and other VAP-1 assocd. diseases)
- IT Endothelium  
(vascular, disease; prepn. of thiazole derivs. as VAP-1 inhibitors for treatment of macular edema and other VAP-1 assocd. diseases)
- IT Blood vessel, disease  
Inflammation  
(vasculitis; prepn. of thiazole derivs. as VAP-1 inhibitors for treatment of macular edema and other VAP-1 assocd. diseases)
- IT 737822-91-2P, Methyl N-[4-[2-[2-(acetylamino)thiazol-4-yl]ethyl]phenyl]imidothiocarbamate hydroiodide 737823-19-7P, N-[4-[2-[4-(Aminomethyl)phenyl]ethyl]thiazol-2-yl]acetamide 737823-37-9P, N-[4-[2-[4-[(Aminooxy)methyl]phenyl]ethyl]thiazol-2-yl]acetamide 737824-46-3P, N-[4-[2-(4-Aminophenyl)ethyl]-5-[4-(methylsulfonyl)benzyl]thiazol-2-yl]acetamide 737826-45-8P,



N-[4-[2-[4-(2-Aminoethyl)phenyl]ethyl]thiazol-2-yl]acetamide hydrochloride

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(VAP-1 inhibitor; prepn. of thiazole derivs. as VAP-1 inhibitors for treatment of macular edema and other VAP-1 assocd. diseases)

IT 183365-33-5P, N-[4-[2-[4-(4,5-Dihydrothiazol-2-ylamino)phenyl]ethyl]thiazol-2-yl]acetamide 737822-86-5P, N-[4-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]thiazol-2-yl]acetamide 737822-89-8P, N-[4-[(E)-2-[4-(4,5-Dihydrothiazol-2-ylamino)phenyl]ethenyl]thiazol-2-yl]acetamide 737822-94-5P, N-[4-[2-[4-[(4,5-Dihydro-1H-imidazol-2-yl)amino]phenyl]ethyl]thiazol-2-yl]acetamide 737822-95-6P, N-[4-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]thiazol-2-yl]-2-methylpropanamide 737823-01-7P, 2-(Acetylamino)-N-[4-[[amino(imino)methyl]amino]phenyl]thiazole-4-carboxamide 737823-04-0P, N-[4-[2-[4-(Ethanimidoylamino)phenyl]ethyl]thiazol-2-yl]acetamide 737823-05-1P, N-[4-[2-[4-[[Amino(imino)methyl]phenyl]ethyl]thiazol-2-yl]acetamide hydrochloride 737823-09-5P, N-[4-[2-[2-(Acetylamino)thiazol-4-yl]ethyl]phenyl]-2-[[amino(imino)methyl]amino]acetamide hydrochloride 737823-12-0P, N-[4-[4-[2-[[Amino(imino)methyl]amino]ethyl]phenyl]thiazol-2-yl]acetamide hydrochloride 737823-23-3P, Ethyl [4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-2-yl]carbamate hydrochloride 737823-29-9P, N-[4-[2-[3-[[Amino(imino)methyl]amino]phenyl]ethyl]-5-bromothiazol-2-yl]acetamide hydrochloride 737823-34-6P, N-[4-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]-5-bromothiazol-2-yl]acetamide hydrochloride 737823-41-5P, N-[4-[2-[4-[[[(Methyleneamino)oxy]methyl]phenyl]ethyl]thiazol-2-yl]acetamide 737823-42-6P, N-[5-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]thiazol-2-yl]acetamide hydrochloride 737823-47-1P, N-[4-[2-[4-[[[(Imino)(methylamino)methyl]amino]phenyl]ethyl]thiazol-2-yl]acetamide 737823-48-2P, N-[4-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]-5-chlorothiazol-2-yl]acetamide hydrochloride 737823-50-6P, N-[4-[2-[4-[[[Amino(imino)methyl]amino]methyl]phenyl]ethyl]thiazol-2-yl]acetamide hydrochloride 737823-52-8P, Ethyl 2-(acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazole-5-carboxylate hydrochloride 737823-55-1P, N-[4-[2-[4-[[[(Ethylamino)(imino)methyl]amino]phenyl]ethyl]thiazol-2-yl]acetamide 737823-56-2P 737823-62-0P, N-[4-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]thiazol-2-yl]benzamide hydrochloride 737823-67-5P, N-[4-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]-5-[4-(methysulfonyl)phenyl]thiazol-2-yl]acetamide hydrochloride 737823-78-8P, 2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-N-methylthiazole-5-carboxamide hydrochloride 737823-84-6P, 2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-N-phenylthiazole-5-carboxamide hydrochloride 737823-88-0P, 2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-N,N-dimethylthiazole-5-carboxamide hydrochloride 737823-92-6P, 2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-N-benzylthiazole-5-carboxamide hydrochloride 737823-96-0P, 2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-N-(4-nitrobenzyl)thiazole-5-carboxamide hydrochloride 737824-00-9P, 2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-N-[4-(methysulfonyl)benzyl]thiazole-5-carboxamide

hydrochloride 737824-05-4P, 2-(Acetylamino)-4-[2-[4-  
[[amino(imino)methyl]amino]phenyl]ethyl]-N-[4-  
(trifluoromethyl)benzyl]thiazole-5-carboxamide hydrochloride  
737824-09-8P, 2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phe  
nyl]ethyl]-N-(3-pyridinyl)thiazole-5-carboxamide dihydrochloride  
737824-13-4P, 2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phe  
nyl]ethyl]-N-(4-phenoxybenzyl)thiazole-5-carboxamide hydrochloride  
737824-15-6P, Ethyl 4-[[2-(acetylamino)-4-[2-[4-  
[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]carbonyl]-1-  
piperazinecarboxylate 737824-17-8P, N-[5-[(4-Acetyl-1-  
piperazinyl)carbonyl]-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethy  
l]thiazol-2-yl]acetamide 737824-19-0P, N-[4-[2-[4-  
[[Amino(imino)methyl]amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)-1-  
piperazinyl]carbonyl]thiazol-2-yl]acetamide hydrochloride  
737824-21-4P, N-[4-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]-5-  
(4-thiomorpholinylcarbonyl)thiazol-2-yl]acetamide hydrochloride  
737824-23-6P, N-[4-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]-5-  
[(1,1-dioxido-4-thiomorpholinyl)carbonyl]thiazol-2-yl]acetamide  
hydrochloride 737824-25-8P, Ethyl 1-[[2-(acetylamino)-4-[2-[4-  
[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]carbonyl]-4-  
piperidinecarboxylate hydrochloride 737824-27-0P,  
1-[[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]  
thiazol-5-yl]carbonyl]-4-piperidinecarboxamide hydrochloride  
737824-30-5P, 1-[[2-(Acetylamino)-4-[2-[4-  
[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]carbonyl]-N-  
methyl-4-piperidinecarboxamide hydrochloride 737824-32-7P,  
1-[[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]  
thiazol-5-yl]carbonyl]-N,N-dimethyl-4-piperidinecarboxamide  
hydrochloride 737824-34-9P, N-[4-[2-[4-  
[[Amino(imino)methyl]amino]phenyl]ethyl]-5-phenylthiazol-2-  
yl]acetamide hydrochloride 737824-40-7P, N-[4-[2-[4-  
[[Amino(imino)methyl]amino]phenyl]ethyl]-5-benzylthiazol-2-  
yl]acetamide hydrochloride 737824-54-3P, N-[4-[2-[4-  
[[Amino(imino)methyl]amino]phenyl]ethyl]-5-[4-  
(methylsulfonyl)benzyl]thiazol-2-yl]acetamide 737824-56-5P,  
N-[4-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]-5-[4-  
(methylsulfonyl)benzyl]thiazol-2-yl]acetamide hydrochloride  
737824-57-6P, N-[4-[2-[4-[[Hydrazino(imino)methyl]amino]phenyl]ethyl  
]-5-[4-(methylsulfonyl)benzyl]thiazol-2-yl]acetamide 737824-60-1P,  
N-[4-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]-5-[4-  
(ethylsulfonyl)benzyl]thiazol-2-yl]acetamide hydrochloride  
737824-70-3P, Ethyl [4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl  
]-5-[[4-(methylsulfonyl)phenyl]methyl]thiazol-2-yl]carbamate  
737824-76-9P, N-[4-[2-[4-(Aminomethyl)phenyl]ethyl]-5-[4-  
(methylsulfonyl)benzyl]thiazol-2-yl]acetamide **737824-82-7P**  
, N-[4-[2-[4-(4,5-Dihydrothiazol-2-ylamino)phenyl]ethyl]-5-[4-  
(methylsulfonyl)benzyl]thiazol-2-yl]acetamide 737824-83-8P,  
N-[4-[2-[4-[(4,5-Dihydro-1H-imidazol-2-yl)amino]phenyl]ethyl]-5-[4-  
(methylsulfonyl)benzyl]thiazol-2-yl]acetamide 737824-84-9P,  
N-[4-[2-[4-(Ethanimidoylamino)phenyl]ethyl]-5-[4-  
(methylsulfonyl)benzyl]thiazol-2-yl]acetamide 737824-85-0P,  
N-[4-[2-[4-[(Iminomethyl)amino]phenyl]ethyl]thiazol-2-yl]acetamide  
737824-86-1P, N-[4-[2-[4-[[Hydrazino(imino)methyl]amino]phenyl]ethyl  
]thiazol-2-yl]acetamide 737824-87-2P, N-[4-[2-[4-(2-Amino-2-  
iminoethyl)phenyl]ethyl]thiazol-2-yl]acetamide 737824-92-9P,  
N-[4-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]-5-[4-  
(methylthio)benzyl]thiazol-2-yl]acetamide 737824-96-3P,  
N-[4-[4-[3-[[Amino(imino)methyl]amino]propyl]phenyl]-5-[4-  
(methylsulfonyl)phenyl]thiazol-2-yl]acetamide hydrochloride  
737825-09-1P, N-[4-[2-[4-[(Aminooxy)methyl]phenyl]ethyl]-5-[4-  
(methylsulfonyl)phenyl]thiazol-2-yl]acetamide 737825-15-9P,  
N-[4-[2-[4-[[[Amino(imino)methyl]amino]methyl]phenyl]ethyl]-5-[4-

(methylsulfonyl)phenyl]thiazol-2-yl]acetamide hydrochloride  
737825-19-3P, Methyl 4-[[2-(acetylamino)-4-[2-[4-  
[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]methyl]benzoate  
hydrochloride 737825-30-8P, 4-[[2-(Acetylamino)-4-[2-[4-  
[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]methyl]-N,N-  
dimethylbenzamide hydrochloride 737825-35-3P, 4-[[2-(Acetylamino)-  
4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]methyl]-  
N-methylbenzamide hydrochloride 737825-38-6P, N-[4-[2-[4-  
[[Amino(imino)methyl]amino]phenyl]ethyl]-5-  
[(dimethylamino)methyl]thiazol-2-yl]acetamide dihydrochloride  
737825-42-2P, N-[5-[(4-Acetyl-1-piperazinyl)methyl]-4-[2-[4-  
[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-2-yl]acetamide  
dihydrochloride 737825-45-5P, N-[4-[2-[4-  
[[Amino(imino)methyl]amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)-1-  
piperazinyl]methyl]thiazol-2-yl]acetamide dihydrochloride  
737825-49-9P, N-[4-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]-5-  
(4-thiomorpholinylmethyl)thiazol-2-yl]acetamide dihydrochloride  
737825-52-4P, 2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phe  
nyl]ethyl]-N-[2-(dimethylamino)-2-oxoethyl]thiazole-5-carboxamide  
hydrochloride 737825-56-8P, 2-(Acetylamino)-4-[2-[4-  
[[amino(imino)methyl]amino]phenyl]ethyl]-N-[3-(dimethylamino)-3-  
oxopropyl]thiazole-5-carboxamide hydrochloride 737825-60-4P,  
2-(Acetylamino)-N-[2-(acetylamino)ethyl]-4-[2-[4-  
[[amino(imino)methyl]amino]phenyl]ethyl]thiazole-5-carboxamide  
hydrochloride 737825-64-8P, 2-(Acetylamino)-4-[2-[4-  
[[amino(imino)methyl]amino]phenyl]ethyl]-N-[2-  
[(methylsulfonyl)amino]ethyl]thiazole-5-carboxamide hydrochloride  
737825-68-2P, 2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phe  
nyl]ethyl]-N-[3-(dimethylamino)-3-oxopropyl]-N-methylthiazole-5-  
carboxamide hydrochloride 737825-70-6P, 2-(Acetylamino)-4-[2-[4-  
[[amino(imino)methyl]amino]phenyl]ethyl]-N-[3-[benzyl(methyl)amino]-  
3-oxopropyl]thiazole-5-carboxamide hydrochloride 737825-72-8P,  
2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-N-  
[4-(dimethylamino)-4-oxobutyl]thiazole-5-carboxamide hydrochloride  
737825-74-0P, (2R)-1-[[2-(Acetylamino)-4-[2-[4-  
[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]carbonyl]-N,N-  
dimethyl-2-pyrrolidinecarboxamide hydrochloride 737825-76-2P,  
(2S)-1-[[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]e  
thyl]thiazol-5-yl]carbonyl]-N,N-dimethyl-2-pyrrolidinecarboxamide  
hydrochloride 737825-78-4P, 2-(Acetylamino)-4-[2-[4-  
[[amino(imino)methyl]amino]phenyl]ethyl]-N-[2-  
(methylsulfonyl)ethyl]thiazole-5-carboxamide hydrochloride  
737825-80-8P, 2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phe  
nyl]ethyl]-N-(4-pyridinylmethyl)thiazole-5-carboxamide  
dihydrochloride 737825-82-0P, 2-(Acetylamino)-4-[2-[4-  
[[amino(imino)methyl]amino]phenyl]ethyl]-N-[3-  
pyridinylmethyl]thiazole-5-carboxamide dihydrochloride  
737825-84-2P, 2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phe  
nyl]ethyl]-N-[2-[(2-phenylacetyl)amino]ethyl]thiazole-5-carboxamide  
hydrochloride 737825-86-4P, 2-(Acetylamino)-4-[2-[4-  
[[amino(imino)methyl]amino]phenyl]ethyl]-N-[5-(dimethylamino)-5-  
oxopentyl]thiazole-5-carboxamide hydrochloride 737825-88-6P,  
2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-N-  
[3-(benzylamino)-3-oxopropyl]thiazole-5-carboxamide hydrochloride  
737825-90-0P, 2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phe  
nyl]ethyl]-N-[6-(dimethylamino)-6-oxohexyl]thiazole-5-carboxamide  
hydrochloride 737825-92-2P, 2-(Acetylamino)-4-[2-[4-  
[[amino(imino)methyl]amino]phenyl]ethyl]-N-[3-(4-  
morpholinyl)propyl]thiazole-5-carboxamide dihydrochloride  
737825-94-4P, 2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phe  
nyl]ethyl]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]thiazole-5-carboxamide  
hydrochloride 737825-96-6P, 2-(Acetylamino)-4-[2-[4-

Ross Shipe EIC 1700 Remsen 4B31 571/272-6018



[[Amino(imino)methyl]amino]phenyl]ethyl]-5-[[4-(1-pyrrolidinylcarbonyl)-1-piperazinyl]methyl]thiazol-2-yl]acetamide dihydrochloride 737826-90-3P, N-[4-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]-5-[[4-[(4-methyl-1-piperazinyl)carbonyl]-1-piperazinyl]methyl]thiazol-2-yl]acetamide trihydrochloride 737826-92-5P, 3-[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]-N,N-dimethylpropanamide hydrochloride 737826-98-1P, 3-[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]-N-methylpropanamide hydrochloride 737827-00-8P, 3-[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]propanamide hydrochloride 737827-02-0P, 1-[[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]methyl]-N,N-dimethyl-4-piperidinecarboxamide dihydrochloride 737827-05-3P, 1-[[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]methyl]-N-methyl-4-piperidinecarboxamide dihydrochloride 737827-07-5P, 1-[[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]methyl]-4-piperidinecarboxamide dihydrochloride 737827-09-7P, (3R)-1-[[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]methyl]-N,N-dimethyl-3-piperidinecarboxamide dihydrochloride 737827-14-4P, (3R)-1-[[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]methyl]-N-methyl-3-piperidinecarboxamide dihydrochloride 737827-16-6P, (3S)-1-[[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]methyl]-N,N-dimethyl-3-piperidinecarboxamide dihydrochloride 737827-21-3P, (3S)-1-[[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]methyl]-N-methyl-3-piperidinecarboxamide dihydrochloride 737827-23-5P, N-[4-[2-(2-Amino-1H-benzimidazol-6-yl)ethyl]-5-[4-(methylsulfonyl)benzyl]thiazol-2-yl]acetamide 737827-26-8P, N-[4-[2-(2-Amino-1H-benzimidazol-6-yl)ethyl]thiazol-2-yl]acetamide 737827-29-1P, N-[[2-(Acetylamino)-4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]thiazol-5-yl]methyl]-N-methylacetamide hydrochloride 737827-34-8P, N-[4-[2-[4-[(2-Aminoethyl)amino]phenyl]ethyl]thiazol-2-yl]acetamide dihydrochloride 737827-36-0P, N-[4-[3-[2-[[Amino(imino)methyl]amino]ethyl]phenyl]thiazol-2-yl]acetamide hydrochloride 737827-42-8P, N-[4-[2-[4-[[Amino(imino)methyl]amino]phenyl]ethyl]-5-[2-[4-(methylsulfonyl)phenyl]ethyl]thiazol-2-yl]acetamide hydrochloride 737827-47-3P, N-[4-[2-[4-[2-[[Amino(imino)methyl]amino]ethyl]phenyl]ethyl]thiazol-2-yl]acetamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(VAP-1 inhibitor; prepn. of thiazole derivs. as VAP-1 inhibitors for treatment of macular edema and other VAP-1 assocd. diseases)

IT 2065-75-0P, 2-Bromomalonaldehyde 6362-58-9P, Methyl 2-oxo-3-phenylpropanoate 16444-13-6P, N-(4-Formylthiazol-2-yl)acetamide 28229-69-8P, 2-(3-Bromophenyl)ethanol 50602-38-5P, 2-(Acetylamino)thiazole-4-carboxylic acid 51307-38-1P, N-[4-(Hydroxymethyl)thiazol-2-yl]acetamide 62591-33-7P, Ethyl 2-(acetylamino)-4-(chloromethyl)thiazole-5-carboxylate 63077-41-8P, N-[2-[4-(2-Chloroacetyl)phenyl]ethyl]acetamide 77505-86-3P, Ethyl 2-amino-5-benzylthiazole-4-carboxylate 80625-18-9P, Methyl 2-amino-5-phenylthiazole-4-carboxylate 92819-12-0P, Ethyl 2-(acetylamino)thiazole-4-carboxylate 105512-85-4P, 4-[4-(Methylthio)phenyl]thiazol-2-amine 111608-67-4P, [2-(Acetylamino)thiazol-4-yl]methyl acetate 123392-44-9P, Methyl 3-[4-(methylthio)phenyl]propanoate 127942-30-7P, Ethyl 2-aminothiazole-4-carboxylate hydrobromide

183365-28-8P, N-[4-[(E)-2-(4-Nitrophenyl)ethenyl]thiazol-2-yl]acetamide 183365-29-9P, N-[4-[2-(4-Aminophenyl)ethyl]thiazol-2-yl]acetamide 249937-07-3P, [2-(3-Bromophenyl)ethoxy](tert-butyl)dimethylsilane 252662-37-6P, N-(5-Formylthiazol-2-yl)acetamide 292858-05-0P, Ethyl 3-bromo-2-oxo-4-phenylbutanoate 737822-87-6P, (2-Aminothiazol-4-yl)methyl acetate hydrochloride 737822-88-7P, N-[4-[(Z)-2-(4-Nitrophenyl)ethenyl]thiazol-2-yl]acetamide 737822-90-1P, N-[4-[(E)-2-(4-Aminophenyl)ethenyl]thiazol-2-yl]acetamide 737822-92-3P, N-[4-[2-[4-[(Benzoylamino)carbonothioyl]amino]phenyl]ethyl]thiazol-2-yl]acetamide 737822-93-4P, N-[4-[2-[4-[(Aminocarbonothioyl)amino]phenyl]ethyl]thiazol-2-yl]acetamide 737822-96-7P, Ethyl 2-(isobutyrylamino)thiazole-4-carboxylate 737822-97-8P, N-[4-(Hydroxymethyl)thiazol-2-yl]-2-methylpropanamide 737822-98-9P, N-(4-Formylthiazol-2-yl)-2-methylpropanamide 737822-99-0P, 2-Methyl-N-[4-[(E)-2-(4-nitrophenyl)ethenyl]thiazol-2-yl]propanamide 737823-00-6P, N-[4-[2-(4-Aminophenyl)ethyl]thiazol-2-yl]-2-methylpropanamide 737823-02-8P, tert-Butyl [4-[[2-(acetylamino)thiazol-4-yl]carbonyl]amino]phenyl]carbamate 737823-03-9P, 2-(Acetylamino)-N-(4-aminophenyl)thiazole-4-carboxamide hydrochloride 737823-06-2P, N-[4-[(Z)-2-(4-Cyanophenyl)ethenyl]thiazol-2-yl]acetamide 737823-07-3P, N-[4-[2-(4-Cyanophenyl)ethyl]thiazol-2-yl]acetamide 737823-08-4P, 4-[2-[2-(Acetylamino)thiazol-4-yl]ethyl]benzenecarboximide acid ethyl ester hydrochloride 737823-10-8P, tert-Butyl [2-[[4-[2-[2-(acetylamino)thiazol-4-yl]ethyl]phenyl]amino]-2-oxoethyl]carbamate 737823-11-9P, N-[4-[2-[2-(Acetylamino)thiazol-4-yl]ethyl]phenyl]-2-aminoacetamide hydrochloride 737823-13-1P, N-[2-[4-(2-Aminothiazol-4-yl)phenyl]ethyl]acetamide hydrochloride 737823-14-2P, 4-[4-(2-Aminoethyl)phenyl]thiazol-2-amine dihydrochloride 737823-15-3P, tert-Butyl [2-[4-(2-aminothiazol-4-yl)phenyl]ethyl]carbamate 737823-16-4P, tert-Butyl [2-[4-[2-(acetylamino)thiazol-4-yl]phenyl]ethyl]carbamate 737823-17-5P, N-[4-[4-(2-Aminoethyl)phenyl]thiazol-2-yl]acetamide hydrochloride 737823-18-6P 737823-20-0P, N-[4-[2-[4-(Hydroxymethyl)phenyl]ethyl]thiazol-2-yl]acetamide 737823-21-1P, N-[4-[2-[4-(Bromomethyl)phenyl]ethyl]thiazol-2-yl]acetamide 737823-22-2P, N-[4-[2-[4-[(Diethylamino)methyl]phenyl]ethyl]thiazol-2-yl]acetamide 737823-24-4P, Ethyl [4-(hydroxymethyl)thiazol-2-yl]carbamate 737823-25-5P, Ethyl [4-(formylthiazol-2-yl)carbamate 737823-26-6P, Ethyl [4-[2-(4-nitrophenyl)ethenyl]thiazol-2-yl]carbamate 737823-27-7P, Ethyl [4-[2-(4-aminophenyl)ethyl]thiazol-2-yl]carbamate 737823-28-8P 737823-30-2P, N-[4-[2-(3-Nitrophenyl)ethenyl]thiazol-2-yl]acetamide 737823-31-3P, N-[4-[2-(3-Aminophenyl)ethyl]thiazol-2-yl]acetamide 737823-32-4P 737823-33-5P 737823-35-7P 737823-36-8P 737823-38-0P, Methyl 4-[(Z)-2-[2-(acetylamino)thiazol-4-yl]ethenyl]benzoate 737823-39-1P, Methyl 4-[2-[2-(acetylamino)thiazol-4-yl]ethyl]benzoate 737823-40-4P, N-[4-[2-[4-[(1,3-Dioxo-1,3-dihydro-2H-indol-2-yl)oxy]methyl]phenyl]ethyl]thiazol-2-yl]acetamide 737823-44-8P, N-[5-[(Z)-2-(4-Nitrophenyl)ethenyl]thiazol-2-yl]acetamide 737823-45-9P, N-[5-[2-(4-Aminophenyl)ethyl]thiazol-2-yl]acetamide 737823-46-0P 737823-49-3P 737823-51-7P 737823-53-9P, Ethyl 2-(acetylamino)-4-[(E)-2-(4-nitrophenyl)ethenyl]thiazole-5-carboxylate 737823-54-0P, Ethyl 2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]thiazole-5-carboxylate 737823-57-3P, Ethyl 2-[[[(benzyloxy)carbonyl]amino]thiazole-4-carboxylate 737823-58-4P, Benzyl [4-(hydroxymethyl)thiazol-2-yl]carbamate 737823-59-5P, Benzyl [4-(formylthiazol-2-yl)carbamate 737823-60-8P, Benzyl [4-[(E)-2-(4-nitrophenyl)ethenyl]thiazol-2-yl]carbamate 737823-61-9P, Benzyl [4-[2-(4-aminophenyl)ethyl]thiazol-2-

yl]carbamate 737823-63-1P, 4-[(E)-2-(4-Nitrophenyl)ethenyl]thiazol-2-amine 737823-64-2P, N-[4-[(E)-2-(4-Nitrophenyl)ethenyl]thiazol-2-yl]benzamide 737823-65-3P, N-[4-[2-(4-Aminophenyl)ethyl]thiazol-2-yl]benzamide 737823-66-4P 737823-68-6P 737823-69-7P, 3-[4-(Methylsulfanyl)phenyl]-2-oxopropanoic acid 737823-70-0P, Methyl 3-[4-(methylsulfanyl)phenyl]-2-oxopropanoate 737823-71-1P, Methyl 2-amino-5-[4-(methylthio)phenyl]thiazole-4-carboxylate 737823-72-2P, Methyl 2-(acetylamino)-5-[4-(methylthio)phenyl]thiazole-4-carboxylate 737823-73-3P, N-[4-Formyl-5-[4-(methylthio)phenyl]thiazol-2-yl]acetamide 737823-74-4P, N-[5-[4-(Methylthio)phenyl]-4-[(E)-2-(4-nitrophenyl)ethenyl]thiazol-2-yl]acetamide 737823-75-5P, N-[5-[4-(Methylsulfonyl)phenyl]-4-[(E)-2-(4-nitrophenyl)ethenyl]thiazol-2-yl]acetamide 737823-76-6P, N-[4-[2-(4-Aminophenyl)ethyl]-5-[4-(methylsulfonyl)phenyl]thiazol-2-yl]acetamide 737823-77-7P 737823-79-9P, Ethyl 2-(acetylamino)-4-[2-[4-[(tert-butoxycarbonyl)amino]phenyl]ethyl]thiazole-5-carboxylate 737823-80-2P, 2-(Acetylamino)-4-[2-[4-[(tert-butoxycarbonyl)amino]phenyl]ethyl]thiazole-5-carboxylic acid 737823-81-3P, tert-Butyl [4-[2-[2-(acetylamino)-5-[(methylamino)carbonyl]thiazol-4-yl]ethyl]phenyl]carbamate 737823-82-4P, 2-(Acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-methylthiazole-5-carboxamide 737823-83-5P 737823-85-7P, tert-Butyl [4-[2-[2-(acetylamino)-5-(anilino)carbonyl]thiazol-4-yl]ethyl]phenyl]carbamate 737823-86-8P, 2-(Acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-phenylthiazole-5-carboxamide 737823-87-9P 737823-89-1P, tert-Butyl [4-[2-[2-(acetylamino)-5-[(dimethylamino)carbonyl]thiazol-4-yl]ethyl]phenyl]carbamate 737823-90-4P, 2-(Acetylamino)-4-[2-(4-aminophenyl)ethyl]-N,N-dimethylthiazole-5-carboxamide 737823-91-5P 737823-93-7P, tert-Butyl [4-[2-[2-(acetylamino)-5-[(benzylamino)carbonyl]thiazol-4-yl]ethyl]phenyl]carbamate 737823-94-8P, 2-(Acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-benzylthiazole-5-carboxamide 737823-95-9P 737823-97-1P, tert-Butyl [4-[2-[2-(acetylamino)-5-[(4-nitrobenzyl)amino]carbonyl]thiazol-4-yl]ethyl]phenyl]carbamate 737823-98-2P, 2-(Acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-(4-nitrobenzyl)thiazole-5-carboxamide 737823-99-3P 737824-01-0P, tert-Butyl [4-[2-[2-(acetylamino)-5-[[[4-(methylthio)phenyl]methyl]amino]carbonyl]thiazol-4-yl]ethyl]phenyl]carbamate 737824-02-1P, tert-Butyl [4-[2-[2-(acetylamino)-5-[[[4-(methylsulfonyl)phenyl]methyl]amino]carbonyl]thiazol-4-yl]ethyl]phenyl]carbamate 737824-03-2P, 2-(Acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-[4-(methylsulfonyl)benzyl]thiazole-5-carboxamide 737824-04-3P 737824-06-5P, tert-Butyl [4-[2-[2-(acetylamino)-5-[[[4-(trifluoromethyl)phenyl]methyl]amino]carbonyl]thiazol-4-yl]ethyl]phenyl]carbamate 737824-07-6P, 2-(Acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-[4-(trifluoromethyl)benzyl]thiazole-5-carboxamide 737824-08-7P 737824-10-1P, 2-(Acetylamino)-4-[2-(4-aminophenyl)ethyl]thiazole-5-carboxylic acid 737824-11-2P 737824-12-3P 737824-14-5P 737824-16-7P 737824-18-9P 737824-20-3P 737824-22-5P 737824-24-7P 737824-26-9P 737824-28-1P 737824-29-2P 737824-31-6P 737824-33-8P 737824-35-0P, Methyl 2-(acetylamino)-5-phenylthiazole-4-carboxylate 737824-36-1P, N-(4-Formyl-5-phenylthiazol-2-yl)acetamide 737824-37-2P 737824-38-3P, N-[4-[2-(4-Aminophenyl)ethyl]-5-phenylthiazol-2-yl]acetamide 737824-39-4P 737824-41-8P, Ethyl 2-(acetylamino)-5-benzylthiazole-4-carboxylate 737824-42-9P, N-(5-Benzyl-4-formylthiazol-2-yl)acetamide 737824-43-0P 737824-44-1P, N-[4-[2-(4-Aminophenyl)ethyl]-5-benzylthiazol-2-yl]acetamide 737824-45-2P 737824-47-4P, Ethyl 4-[4-(methylthio)phenyl]-2-oxobutanoate 737824-48-5P, Ethyl



3-bromo-4-[4-(methylthio)phenyl]-2-oxobutanoate 737824-49-6P,  
Ethyl 2-amino-5-[[4-(methylthio)phenyl]methyl]thiazole-4-carboxylate  
737824-50-9P, Ethyl 2-(acetylamino)-5-[[4-(methylthio)phenyl]methyl]thiazole-4-carboxylate 737824-51-0P,  
N-[4-Formyl-5-[4-(methylthio)benzyl]thiazol-2-yl]acetamide  
737824-52-1P 737824-53-2P 737824-55-4P 737824-58-7P,  
N-[4-[2-[4-[(Aminocarbonothioyl)amino]phenyl]ethyl]-5-[4-(methylsulfonyl)benzyl]thiazol-2-yl]acetamide 737824-59-8P  
737824-61-2P, Ethyl 3-[4-(ethylthio)phenyl]propanoate  
737824-62-3P, Ethyl 4-[4-(ethylthio)phenyl]-2-oxobutanoate  
737824-63-4P, Ethyl 3-bromo-4-[4-(ethylthio)phenyl]-2-oxobutanoate  
737824-64-5P 737824-65-6P 737824-66-7P, N-[5-[4-(Ethylthio)benzyl]-4-formylthiazol-2-yl]acetamide 737824-67-8P  
737824-68-9P 737824-69-0P 737824-71-4P, tert-Butyl  
[4-[2-[2-(acetylamino)-5-[[4-(methylsulfonyl)phenyl]methyl]thiazol-4-yl]ethyl]phenyl]carbamate 737824-72-5P, tert-Butyl  
[4-[2-[2-amino-5-[[4-(methylsulfonyl)phenyl]methyl]thiazol-4-yl]ethyl]phenyl]carbamate 737824-73-6P, Ethyl [4-[2-[4-[(tert-butoxycarbonyl)amino]phenyl]ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]thiazol-2-yl]carbamate 737824-74-7P,  
Ethyl [4-[2-(4-aminophenyl)ethyl]-5-[[4-(methylsulfonyl)phenyl]methyl]thiazol-2-yl]carbamate 737824-75-8P  
737824-77-0P, Methyl 4-[(Z)-2-[2-(acetylamino)-5-[[4-(methylthio)phenyl]methyl]thiazol-4-yl]ethenyl]benzoate  
737824-78-1P, Methyl 4-[(Z)-2-[2-(acetylamino)-5-[[4-(methylsulfonyl)phenyl]methyl]thiazol-4-yl]ethenyl]benzoate  
737824-79-2P, Methyl 4-[2-[2-(acetylamino)-5-[[4-(methylsulfonyl)phenyl]methyl]thiazol-4-yl]ethyl]benzoate  
737824-80-5P, N-[4-[2-[4-(Hydroxymethyl)phenyl]ethyl]-5-[4-(methylsulfonyl)benzyl]thiazol-2-yl]acetamide 737824-81-6P,  
N-[4-[2-[4-(Chloromethyl)phenyl]ethyl]-5-[4-(methylsulfonyl)benzyl]thiazol-2-yl]acetamide 737824-88-3P,  
N-[4-[2-[4-(Chloromethyl)phenyl]ethyl]thiazol-2-yl]acetamide  
737824-89-4P, N-[4-[2-[4-(Cyanomethyl)phenyl]ethyl]thiazol-2-yl]acetamide 737824-90-7P, 2-[4-[2-[2-(Acetylaminio)thiazol-4-yl]ethyl]phenyl]ethanimidic acid methyl ester hydrochloride  
737824-91-8P, N-[4-[2-[4-(2-Amino-2-iminoethyl)phenyl]ethyl]thiazol-2-yl]acetamide hydrochloride 737824-93-0P 737824-94-1P,  
N-[4-[2-(4-Aminophenyl)ethyl]-5-[4-(methylsulfonyl)benzyl]thiazol-2-yl]acetamide 737824-95-2P 737824-97-4P, Methyl  
4-[[2-bromo-4-(methylthio)phenyl]acetyl]benzoate 737824-98-5P,  
Methyl 4-[2-amino-5-[4-(methylthio)phenyl]thiazol-4-yl]benzoate  
737824-99-6P, [4-[2-Amino-5-[4-(methylthio)phenyl]thiazol-4-yl]phenyl]methanol 737825-00-2P, 4-[2-(Acetylaminio)-5-[4-(methylsulfonyl)phenyl]thiazol-4-yl]benzyl acetate 737825-01-3P,  
N-[4-[4-(Hydroxymethyl)phenyl]-5-[4-(methylsulfonyl)phenyl]thiazol-2-yl]acetamide 737825-02-4P, N-[4-(4-Formylphenyl)-5-[4-(methylsulfonyl)phenyl]thiazol-2-yl]acetamide 737825-03-5P, Ethyl  
(2E)-3-[4-[2-(acetylamino)-5-[4-(methylsulfonyl)phenyl]thiazol-4-yl]phenyl]-2-propenoate 737825-04-6P,  
N-[4-[4-(3-Hydroxypropyl)phenyl]-5-[4-(methylsulfonyl)phenyl]thiazol-2-yl]acetamide 737825-05-7P, N-[4-[4-(3-Bromopropyl)phenyl]-5-[4-(methylsulfonyl)phenyl]thiazol-2-yl]acetamide 737825-06-8P,  
N-[4-[4-[3-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)propyl]phenyl]-5-[4-(methylsulfonyl)phenyl]thiazol-2-yl]acetamide 737825-07-9P,  
N-[4-[4-(3-Aminopropyl)phenyl]-5-[4-(methylsulfonyl)phenyl]thiazol-2-yl]acetamide 737825-08-0P 737825-10-4P, Methyl  
4-[(E)-2-[2-(acetylamino)-5-[4-(methylthio)phenyl]thiazol-4-yl]ethenyl]benzoate 737825-11-5P, Methyl 4-[(E)-2-[2-(acetylamino)-5-[4-(methylsulfonyl)phenyl]thiazol-4-yl]ethenyl]benzoate  
737825-12-6P, Methyl 4-[2-[2-(acetylamino)-5-[4-(methylsulfonyl)phenyl]thiazol-4-yl]ethyl]benzoate 737825-13-7P,

N-[4-[2-[4-(Hydroxymethyl)phenyl]ethyl]-5-[4-(methylsulfonyl)phenyl]thiazol-2-yl]acetamide 737825-14-8P,  
 N-[4-[2-[4-[[1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl]oxy]methyl]phenyl]ethyl]-5-[4-(methylsulfonyl)phenyl]thiazol-2-yl]acetamide 737825-16-0P, N-[4-[2-[4-(Bromomethyl)phenyl]ethyl]-5-[4-(methylsulfonyl)phenyl]thiazol-2-yl]acetamide 737825-17-1P,  
 N-[4-[2-[4-(Aminomethyl)phenyl]ethyl]-5-[4-(methylsulfonyl)phenyl]thiazol-2-yl]acetamide 737825-18-2P  
 737825-20-6P, Ethyl 4-(4-iodophenyl)-2-oxobutanoate 737825-21-7P,  
 Ethyl 3-bromo-4-(4-iodophenyl)-2-oxobutanoate 737825-22-8P, Ethyl 2-amino-5-(4-iodobenzyl)thiazole-4-carboxylate hydrobromide  
 737825-23-9P, Ethyl 2-(acetylamino)-5-(4-iodobenzyl)thiazole-4-carboxylate 737825-24-0P, N-[4-Formyl-5-(4-iodobenzyl)thiazol-2-yl]acetamide 737825-25-1P, N-[5-(4-Iodobenzyl)-4-[2-(4-nitrophenyl)vinyl]thiazol-2-yl]acetamide 737825-27-3P  
 737825-28-4P, Methyl 4-[[2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]thiazol-5-yl]methyl]benzoate 737825-29-5P  
 737825-31-9P, Methyl 4-[[2-(acetylamino)-4-[2-[4-[(tert-butoxycarbonyl)amino]phenyl]ethyl]thiazol-5-yl]methyl]benzoate  
 737825-32-0P, 4-[[2-(Acetylamino)-4-[2-[4-[(tert-butoxycarbonyl)amino]phenyl]ethyl]thiazol-5-yl]methyl]benzoic acid  
 737825-33-1P, tert-Butyl [4-[2-[2-(acetylamino)-5-[[4-[(dimethylamino)carbonyl]phenyl]methyl]thiazol-4-yl]ethyl]phenyl]carbamate 737825-34-2P 737825-36-4P, tert-Butyl [4-[2-[2-(acetylamino)-5-[[4-[(methylamino)carbonyl]phenyl]methyl]thiazol-4-yl]ethyl]phenyl]carbamate 737825-37-5P 737825-39-7P  
 737825-40-0P, N-[4-[2-(4-Aminophenyl)ethyl]-5-[(dimethylamino)methyl]thiazol-2-yl]acetamide 737825-41-1P  
 737825-43-3P 737825-44-4P 737825-46-6P 737825-48-8P  
 737825-50-2P 737825-51-3P 737825-53-5P, tert-Butyl [4-[2-[2-(acetylamino)-5-[[2-(dimethylamino)-2-oxoethyl]amino]carbonyl]thiazol-4-yl]ethyl]phenyl]carbamate  
 737825-54-6P, 2-(Acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-[2-(dimethylamino)-2-oxoethyl]thiazole-5-carboxamide hydrochloride  
 737825-55-7P 737825-57-9P, tert-Butyl [4-[2-[2-(acetylamino)-5-[[3-(dimethylamino)-3-oxopropyl]amino]carbonyl]thiazol-4-yl]ethyl]phenyl]carbamate 737825-58-0P, 2-(Acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-[3-(dimethylamino)-3-oxopropyl]thiazole-5-carboxamide hydrochloride 737825-59-1P 737825-61-5P, tert-Butyl [4-[2-[2-(acetylamino)-5-[[2-(acetylamino)ethyl]amino]carbonyl]thiazol-4-yl]ethyl]phenyl]carbamate 737825-62-6P, 2-(Acetylamino)-N-[2-(acetylamino)ethyl]-4-[2-(4-aminophenyl)ethyl]thiazole-5-carboxamide hydrochloride 737825-63-7P 737825-65-9P, tert-Butyl [4-[2-[2-(acetylamino)-5-[[2-[(methylsulfonyl)amino]ethyl]amino]carbonyl]thiazol-4-yl]ethyl]phenyl]carbamate 737825-66-0P,  
 2-(Acetylamino)-4-[2-(4-aminophenyl)ethyl]-N-[2-[(methylsulfonyl)amino]ethyl]thiazole-5-carboxamide hydrochloride  
 737825-67-1P 737825-69-3P 737825-71-7P 737825-73-9P  
 737825-75-1P 737825-77-3P 737825-79-5P 737825-81-9P  
 737825-83-1P 737825-85-3P 737825-87-5P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; prepn. of thiazole derivs. as VAP-1 inhibitors for treatment of macular edema and other VAP-1 assocd. diseases)

IT 737825-89-7P 737825-91-1P 737825-93-3P 737825-95-5P  
 737825-97-7P 737825-99-9P 737826-01-6P 737826-03-8P  
 737826-04-9P 737826-06-1P 737826-08-3P 737826-10-7P  
 737826-12-9P 737826-14-1P 737826-17-4P, tert-Butyl [4-[2-[2-(acetylamino)-5-[[methoxy(methyl)amino]carbonyl]thiazol-4-yl]ethyl]phenyl]carbamate 737826-18-5P, tert-Butyl [4-[2-[2-(acetylamino)-5-formylthiazol-4-yl]ethyl]phenyl]carbamate

737826-19-6P 737826-20-9P, (2S)-1-[[2-(Acetylamino)-4-[2-(4-aminophenyl)ethyl]thiazol-5-yl]methyl]-N,N-dimethyl-2-pyrrolidinecarboxamide 737826-21-0P 737826-23-2P, tert-Butyl [4-[2-[2-(acetylamino)-5-[[[3-(N,N-dimethylamino)-3-oxopropyl]amino]methyl]thiazol-4-yl]ethyl]phenyl]carbamate 737826-24-3P, tert-Butyl [4-[2-[2-(acetylamino)-5-[[[3-(N,N-dimethylamino)-3-oxopropyl]amino]methyl]thiazol-4-yl]ethyl]phenyl]carbamate 737826-25-4P, 3-[[[2-(Acetylamino)-4-[2-(4-aminophenyl)ethyl]thiazol-5-yl]methyl]amino]-N,N-dimethylpropanamide 737826-26-5P 737826-28-7P, Methyl 4-[2-[2-(acetylamino)-4-[2-[4-[(tert-butoxycarbonyl)amino]phenyl]ethyl]thiazol-5-yl]vinyl]benzoate 737826-29-8P, Methyl 4-[2-[2-(acetylamino)-4-[2-[4-[(tert-butoxycarbonyl)amino]phenyl]ethyl]thiazol-5-yl]ethyl]benzoate 737826-30-1P, 4-[2-[2-(Acetylamino)-4-[2-[4-[(tert-butoxycarbonyl)amino]phenyl]ethyl]thiazol-5-yl]ethyl]benzoic acid 737826-31-2P, tert-Butyl [4-[2-[2-(acetylamino)-5-[2-[4-[(methylamino)carbonyl]phenyl]ethyl]thiazol-4-yl]ethyl]phenyl]carbamate 737826-32-3P 737826-34-5P, tert-Butyl [4-[2-[2-(Acetylamino)-5-[2-[4-[(dimethylamino)carbonyl]phenyl]ethyl]thiazol-4-yl]ethyl]phenyl]carbamate 737826-35-6P 737826-37-8P, Methyl N-[4-[[2-(acetylamino)-4-[2-[4-[(tert-butoxycarbonyl)amino]phenyl]ethyl]thiazol-5-yl]methyl]phenyl]carbamate 737826-38-9P 737826-40-3P, Ethyl 1-[[2-(acetylamino)-4-[(Z)-2-(4-nitrophenyl)ethenyl]thiazol-5-yl]methyl]-4-piperidinecarboxylate 737826-41-4P 737826-46-9P, tert-Butyl [2-[4-[2-(2-aminothiazol-4-yl)ethyl]phenyl]ethyl]carbamate 737826-47-0P, tert-Butyl [2-[4-[2-[2-(acetylamino)thiazol-4-yl]ethyl]phenyl]ethyl]carbamate 737826-49-2P 737826-51-6P, N-[4-[4-(Methylthio)phenyl]thiazol-2-yl]acetamide 737826-52-7P, N-[4-[4-(Methylsulfinyl)phenyl]thiazol-2-yl]acetamide 737826-53-8P, [[4-[2-(Acetylamino)thiazol-4-yl]phenyl]thio]methyl acetate 737826-54-9P, [[4-[2-(Acetylamino)thiazol-4-yl]phenyl]sulfonyl]methyl acetate 737826-55-0P, Sodium 4-[2-(acetylamino)thiazol-4-yl]benzenesulfinate 737826-56-1P, N-[4-[4-[(2-Hydroxyethyl)sulfonyl]phenyl]thiazol-2-yl]acetamide 737826-57-2P, N-[4-[4-[(2-Aminoethyl)sulfonyl]phenyl]thiazol-2-yl]acetamide 737826-58-3P 737826-60-7P, N-Methoxy-N-methyl-3-(methylsulfonyl)benzamide 737826-61-8P, Methyl (2E)-3-[3-(methylsulfonyl)phenyl]-2-propenoate 737826-62-9P, Methyl 3-[3-(methylsulfonyl)phenyl]propanoate 737826-63-0P, Ethyl 4-[3-(methylsulfonyl)phenyl]-2-oxobutanoate 737826-64-1P, Ethyl 3-bromo-4-[3-(methylsulfonyl)phenyl]-2-oxobutanoate 737826-65-2P, Ethyl 2-amino-5-[[3-(methylsulfonyl)phenyl]methyl]thiazole-4-carboxylate 737826-66-3P, Ethyl 2-(acetylamino)-5-[[3-(methylsulfonyl)phenyl]methyl]thiazole-4-carboxylate 737826-67-4P, N-[4-Formyl-5-[3-(methylsulfonyl)benzyl]thiazol-2-yl]acetamide 737826-68-5P 737826-69-6P, N-[4-[2-(4-Aminophenyl)ethyl]-5-[3-(methylsulfonyl)benzyl]thiazol-2-yl]acetamide 737826-70-9P 737826-72-1P 737826-73-2P 737826-75-4P 737826-76-5P 737826-78-7P 737826-79-8P 737826-81-2P, 9H-Fluoren-9-ylmethyl 4-[[2-(acetylamino)-4-[(Z)-2-(4-nitrophenyl)ethenyl]thiazol-5-yl]methyl]-1-piperazinecarboxylate 737826-82-3P, 9H-Fluoren-9-ylmethyl 4-[[2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]thiazol-5-yl]methyl]-1-piperazinecarboxylate 737826-83-4P 737826-84-5P 737826-85-6P 737826-87-8P 737826-89-0P 737826-91-4P 737826-93-6P, Ethyl 3-[2-(acetylamino)-4-[2-[4-[(tert-butoxycarbonyl)amino]phenyl]ethyl]thiazol-5-yl]-2-propenoate 737826-94-7P, Ethyl 3-[2-(acetylamino)-4-[2-[4-[(tert-butoxycarbonyl)amino]phenyl]ethyl]thiazol-5-yl]propanoate 737826-95-8P 737826-96-9P 737826-97-0P 737826-99-2P 737827-01-9P 737827-03-1P 737827-04-2P

737827-06-4P 737827-08-6P 737827-10-0P 737827-11-1P  
 737827-12-2P 737827-13-3P 737827-15-5P 737827-17-7P  
 737827-18-8P 737827-19-9P 737827-20-2P 737827-22-4P  
 737827-24-6P 737827-25-7P, N-[4-[2-(3,4-Diaminophenyl)ethyl]-5-[4-(methylsulfonyl)benzyl]thiazol-2-yl]acetamide 737827-27-9P  
 737827-28-0P, N-[4-[2-(3,4-Diaminophenyl)ethyl]thiazol-2-yl]acetamide 737827-30-4P 737827-31-5P 737827-32-6P,  
 N-[[2-(Acetyl amino)-4-[2-(4-aminophenyl)ethyl]thiazol-5-yl]methyl]-N-methylacetamide 737827-33-7P 737827-35-9P, tert-Butyl  
 [2-[[4-[2-[2-(acetyl amino)thiazol-4-yl]ethyl]phenyl]amino]ethyl]carbamate 737827-37-1P, 1-[3-[2-[(tert-Butyldimethylsilyl)oxy]ethyl]phenyl]ethanone 737827-38-2P, N-[4-[3-(2-Hydroxyethyl)phenyl]thiazol-2-yl]acetamide 737827-39-3P, 2-[3-[2-(Acetyl amino)thiazol-4-yl]phenyl]ethyl methanesulfonate 737827-40-6P,  
 N-[4-[3-(2-Aminoethyl)phenyl]thiazol-2-yl]acetamide 737827-41-7P  
 737827-43-9P, tert-Butyl N-[4-[2-[2-(acetyl amino)-5-[(E)-2-[4-(methylsulfonyl)phenyl]ethenyl]thiazol-4-yl]ethyl]phenyl]carbamate  
 737827-44-0P, tert-Butyl N-[4-[2-[2-(acetyl amino)-5-[2-[4-(methylsulfonyl)phenyl]ethyl]thiazol-4-yl]ethyl]phenyl]carbamate  
 737827-45-1P, N-[4-[2-(4-Aminophenyl)ethyl]-5-[2-[4-(methylsulfonyl)phenyl]ethyl]thiazol-2-yl]acetamide 737827-46-2P  
 740816-44-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);  
 RACT (Reactant or reagent)

(intermediate; prepn. of thiazole derivs. as VAP-1 inhibitors for  
 treatment of macular edema and other VAP-1 assocd.  
 diseases)

IT 9001-53-0, Diamine oxidase 9001-66-5, Monoamine oxidase

RL: BSU (Biological study, unclassified); BIOL

(Biological study)

(prepn. of thiazole derivs. as VAP-1 inhibitors for  
 treatment of macular edema and other VAP-1 assocd.  
 diseases)

IT 62-53-3, Aniline, reactions 70-23-5, Ethyl 3-bromo-2-oxopropanoate  
 79-30-1, Isobutyryl chloride 79-44-7, Dimethylcarbamy l chloride  
 95-92-1, Diethyl oxalate 100-11-8, 1-(Bromomethyl)-4-nitrobenzene  
 102-52-3, 1,1,3,3-Tetramethoxypropane 156-06-9,  
 2-Oxo-3-phenylpropanoic acid 501-53-1, Benzyloxycarbonyl chloride  
 524-38-9, 2-Hydroxy-1H-isoindole-1,3(2H)-dione 532-55-8, Benzoyl  
 isothiocyanate 543-24-8, (Acetyl amino)acetic acid 555-16-8,  
 p-Nitrobenzaldehyde, reactions 591-08-2, 1-Acetyl-2-thiourea  
 638-07-3, Ethyl 4-chloro-3-oxobutanoate 877-95-2,  
 N-(2-Phenylethyl)acetamide 1074-82-4, Phthalimide potassium salt  
 1099-45-2, [(Carbethoxy)methylene]triphenylphosphorane 1253-46-9,  
 [4-(Methoxycarbonyl)benzyl]triphenylphosphonium bromide 1778-09-2,  
 1-[4-(Methylthio)phenyl]ethanone 1878-67-7, (3-Bromophenyl)acetic  
 acid 2605-67-6, Methyl 2-(triphenylphosphoranylidene)acetate  
 3446-89-7, 4-(Methylsulfonyl)benzaldehyde 3958-57-4,  
 1-(Bromomethyl)-3-nitrobenzene 4530-20-5, [(tert-  
 Butoxycarbonyl)amino]acetic acid 5345-27-7, 3-  
 (Methylsulfonyl)benzoic acid 5398-36-7, Ethyl 2-aminothiazole-4-  
 carboxylate 17201-43-3, 4-(Bromomethyl)benzonitrile 18162-48-6,  
 tert-Butyldimethylsilyl chloride 18600-42-5, (4-Nitrobenzyl)amine  
 hydrochloride 19975-56-5, 2-(Methylsulfonyl)-4,5-dihydrothiazole  
 39684-80-5, tert-Butyl (2-bromoethyl)carbamate 40235-68-5,  
 3-Chloro-2-oxopropyl acetate 51779-32-9, Di(tert-butyl)  
 iminodicarboxylate 63545-55-1, 3-(4-Mercaptophenyl)propanoic acid  
 64920-29-2, Ethyl 2-oxo-4-phenylbutanoate 71026-66-9, tert-Butyl  
 (4-aminophenyl)carbamate 77900-13-1 83171-39-5,  
 [4-(Methylthio)benzyl]amine 111608-52-7, Ethyl  
 [4-(chloromethyl)thiazol-2-yl]carbamate 149596-90-7,  
 (2S)-2-[(N,N-Dimethylamino)carbonyl]pyrrolidine hydrochloride

152120-54-2, N,N'-Bis(tert-butoxycarbonyl)-1H-pyrazole-1-carboximidamide 157126-75-5, Ethyl 3-(4-iodophenyl)propanoate 162011-69-0, Methyl 4-[[4-(methylthio)phenyl]acetyl]benzoate 188814-80-4, Ethyl 2-(methylsulfanyl)-4,5-dihydro-1H-imidazole-1-carboxylate 737823-43-7 737825-26-2

RL: RCT (Reactant); RACT (Reactant or reagent)  
(prepn. of thiazole derivs. as VAP-1 inhibitors for  
treatment of macular edema and other VAP-1 assocd.  
diseases)

L32 ANSWER 11 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:220328 HCAPLUS

DOCUMENT NUMBER: 140:270869

TITLE: Preparation of pyrimidinylindolecarboxamides and pyrimidinylbenzimidazolecarboxamides as inhibitors of IκB kinase.

INVENTOR(S): Ritzeler, Olaf; Jaehne, Gerhard

PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany

SOURCE: PCT Int. Appl., 56 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004022553	A1	20040318	WO 2003-EP8629	20030805
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10237722	A1	20040819	DE 2002-10237722	20020817
CA 2498559	AA	20040318	CA 2003-2498559	20030805
EP 1530568	A1	20050518	EP 2003-793685	20030805
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005539054	T2	20051222	JP 2004-533319	20030805
US 2005197353	A1	20050908	US 2003-642970	20030818
NO 2005001337	A	20050503	NO 2005-1337	




PRIORITY APPLN. INFO.:	DE 2002-10237722	A	200503 15
			200208 17
	US 2002-434749P	P	200212 19
	WO 2003-EP8629	W	200308 05

OTHER SOURCE(S):           MARPAT 140:270869  
GI




AB Title compds. [I; X, M = N, CH; R1, R11 = H, F, Cl, Br, iodo, alkyl, cyano, CF3, OR5, NR5R6, COR5, SOxR5, etc.; x = 0-2; R3, R5, R6 = H, alkyl; R2 = (substituted) imidazolyl, imidazolidinyl, indazolyl, isothiazolyl, isoxazolyl, morpholinyl, piperazinyl, pyrazolyl, tetrazolyl, thiadiazolyl, thiazolyl, thiomorpholinyl, triazolyl, etc.; R4 = (substituted) (fused) pyrrolyl, furyl, thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, tetrazolyl, phthalazinyl, isoquinolinyl, quinoxalinyl, quinazolinyl, etc.], were prepd. Thus, 2-(2-methylaminopyrimidin-4-yl)-1H-indole-5-carboxylic acid [(S)-2-diphenylamino-1-hydrazinocarbonyl ethyl]amide (prepn. given) in CH2Cl2 was treated with phosgene followed by stirring for 15 h to give 76% 2-(2-methylaminopyrimidin-4-yl)-1H-indole-5-carboxylic acid [(S)-2-diphenylamino-1-(5-oxo-4,5-dihydro[1,3,4]-oxadiazol-2-yl)ethyl]amide. The latter inhibited IκB kinase with IC50 = 0.050 μM.

IT 33142-18-6P 673488-60-3P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);  
 RACT (Reactant or reagent)  
 (prepn. of pyrimidinylindolecarboxamides and  
 pyrimidinylbenzimidazolecarboxamides as inhibitors of IκB  
 kinase)  
 RN 33142-18-6 HCAPLUS  
 CN 2-Thiazolamine, N-phenyl- (9CI) (CA INDEX NAME)



RN 673488-60-3 HCAPLUS

CN Alanine, N,N-bis[(1,1-dimethylethoxy)carbonyl]-3-(phenyl-2-thiazolylamino)-, methyl ester (9CI) (CA INDEX NAME)



IC ICM C07D401-14

ICS C07D403-12

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1

ST pyrimidinylindolecarboxamide pyrimidinylbenzimidazolecarboxamide  
 prepn IkB kinase inhibitor; cancer gout septic shock viral infection  
**treatment** pyrimidinylindolecarboxamide  
 pyrimidinylbenzimidazolecarboxamide; influenza hepatitis aids  
 malaria leprosy **treatment** pyrimidinylindolecarboxamide  
 pyrimidinylbenzimidazolecarboxamide prepn; fungal infection brain  
**inflammation lung disease treatment**  
 pyrimidinylindolecarboxamide pyrimidinylbenzimidazolecarboxamide;  
 chronic bronchitis **asthma** acute synovitis  
**treatment** pyrimidinylindolecarboxamide  
 pyrimidinylbenzimidazolecarboxamide prepn; acute respiratory  
 distress syndrome tuberculosis **psoriasis treatment**  
 pyrimidinylindolecarboxamide pyrimidinylbenzimidazolecarboxamide

IT **Inflammation**

(Crohn's **disease, treatment**; prepn. of  
 pyrimidinylindolecarboxamides and pyrimidinylbenzimidazolecarboxa  
 mides as inhibitors of IkB kinase)

IT Intestine, **disease**

(Crohn's, **treatment**; prepn. of  
 pyrimidinylindolecarboxamides and pyrimidinylbenzimidazolecarboxa  
 mides as inhibitors of IkB kinase)

IT **Disease, animal**

(arthropathy, **treatment**; prepn. of  
 pyrimidinylindolecarboxamides and pyrimidinylbenzimidazolecarboxa  
 mides as inhibitors of IkB kinase)

IT Bronchi, **disease****Inflammation**

(chronic bronchitis, **treatment**; prepn. of  
 pyrimidinylindolecarboxamides and pyrimidinylbenzimidazolecarboxa  
 mides as inhibitors of IkB kinase)

IT Lung, **disease**

(chronic **inflammatory lung disease**  
**treatment**; prepn. of pyrimidinylindolecarboxamides and  
 pyrimidinylbenzimidazolecarboxamides as inhibitors of IkB  
 kinase)

IT Muscle, **disease**

(degeneration, **treatment**; prepn. of



pyrimidinylindolecarboxamides and pyrimidinylbenzimidazolecarboxamides as inhibitors of IκB kinase)

IT Human adenovirus  
Human herpesvirus  
(**disease treatment**; prepn. of pyrimidinylindolecarboxamides and pyrimidinylbenzimidazolecarboxamides as inhibitors of IκB kinase)

IT Joint, anatomical  
(**disease, treatment**; prepn. of pyrimidinylindolecarboxamides and pyrimidinylbenzimidazolecarboxamides as inhibitors of IκB kinase)

IT Heart, **disease**  
(infarction, **treatment**; prepn. of pyrimidinylindolecarboxamides and pyrimidinylbenzimidazolecarboxamides as inhibitors of IκB kinase)

IT Intestine, **disease**  
(**inflammatory, treatment**; prepn. of pyrimidinylindolecarboxamides and pyrimidinylbenzimidazolecarboxamides as inhibitors of IκB kinase)

IT Muscle, **disease**  
Pain  
(myalgia, **treatment**; prepn. of pyrimidinylindolecarboxamides and pyrimidinylbenzimidazolecarboxamides as inhibitors of IκB kinase)

IT Tumor necrosis factors  
RL: **BSU (Biological study, unclassified); BIOL (Biological study)**  
(overexpression treatment; prepn. of pyrimidinylindolecarboxamides and pyrimidinylbenzimidazolecarboxamides as inhibitors of IκB kinase)

IT Inflammation  
Spinal column, **disease**  
(spondylitis, **treatment**; prepn. of pyrimidinylindolecarboxamides and pyrimidinylbenzimidazolecarboxamides as inhibitors of IκB kinase)

IT Artery, **disease**  
(stenosis, **treatment**; prepn. of pyrimidinylindolecarboxamides and pyrimidinylbenzimidazolecarboxamides as inhibitors of IκB kinase)

IT Arthritis  
Synovial membrane, **disease**  
(synovitis, **treatment**; prepn. of pyrimidinylindolecarboxamides and pyrimidinylbenzimidazolecarboxamides as inhibitors of IκB kinase)

IT AIDS (**disease**)  
Alzheimer's **disease**  
Arthritis  
**Asthma**  
Atherosclerosis  
Cachexia  
Connective tissue, **disease**  
Diabetes mellitus  
Encephalitis  
Gout  
Hepatitis  
Inflammation  
Influenza  
Leprosy  
Malaria  
Multiple sclerosis  
Mycosis  
Neoplasm

Osteoarthritis  
Periodontium, disease

**Psoriasis**

Rheumatoid arthritis  
Transplant rejection

Tuberculosis

Ulcer

(treatment; prepn. of pyrimidinylindolecarboxamides and  
pyrimidinylbenzimidazolecarboxamides as inhibitors of IκB  
kinase)

IT 159606-08-3, IκB Kinase

RL: **BSU (Biological study, unclassified); BIOL  
(Biological study)**

(inhibitors; prepn. of pyrimidinylindolecarboxamides and  
pyrimidinylbenzimidazolecarboxamides as inhibitors of IκB  
kinase)

IT 669713-30-8P 669713-32-0P 673488-41-0P 673488-42-1P  
673488-43-2P 673488-44-3P 673488-45-4P 673488-46-5P  
673488-47-6P 673488-48-7P 673488-49-8P 673488-50-1P  
673488-51-2P 673488-52-3P 673488-53-4P

RL: **PAC (Pharmacological activity); SPN (Synthetic  
preparation); THU (Therapeutic use); BIOL (Biological  
study); PREP (Preparation); USES (Uses)**

(prepn. of pyrimidinylindolecarboxamides and  
pyrimidinylbenzimidazolecarboxamides as inhibitors of IκB  
kinase)

IT 22536-61-4P, 2-Chloro-5-methylpyrimidine 26054-60-4P  
**33142-18-6P** 57356-49-7P, 2-Anilinopyrimidine 67751-23-9P  
72358-70-4P 106157-94-2P 180869-38-9P 180869-39-0P  
201338-62-7P 669713-33-1P 669713-34-2P 669713-35-3P  
669713-36-4P 669713-38-6P 669713-39-7P 669713-40-0P  
669713-43-3P 669713-45-5P 673488-54-5P 673488-55-6P  
673488-56-7P 673488-57-8P 673488-58-9P 673488-59-0P  
**673488-60-3P** 673488-61-4P 673488-62-5P 673488-63-6P  
673488-64-7P 673488-65-8P 673488-66-9P 673488-67-0P  
673488-68-1P 673488-69-2P 673488-70-5P 673488-71-6P  
673488-72-7P 673488-73-8P

RL: **RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);  
RACT (Reactant or reagent)**

(prepn. of pyrimidinylindolecarboxamides and  
pyrimidinylbenzimidazolecarboxamides as inhibitors of IκB  
kinase)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR  
THIS RECORD. ALL CITATIONS AVAILABLE IN  
THE RE FORMAT

L32 ANSWER 12 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:220082 HCAPLUS

DOCUMENT NUMBER: 140:253556

TITLE: Preparation of 5-thiazolecarboxamides as protein  
tyrosine kinase inhibitors

INVENTOR(S): Das, Jagabandhu; Padmanabha, Ramesh; Chen, Ping;  
Norris, Derek J.; Doweiko, Arthur M. P.;  
Barrish, Joel C.; Wityak, John; Lombardo, Louis  
J.; Lee, Francis Y. F.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 184 pp., Cont.-in-part of  
U.S. 6,596,746.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 2

## PATENT INFORMATION:

PATENT NO. -----	KIND ----	DATE -----	APPLICATION NO. -----	DATE
US 2004054186	A1	20040318	US 2003-395503	200303 24
US 6596746	B1	20030722	US 2000-548929	200004 13
US 2004024208	A1	20040205	US 2003-378372	200303 03
US 6979694	B2	20051227		
US 2004073026	A1	20040415	US 2003-378461	200303 03
US 2004077875	A1	20040422	US 2003-378373	200303 03
CA 2519898	AA	20041007	CA 2004-2519898	200403 23
WO 2004085388	A2	20041007	WO 2004-US8827	200403 23
WO 2004085388	A3	20050630		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1610780	A2	20060104	EP 2004-758053	200403 23
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
US 2005261305	A1	20051124	US 2005-138793	200505 25
US 2005288303	A1	20051229	US 2005-138942	200505 26
NO 2005004359	A	20051019	NO 2005-4359	200509 20
PRIORITY APPLN. INFO.:			US 1999-129510P	P 199904 15
			US 2000-548929	A2 200004 13

US 2003-378373	A1	200303 03
US 2003-395503	A	200303 24
WO 2004-US8827	W	200403 23

OTHER SOURCE(S):           MARPAT 140:253556  
GI




AB The title compds. [I; Q = (un)substituted 5-6 membered heteroaryl, aryl; Z = a single bond, R15C:CH, (CH2)m (m = 1-2); X1, X2 = H; X1 and X2 together = O, S; R1 = H, alkyl, alkenyl, etc.; R2, R3 = H, alkyl, alkenyl, etc.; R4, R5 = H, alkyl, alkenyl, etc.], useful in the treatment of protein tyrosine kinase-assocd. disorders such as immunol. and oncol. disorders (no data), were prepd. E.g., a multi-step synthesis of thiazole II was given. Compds. I are effective at 0.1-100 mg/kg/day. The pharmaceutical compn. comprising the title compds. is claimed.

IT 302963-67-3P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(prepn. of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors)

RN 302963-67-3 HCAPLUS


CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[(3,4,5-trimethoxyphenyl)amino]- (9CI) (CA INDEX NAME)




IT 302961-94-0P 302961-95-1P 302961-96-2P  
 302961-99-5P 302962-00-1P 302962-01-2P  
 302962-02-3P 302962-03-4P 302962-18-1P  
 302962-19-2P 302963-29-7P 302963-65-1P  
 302963-66-2P 302963-68-4P 302963-69-5P  
 302963-70-8P 302963-71-9P 302963-72-0P  
 302963-73-1P 302963-74-2P 302963-75-3P  
 302963-76-4P 302963-77-5P 302963-81-1P  
 302963-82-2P 302963-87-7P 302963-88-8P  
 302963-89-9P 302963-90-2P 302963-91-3P  
 RL: PAC (Pharmacological activity); SPN (Synthetic  
 preparation); THU (Therapeutic use); BIOL (Biological  
 study); PREP (Preparation); USES (Uses)  
 (prepn. of 5-thiazolecarboxamides as protein tyrosine kinase  
 inhibitors)  
 RN 302961-94-0 HCAPLUS  
 CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-(phenylamino)-  
 (9CI) (CA INDEX NAME)




RN 302961-95-1 HCAPLUS  
 CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[(3-  
 ethylphenyl)amino]- (9CI) (CA INDEX NAME)



RN 302961-96-2 HCAPLUS  
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[(3,5-dimethylphenyl)amino]- (9CI) (CA INDEX NAME)




RN 302961-99-5 HCAPLUS  
CN 5-Thiazolecarboxamide, 2-[(3-aminophenyl)amino]-N-(2-chloro-6-methylphenyl)- (9CI) (CA INDEX NAME)




RN 302962-00-1 HCAPLUS

CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[(3-hydroxyphenyl)amino]- (9CI) (CA INDEX NAME)




RN 302962-01-2 HCAPLUS

CN 5-Thiazolecarboxamide, 2-[(3-bromophenyl)amino]-N-(2-chloro-6-methylphenyl)- (9CI) (CA INDEX NAME)




RN 302962-02-3 HCAPLUS

CN 5-Thiazolecarboxamide, N-(2,6-dimethylphenyl)-2-(phenylamino)- (9CI) (CA INDEX NAME)






RN 302962-03-4 HCAPLUS

CN 5-Thiazolecarboxamide, N-(2,6-dimethylphenyl)-2-(methylphenylamino)-  
(9CI) (CA INDEX NAME)


RN 302962-18-1 HCAPLUS

CN 5-Thiazolecarboxamide, 2-[(3-aminophenyl)amino]-N-(2,6-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 302962-19-2 HCAPLUS


CN 5-Thiazolecarboxamide, 2-[(3-bromophenyl)amino]-N-(2,6-dimethylphenyl)- (9CI) (CA INDEX NAME)



RN 302963-29-7 HCAPLUS  
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-(2-naphthalenylamino)- (9CI) (CA INDEX NAME)




RN 302963-65-1 HCAPLUS  
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[3-[[3-(1H-imidazol-1-yl)propyl]amino]phenyl]amino]- (9CI) (CA INDEX NAME)




RN 302963-66-2 HCAPLUS

CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[5-[[3-(1H-imidazol-1-yl)propyl]amino]-2-nitrophenyl]amino] - (9CI) (CA INDEX NAME)




RN 302963-68-4 HCAPLUS

CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[(4-methoxyphenyl)amino] - (9CI) (CA INDEX NAME)




RN 302963-69-5 HCAPLUS

CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[(3-methoxyphenyl)amino] - (9CI) (CA INDEX NAME)




RN 302963-70-8 HCAPLUS

CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[(2-methoxyphenyl)amino] - (9CI) (CA INDEX NAME)




RN 302963-71-9 HCAPLUS


CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[(3,5-dimethoxyphenyl)amino] - (9CI) (CA INDEX NAME)




RN 302963-72-0 HCAPLUS  
 CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[4-(dimethylamino)phenyl]amino] - (9CI) (CA INDEX NAME)




RN 302963-73-1 HCAPLUS  
 CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[4-(4-morpholinyl)phenyl]amino] - (9CI) (CA INDEX NAME)




RN 302963-74-2 HCAPLUS  
 CN Benzeneacetic acid, 3-[[5-[[[(2-chloro-6-methylphenyl)amino]carbonyl]-2-thiazolyl]amino] - (9CI) (CA INDEX NAME)




RN 302963-75-3 HCAPLUS  
 CN Benzenebutanoic acid, 3-[[5-[[[(2-chloro-6-methylphenyl)amino]carbonyl]-2-thiazolyl]amino]- (9CI) (CA INDEX NAME)



RN 302963-76-4 HCAPLUS  
 CN Benzeneacetic acid, 4-[[5-[[[(2-chloro-6-methylphenyl)amino]carbonyl]-2-thiazolyl]amino]- (9CI) (CA INDEX NAME)




RN 302963-77-5 HCAPLUS  
 CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[(2-methyl-1H-benzimidazol-5-yl)amino]- (9CI) (CA INDEX NAME)




RN 302963-81-1 HCAPLUS

CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[(1-methyl-1H-benzimidazol-6-yl)amino] - (9CI) (CA INDEX NAME)



RN 302963-82-2 HCAPLUS


CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[(1-methyl-1H-benzimidazol-5-yl)amino] - (9CI) (CA INDEX NAME)



RN 302963-87-7 HCAPLUS

CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[3-[3-(1H-imidazol-1-yl)propoxy]phenyl]amino] - (9CI) (CA INDEX NAME)







RN 302963-88-8 HCAPLUS

CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[4-[3-(1H-imidazol-1-yl)propoxy]phenyl]amino] - (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 302963-89-9 HCAPLUS  
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[4-[2-(1H-imidazol-1-yl)ethoxy]-3-methoxyphenyl]amino] - (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 302963-90-2 HCAPLUS  
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[[3-[[[3-(1H-imidazol-1-yl)propyl]amino]sulfonyl]phenyl]amino] - (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 302963-91-3 HCAPLUS  
 CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[4-[[[3-(1H-imidazol-1-yl)propyl]amino]sulfonyl]phenyl]amino]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




IT 302964-13-2P 302964-14-3P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);  
RACT (Reactant or reagent)  
(prepn. of 5-thiazolecarboxamides as protein tyrosine kinase  
inhibitors)  
RN 302964-13-2 HCAPLUS  
CN 5-Thiazolecarboxylic acid, 2-[(5-fluoro-2-nitrophenyl)amino]-, ethyl  
ester (9CI) (CA INDEX NAME)



RN 302964-14-3 HCAPLUS

CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[(5-fluoro-2-nitrophenyl)amino] - (9CI) (CA INDEX NAME)



IC ICM C07D041-02

ICS C07D043-02; C07D213-72; C07D207-22

INCL 546268100; 546304000; 548517000; 548557000; 548530000

CC 28-7 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

IT Nervous system, **disease**

(Guillain-Barre syndrome, **treatment** of; prepn. of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors)

IT Transcription factors

RL: BSU (Biological study, unclassified); BIOL

(Biological study)

(IκB (inhibitor of NF-κB), co-administration with inhibitors of; prepn. of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors for treating immunol. and oncol. disorders in combination with other agents)

IT Allergy

Inflammation

Nose, **disease**

(allergic rhinitis, **treatment** of; prepn. of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors)

IT Autoimmune **disease**

Inflammation

Thyroid gland, **disease**

(autoimmune thyroiditis, **treatment** of; prepn. of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors)

IT Lung, **disease**

(chronic obstructive pulmonary **disease**, **treatment** of; prepn. of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors)

IT Tumor necrosis factors  
 RL: **THU (Therapeutic use); BIOL (Biological study)**  
 ; USES (Uses)  
 (co-administration with TNF- $\alpha$  inhibitors; prepn. of  
 5-thiazolecarboxamides as protein tyrosine kinase inhibitors for  
 treating immunol. and oncol. disorders in combination with other  
 agents)

IT CD40 (antigen)  
 RL: **BSU (Biological study, unclassified); BIOL**  
**(Biological study)**  
 (co-administration with agents blocking the interaction between  
 CD40 and gp39; prepn. of 5-thiazolecarboxamides as protein  
 tyrosine kinase inhibitors for treating immunol. and oncol.  
 disorders in combination with other agents)

IT Tumor necrosis factor receptors  
 RL: **THU (Therapeutic use); BIOL (Biological study)**  
 ; USES (Uses)  
 (co-administration with sol.; prepn. of 5-thiazolecarboxamides as  
 protein tyrosine kinase inhibitors for treating immunol. and  
 oncol. disorders in combination with other agents)

IT Antibodies and Immunoglobulins  
 Steroids, biological studies  
 RL: **THU (Therapeutic use); BIOL (Biological study)**  
 ; USES (Uses)  
 (co-administration; prepn. of 5-thiazolecarboxamides as protein  
 tyrosine kinase inhibitors for treating immunol. and oncol.  
 disorders in combination with other agents)

IT Eye, **disease**  
 (diabetic retinopathy, **treatment** of; prepn. of  
 5-thiazolecarboxamides as protein tyrosine kinase inhibitors)

IT Macrolides  
 RL: **THU (Therapeutic use); BIOL (Biological study)**  
 ; USES (Uses)  
 (epothilones, co-administration; prepn. of 5-thiazolecarboxamides  
 as protein tyrosine kinase inhibitors for treating immunol. and  
 oncol. disorders in combination with other agents)

IT Allergy  
 (hypersensitivity, **treatment** of T-cell mediated  
 hypersensitivity **disease**; prepn. of  
 5-thiazolecarboxamides as protein tyrosine kinase inhibitors)

IT Intestine, **disease**  
 (**inflammatory, treatment** of; prepn. of  
 5-thiazolecarboxamides as protein tyrosine kinase inhibitors)

IT Antibodies and Immunoglobulins  
 RL: **THU (Therapeutic use); BIOL (Biological study)**  
 ; USES (Uses)  
 (monoclonal, co-administration with monoclonal antibody OKT3;  
 prepn. of 5-thiazolecarboxamides as protein tyrosine kinase  
 inhibitors for treating immunol. and oncol. disorders in  
 combination with other agents)

IT T cell (lymphocyte)  
 (prepn. of 5-thiazolecarboxamides as protein tyrosine kinase  
 inhibitors for **treating** T-cell mediated  
**diseases**)

IT Allergy  
**Asthma**  
 Ischemia  
 Lupus erythematosus  
 Multiple sclerosis  
 Neoplasm  
**Psoriasis**  
 Rheumatoid arthritis

Transplant rejection  
 (treatment of; prepn. of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors)

IT 329900-75-6, Cyclooxygenase-2  
 RL: **BSU (Biological study, unclassified); BIOL (Biological study)**  
 (co-administration with cyclooxygenase-2 inhibitors; prepn. of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors for treating immunol. and oncol. disorders in combination with other agents)

IT 50-07-7, Mitomycin C 50-44-2, 6-Mercaptopurine 51-21-8, 5-Fluorouracil 54-62-6, Aminopterin 57-22-7, Vincristine 59-05-2, Methotrexate 147-94-4, Cytosine arabinoside 148-82-3, Melphalan 518-28-5, Podophyllotoxin 801-52-5, Porfiromycin 865-21-4, Vinblastine 2410-93-7, Methopterin 7440-57-5D, Gold, compds. 15228-71-4, Leurosine 15663-27-1, Cisplatin 20830-81-3, Daunorubicin 23214-92-8, Doxorubicin 23360-92-1, Leurosine 29767-20-2, Teniposide 33069-62-4, Paclitaxel 33419-42-0, Etoposide 41575-94-4, Carboplatin 50935-04-1 53123-88-9, Rapamycin 53643-48-4, Vindesine 59865-13-3, Cyclosporin A 95058-81-4, Gemcitabine 104987-11-3, FK506 114899-77-3, Ecteinascidin 743 117091-64-2, Etoposide phosphate 128794-94-5, Mycophenolate mofetil  
 RL: **THU (Therapeutic use); BIOL (Biological study)**  
 ; USES (Uses)  
 (co-administration; prepn. of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors for treating immunol. and oncol. disorders in combination with other agents)

IT 79079-06-4, Her1 kinase 114051-78-4, Lck kinase 137632-09-8, Her2 kinase 140208-17-9, Lyn kinase 141349-87-3, Fyn kinase 141349-89-5, Src kinase 141349-91-9, Yes kinase 144941-32-2, Fgr kinase 144941-35-5, Blk kinase 145539-86-2, Hck kinase  
 RL: **BSU (Biological study, unclassified); BIOL (Biological study)**  
 (prepn. of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors)

IT 21697-42-7P 302957-83-1P 302957-85-3P 302957-89-7P  
 302957-93-3P 302957-95-5P 302957-97-7P 302958-00-5P  
 302958-02-7P 302958-03-8P 302958-04-9P 302958-05-0P  
 302958-06-1P 302959-19-9P 302959-21-3P 302959-25-7P  
 302959-38-2P 302959-76-8P 302961-18-8P 302961-98-4P  
 302963-13-9P 302963-14-0P 302963-42-4P 302963-43-5P  
 302963-44-6P 302963-67-3P  
 RL: **PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)**  
 (prepn. of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors)

IT 302957-87-5P 302957-91-1P 302957-94-4P 302957-96-6P  
 302957-99-9P 302958-01-6P 302958-07-2P 302958-08-3P  
 302958-09-4P 302958-10-7P 302958-11-8P 302958-12-9P  
 302958-13-0P 302958-14-1P 302958-15-2P 302958-16-3P  
 302958-17-4P 302958-18-5P 302958-19-6P 302958-20-9P  
 302958-21-0P 302958-22-1P 302958-23-2P 302958-24-3P  
 302958-25-4P 302958-26-5P 302958-27-6P 302958-28-7P  
 302958-29-8P 302958-30-1P 302958-31-2P 302958-32-3P  
 302958-33-4P 302958-34-5P 302958-35-6P 302958-36-7P  
 302958-37-8P 302958-38-9P 302958-39-0P 302958-40-3P  
 302958-41-4P 302958-42-5P 302958-43-6P 302958-44-7P  
 302958-45-8P 302958-46-9P 302958-47-0P 302958-48-1P  
 302958-49-2P 302958-50-5P 302958-51-6P 302958-52-7P



302958-53-8P	302958-54-9P	302958-55-0P	302958-56-1P
302958-57-2P	302958-58-3P	302958-59-4P	302958-60-7P
302958-61-8P	302958-62-9P	302958-63-0P	302958-64-1P
302958-65-2P	302958-66-3P	302958-67-4P	302958-68-5P
302958-69-6P	302958-70-9P	302958-71-0P	302958-72-1P
302958-73-2P	302958-74-3P	302958-75-4P	302958-76-5P
302958-77-6P	302958-78-7P	302958-79-8P	302958-80-1P
302958-81-2P	302958-82-3P	302958-83-4P	302958-84-5P
302958-85-6P	302958-86-7P	302958-87-8P	302958-88-9P
302958-89-0P	302958-90-3P	302958-91-4P	302958-92-5P
302958-93-6P	302958-94-7P	302958-95-8P	302958-96-9P
302958-97-0P	302958-98-1P	302958-99-2P	302959-00-8P
302959-01-9P	302959-02-0P	302959-03-1P	302959-04-2P
302959-05-3P	302959-06-4P	302959-07-5P	302959-08-6P
302959-09-7P	302959-10-0P	302959-11-1P	302959-12-2P
302959-13-3P	302959-14-4P	302959-15-5P	302959-16-6P
302959-17-7P	302959-18-8P	302959-20-2P	302959-23-5P
302959-24-6P	302959-27-9P	302959-29-1P	302959-31-5P
302959-34-8P	302959-35-9P	302959-37-1P	302959-39-3P
302959-41-7P	302959-42-8P	302959-43-9P	302959-44-0P
302959-45-1P	302959-46-2P	302959-47-3P	302959-48-4P
302959-49-5P	302959-50-8P	302959-51-9P	302959-52-0P
302959-53-1P	302959-54-2P	302959-55-3P	302959-56-4P
302959-57-5P	302959-58-6P	302959-59-7P	302959-60-0P
302959-61-1P	302959-62-2P	302959-63-3P	302959-64-4P
302959-65-5P	302959-66-6P	302959-67-7P	302959-68-8P
302959-69-9P	302959-70-2P	302959-71-3P	302959-72-4P
302959-73-5P	302959-74-6P	302959-75-7P	302959-77-9P
302959-78-0P	302959-79-1P	302959-80-4P	302959-81-5P
302959-82-6P	302959-83-7P	302959-84-8P	302959-85-9P
302959-86-0P	302959-87-1P	302959-88-2P	302959-89-3P
302959-90-6P	302959-91-7P	302959-92-8P	302959-93-9P
302959-94-0P	302959-95-1P	302959-96-2P	302959-97-3P
302959-98-4P	302959-99-5P	302960-00-5P	302960-01-6P
302960-02-7P	302960-03-8P	302960-04-9P	302960-05-0P
302960-06-1P	302960-07-2P	302960-08-3P	302960-09-4P
302960-10-7P	302960-11-8P	302960-12-9P	302960-13-0P
302960-14-1P	302960-15-2P	302960-16-3P	302960-17-4P
302960-18-5P	302960-19-6P	302960-20-9P	302960-21-0P
302960-22-1P	302960-23-2P	302960-24-3P	302960-25-4P
302960-26-5P	302960-27-6P	302960-28-7P	302960-29-8P
302960-30-1P	302960-31-2P	302960-32-3P	302960-33-4P
302960-34-5P	302960-35-6P	302960-36-7P	302960-37-8P
302960-38-9P	302960-39-0P	302960-40-3P	302960-41-4P
302960-42-5P	302960-43-6P	302960-44-7P	302960-45-8P
302960-46-9P	302960-47-0P		

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors)

IT	302960-48-1P	302960-49-2P	302960-50-5P	302960-51-6P
	302960-52-7P	302960-53-8P	302960-54-9P	302960-55-0P
	302960-56-1P	302960-57-2P	302960-58-3P	302960-59-4P
	302960-60-7P	302960-61-8P	302960-62-9P	302960-63-0P
	302960-64-1P	302960-65-2P	302960-67-4P	302960-69-6P
	302960-70-9P	302960-71-0P	302960-72-1P	302960-73-2P
	302960-74-3P	302960-75-4P	302960-76-5P	302960-77-6P
	302960-78-7P	302960-79-8P	302960-80-1P	302960-81-2P
	302960-82-3P	302960-83-4P	302960-84-5P	302960-85-6P
	302960-86-7P	302960-87-8P	302960-88-9P	302960-89-0P
	302960-90-3P	302960-91-4P	302960-92-5P	302960-93-6P

302960-94-7P	302960-95-8P	302960-96-9P	302960-97-0P
302960-98-1P	302960-99-2P	302961-00-8P	302961-01-9P
302961-02-0P	302961-03-1P	302961-04-2P	302961-05-3P
302961-06-4P	302961-07-5P	302961-08-6P	302961-09-7P
302961-10-0P	302961-11-1P	302961-12-2P	302961-13-3P
302961-14-4P	302961-15-5P	302961-16-6P	302961-17-7P
302961-19-9P	302961-20-2P	302961-21-3P	302961-22-4P
302961-23-5P	302961-24-6P	302961-25-7P	302961-26-8P
302961-27-9P	302961-28-0P	302961-29-1P	302961-30-4P
302961-31-5P	302961-32-6P	302961-33-7P	302961-34-8P
302961-35-9P	302961-36-0P	302961-37-1P	302961-38-2P
302961-39-3P	302961-40-6P	302961-41-7P	302961-42-8P
302961-43-9P	302961-44-0P	302961-45-1P	302961-46-2P
302961-47-3P	302961-48-4P	302961-49-5P	302961-50-8P
302961-51-9P	302961-52-0P	302961-53-1P	302961-54-2P
302961-55-3P	302961-56-4P	302961-57-5P	302961-58-6P
302961-59-7P	302961-60-0P	302961-61-1P	302961-62-2P
302961-63-3P	302961-64-4P	302961-65-5P	302961-66-6P
302961-67-7P	302961-69-9P	302961-70-2P	302961-71-3P
302961-72-4P	302961-73-5P	302961-74-6P	302961-75-7P
302961-76-8P	302961-77-9P	302961-78-0P	302961-79-1P
302961-80-4P	302961-81-5P	302961-82-6P	302961-83-7P
302961-84-8P	302961-85-9P	302961-86-0P	302961-87-1P
302961-88-2P	302961-89-3P	302961-90-6P	302961-91-7P
302961-92-8P	302961-93-9P	302961-94-0P	
302961-95-1P	302961-96-2P	302961-97-3P	
302961-99-5P	302962-00-1P	302962-01-2P	
302962-02-3P	302962-03-4P	302962-04-5P	
302962-05-6P	302962-06-7P	302962-07-8P	302962-08-9P
302962-09-0P	302962-10-3P	302962-11-4P	302962-12-5P
302962-13-6P	302962-14-7P	302962-15-8P	302962-16-9P
302962-17-0P	302962-18-1P	302962-19-2P	
302962-20-5P	302962-21-6P	302962-22-7P	302962-23-8P
302962-24-9P	302962-25-0P	302962-27-2P	302962-29-4P
302962-30-7P	302962-31-8P	302962-32-9P	302962-33-0P
302962-34-1P	302962-35-2P	302962-36-3P	302962-37-4P
302962-38-5P	302962-39-6P	302962-40-9P	302962-41-0P
302962-42-1P	302962-43-2P	302962-44-3P	302962-45-4P
302962-46-5P	302962-47-6P	302962-48-7P	302962-49-8P
302962-50-1P	302962-51-2P	302962-52-3P	302962-53-4P
302962-54-5P	302962-55-6P	302962-56-7P	302962-57-8P
302962-58-9P	302962-59-0P	302962-60-3P	302962-61-4P
302962-62-5P	302962-63-6P	302962-64-7P	302962-65-8P
302962-66-9P	302962-67-0P	302962-68-1P	302962-69-2P
302962-70-5P	302962-71-6P	302962-72-7P	302962-73-8P
302962-74-9P	302962-76-1P	302962-77-2P	302962-79-4P
302962-81-8P	302962-83-0P	302962-85-2P	302962-87-4P
302962-89-6P	302962-91-0P	302962-92-1P	302962-94-3P
302962-96-5P	302962-98-7P	302963-00-4P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors)

IT	302963-02-6P	302963-04-8P	302963-05-9P	302963-07-1P
	302963-09-3P	302963-11-7P	302963-15-1P	302963-16-2P
	302963-18-4P	302963-20-8P	302963-22-0P	302963-23-1P
	302963-24-2P	302963-25-3P	302963-26-4P	302963-27-5P
	302963-28-6P	302963-29-7P	302963-30-0P	302963-31-1P
	302963-32-2P	302963-33-3P	302963-34-4P	302963-35-5P
	302963-36-6P	302963-37-7P	302963-38-8P	302963-39-9P
	302963-40-2P	302963-41-3P	302963-45-7P	302963-46-8P

302963-47-9P 302963-48-0P 302963-49-1P 302963-50-4P  
302963-51-5P 302963-52-6P 302963-53-7P 302963-54-8P  
302963-55-9P 302963-56-0P 302963-57-1P 302963-58-2P  
302963-59-3P 302963-60-6P 302963-61-7P 302963-62-8P  
302963-63-9P 302963-64-0P 302963-65-1P  
302963-66-2P 302963-68-4P 302963-69-5P  
302963-70-8P 302963-71-9P 302963-72-0P  
302963-73-1P 302963-74-2P 302963-75-3P  
302963-76-4P 302963-77-5P 302963-78-6P  
302963-79-7P 302963-80-0P 302963-81-1P  
302963-82-2P 302963-83-3P 302963-84-4P 302963-85-5P  
302963-86-6P 302963-87-7P 302963-88-8P  
302963-89-9P 302963-90-2P 302963-91-3P  
302963-93-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors)

IT 3122-78-9P 3122-84-7P 129912-21-6P 210917-98-9P 244236-52-0P  
302963-94-6P 302963-95-7P 302963-96-8P 302963-97-9P  
302963-98-0P 302963-99-1P 302964-00-7P 302964-01-8P  
302964-02-9P 302964-03-0P 302964-04-1P 302964-05-2P  
302964-06-3P 302964-07-4P 302964-08-5P 302964-09-6P  
302964-10-9P 302964-12-1P 302964-13-2P  
302964-14-3P 302964-15-4P 302964-16-5P 302964-17-6P  
302964-18-7P 302964-19-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors)

IT 138238-67-2, BCR-ABL kinase

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(wherein cancer is sensitive(or resistant) to treatment by an inhibitor of; prepn. of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors for treating cancer)

L32 ANSWER 13 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:143145 HCAPLUS

DOCUMENT NUMBER: 140:199317

TITLE: Preparation of 2-(3-aminoaryl)amino-4-arylthiazoles as tyrosine phosphokinase c-kit inhibitors.

INVENTOR(S): Ciufolini, Marco; Wermuth, Camille; Gielthen, Bruno; Moussy, Alain

PATENT ASSIGNEE(S): Ab Science, Fr.

SOURCE: PCT Int. Appl., 125 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	
WO 2004014903	A1	20040219	WO 2003-IB3685	20030731

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD,

Ross Shipe EIC 1700 Remsen 4B31 571/272-6018

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,  
 LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,  
 NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,  
 SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,  
 ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,  
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,  
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
 NE, SN, TD, TG

CA 2494695 AA 20040219 CA 2003-2494695

200307  
31

EP 1525200 A1 20050427 EP 2003-784419

200307  
31

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,  
 PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU,  
 SK

BR 2003013165 A 20050614 BR 2003-13165

200307  
31

JP 2005539021 T2 20051222 JP 2004-527232

200307  
31

US 2004110810 A1 20040610 US 2003-632101

200308  
01

US 2005239852 A1 20051027 US 2005-523018

200502  
02

NO 2005001115 A 20050302 NO 2005-1115

200503  
02

PRIORITY APPLN. INFO.:



US 2002-400064P P

200208  
02

WO 2003-IB3685 W

200307  
31

OTHER SOURCE(S): MARPAT 140:199317  
 GI




AB Title compds. [I; (substituted) alkyl, aryl, heteroaryl, CONHR, COR, CONRR'; R, R' = H, aryl, heteroaryl, alkyl, cycloalkyl; R2-R5 = H halo, alkyl, CF3, alkoxy; R6, R7 = (substituted) aryl, heteroaryl, H, halo, amino, NO2, etc.], were prepd. Thus, 2-(2-methyl-5-aminophenyl)-4-(3-pyridyl)thiazole (prepn. given) in CH2Cl2 was treated with Me3Al in PhMe at 0°; the mixt. was stirred 0.5 h at room temp. and Me 4-[(4-methylpiperazin-1-yl)methyl]benzoate in CH2Cl2 was added followed by reflux for 5 h to give 72% title compd. (II). Numerous I inhibited c-kit with IC50 <10 μM.

IT 660837-07-0P 660837-08-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(prepn. of aminoarylaminophenylthiazoles as tyrosine phosphokinase c-kit inhibitors)


RN 660837-07-0 HCAPLUS

CN Carbamic acid, [4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]aminophenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 660837-08-1 HCAPLUS

CN 1,3-Benzenediamine, 4-methyl-N3-[4-(3-pyridinyl)-2-thiazolyl]- (9CI)  
(CA INDEX NAME)




IT 660836-74-8P 660836-76-0P 660836-78-2P  
 660836-79-3P 660836-80-6P 660836-81-7P  
 660836-82-8P 660836-83-9P 660836-84-0P  
 660836-88-4P 660836-89-5P 660836-90-8P  
 660836-98-6P 660836-99-7P 660837-13-8P  
 660837-14-9P 660837-16-1P 660837-17-2P  
 660837-18-3P 660837-20-7P 660837-33-2P  
 660837-44-5P 660837-45-6P 660837-46-7P  
 660837-47-8P 660837-48-9P 660837-49-0P  
 660837-50-3P 660837-52-5P 660837-54-7P  
 660837-55-8P 660837-56-9P 660837-57-0P  
 660837-60-5P 660837-61-6P 660837-62-7P  
 660837-63-8P 660837-66-1P 660837-67-2P  
 660837-78-5P 660837-82-1P 660837-85-4P  
 660837-86-5P 660837-87-6P 660837-88-7P  
 660837-89-8P 660837-90-1P 660837-91-2P  
 660837-92-3P 660837-93-4P 660837-94-5P  
 660837-95-6P 660837-96-7P 660837-97-8P  
 660837-99-0P 660838-01-7P 660838-02-8P  
 660838-03-9P 660838-04-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of aminoarylthiazoles as tyrosine phosphokinase c-kit inhibitors)


RN 660836-74-8 HCAPLUS

CN Benzamide, 4-[(diethylamino)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 660836-76-0 HCAPLUS


CN Benzamide, 4-[(dipropylamino)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 660836-78-2 HCAPLUS


CN Benzamide, 3-iodo-N-[4-methyl-3-[[4-(3-pyridinyl)-2-

thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 660836-79-3 HCAPLUS

CN Benzamide, 4-(hydroxymethyl)-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 660836-80-6 HCAPLUS

CN Benzoic acid, 4-[[[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 660836-81-7 HCAPLUS


CN 2-Propynamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]-3-phenyl- (9CI) (CA INDEX NAME)




RN 660836-82-8 HCAPLUS

CN Benzamide, 4-amino-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)







RN 660836-83-9 HCAPLUS  
 CN Benzamide, 2-iodo-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 660836-84-0 HCAPLUS  
 CN Benzamide, 4-iodo-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 660836-88-4 HCAPLUS  
 CN Carbamic acid, [[4-[[[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]amino]carbonyl]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 660836-89-5 HCAPLUS  
 CN Benzamide, 4-hydroxy-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 660836-90-8 HCAPLUS  
 CN Benzamide, 4-[[bis(1-methylethyl)amino]methyl]-N-[4-methyl-3-[[4-(3-

pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 660836-98-6 HCAPLUS

CN Benzamide, 3-methyl-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 660836-99-7 HCAPLUS

CN Benzamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 660837-13-8 HCAPLUS

CN 4-Thiazolecarboxylic acid, 2-[[5-[(3-iodobenzoyl)amino]-2-methylphenyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 660837-14-9 HCAPLUS


CN 4-Thiazolecarboxylic acid, 2-[[2-methyl-5-[[4-[(4-methyl-1-piperazinyl)methyl]benzoyl]amino]phenyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 660837-16-1 HCAPLUS  
 CN Benzamide, 3-bromo-N-[3-[[4-(4-chlorophenyl)-5-methyl-2-thiazolyl]amino]-4-methylphenyl]- (9CI) (CA INDEX NAME)




RN 660837-17-2 HCAPLUS  
 CN Carbamic acid, [3-[[4-(4-chlorophenyl)-5-methyl-2-thiazolyl]amino]-4-methylphenyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)



RN 660837-18-3 HCAPLUS  
 CN 4-Thiazolecarboxylic acid, 2-[[5-[(3-bromobenzoyl)amino]-2-methylphenyl]amino]-5-(4-chlorophenyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 660837-20-7 HCAPLUS  
 CN 4-Thiazolecarboxamide, 2-[[5-[(3-bromobenzoyl)amino]-2-methylphenyl]amino]-5-(4-chlorophenyl)-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 660837-33-2 HCAPLUS

CN Benzamide, 3-bromo-4-methyl-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 660837-44-5 HCAPLUS

CN Benzamide, 4-cyano-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 660837-45-6 HCAPLUS

CN Benzamide, 4-fluoro-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 660837-46-7 HCAPLUS


CN Urea, N-(2-fluorophenyl)-N'-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 660837-47-8 HCAPLUS  
CN Urea, N-(2-chlorophenyl)-N'-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 660837-48-9 HCAPLUS  
CN Urea, N-(3-fluorophenyl)-N'-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 660837-49-0 HCAPLUS  
CN Urea, N-(4-methylphenyl)-N'-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 660837-50-3 HCAPLUS  
CN Benzamide, 3-bromo-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 660837-52-5 HCAPLUS  
CN Benzamide, 3-fluoro-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 660837-54-7 HCAPLUS

CN Benzamide, 4-(dimethylamino)-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 660837-55-8 HCAPLUS

CN Benzamide, 2-fluoro-5-methyl-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 660837-56-9 HCAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 660837-57-0 HCAPLUS

CN Benzamide, 4-(1-methylethoxy)-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 660837-60-5 HCAPLUS

CN Benzamide, 3-cyano-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 660837-61-6 HCAPLUS

CN Benzamide, 2-fluoro-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 660837-62-7 HCAPLUS

CN Benzamide, 4-(aminomethyl)-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 660837-63-8 HCAPLUS

CN Benzamide, 3-methoxy-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 660837-66-1 HCAPLUS


CN 4-Pyridinecarboxamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 660837-67-2 HCAPLUS


CN 4-Pyridinecarboxamide, 2,6-dichloro-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)






RN 660837-78-5 HCAPLUS

CN Benzamide, 4-(1-methoxyethyl)-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 660837-82-1 HCAPLUS

CN Benzamide, 3-(dimethylamino)-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 660837-85-4 HCAPLUS

CN Cyclohexanecarboxamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 660837-86-5 HCAPLUS

CN Hexanoic acid, 6-[[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]amino]-6-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 660837-87-6 HCAPLUS

CN Cyclohexanecarboxamide, 1-methyl-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 660837-88-7 HCAPLUS

CN Cyclohexanecarboxamide, 4-(1,1-dimethylethyl)-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 660837-89-8 HCAPLUS

CN 4-Morpholinebutanamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 660837-90-1 HCAPLUS

CN Carbamic acid, [4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)




RN 660837-91-2 HCAPLUS

CN Urea, N-(4-methoxyphenyl)-N'-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 660837-92-3 HCAPLUS

CN Urea, N-(4-bromophenyl)-N'-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 660837-93-4 HCAPLUS

CN Urea, N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]-N'-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 660837-94-5 HCAPLUS

CN Urea, N-(4-fluorophenyl)-N'-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 660837-95-6 HCAPLUS

CN Urea, N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]-N'-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 660837-96-7 HCAPLUS

CN Benzoic acid, 4-[[[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]amino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 660837-97-8 HCAPLUS

CN Urea, N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]-N'-2-thienyl- (9CI) (CA INDEX NAME)




RN 660837-99-0 HCAPLUS

CN Urea, N-(2,4-dimethoxyphenyl)-N'-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 660838-01-7 HCAPLUS


CN Urea, N-(3,5-dimethyl-4-isoxazolyl)-N'-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 660838-02-8 HCAPLUS  
 CN Urea, N-(2-iodophenyl)-N'-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 660838-03-9 HCAPLUS  
 CN Urea, N-[4-(difluoromethoxy)phenyl]-N'-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 660838-04-0 HCAPLUS  
 CN Urea, N-[4-(dimethylamino)phenyl]-N'-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]- (9CI) (CA INDEX NAME)



IC ICM C07D417-04  
 ICS C07D417-14; C07D277-42; C07D277-56; A61K031-426; A61K031-427;  
 A61K031-4439; A61K031-497; A61P035-00; A61P037-00; A61P029-00  
 CC 28-7 (Heterocyclic Compounds (More Than One Hetero Atom))  
 Section cross-reference(s): 1, 63  
 ST aminoarylthiazole prepn tyrosine phosphokinase ckit  
 inhibitor; nodular panarteritis **treatment**

arylaminothiazole prepn; Sjogrens syndrome polymyositis  
 dermatomyositis cutaneous lupus **treatment**  
 arylaminothiazole prepn; discoid systemic lupus erythematosus  
**treatment** thiazole arylamino prepn; rheumatoid arthritis  
 polyarthritis **treatment** aminoarylaminioarylthiazole prepn;  
 Crohns **disease** ulcerative colitis **psoriasis**  
 multiple sclerosis **treatment** arylaminothiazole; autoimmune  
**disease** gouty arthritis osteoarthritis **treatment**  
 arylaminothiazole; blood sucking parasitic infestation  
**treatment** arylaminothiazole; **inflammation** insect  
 bite allergic contact dermatitis **treatment**  
 arylaminothiazole prepn; atopic dermatitis angioedema urticaria  
 anaphylactic syndrome **treatment** thiazole; allergic  
 sinusitis rhinitis **asthma treatment** arylthiazole  
 prepn; neoplasm mastocytosis mastocytoma small cell lung cancer  
**treatment** arylaminothiazole; gastrointestinal stromal tumor  
**treatment** arylthiazole prepn  
 IT **Inflammation**  
 (Crohn's **disease, treatment**; prepn. of  
 aminoarylaminioarylthiazoles as tyrosine phosphokinase c-kit  
 inhibitors)  
 IT Intestine, **disease**  
 (Crohn's, **treatment**; prepn. of  
 aminoarylaminioarylthiazoles as tyrosine phosphokinase c-kit  
 inhibitors)  
 IT Allergy  
 Inflammation  
 Nose, **disease**  
 (allergic rhinitis, **treatment**; prepn. of  
 aminoarylaminioarylthiazoles as tyrosine phosphokinase c-kit  
 inhibitors)  
 IT Intestine, **disease**  
 (autoimmune enteropathy **treatment**; prepn. of  
 aminoarylaminioarylthiazoles as tyrosine phosphokinase c-kit  
 inhibitors)  
 IT Eye, **disease**  
 Inflammation  
 (conjunctivitis, **treatment**; prepn. of  
 aminoarylaminioarylthiazoles as tyrosine phosphokinase c-kit  
 inhibitors)  
 IT **Disease, animal**  
 (cutaneous necrotizing venulitis **treatment**; prepn. of  
 aminoarylaminioarylthiazoles as tyrosine phosphokinase c-kit  
 inhibitors)  
 IT Inflammation  
 Kidney, **disease**  
 (glomerulonephritis, proliferative glomerulonephritis  
**treatment**; prepn. of aminoarylaminioarylthiazoles as  
 tyrosine phosphokinase c-kit inhibitors)  
 IT Intestine  
 (**inflammatory disease treatment**;  
 prepn. of aminoarylaminioarylthiazoles as tyrosine phosphokinase  
 c-kit inhibitors)  
 IT Skin, **disease**  
 (insect bite, insect bite skin **inflammation**  
**treatment**; prepn. of aminoarylaminioarylthiazoles as  
 tyrosine phosphokinase c-kit inhibitors)  
 IT **Disease, animal**  
 (nodular panarteritis **treatment**; prepn. of  
 aminoarylaminioarylthiazoles as tyrosine phosphokinase c-kit  
 inhibitors)  
 IT Connective tissue, **disease**

(scleroderma, local and systemic scleroderma **treatment**;  
prepn. of aminoarylaminopyrimidines as tyrosine phosphokinase  
c-kit inhibitors)

IT Inflammation  
Respiratory system, **disease**  
(sinusitis, allergic sinusitis **treatment**; prep. of  
aminoarylaminopyrimidines as tyrosine phosphokinase c-kit  
inhibitors)

IT Allergy  
**Asthma**  
Autoimmune **disease**  
Dermatomyositis  
Gout  
Inflammation  
Multiple sclerosis  
Myelodysplastic syndromes  
Neoplasm  
Osteoarthritis  
**Psoriasis**  
Rheumatoid arthritis  
Sjogren's syndrome  
Transplant rejection  
Urticaria  
(**treatment**; prep. of aminoarylaminopyrimidines as  
tyrosine phosphokinase c-kit inhibitors)

IT Inflammation  
Intestine, **disease**  
(ulcerative colitis, **treatment**; prep. of  
aminoarylaminopyrimidines as tyrosine phosphokinase c-kit  
inhibitors)

IT 138359-29-2, c-Kit kinase  
RL: **BSU (Biological study, unclassified); BIOL**  
(**Biological study**)  
(inhibitors; prep. of aminoarylaminopyrimidines as tyrosine  
phosphokinase c-kit inhibitors)

IT 660837-07-0P 660837-08-1P  
RL: **PAC (Pharmacological activity); RCT (Reactant); SPN**  
(Synthetic preparation); **THU (Therapeutic use); BIOL**  
(**Biological study**); **PREP (Preparation); RACT (Reactant or**  
**reagent); USES (Uses)**  
(prep. of aminoarylaminopyrimidines as tyrosine phosphokinase  
c-kit inhibitors)

IT 660836-74-8P 660836-75-9P 660836-76-0P  
660836-77-1P 660836-78-2P 660836-79-3P  
660836-80-6P 660836-81-7P 660836-82-8P  
660836-83-9P 660836-84-0P 660836-85-1P  
660836-86-2P 660836-87-3P 660836-88-4P  
660836-89-5P 660836-90-8P 660836-91-9P  
660836-92-0P 660836-93-1P 660836-94-2P 660836-95-3P  
660836-96-4P 660836-97-5P 660836-98-6P  
660836-99-7P 660837-00-3P 660837-01-4P 660837-02-5P  
660837-03-6P 660837-04-7P 660837-05-8P 660837-06-9P  
660837-09-2P 660837-10-5P 660837-11-6P 660837-12-7P  
660837-13-8P 660837-14-9P 660837-15-0P  
660837-16-1P 660837-17-2P 660837-18-3P  
660837-20-7P 660837-24-1P 660837-28-5P 660837-29-6P  
660837-30-9P 660837-31-0P 660837-33-2P 660837-36-5P  
660837-39-8P 660837-41-2P 660837-42-3P 660837-43-4P  
660837-44-5P 660837-45-6P 660837-46-7P  
660837-47-8P 660837-48-9P 660837-49-0P  
660837-50-3P 660837-51-4P 660837-52-5P  
660837-53-6P 660837-54-7P 660837-55-8P



660837-56-9P 660837-57-0P 660837-58-1P  
660837-59-2P 660837-60-5P 660837-61-6P  
660837-62-7P 660837-63-8P 660837-64-9P  
660837-65-0P 660837-66-1P 660837-67-2P  
660837-68-3P 660837-69-4P 660837-70-7P 660837-71-8P  
660837-72-9P 660837-73-0P 660837-74-1P 660837-75-2P  
660837-76-3P 660837-77-4P 660837-78-5P 660837-79-6P  
660837-80-9P 660837-81-0P 660837-82-1P 660837-83-2P  
660837-84-3P 660837-85-4P 660837-86-5P  
660837-87-6P 660837-88-7P 660837-89-8P  
660837-90-1P 660837-91-2P 660837-92-3P  
660837-93-4P 660837-94-5P 660837-95-6P  
660837-96-7P 660837-97-8P 660837-98-9P  
660837-99-0P 660838-00-6P 660838-01-7P  
660838-02-8P 660838-03-9P 660838-04-0P

RL: PAC (Pharmacological activity); SPN (Synthetic  
preparation); THU (Therapeutic use); BIOL (Biological  
study); PREP (Preparation); USES (Uses)

(prepn. of aminoarylaminopyrimidines as tyrosine phosphokinase  
c-kit inhibitors)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR  
THIS RECORD. ALL CITATIONS AVAILABLE IN  
THE RE FORMAT

L32 ANSWER 14 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:591307 HCAPLUS

DOCUMENT NUMBER: 139:143997

TITLE: Methods using Edg receptor  
modulators for the treatment  
of Edg receptor-associated  
conditions

INVENTOR(S): Shankar, Geetha; Solow-Cordero, David; Spencer,  
Juliet V.; Gluchowski, Charles

PATENT ASSIGNEE(S): Ceretek LLC, USA

SOURCE: PCT Int. Appl., 293 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	
WO 2003062392	A2	20030731	WO 2003-US1881	200301 21
WO 2003062392	A3	20050120		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2473740	AA	20030731	CA 2003-2473740	200301 21

Ross Shipe EIC 1700 Remsen 4B31 571/272-6018

EP 1513522	A2	20050316	EP 2003-710713	200301 21
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005519915	T2	20050707	JP 2003-562260	200301 21
US 2005261298	A1	20051124	US 2003-390428	200303 14
PRIORITY APPLN. INFO.:			US 2002-350445P	P 200201 18
			US 2002-350446P	P 200201 18
			US 2002-350447P	P 200201 18
			US 2002-350448P	P 200201 18
			WO 2003-US1881	W 200301 21
			US 2003-352579	B2 200301 27

## OTHER SOURCE(S): MARPAT 139:143997


AB The invention provides a method of modulating an Edg-2, Edg-3, Ed-4 or Edg7 **receptor**-mediated biol. activity in a cell. A cell expressing the Edg-2, Edg-3, Edg-4 or Edg 7 **receptor** is contacted with a **modulator** of the Edg-2, Edg-3, Ed-4 or Edg 7 **receptor** sufficient to modulate **receptor** mediated biol. activity. In another aspect, the present invention provides a method for modulating an Edg-2, Edg-3, Ed-4 or Edg-7 **receptor** mediated biol. in a subject. A therapeutically effective amt. of a **modulator** of the Edg-2, Edg-3, Ed-4 or Edg7 **receptor** is administered to the subject. Prepn. of compds., e.g. 4,4,4-trifluoro-3-oxo-N-(5-phenyl-2H-pyrazol-3-yl)butyramide, is described.

IT 353771-45-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(Edg receptor modulators for treatment of Edg receptor-assocd. conditions)

RN 353771-45-6 HCAPLUS

CN Acetic acid, [4-bromo-2-[[2-[(4-chlorophenyl)amino]-4-oxo-5(4H)-thiazolylidene]methyl]phenoxy]- (9CI) (CA INDEX NAME)




IT 569656-05-9

RL: RCT (Reactant); RACT (Reactant or reagent)  
(Edg receptor modulators for  
treatment of Edg receptor-assocd.  
conditions)

RN 569656-05-9 HCAPLUS

CN Acetic acid, [4-bromo-2-[[2-[(4-chlorophenyl)amino]-4-oxo-5(4H)-  
thiazolylidene]methyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



IC ICM C12N

CC 1-12 (Pharmacology)

Section cross-reference(s): 28

ST Edg receptor modulator therapeutic;  
phenylpyrazolylbutyramide deriv prepn Edg receptor  
modulator therapeutic

IT Animal cell line

(A431; Edg receptor modulators for  
treatment of Edg receptor-assocd.  
conditions)

IT Animal cell line

(CAOV-3; Edg receptor modulators for  
treatment of Edg receptor-assocd.  
conditions)

IT Inflammation

(Crohn's disease; Edg receptor  
modulators for treatment of Edg  
receptor-assocd. conditions)

IT Intestine, disease

(Crohn's; Edg receptor modulators for  
treatment of Edg receptor-assocd.  
conditions)

IT G protein-coupled receptors

RL: BSU (Biological study, unclassified); BIOL  
(Biological study)

(EDG-1 (endothelial differentiation gene 1); Edg receptor  
modulators for treatment of Edg

receptor-assocd. conditions)

IT G protein-coupled receptors  
 RL: BSU (Biological study, unclassified); BIOL  
 (Biological study)  
 (EDG-2 (endothelial differentiation gene 2); Edg receptor  
 modulators for treatment of Edg  
 receptor-assocd. conditions)

IT G protein-coupled receptors  
 RL: BSU (Biological study, unclassified); BIOL  
 (Biological study)  
 (EDG-3 (endothelial differentiation gene 3); Edg receptor  
 modulators for treatment of Edg  
 receptor-assocd. conditions)

IT G protein-coupled receptors  
 RL: BSU (Biological study, unclassified); BIOL  
 (Biological study)  
 (EDG-5 (endothelial differentiation gene 5); Edg receptor  
 modulators for treatment of Edg  
 receptor-assocd. conditions)

IT G protein-coupled receptors  
 RL: BSU (Biological study, unclassified); BIOL  
 (Biological study)  
 (EDG-6 (endothelial differentiation gene 6); Edg receptor  
 modulators for treatment of Edg  
 receptor-assocd. conditions)

IT G protein-coupled receptors  
 RL: BSU (Biological study, unclassified); BIOL  
 (Biological study)  
 (EDG-8 (endothelial differentiation gene 8); Edg receptor  
 modulators for treatment of Edg  
 receptor-assocd. conditions)

IT Angiogenesis  
 Angiogenesis inhibitors  
 Anti-inflammatory agents  
 Anti-ischemic agents  
 Antiasthmatics  
 Antimigraine agents  
 Antirheumatic agents  
 Antitumor agents  
 Apoptosis  
 Asthma  
 Atherosclerosis  
 Behcet's syndrome  
 Cardiovascular agents  
 Cardiovascular system, disease  
 Cell migration  
 Cell proliferation  
 Cytotoxic agents  
 Fibroblast  
 Gastrointestinal agents  
 Human  
 Inflammation  
 Ischemia  
 Kidney, neoplasm  
 Lung, disease  
 Lung, neoplasm  
 Mammary gland, neoplasm  
 Neoplasm  
 Neuron  
 Ovary, neoplasm  
 Pancreas, neoplasm  
 Peritoneum, neoplasm

Platelet (blood)  
 Platelet activation  
 Platelet activation  
 Prostate gland, neoplasm  
     **Psoriasis**  
 Rheumatoid arthritis  
 Stomach, neoplasm  
 Thyroid gland, neoplasm  
 Uterus, neoplasm  
 Vasoconstriction  
 Vasodilators  
 Wound  
 Wound healing promoters  
     (Edg receptor modulators for  
     treatment of Edg receptor-assocd.  
     conditions)  
 IT Carbohydrates, biological studies  
 Nucleic acids  
 Organic compounds, biological studies  
 Peptides, biological studies  
 RL: PAC (Pharmacological activity); THU (Therapeutic  
 use); BIOL (Biological study); USES (Uses)  
     (Edg receptor modulators for  
     treatment of Edg receptor-assocd.  
     conditions)  
 IT Receptors  
 RL: BSU (Biological study, unclassified); BIOL  
 (Biological study)  
     (Edg-4; Edg receptor modulators for  
     treatment of Edg receptor-assocd.  
     conditions)  
 IT Receptors  
 RL: BSU (Biological study, unclassified); BIOL  
 (Biological study)  
     (Edg-7; Edg receptor modulators for  
     treatment of Edg receptor-assocd.  
     conditions)  
 IT Receptors  
 RL: BSU (Biological study, unclassified); BIOL  
 (Biological study)  
     (Edg; Edg receptor modulators for  
     treatment of Edg receptor-assocd.  
     conditions)  
 IT Animal cell line  
     (HT-1080; Edg receptor modulators for  
     treatment of Edg receptor-assocd.  
     conditions)  
 IT Animal cell line  
     (HTC; Edg receptor modulators for  
     treatment of Edg receptor-assocd.  
     conditions)  
 IT Animal cell line  
     (HUVEC; Edg receptor modulators for  
     treatment of Edg receptor-assocd.  
     conditions)  
 IT Chemotaxis  
     (LPA-stimulated; Edg receptor modulators for  
     treatment of Edg receptor-assocd.  
     conditions)  
 IT Animal cell line  
     (MDA-MB-231; Edg receptor modulators for  
     treatment of Edg receptor-assocd.

conditions)  
 IT Animal cell line  
 (MDA-MB-453; Edg receptor modulators for  
 treatment of Edg receptor-assocd.  
 conditions)  
 IT Animal cell line  
 (OV202; Edg receptor modulators for  
 treatment of Edg receptor-assocd.  
 conditions)  
 IT Animal cell line  
 (SKOV3; Edg receptor modulators for  
 treatment of Edg receptor-assocd.  
 conditions)  
 IT Respiratory distress syndrome  
 (adult; Edg receptor modulators for  
 treatment of Edg receptor-assocd.  
 conditions)  
 IT Antiarteriosclerotics  
 (antiatherosclerotics; Edg receptor modulators  
 for treatment of Edg receptor-assocd.  
 conditions)  
 IT Anemia (disease)  
 Autoimmune disease  
 (autoimmune hemolytic anemia; Edg receptor  
 modulators for treatment of Edg  
 receptor-assocd. conditions)  
 IT Immunity  
 (autoimmunity; Edg receptor modulators for  
 treatment of Edg receptor-assocd.  
 conditions)  
 IT Lysophosphatidic acids  
 RL: BSU (Biological study, unclassified); BIOL  
 (Biological study)  
 (cell proliferation stimulated by; Edg receptor  
 modulators for treatment of Edg  
 receptor-assocd. conditions)  
 IT Carcinoma  
 Myoblast  
 Pheochromocytoma  
 (cell; Edg receptor modulators for  
 treatment of Edg receptor-assocd.  
 conditions)  
 IT Artery  
 (cerebral, vasoconstriction; Edg receptor  
 modulators for treatment of Edg  
 receptor-assocd. conditions)  
 IT Uterus, neoplasm  
 (cervix; Edg receptor modulators for  
 treatment of Edg receptor-assocd.  
 conditions)  
 IT Resolution (separation)  
 (chromatog.; Edg receptor modulators for  
 treatment of Edg receptor-assocd.  
 conditions)  
 IT Infection  
 (chronic active hepatitis; Edg receptor  
 modulators for treatment of Edg  
 receptor-assocd. conditions)  
 IT Inflammation  
 Kidney, disease  
 (chronic glomerulonephritis; Edg receptor  
 modulators for treatment of Edg

receptor-assocd. conditions)  
IT Temperature effects, biological  
(cold, transcomeal freezing; Edg receptor  
modulators for treatment of Edg  
receptor-assocd. conditions)  
IT Intestine, neoplasm  
(colon; Edg receptor modulators for  
treatment of Edg receptor-assocd.  
conditions)  
IT Intestine, neoplasm  
(colorectal; Edg receptor modulators for  
treatment of Edg receptor-assocd.  
conditions)  
IT Burn  
(cutaneous; Edg receptor modulators for  
treatment of Edg receptor-assocd.  
conditions)  
IT Meninges  
(disease, subarachnoid hemorrhage; Edg receptor  
modulators for treatment of Edg  
receptor-assocd. conditions)  
IT Uterus, neoplasm  
(endometrium; Edg receptor modulators for  
treatment of Edg receptor-assocd.  
conditions)  
IT Blood vessel  
(endothelium; Edg receptor modulators for  
treatment of Edg receptor-assocd.  
conditions)  
IT Epithelium  
(epithelial cell; Edg receptor modulators for  
treatment of Edg receptor-assocd.  
conditions)  
IT Carcinoma  
(epithelioid; Edg receptor modulators for  
treatment of Edg receptor-assocd.  
conditions)  
IT Sarcoma  
(fibrosarcoma, cell; Edg receptor modulators  
for treatment of Edg receptor-assocd.  
conditions)  
IT Carcinoma  
(hepatocellular; Edg receptor modulators for  
treatment of Edg receptor-assocd.  
conditions)  
IT Liver, neoplasm  
(hepatoma; Edg receptor modulators for  
treatment of Edg receptor-assocd.  
conditions)  
IT Phosphatidylinositols  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(hydrolysis; Edg receptor modulators for  
treatment of Edg receptor-assocd.  
conditions)  
IT Fatty acids, biological studies  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(level of; Edg receptor modulators for  
treatment of Edg receptor-assocd.  
conditions)  
IT Receptors

RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(lysophosphatidic acid; Edg receptor modulators  
for treatment of Edg receptor-assocd.  
conditions)

IT Neoplasm  
(metastasis; Edg receptor modulators for  
treatment of Edg receptor-assocd.  
conditions)

IT Headache  
(migraine; Edg receptor modulators for  
treatment of Edg receptor-assocd.  
conditions)

IT Kidney, disease  
(non-glomerular nephrosis; Edg receptor  
modulators for treatment of Edg  
receptor-assocd. conditions)

IT Blood vessel, disease  
(occlusion; Edg receptor modulators for  
treatment of Edg receptor-assocd.  
conditions)

IT Egg  
(oocyte, *Xenopus laevis*; Edg receptor  
modulators for treatment of Edg  
receptor-assocd. conditions)

IT *Xenopus laevis*  
(oocyte; Edg receptor modulators for  
treatment of Edg receptor-assocd.  
conditions)

IT Ovary  
(ovarian cell; Edg receptor modulators for  
treatment of Edg receptor-assocd.  
conditions)

IT Actins  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(polymn.; Edg receptor modulators for  
treatment of Edg receptor-assocd.  
conditions)

IT Intestine, neoplasm  
(small; Edg receptor modulators for  
treatment of Edg receptor-assocd.  
conditions)

IT Blood vessel, disease  
(spasm; Edg receptor modulators for  
treatment of Edg receptor-assocd.  
conditions)

IT Brain, disease  
(stroke; Edg receptor modulators for  
treatment of Edg receptor-assocd.  
conditions)

IT Hemorrhage  
(subarachnoid; Edg receptor modulators for  
treatment of Edg receptor-assocd.  
conditions)

IT Injury  
(surface epithelial cell; Edg receptor  
modulators for treatment of Edg  
receptor-assocd. conditions)

IT Interleukin 8  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)



(synthesis; Edg receptor modulators for treatment of Edg receptor-assocd. conditions)

IT Lupus erythematosus  
(systemic; Edg receptor modulators for treatment of Edg receptor-assocd. conditions)

IT Purpura (disease)  
(thrombocytopenic, chronic; Edg receptor modulators for treatment of Edg receptor-assocd. conditions)

IT Inflammation  
Intestine, disease  
(ulcerative colitis; Edg receptor modulators for treatment of Edg receptor-assocd. conditions)

IT Endothelium  
(vascular; Edg receptor modulators for treatment of Edg receptor-assocd. conditions)

IT Hepatitis  
(viral, chronic active; Edg receptor modulators for treatment of Edg receptor-assocd. conditions)

IT 182762-25-0, GenBank X83864 218763-60-1, GenBank AJ000479  
259476-69-2, GenBank AF233092 262400-57-7, GenBank AF233090  
384729-36-6, GenBank U78192 385223-15-4, GenBank AF011466  
390105-18-7, GenBank AF034780 390174-36-4, GenBank AF233365  
390523-03-2, GenBank AF317676 392101-34-7, GenBank AF127138  
RL: BSU (Biological study, unclassified); PRP  
(Properties); BIOL (Biological study)  
(Edg receptor modulators for treatment of Edg receptor-assocd. conditions)

IT 473390-98-6  
RL: FMU (Formation, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); USES (Uses)  
(Edg receptor modulators for treatment of Edg receptor-assocd. conditions)

IT 353273-74-2P 569655-94-3P 569655-95-4P 569655-96-5P  
569656-23-1P 569656-24-2P  
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(Edg receptor modulators for treatment of Edg receptor-assocd. conditions)

IT 94835-69-5P  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(Edg receptor modulators for treatment of Edg receptor-assocd. conditions)

IT 7741-53-9P 40622-01-3P 173275-26-8P 304650-31-5P  
311799-07-2P 312501-62-5P 312519-16-7P 331945-22-3P  
334498-72-5P 342384-25-2P 353253-35-7P 353771-45-6P

355000-90-7P 569656-08-2P 569656-09-3P 569656-10-6P  
 569656-11-7P 569656-12-8P 569656-13-9P 569656-14-0P  
 569656-15-1P 569656-16-2P 569656-17-3P 569656-18-4P  
 569656-19-5P 569656-20-8P 569656-21-9P 569656-25-3P  
 569656-26-4P 569656-27-5P 569656-29-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Edg receptor modulators for treatment of Edg receptor-assocd. conditions)

IT 49843-94-9 90212-73-0 107235-67-6 136382-28-0 171286-07-0  
 177360-28-0 292076-38-1 306764-68-1 309282-30-2 311773-65-6  
 312594-43-7 321679-76-9 322662-05-5 327167-87-3 329350-38-1  
 330630-42-7 331274-84-1 332161-39-4 337349-59-4 337469-26-8  
 337498-14-3 346699-98-7 353463-50-0 353793-15-4 364051-15-0  
 383164-60-1 389079-78-1 400064-03-1 569655-97-6 569655-98-7  
 569656-22-0 569656-28-6

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(Edg receptor modulators for treatment of Edg receptor-assocd. conditions)

IT 50-30-6, 2,6-Dichlorobenzoic acid 50-45-3, 2,3-Dichlorobenzoic acid  
 70-11-1, 2-Bromoacetophenone 79-19-6, Thiosemicarbazide  
 83-38-5, 2,6-Dichlorobenzaldehyde 91-56-5, 1H-Indole-2,3-dione  
 93-17-4, 3,4-Dimethoxyphenylacetonitrile 93-55-0, Propiophenone  
 98-59-9, p-Toluenesulfonyl chloride 98-88-4, Benzoyl chloride  
 98-95-3, Nitrobenzene, reactions 100-65-2, N-Phenylhydroxylamine  
 108-31-6, Maleic anhydride, reactions 108-38-3, 1,3-Dimethylbenzene, reactions  
 120-72-9, Indole, reactions 123-11-5, p-Anisaldehyde, reactions 140-75-0, 4-Fluorobenzylamine  
 302-01-2, Hydrazine, reactions 363-58-6 372-31-6, Ethyl 4,4,4-trifluoroacetoacetate  
 406-00-8, 4-Fluorophenylhydroxylamine 434-75-3, 2-Chloro-6-fluorobenzoic acid  
 533-18-6, o-Tolyl acetate 556-90-1, Pseudothiohydantoin 619-05-6, 3,4-Diaminobenzoic acid  
 619-41-0, 2-Bromo-4'-methylacetophenone 829-20-9 1226-42-2, 4,4'-Dimethoxybenzil  
 1468-83-3, 3-Acetylthiophene 1476-23-9, Allyl isocyanate 1572-10-7  
 2642-63-9, 3',4'-Dichloroacetophenone 4506-71-2 5242-26-2 5351-85-9  
 6629-60-3, Ethylhydrazine oxalate 13100-05-5 13380-67-1 19541-95-8  
 23448-86-4 23821-37-6 36817-57-9 39151-19-4 64900-65-8, 2-Chlorobenzenesulfonyl isocyanate  
 72411-52-0 82799-44-8 89570-85-4 96799-03-0 96799-04-1 569656-04-8  
 569656-05-9 569656-06-0

RL: RCT (Reactant); RACT (Reactant or reagent)

(Edg receptor modulators for treatment of Edg receptor-assocd. conditions)

IT 5351-91-7P 5467-70-9P 6292-74-6P 7420-34-0P 7741-54-0P  
 43071-45-0P 76293-13-5P 82799-45-9P 86358-85-2P 91912-53-7P  
 112612-58-5P 113054-02-7P 149246-80-0P 149246-86-6P  
 208519-10-2P 208519-15-7P 329069-72-9P 502132-61-8P  
 569655-99-8P 569656-00-4P 569656-01-5P 569656-02-6P  
 569656-03-7P 569656-07-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(Edg receptor modulators for treatment of Edg receptor-assocd. conditions)

IT 26993-30-6, Sphingosine-1-phosphate  
 RL: BSU (Biological study, unclassified); BIOL

(Biological study)  
 (calcium mobilization stimulated by; Edg receptor  
 modulators for treatment of Edg  
 receptor-assocd. conditions)

IT 60-92-4, Cyclic AMP  
 RL: BSU (Biological study, unclassified); BIOL  
 (Biological study)  
 (formation inhibition; Edg receptor modulators  
 for treatment of Edg receptor-assocd.  
 conditions)

IT 7440-70-2, Calcium, biological studies  
 RL: BSU (Biological study, unclassified); BIOL  
 (Biological study)  
 (mobilization; Edg receptor modulators for  
 treatment of Edg receptor-assocd.  
 conditions)

IT 127464-60-2, Vascular endothelial growth factor  
 RL: BSU (Biological study, unclassified); BIOL  
 (Biological study)  
 (synthesis; Edg receptor modulators for  
 treatment of Edg receptor-assocd.  
 conditions)

L32 ANSWER 15 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:888719 HCAPLUS

DOCUMENT NUMBER: 137:384854

TITLE: Preparation of diaryl ureas as antiinflammatory  
 agents

INVENTOR(S): Cirillo, Pier F.; Goldberg, Daniel R.; Hammach,  
 Abdelhakim; Moss, Neil; Regan, John Robinson

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 67 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002092576	A1	20021121	WO 2002-US14733	20020508
W: AE, AU, BG, BR, CA, CN, CO, CZ, EC, EE, HR, HU, ID, IL, IN, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
CA 2445003	AA	20021121	CA 2002-2445003	20020508
EP 1392661	A1	20040303	EP 2002-734324	20020508
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR				
JP 2004530690	T2	20041007	JP 2002-589462	20020508
US 2003008868	A1	20030109	US 2002-143322	20020508

US 6852717  
PRIORITY APPLN. INFO.:

B2 20050208

US 2001-291425P

P

10


200105  
16

WO 2002-US14733

W

200205  
08

GI



AB The title diaryl ureas, useful in pharmaceutic compns. for treating a cytokine mediated diseases or conditions involving inflammation such as chronic inflammatory diseases, were prepd. Thus, treating 4-(2-chloropyrimidin-4-yloxy)naphthalen-1-ylamine with Et<sub>3</sub>N in DMF followed by addn. of Et<sub>4</sub>NCN, and treatment of the resulting nitrile with phosgene, and reacting the intermediate with 5-tert-butyl-o-anisidine afforded the urea I.


IT 476011-68-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of diaryl ureas as antiinflammatory agents)

RN 476011-68-4 HCAPLUS

CN 4-Thiazolecarboxylic acid, 2-[[5-(1,1-dimethylethyl)-2-methoxy-3-nitrophenyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



IC ICM C07D239-34

ICS A61K031-505; C07D251-42; C07D239-47; C07D417-12; C07D401-12; C07D231-40; A61P029-00

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))  
Section cross-reference(s): 1

IT Inflammation

(Crohn's disease, treatment of; prepn. of diaryl ureas as antiinflammatory agents)

IT Intestine, disease

(Crohn's, treatment of; prepn. of diaryl ureas as antiinflammatory agents)

IT Nervous system, disease

(Guillain-Barre syndrome, **treatment** of; prepn. of diaryl ureas as antiinflammatory agents)

IT Lung, **disease**  
(chronic obstructive pulmonary disease, **treatment** of; prepn. of diaryl ureas as antiinflammatory agents)

IT Inflammation  
Intestine, **disease**  
(enterocolitis, **treatment** of necrotizing; prepn. of diaryl ureas as antiinflammatory agents)

IT Heart, **disease**  
(failure, **treatment** of; prepn. of diaryl ureas as antiinflammatory agents)

IT Inflammation  
Kidney, **disease**  
(glomerulonephritis, **treatment** of; prepn. of diaryl ureas as antiinflammatory agents)

IT Heart, **disease**  
(infarction, **treatment** of; prepn. of diaryl ureas as antiinflammatory agents)

IT Tumor necrosis factors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(inhibitors of TNF prodn.; prepn. of diaryl ureas as antiinflammatory agents)

IT Brain, **disease**  
(stroke, **treatment** of; prepn. of diaryl ureas as antiinflammatory agents)

IT Bone resorption  
Bone resorption inhibitors  
(**treatment** of bone resorption diseases; prepn. of diaryl ureas as antiinflammatory agents)

IT Cytokines  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(**treatment** of cytokine mediated disease or condition; prepn. of diaryl ureas as antiinflammatory agents)

IT Skin, **disease**  
(**treatment** of dermatoses with acute inflammatory components; prepn. of diaryl ureas as antiinflammatory agents)

IT Alzheimer's disease  
Asthma  
Atherosclerosis  
Diabetes mellitus  
Multiple organ failure  
Multiple sclerosis  
Pain  
Psoriasis  
Rheumatoid arthritis  
Sepsis  
(**treatment** of; prepn. of diaryl ureas as antiinflammatory agents)

IT Inflammation  
Intestine, **disease**  
(ulcerative colitis, **treatment** of; prepn. of diaryl ureas as antiinflammatory agents)

IT 285983-44-0P 473269-90-8P 473269-96-4P 473271-63-5P  
473271-65-7P 473271-70-4P 473271-82-8P 473271-86-2P  
473271-87-3P 473271-90-8P 473271-91-9P 473271-96-4P  
473272-06-9P 473272-08-1P 473272-09-2P 473272-15-0P

473272-16-1P	476009-04-8P	476009-05-9P	476009-07-1P
476009-08-2P	476009-10-6P	476009-12-8P	476009-16-2P
476009-18-4P	476009-19-5P	476009-21-9P	476009-22-0P
476009-23-1P	476009-25-3P	476009-27-5P	476009-28-6P
476009-30-0P	476009-34-4P	476009-38-8P	476009-40-2P
476009-42-4P	476009-43-5P	476009-46-8P	476009-48-0P
476009-49-1P	476009-52-6P	476009-54-8P	476009-56-0P
476009-58-2P	476009-60-6P	476009-62-8P	476009-63-9P
476009-65-1P	476009-66-2P	476009-67-3P	476009-68-4P
476009-70-8P	476009-71-9P	476009-72-0P	476009-74-2P
476009-78-6P	476009-80-0P	476009-82-2P	476009-84-4P
476009-87-7P	476009-89-9P	476009-91-3P	476009-93-5P
476009-95-7P	476009-97-9P	476010-05-6P	476010-09-0P
476010-11-4P	476010-14-7P	476010-16-9P	476010-17-0P
476010-19-2P	476010-20-5P	476010-22-7P	476010-24-9P
476010-26-1P	476010-28-3P	476010-30-7P	476010-32-9P
476010-34-1P	476010-36-3P	476010-38-5P	476010-40-9P
476010-42-1P	476010-44-3P	476010-46-5P	476010-48-7P
476010-50-1P	476010-52-3P	476010-53-4P	476010-54-5P
476010-56-7P	476010-58-9P	476010-60-3P	476010-62-5P
476010-64-7P	476010-65-8P	476010-68-1P	476010-72-7P
476010-74-9P	476010-77-2P	476010-79-4P	476010-81-8P
476010-84-1P	476010-86-3P	476010-88-5P	476010-90-9P
476010-92-1P	476010-96-5P	476010-98-7P	476010-99-8P
476011-01-5P	476011-03-7P	476011-05-9P	476011-06-0P
476011-08-2P	476011-10-6P	476011-12-8P	476011-14-0P
476011-16-2P	476011-18-4P	476011-20-8P	476011-22-0P
476011-24-2P	476011-26-4P	476011-28-6P	476011-30-0P
476011-32-2P	476011-34-4P	476011-36-6P	476011-37-7P
476011-39-9P	476011-41-3P	476011-43-5P	476011-45-7P
476011-47-9P	476011-49-1P	476011-51-5P	476011-53-7P
476011-55-9P	476012-73-4P		

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of diaryl ureas as antiinflammatory agents)

IT 341-92-4P, 1-Fluoro-4-nitronaphthalene 341-95-7P,  
4-Nitro-1-naphthalenediazonium tetrafluoroborate 473269-91-9P  
473269-92-0P 476011-58-2P 476011-59-3P 476011-60-6P  
476011-62-8P 476011-64-0P 476011-66-2P 476011-67-3P  
**476011-68-4P** 476011-71-9P 476011-73-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);  
RACT (Reactant or reagent)

(prepn. of diaryl ureas as antiinflammatory agents)

L32 ANSWER 16 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:814851 HCAPLUS

DOCUMENT NUMBER: 137:310930

TITLE: Preparation of 3-(azahetero)aryl-1H-pyrazolo[3,4-d]pyrimidin-3-amines as protein kinase inhibitors with antiangiogenic properties

INVENTOR(S): Hirst, Gavin C.; Rafferty, Paul; Ritter, Kurt; Calderwood, David; Wishart, Neil; Arnold, Lee D.; Friedman, Michael M.

PATENT ASSIGNEE(S): Abbott Laboratories, USA

SOURCE: U.S. Pat. Appl. Publ., 426 pp., Cont.-in-part of U.S. Ser. No. 663,780.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002156081	A1	20021024	US 2001-815310	20010322
US 6921763	B2	20050726		
US 6660744	B1	20031209	US 2000-663780	20000915
CA 2440724	AA	20021017	CA 2002-2440724	20020322
WO 2002080926	A1	20021017	WO 2002-US9104	20020322
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1385524	A1	20040204	EP 2002-746301	20020322
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CN 1520298	A	20040811	CN 2002-810250	20020322
JP 2004531513	T2	20041014	JP 2002-578965	20020322
BR 2002005889	A	20041109	BR 2002-5889	20020322
ZA 2003006886	A	20040716	ZA 2003-6886	20030903
NO 2003004176	A	20031121	NO 2003-4176	20030919
BG 108269	A	20041230	BG 2003-108269	20031014
PRIORITY APPLN. INFO.:			US 1999-154620P	P 19990917
			US 2000-663780	A2 20000915
			US 2001-815310	A 20010322




WO 2002-US9104

W

200203  
22

OTHER SOURCE(S): MARPAT 137:310930  
GI



AB Title compds. I [wherein  $G$  = (un)substituted 5-6 membered (azahetero)aryl;  $R^2$  = H or (un)substituted trityl, cycloalkenyl, azaheteroaryl, or  $C_6H_4-4-CH_2E$ ;  $E$  = (un)substituted alkyl-OR, alkyl-CO<sub>2</sub>R, alkylheteroaryl, alkylheterocycloalkyl, or alkyl-NR<sub>2</sub>;  $R$  = independently H or (un)substituted (cyclo)alkyl, or aryl(alkyl);  $R^3$  = independently H, OH, or (un)substituted alkyl, alkyl-CO, (hetero)aryl-CO, or alkoxy; or racemic diastereomeric mixts., optical isomers, pharmaceutically acceptable salts, prodrugs, and/or biol. active metabolites thereof] were prepd. For example, 3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine was coupled with 4-fluorobenzaldehyde in the presence of NaH in DMF to give 4-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)benzaldehyde. Treatment of the 3-iodopyrazolopyrimidine with N-[2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2-fluoro-4-(trifluoromethyl)benzamide, Pd(PPh<sub>3</sub>)<sub>4</sub>, and Na<sub>2</sub>CO<sub>3</sub> in H<sub>2</sub>O afforded the N-[4-(pyrazolopyrimidin-3-yl)phenyl]benzamide. Addn. of morpholine to the benzaldehyde in the presence of Na(AcO)<sub>3</sub>BH in dichloroethane produced II. All exemplified compds. significantly inhibited either FGFR, PDGFR, KDR, Tie-2, Lck, Fyn, Blk, Lyn, or Src at concn. of  $\leq 50 \mu M$ . Certain compds. of the invention also significantly inhibited cdc2 or cellular VEGF-induced KDR tyrosine kinase phosphorylation at concns. of  $\leq 50 \mu M$ . Thus, I are useful for the treatment of a wide variety of disease states ameliorated by the inhibition of protein tyrosine kinase activity essential for angiogenic processes (no data).


IT 330793-97-0P, N-(4-Bromophenyl)-N-(4-ethyl-1,3-thiazol-2-yl)amine 330793-98-1P, N-(4-Ethyl-1,3-thiazol-2-yl)-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]amine  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);



RACT (Reactant or reagent)  
(intermediate; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)


RN 330793-97-0 HCAPLUS

CN 2-Thiazolamine, N-(4-bromophenyl)-4-ethyl- (9CI) (CA INDEX NAME)



RN 330793-98-1 HCAPLUS

CN 2-Thiazolamine, 4-ethyl-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]- (9CI) (CA INDEX NAME)



IC ICM A61K031-519

ICS C07D487-04

INCL 514247000

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))  
Section cross-reference(s): 1

IT **Inflammation**

(Crohn's disease; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Tyrosine kinase receptors

RL: BSU (Biological study, unclassified); BIOL  
(Biological study)

(Tie, TIE-2; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Tyrosine kinase receptors

RL: BSU (Biological study, unclassified); BIOL  
(Biological study)

(Tie-1; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Vascular endothelial growth factor receptors

RL: BSU (Biological study, unclassified); BIOL  
(Biological study)

(VEGF, VEGF-B, VEGF-C, VEGF-D, or VEGF-E, combination therapy agent; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Antibodies and Immunoglobulins

RL: BSU (Biological study, unclassified); BIOL  
(Biological study)

(antiidotypic, combination therapy agent; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL

(Biological study)  
 (c-fgr; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as  
 protein kinase inhibitors with antiangiogenic properties)

IT Angiogenic factors  
 Hepatocyte growth factor  
 RL: BSU (Biological study, unclassified); BIOL  
 (Biological study)  
 (combination therapy agent; prepn. of [(hetero)aryl]pyrazolo[3,4-  
 d]pyrimidinamines as protein kinase inhibitors with  
 antiangiogenic properties)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL  
 (Biological study)  
 (fyn; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as  
 protein kinase inhibitors with antiangiogenic properties)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL  
 (Biological study)  
 (gene hck; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines  
 as protein kinase inhibitors with antiangiogenic properties)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL  
 (Biological study)  
 (gene lyn; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines  
 as protein kinase inhibitors with antiangiogenic properties)

IT Intestine, disease  
 (inflammatory; prepn. of [(hetero)aryl]pyrazolo[3,4-  
 d]pyrimidinamines as protein kinase inhibitors with  
 antiangiogenic properties)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL  
 (Biological study)  
 (p62c-yes; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines  
 as protein kinase inhibitors with antiangiogenic properties)

IT Anemia (disease)  
 Angiogenesis  
 Angiogenesis inhibitors  
 Anti-inflammatory agents  
 Anti-ischemic agents  
 Antiarthritics  
 Antiasthmatics  
 Antibacterial agents  
 Antidiabetic agents  
 Antiglaucoma agents  
 Antirheumatic agents  
 Antitumor agents  
 Antiulcer agents  
 Asthma  
 Atherosclerosis  
 Cardiovascular agents  
 Cardiovascular system, disease  
 Cirrhosis  
 Contraceptives  
 Eye, disease  
 Fibrosis  
 Fungicides  
 Glaucoma (disease)  
 Hematopoiesis  
 Hodgkin's disease  
 Human  
 Human herpesvirus  
 Human immunodeficiency virus 1

Hypoxia  
 Ischemia  
 Leukemia  
 Lyme disease  
 Lymphoma  
 Melanoma  
 Multiple myeloma  
 Multiple sclerosis  
 Mycosis  
 Necrosis  
 Neoplasm  
 Osteoarthritis  
 Parapoxvirus  
 Preeclampsia  
 Protozoa  
 Protozoacides  
     **Psoriasis**  
 Radiation  
 Rheumatoid arthritis  
 Sarcoidosis  
 Sarcoma  
 Sepsis  
 Sick cell anemia  
 Transplant rejection  
 Ulcer  
 Wound  
     (prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as  
     protein kinase inhibitors with antiangiogenic properties)  
 IT Hepatocyte growth factor receptors  
     Insulin-like growth factor I receptors  
     RL: **BSU (Biological study, unclassified); BIOL**  
     **(Biological study)**  
     (prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as  
     protein kinase inhibitors with antiangiogenic properties)  
 IT Fibroblast growth factor receptors  
     RL: **BSU (Biological study, unclassified); BIOL**  
     **(Biological study)**  
     (type 1; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines  
     as protein kinase inhibitors with antiangiogenic properties)  
 IT Vascular endothelial growth factor receptors  
     RL: **BSU (Biological study, unclassified); BIOL**  
     **(Biological study)**  
     (type VEGFR-1; prepn. of [(hetero)aryl]pyrazolo[3,4-  
     d]pyrimidinamines as protein kinase inhibitors with  
     antiangiogenic properties)  
 IT Vascular endothelial growth factor receptors  
     RL: **BSU (Biological study, unclassified); BIOL**  
     **(Biological study)**  
     (type VEGFR-2; prepn. of [(hetero)aryl]pyrazolo[3,4-  
     d]pyrimidinamines as protein kinase inhibitors with  
     antiangiogenic properties)  
 IT Vascular endothelial growth factor receptors  
     RL: **BSU (Biological study, unclassified); BIOL**  
     **(Biological study)**  
     (type VEGFR-3; prepn. of [(hetero)aryl]pyrazolo[3,4-  
     d]pyrimidinamines as protein kinase inhibitors with  
     antiangiogenic properties)  
 IT Platelet-derived growth factor receptors  
     RL: **BSU (Biological study, unclassified); BIOL**  
     **(Biological study)**  
     ( $\alpha$ ; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines  
     as protein kinase inhibitors with antiangiogenic properties)

IT Platelet-derived growth factor receptors  
RL: **BSU (Biological study, unclassified); BIOL**  
**(Biological study)**  
( $\beta$ ; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines  
as protein kinase inhibitors with antiangiogenic properties)

IT 106096-92-8, FGF-1 106096-93-9, FGF-2  
RL: **BSU (Biological study, unclassified); BIOL**  
**(Biological study)**  
(combination therapy agent; prepn. of [(hetero)aryl]pyrazolo[3,4-  
d]pyrimidinamines as protein kinase inhibitors with  
antiangiogenic properties)

IT 330793-90-3P 330793-91-4P, cis-4-[4-Amino-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-  
yl]benzaldehyde 330793-95-8P, N-(6-Chloro-1,3-benzothiazol-2-yl)-N-  
[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]amine  
330793-96-9P 330793-97-0P, N-(4-Bromophenyl)-N-(4-ethyl-  
1,3-thiazol-2-yl)amine 330793-98-1P, N-(4-Ethyl-1,3-  
thiazol-2-yl)-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-  
yl)phenyl]amine 330793-99-2P, 4-Amino-1-(4-nitrophenyl)-3-iodo-1H-  
pyrazolo[3,4-d]pyrimidine 330794-00-8P, 3-Iodo-1-trityl-1H-  
pyrazolo[3,4-d]pyrimidin-4-amine 330794-01-9P,  
4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-  
yl]benzaldehyde 330794-02-0P, 1-Bromo-2-fluoro-5-methoxy-4-  
nitrobenzene 330794-03-1P, 4-Bromo-5-fluoro-2-methoxyaniline  
330794-04-2P, tert-Butyl N-(4-bromo-5-fluoro-2-  
methoxyphenyl)carbamate 330794-05-3P, tert-Butyl  
N-[5-fluoro-2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-  
yl)phenyl]carbamate 330794-06-4P, 3-Iodo-1-(1-methyl-4-piperidyl)-  
1H-pyrazolo[3,4-d]pyrimidin-4-amine 330794-08-6P, trans-tert-Butyl  
N-[2-[[[4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-  
pyrazolo[3,4-d]pyrimidin-3-yl]]anilino]methyl]phenyl]carbamate  
acetate 330794-09-7P, tert-Butyl N-(4-bromo-2-  
chlorophenyl)carbamate 330794-10-0P, tert-Butyl  
N-[2-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-  
yl)phenyl]carbamate 330794-11-1P, Trans-tert-Butyl  
N-[4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-  
d]pyrimidin-3-yl]-2-chlorophenyl]carbamate 330794-12-2P,  
Trans-3-(4-Amino-3-chlorophenyl)-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
330794-13-3P, 1-(4-Bromophenyl)-3-methyl-5-phenyl-4,5-dihydro-1H-  
pyrazole 330794-14-4P, 3-Methyl-5-phenyl-1-[4-(4,4,5,5-tetramethyl-  
1,3,2-dioxaborolan-2-yl)phenyl]-4,5-dihydro-1H-pyrazole  
330794-15-5P 330794-17-7P, tert-Butyl N-[3-[3-[4-amino-3-(4-  
phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-3-  
oxopropyl]-N-(2-hydroxyethyl)carbamate 330794-18-8P, tert-Butyl  
N-[3-[4-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-  
yl]piperidino]-3-oxopropyl]-N-(2-hydroxyethyl)carbamate  
330794-19-9P, tert-Butyl 2-[4-[4-amino-3-(4-phenoxyphenyl)-1H-  
pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]acetate 330794-20-2P,  
Benzyl 4-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-  
piperidinecarboxylate 330794-21-3P, Benzyl 4-[4-amino-3-[4-[(tert-  
butoxycarbonyl)amino]-3-methoxyphenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-  
yl]-1-piperidinecarboxylate 330794-22-4P, Benzyl  
4-[4-amino-3-(4-amino-3-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-  
yl]-1-piperidinecarboxylate 330794-23-5P, Trans-Benzyl  
4-[4-amino-3-[3-methoxy-4-[(2-phenylcyclopropyl)carbonyl]amino]phen  
yl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinecarboxylate  
330794-24-6P, Benzyl 4-[4-amino-3-[3-methoxy-4-[(5-methyl-2-  
furyl)methyl]amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-  
piperidinecarboxylate 330794-25-7P, tert-Butyl  
4-[(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl]-4-  
hydroxy-1-piperidinecarboxylate 330794-26-8P, tert-Butyl

4-[[4-amino-3-[4-[[[(benzyloxy)carbonyl]amino]-3-methoxyphenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-4-hydroxy-1-piperidinecarboxylate 330794-27-9P, tert-Butyl  
4-[[4-amino-3-(4-amino-3-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-4-hydroxy-1-piperidinecarboxylate 330794-28-0P, Trans-tert-Butyl 4-[[4-amino-3-[3-methoxy-4-[[[(2-phenylcyclopropyl)carbonyl]amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-4-hydroxy-1-piperidinecarboxylate 330794-29-1P  
461696-99-1P, 4-(4-Amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)benzaldehyde 461697-00-7P 461697-02-9P, 2-(4-Amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-ethanol 461697-03-0P,  
[2-[4-Amino-3-[3-methoxy-4-[[[(1-methyl-1H-indol-2-yl)carbonyl]amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]methanesulfonate 461697-30-3P, N-[2-Methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1-methyl-1H-2-indolecarboxamide 461697-31-4P, N-[4-[4-Amino-1-[2-(4-methylpiperazino)ethyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461697-34-7P, N-[4-[4-Amino-1-(2-morpholinoethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461697-36-9P, N-[4-[4-Amino-1-[2-[(2-hydroxyethyl)amino]ethyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461697-38-1P,  
N-[4-[4-Amino-1-[2-(dimethylamino)ethyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461697-40-5P, N-[4-[4-Amino-1-[2-(1H-1-imidazolyl)ethyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461697-53-0P, 4-(4-Amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-2-cyclopenten-1-ol 461697-57-4P, tert-Butyl 4-[4-amino-3-(4-amino-3-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinecarboxylate 461697-66-5P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461697-98-3P, 3-Iodo-1-(1-methyl-3-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461698-01-1P, 3-Iodo-1-[1-(2-methoxyethyl)-3-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461698-02-2P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-chlorophenyl]-4-(trifluoromethyl)benzamide 461698-04-4P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-chlorophenyl]-4-(trifluoromethoxy)benzamide 461698-10-2P, N-[4-[4-Amino-1-[1-(1H-2-imidazolyl)carbonyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-trans-2-phenyl-1-cyclopropanecarboxamide 461698-14-6P 461698-21-5P 461698-24-8P 461698-45-3P, tert-Butyl 4-[4-amino-3-(4-aminophenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinecarboxylate 461698-46-4P, tert-Butyl 4-[4-amino-3-[4-[[[(benzyloxy)carbonyl]amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinecarboxylate 461698-79-3P, 3-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)anilino]-1H-benzo[d]isothiazole-1,1-dione 461698-84-0P, N-(4-Bromophenyl)-2-fluoro-1-benzenecarbothioamide 461698-85-1P 461698-86-2P, N-(Benzo[d]isoxazol-3-yl)-N-(4-bromophenyl)amine 461698-87-3P, N-(Benzo[d]isoxazol-3-yl)-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]amine 461698-94-2P, Benzenecarboximidic acid, N-(4-bromophenyl)-2-fluoro-, hydrazide 461698-95-3P, N-(4-Bromophenyl)-N-(1H-3-indazolyl)amine 461698-96-4P, N-(1H-3-Indazolyl)-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]amine 461698-99-7P, N-(4-Bromophenyl)-2-fluoro-4-(trifluoromethyl)benzamide 461699-00-3P, N-(4-Bromophenyl)-2-fluoro-4-(trifluoromethyl)-1-benzenecarbothioamide 461699-01-4P, Benzenecarboximidic acid, N-(4-bromophenyl)-2-fluoro-4-(trifluoromethyl)-, hydrazide 461699-02-5P, N-(4-Bromophenyl)-N-[6-(trifluoromethyl)benzo[d]isoxazol-3-yl]amine 461699-03-6P,



N-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-N-[6-(trifluoromethyl)benzo[d]isoxazol-3-yl]amine 461699-05-8P,  
3-Iodo-1-[1-(2-methoxyethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461699-06-9P 461699-09-2P,  
3-Iodo-1-(3-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine  
461699-13-8P, tert-Butyl 3-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-piperidinecarboxylate 461699-14-9P, tert-Butyl  
3-[4-amino-3-[4-[(5,7-dimethyl-1,3-benzoxazol-2-yl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinecarboxylate  
461699-18-3P, 3-Iodo-1-(3-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine dihydrochloride 461699-19-4P, 9H-Fluoren-9-ylmethyl  
N-[2-[3-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidino]-1,1-dimethyl-2-oxoethyl]-N-methylcarbamate 461699-20-7P  
461699-22-9P, tert-Butyl 3-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)azetane-1-carboxylate 461699-23-0P, tert-Butyl  
3-[4-amino-3-[4-[(5,7-dimethyl-1,3-benzoxazol-2-yl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]azetane-1-carboxylate 461699-27-4P,  
1-(3-Azetanyl)-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461699-28-5P, 3-Iodo-1-(1-methyl-3-azetanyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461699-30-9P, 2-(4-Bromoanilino)-1,3-benzoxazole-5-carbonitrile 461699-31-0P, 2-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)anilino]-1,3-benzoxazole-5-carbonitrile 461699-34-3P, 2-Amino-4-(trifluoromethoxy)phenol 461699-35-4P,  
N-(4-Bromophenyl)-5-(trifluoromethoxy)-1,3-benzoxazol-2-amine 461699-36-5P, N-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-(trifluoromethoxy)-1,3-benzoxazol-2-amine 461699-38-7P, N-(4-Bromophenyl)-5-ethyl-1,3-benzoxazol-2-amine 461699-39-8P, N-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-ethyl-1,3-benzoxazol-2-amine 461699-41-2P,  
Cis-1-[4-(Dimethylamino)cyclohexyl]-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461699-42-3P, trans-1-[4-(Dimethylamino)cyclohexyl]-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461699-46-7P, N-(4-Bromophenyl)-5-chloro-1,3-benzoxazol-2-amine 461699-47-8P, N-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-chloro-1,3-benzoxazol-2-amine 461699-48-9P,  
N-(4-Bromophenyl)-5-methyl-1,3-benzoxazol-2-amine 461699-49-0P, N-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-methyl-1,3-benzoxazol-2-amine 461699-50-3P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-iodo-1-[cis-4-(4-morpholinyl)cyclohexyl]- 461699-51-4P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-iodo-1-[cis-4-[(2-methoxyethyl)amino]cyclohexyl]- 461699-52-5P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-iodo-1-[cis-4-(methylamino)cyclohexyl]- 461699-61-6P, N-(4-Bromophenyl)-N-(5,7-dimethyl-1,3-benzothiazol-2-yl)amine 461699-78-5P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461699-82-1P, 2-Methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline bismaleate 461701-01-9P, 3-Iodo-1-(tetrahydro-1H-pyrrol-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine monohydrochloride 461701-02-0P, 3-Iodo-1-(1-methyltetrahydro-1H-pyrrol-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461701-03-1P, N-(4-Bromophenyl)-5,7-dimethyl-1,3-benzoxazol-2-amine 461701-05-3P, 3-Iodo-1-[1-(2-methoxyethyl)tetrahydro-1H-pyrrol-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461701-07-5P, N-(4-Bromo-2-fluorophenyl)-5,7-dimethyl-1,3-benzoxazol-2-amine 461701-08-6P, N-[2-Fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461701-10-0P, 2-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]imidazo[1,2-a]pyridine 461701-12-2P, 1-[3-(4-Amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)tetrahydro-1H-pyrrol-1-yl]-2-(dimethylamino)-1-ethanone 461701-14-4P, 9H-Fluoren-9-ylmethyl N-[2-[3-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)tetrahydro-1H-pyrrol-1-yl]-1,1-dimethyl-2-oxoethyl]-

N-methylcarbamate 461701-15-5P 461701-17-7P, tert-Butyl  
 3-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-  
 pyrrolidinecarboxylate 461701-18-8P, tert-Butyl  
 3-[4-amino-3-[4-[(5,7-dimethyl-1,3-benzoxazol-2-yl)amino]phenyl]-1H-  
 pyrazolo[3,4-d]pyrimidin-1-yl]-1-pyrrolidinecarboxylate  
 461701-21-3P, N-(4-Bromophenyl)-7-isopropyl-1,3-benzoxazol-2-amine  
 461701-22-4P, N-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-  
 yl)phenyl]-7-isopropyl-1,3-benzoxazol-2-amine 461701-38-2P,  
 4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-  
 d]pyrimidin-3-yl]benzaldehyde 461701-54-2P 461702-08-9P,  
 1-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]-1H-  
 benzo[d]imidazole 461702-16-9P, N-[4-[4-Amino-1-[1-[(2-methyl-1H-  
 imidazol-4-yl)methyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-  
 2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-21-6P  
 461702-22-7P, N-[4-[4-Amino-1-[1-(2-fluoroethyl)-4-piperidyl]-1H-  
 pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-  
 indolecarboxamide 461702-24-9P, N-[4-[4-Amino-1-[1-(2,2-  
 difluoroethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-  
 methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-39-6P,  
 1-(3-Bromopropyl)-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
 461702-40-9P, 3-Iodo-1-[3-(4-methylpiperazino)propyl]-1H-  
 pyrazolo[3,4-d]pyrimidin-4-amine 461702-42-1P,  
 3-Iodo-1-(3-morpholinopropyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
 461702-44-3P, 1-[3-(1H-1-Imidazolyl)propyl]-3-iodo-1H-pyrazolo[3,4-  
 d]pyrimidin-4-amine 461702-55-6P, Cyclohexanecarboxylic acid,  
 4-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-, ethyl ester,  
 cis- 461702-59-0P, N-(4-Bromophenyl)-N-(2-pyrimidinyl)amine  
 461702-62-5P, 1-(2-Chloro-4-pyridyl)-3-iodo-1H-pyrazolo[3,4-  
 d]pyrimidin-4-amine 461702-63-6P 461702-66-9P, (S)-tert-Butyl  
 3-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-  
 piperidinecarboxylate 461702-68-1P 461702-69-2P,  
 (S)-3-Iodo-1-[1-(2-methoxyethyl)-3-piperidyl]-1H-pyrazolo[3,4-  
 d]pyrimidin-4-amine 461702-98-7P, N-[2-Methoxy-4-(4,4,5,5-  
 tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1H-3-indolecarboxamide  
 471925-68-5P, 3-(4-Phenoxyphenyl)-1-(3-propylidenecyclobutyl)-1H-  
 pyrazolo[3,4-d]pyrimidin-4-amine 471925-82-3P 471925-83-4P,  
 N-[4-[4-Amino-1-[1-(1-methyl-4-piperidyl)-4-piperidyl]-1H-  
 pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]aniline  
 471925-90-3P, 1-[1-(1H-2-Imidazolylmethyl)-4-piperidyl]-3-iodo-1H-  
 pyrazolo[3,4-d]pyrimidin-4-amine 471925-91-4P, tert-Butyl  
 N-[4-[4-amino-1-[1-(1H-2-imidazolylmethyl)-4-piperidyl]-1H-  
 pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]carbamate  
 471925-92-5P, 3-(4-Amino-3-methoxyphenyl)-1-[1-(1H-2-  
 imidazolylmethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
 471925-99-2P, 2-Fluoro-6-[(2-methoxyethyl)amino]benzonitrile  
 471927-37-4P, 5-Ethoxy-3-methyl-1-[4-(4,4,5,5-tetramethyl-1,3-  
 dioxolan-2-yl)phenyl]-1H-pyrazole  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);  
 RACT (Reactant or reagent)  
 (intermediate; prepn. of [(hetero)aryl]pyrazolo[3,4-  
 d]pyrimidinamines as protein kinase inhibitors with  
 antiangiogenic properties)  
 IT 144697-17-6 144941-35-5, Blk protein kinase  
 RL: BSU (Biological study, unclassified); BIOL  
 (Biological study)  
 (prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as  
 protein kinase inhibitors with antiangiogenic properties)  
 IT 330785-88-1P, 1-(1-Benzyl-4-piperidinyl)-3-(4-phenoxyphenyl)-1H-  
 pyrazolo[3,4-d]pyrimidin-4-amine  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN  
 (Synthetic preparation); THU (Therapeutic use); BIOL  
 (Biological study); PREP (Preparation); RACT (Reactant or

reagent); USES (Uses)

(protein kinase inhibitor.; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT 330788-71-1P 330788-72-2P 330788-73-3P 330788-74-4P  
330788-75-5P 330788-76-6P 330788-77-7P 330788-78-8P  
330788-79-9P 330788-80-2P 330788-81-3P 330788-82-4P  
330788-83-5P 330788-84-6P 330788-85-7P 330788-86-8P  
330788-87-9P 330788-88-0P 471925-84-5P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(protein kinase inhibitor; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT 330785-90-5P, 3-(4-Phenoxyphenyl)-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330786-11-3P 330786-13-5P,  
4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-cyclohexanone 330786-15-7P, tert-Butyl cis-4-[4-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]cyclohexyl]-1-piperazinecarboxylate 330786-16-8P, tert-Butyl trans-4-[4-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]cyclohexyl]-1-piperazinecarboxylate 330786-24-8P,  
3-(4-Phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330786-58-8P, Cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-(2-phenoxy-5-pyrimidinyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330786-63-5P,  
Cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-(2-pyrimidinyl)oxy]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330786-67-9P 330787-59-2P 330787-63-8P 330787-67-2P,  
3-[4-(Benzyloxy)phenyl]-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-88-7P, Cis-2-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]benzonitrile 330787-91-2P, Cis-3-[4-[2-(Aminomethyl)phenoxy]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330788-01-7P 330788-03-9P,  
1-(3-Azetanyl)-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330788-11-9P, Cis-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-cyclobutanol 330788-15-3P,  
Trans-1-[3-[(Benzyloxy)methyl]cyclobutyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330788-68-6P,  
trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(dimethylamino)benzamide 330788-92-6P, Ethyl 2-[4-amino-3-[4-[[2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]acetate 330789-03-2P,  
trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 330789-23-6P, cis-3-[4-(Benzyloxy)phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330789-29-2P, trans-3-[4-(Benzyloxy)phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330789-32-7P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-phenylpropanamide 330789-75-8P,  
Cis-2-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]anilino]-1-phenyl-1-ethanone diacetate 330790-07-3P, Methyl 5-[4-(4-amino-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)phenoxy]-2-furoate 330790-15-3P,  
Cis-2-[3-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]benzaldehyde 330790-20-0P  
330790-21-1P 330790-70-0P, Trans-2-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-hydroxycyclohexyl]acetic acid



330790-74-4P 330790-88-0P, Methyl 2-[4-amino-3-[4-[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]acetate 330790-98-2P, Ethyl 2-[4-amino-3-[4-[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]propanoate 330790-99-3P, Methyl 2-[4-amino-3-[4-[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]propanoate 330791-04-3P, Methyl 4-[4-amino-3-[4-[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]butanoate 330791-51-0P, tert-Butyl N-[4-[4-amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]carbamate 330791-57-6P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine dihydrochloride 330791-68-9P 330791-88-3P, tert-Butyl N-[4-[4-amino-1-(4-nitrophenyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]carbamate 330791-99-6P, trans-3-(4-Amino-2-fluoro-5-methoxyphenyl)-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330792-01-3P, tert-Butyl N-[4-[4-amino-1-(1-methyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]carbamate 330792-23-9P, Trans-3-[4-[(2-Aminobenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330792-33-1P, Trans-3-[4-(5-Ethoxy-1H-1-pyrazolyl)phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine acetate 330792-43-3P, 2-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]acetic acid 330792-49-9P, 3-[3-Methoxy-4-[(5-methyl-2-furyl)methyl]amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461697-04-1P, N-[4-[4-Amino-1-(2-hydroxyethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461697-42-7P, N-[4-[4-Amino-1-(4-oxocyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-trifluoromethylbenzamide 461697-45-0P, Cis-Ethyl 3-[4-[4-amino-3-[4-[(2-fluoro-4-trifluoromethylbenzoyl)amino]-3-methoxyphenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]cyclohexyl]amino]propanoate 461697-46-1P, Trans-Ethyl 3-[4-[4-amino-3-[4-[(2-fluoro-4-trifluoromethylbenzoyl)amino]-3-methoxyphenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]cyclohexyl]amino]propanoate 461697-49-4P, N-[4-(4-Amino-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methoxyphenyl]-2-fluoro-4-trifluoromethylbenzamide 461697-50-7P, N-[4-(4-Amino-1-trityl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methoxyphenyl]-2-fluoro-4-trifluoromethylbenzamide 461697-52-9P, N-[4-[4-Amino-1-(4-hydroxy-2-cyclopentenyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-trifluoromethylbenzamide 461698-20-4P 461698-28-2P, trans-3-[4-[(2-Methoxy-3-pyridyl)methyl]amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461699-12-7P 461701-33-7P, 3-(4-Amino-3-methoxyphenyl)-1-(1-methyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461701-35-9P, N-[4-[4-Amino-1-(1-methyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(trifluoromethyl)benzamide 461702-45-4P, N-[4-[4-Amino-1-(tetrahydro-1H-pyrrol-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-54-5P, cis-Ethyl 4-[4-amino-3-[4-[(5,7-dimethyl-1,3-benzoxazol-2-yl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-cyclohexanecarboxylate 471926-42-8P 471927-18-1P, trans-tert-Butyl N-[4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-5-fluoro-2-methoxyphenyl]carbamate

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL

(Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(protein kinase inhibitor; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT 330785-92-7P, 1-[1-(1-Methyl-4-piperidinyl)-4-piperidinyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine trimaleate  
330785-96-1P, 1-[1-(1-Isopropyl-4-piperidinyl)-4-piperidinyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine trimaleate  
330785-98-3P, 1-[1-(4-Piperidinyl)-4-piperidinyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine trimaleate  
330786-02-2P, 1-[trans-4-(4-Methylpiperazino)cyclohexyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine dimaleate  
330786-06-6P, 1-[4-(4-Methylpiperazino)cyclohexyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine trimaleate  
330786-08-8P, N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-4-fluoro-1-benzenesulfonamide dimaleate 330786-18-0P, Cis-3-(4-Phenoxyphenyl)-1-(4-piperazinocyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine trimaleate 330786-20-4P, Trans-3-(4-Phenoxyphenyl)-1-(4-piperazinocyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine trimaleate 330786-25-9P, 4-Amino-1-cyclopentyl-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidine 330786-27-1P, 3-(4-Phenoxyphenyl)-1-(tetrahydropyran-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine  
330786-29-3P 330786-30-6P 330786-33-9P 330786-36-2P, Cis-3-(4-Anilinophenyl)-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine trimaleate 330786-40-8P, Cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-(6-phenoxy-3-pyridyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine dimaleate 330786-45-3P, Trans-Benzyl N-[4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]carbamate dimaleate 330786-47-5P, Trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]benzamide dimaleate 330786-49-7P, N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-N'-phenylsulfamide dimaleate 330786-51-1P 330786-53-3P 330786-55-5P 330786-57-7P 330786-59-9P, Cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-(2-phenoxy-5-pyrimidinyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine dimaleate 330786-61-3P, Trans-1-[4-(4-Methylpiperazino)cyclohexyl]-3-(2-phenoxy-5-pyrimidinyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine dimaleate 330786-64-6P, Cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-(2-pyrimidinylloxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine trimaleate 330786-66-8P, trans-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-(2-pyrimidinylloxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine dimaleate 330786-69-1P 330786-71-5P 330786-72-6P 330786-73-7P 330786-75-9P 330786-77-1P 330786-78-2P, Cis-4-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]benzamide 330786-79-3P, Cis-4-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]benzoic acid 330786-81-7P 330786-83-9P 330786-85-1P, cis-3-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]benzamide diacetate 330786-86-2P, Cis-3-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]benzoic acid 330786-88-4P 330786-89-5P, Cis-N-[3-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]benzyl]benzamide 330786-91-9P 330786-93-1P, Cis-Benzyl N-[4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]carbamate dimaleate 330786-95-3P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-

1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-N'-benzylurea  
acetate 330786-97-5P, Cis-3-[4-(Benzylamino)-3-methoxyphenyl]-1-[4-  
(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
acetate 330786-99-7P 330787-03-6P, Trans-3-[4-(Benzylamino)-3-  
methoxyphenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-  
d]pyrimidin-4-amine dimaleate 330787-05-8P, Trans-3-[4-[(2,6-  
Dimethoxybenzyl)amino]-3-methoxyphenyl]-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
diacetate 330787-07-0P, Trans-3-[4-[(2-Chloro-6-  
fluorobenzyl)amino]-3-methoxyphenyl]-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
diacetate 330787-09-2P, Cis-3-[4-(Benzylamino)phenyl]-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
diacetate 330787-11-6P, Cis-3-[4-[(2-Methylbenzyl)amino]phenyl]-1-  
[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-  
amine diacetate 330787-13-8P 330787-14-9P, Cis-3-[4-[(2-  
Chlorobenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-  
pyrazolo[3,4-d]pyrimidin-4-amine 330787-15-0P,  
Cis-3-[4-[(2-Bromobenzyl)amino]phenyl]-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
330787-16-1P, Cis-3-[4-[(2-Ethoxybenzyl)amino]phenyl]-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
330787-17-2P, Cis-3-[4-[(2-(Difluoromethoxy)benzyl)amino]phenyl]-1-  
[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-  
amine 330787-19-4P 330787-21-8P 330787-23-0P,  
Cis-2-[[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-  
pyrazolo[3,4-d]pyrimidin-3-yl]anilino]methyl]benzonitrile diacetate  
330787-24-1P, Cis-3-[4-[(2,6-Difluorobenzyl)amino]phenyl]-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
330787-26-3P, Cis-3-[4-[(2-Chloro-6-fluorobenzyl)amino]phenyl]-1-[4-  
(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
acetate 330787-27-4P, Cis-3-[4-[(2-Fluoro-6-  
(trifluoromethyl)benzyl)amino]phenyl]-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
330787-29-6P, Cis-3-[4-[(2-Fluoro-6-methoxybenzyl)amino]phenyl]-1-[4-  
(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
diacetate 330787-30-9P, Cis-3-[4-[(2,6-  
Dichlorobenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-  
pyrazolo[3,4-d]pyrimidin-4-amine 330787-32-1P,  
Cis-3-[4-[(2,6-Dimethoxybenzyl)amino]phenyl]-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
diacetate 330787-34-3P, Cis-3-[4-[(2-Fluoro-4-  
methylbenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-  
pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-38-7P,  
Cis-3-[4-[[1-Methyl-1H-indol-2-yl)methyl]amino]phenyl]-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
diacetate 330787-40-1P, Trans-3-[4-(Benzylamino)phenyl]-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
trimaleate 330787-42-3P, Trans-3-[4-[(2-Methylbenzyl)amino]phenyl]-  
1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-  
amine diacetate 330787-44-5P, Trans-3-[4-[(2,6-  
Dimethoxybenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-  
1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-46-7P,  
Trans-3-[4-[(2-Chlorobenzyl)amino]phenyl]-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
diacetate 330787-48-9P, Trans-3-[4-[(2-Bromobenzyl)amino]phenyl]-1-  
[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-  
amine acetate 330787-50-3P 330787-52-5P 330787-53-6P  
330787-55-8P, Cis-3-[4-[Benzyl(methyl)amino]phenyl]-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
diacetate 330787-57-0P, Cis-3-[4-[Benzyl(ethyl)amino]phenyl]-1-[4-  
(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine

diacetate 330787-61-6P, Cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-(phenethylamino)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
diacetate 330787-65-0P, Cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-[(3-phenylpropyl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
diacetate 330787-66-1P, 1-Cyclopentyl-3-[4-(3-methoxyphenoxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
330787-68-3P, 1-Cyclopentyl-3-[4-(4-fluorophenoxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-69-4P,  
1-Cyclopentyl-3-[4-[3-(trifluoromethyl)phenoxy]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-70-7P,  
1-Cyclopentyl-3-[4-(3-nitrophenoxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-71-8P, 1-Cyclopentyl-3-[4-[4-(trifluoromethoxy)phenoxy]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
330787-72-9P, 1-Cyclopentyl-3-[4-[4-(trifluoromethyl)phenoxy]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
330787-73-0P, 3-[3-(Benzoyloxy)phenyl]-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-75-2P, Cis-3-[4-[(3-Fluorobenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine triacetate 330787-77-4P,  
Cis-3-[4-[(2-Fluorobenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine triacetate 330787-79-6P, Cis-3-[4-[(4-Methoxybenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-81-0P, Cis-3-[4-[(3-Methoxybenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine triacetate 330787-83-2P,  
Cis-3-[4-[(4-Fluorobenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine triacetate 330787-84-3P, Cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-[(3-pyridylmethyl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-85-4P, Cis-3-[4-[(2-Methoxybenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
330787-87-6P, Cis-3-[3-(Benzylamino)phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine triacetate 330787-90-1P, Cis-2-[3-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]benzamide triacetate 330787-93-4P, Cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenoxy]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-95-6P, Cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-(2-nitrophenoxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-96-7P, Cis-3-[4-(2-Aminophenoxy)phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
330787-97-8P, [2-(4-Amino-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-5-phenoxyphenyl]methanol 330787-99-0P 330788-02-8P  
330788-04-0P, 2-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-1-ethanol 330788-06-2P,  
1-[1-(2-Methoxyethyl)-3-azetanyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine acetate 330788-07-3P,  
1-[1-[2-(2-Methoxyethoxy)ethyl]-3-azetanyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330788-08-4P,  
1-[1-(1-Methyl-4-piperidyl)-3-azetanyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330788-09-5P,  
1-[1-[(1-Methyl-1H-imidazol-2-yl)methyl]-3-azetanyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330788-10-8P,  
1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-1-ethanone 330788-12-0P, Trans-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-cyclobutanol  
330788-14-2P 330788-16-4P, trans-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]cyclobutanemethanol 330788-18-6P  
330788-19-7P 330788-20-0P 330788-21-1P 330788-23-3P  
330788-24-4P 330788-25-5P 330788-26-6P 330788-27-7P



330788-28-8P 330788-29-9P 330788-30-2P 330788-31-3P  
330788-32-4P 330788-34-6P, cis-3-[4-[(4-Bromobenzyl)amino]-3-fluorophenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine trimaleate 330788-46-0P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(2,4-difluorophenyl)urea 330788-47-1P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methoxyphenyl)urea 330788-48-2P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methoxyphenyl)urea monoacetate 330788-50-6P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methylphenyl)urea monoacetate 330788-51-7P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methylphenyl)urea 330788-52-8P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N-ethyl-N'-(3-methylphenyl)urea 330788-53-9P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N-benzyl-N'-(2,4-difluorophenyl)urea 330788-54-0P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-N'-(3-methylphenyl)urea 330788-55-1P, N-[4-[4-Amino-1-[1-[2-(dimethylamino)acetyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methylphenyl)urea 330788-57-3P, N-[4-[4-Amino-1-[1-[3-(diethylamino)propanoyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methylphenyl)urea monoacetate 330788-58-4P, N-[4-[4-Amino-1-[1-[2-(methylamino)acetyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methylphenyl)urea 330788-60-8P, N-[4-[4-Amino-1-[1-[3-[(2-hydroxyethyl)amino]propanoyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methylphenyl)urea monoacetate 330788-61-9P 330788-62-0P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1H-indole-2-carboxamide 330788-63-1P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-methyl-1H-indene-2-carboxamide 330788-64-2P 330788-65-3P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-indole-2-carboxamide 330788-66-4P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1H-indole-3-carboxamide 330788-67-5P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-phenylpropanamide 330788-69-7P, Trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(dimethylamino)benzamide trimaleate 330788-70-0P 330788-89-1P 330788-90-4P, 1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-[(phenethylamino)(phenyl)methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330788-91-5P, N-[4-[4-Amino-1-(4-oxocyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methylphenyl)urea 330788-93-7P, N-[4-[4-Amino-1-(2-hydroxyethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-2,3-dichloro-1-benzenesulfonamide 330788-94-8P, N-[4-[4-Amino-1-[2-cyano-4-(4-methylpiperazino)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-2,3-dichloro-1-benzenesulfonamide 330788-95-9P, cis-N-Phenyl-4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxybenzamide 330788-96-0P, trans-N-Phenyl-4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxybenzamide 330788-97-1P,

cis-N-Benzyl-4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxybenzamide 330788-98-2P,  
cis-N-Phenethyl-4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxybenzamide 330788-99-3P,  
cis-N-Phenyl-4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]benzamide 330789-00-9P,  
cis-N-Phenethyl-4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]benzamide 330789-02-1P,  
trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1H-2-indolecarboxamide trimaleate 330789-04-3P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide trimaleate 330789-06-5P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(trifluoromethyl)benzamide trimaleate 330789-08-7P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(trifluoromethoxy)benzamide trimaleate 330789-09-8P, N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-phenylpropanamide 330789-13-4P, 1-[1-(1H-Imidazol-2-ylmethyl)tetrahydro-1H-pyrrol-3-yl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330789-15-6P, 1-[1-(1-Methyl-4-piperidyl)tetrahydro-1H-pyrrol-3-yl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine trimaleate 330789-16-7P, N-[4-[4-Amino-1-[1-(1H-imidazol-2-ylmethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-phenylpropanamide 330789-24-7P, cis-2-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]-6-[(3-methoxypropyl)amino]benzonitrile 330789-26-9P, cis-2-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]-6-[(4-methylphenyl)sulfanyl]benzonitrile trimaleate 330789-28-1P, cis-2-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]-6-(2-pyridylsulfanyl)benzonitrile dimaleate 330789-31-6P, trans-2-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]-6-[(3-methoxypropyl)amino]benzonitrile trimaleate 330789-33-8P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-phenylpropanamide trimaleate 330789-34-9P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-N-methyl-3-phenylpropanamide 330789-35-0P, N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(trifluoromethoxy)benzamide trimaleate 330789-37-2P, [4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino](4-methylpiperazino)methanone dimaleate 330789-39-4P, N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(dimethylamino)benzamide trimaleate 330789-40-7P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-(trifluoromethyl)benzamide 330789-41-8P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-(trifluoromethoxy)benzamide 330789-42-9P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-(trifluoromethoxy)benzamide 330789-43-0P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-

methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 330789-44-1P,  
cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-  
pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-  
(trifluoromethyl)benzamide 330789-46-3P 330789-48-5P,  
Cis-3-[4-[(2-Furylmethyl)amino]-3-methoxyphenyl]-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
acetate 330789-50-9P 330789-52-1P, Trans-3-[4-[(2-  
Furylmethyl)amino]-3-methoxyphenyl]-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
dimaleate 330789-56-5P, Cis-2-[2-[[4-[4-Amino-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-  
yl]anilino]methyl]phenoxy]acetic acid diacetate 330789-58-7P,  
Cis-3-[4-[(2-Furylmethyl)amino]phenyl]-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
diacetate 330789-60-1P, Cis-3-[4-[(5-Methyl-2-  
furyl)methyl]aminophenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-  
pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330789-62-3P,  
Cis-3-[4-[(3-Furylmethyl)amino]phenyl]-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
diacetate 330789-64-5P 330789-66-7P  
, Trans-3-[4-[(2-Furylmethyl)amino]phenyl]-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
diacetate 330789-68-9P, 3-[4-[(5-Methyl-2-  
furyl)methyl]aminophenyl]-1-[1-(1-methyl-4-piperidyl)-4-piperidyl]-  
1H-pyrazolo[3,4-d]pyrimidin-4-amine acetate 330789-70-3P  
330789-71-4P 330789-77-0P 330789-79-2P 330789-81-6P  
330789-83-8P 330789-85-0P 330789-86-1P 330789-88-3P  
330789-90-7P 330789-92-9P 330789-93-0P 330789-96-3P  
330789-98-5P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-  
1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-2-methyl-2-  
phenylpropanamide diacetate 330790-00-6P 330790-02-8P  
330790-03-9P 330790-05-1P, Cis-N-[4-[4-Amino-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-  
yl]phenyl]-1,3-benzoxazol-2-amine diacetate 330790-06-2P,  
2-[4-(4-Amino-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-3-  
yl)phenoxy]acetamide 330790-08-4P, 5-[4-(4-Amino-1-cyclopentyl-1H-  
pyrazolo[3,4-d]pyrimidin-3-yl)phenoxy]-2-furoic acid 330790-09-5P,  
1-Cyclopentyl-3-[4-(3-thienyloxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-  
4-amine 330790-11-9P 330790-12-0P, Cis-3-[3-[Di(2-  
furylmethyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-  
pyrazolo[3,4-d]pyrimidin-4-amine 330790-14-2P 330790-18-6P,  
(2S)-3-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-  
yl]-1-azetanyl]propane-1,2-diol 330790-19-7P, (2R)-3-[3-[4-Amino-3-  
(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-  
azetanyl]propane-1,2-diol 330790-22-2P 330790-23-3P,  
N-Methyl-2-[3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-  
d]pyrimidin-1-yl]-1-azetanyl]acetamide 330790-24-4P,  
N,N-Dimethyl-2-[3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-  
d]pyrimidin-1-yl]-1-azetanyl]acetamide 330790-25-5P,  
N-Isopropyl-2-[3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-  
d]pyrimidin-1-yl]-1-azetanyl]acetamide 330790-26-6P,  
N-(3-Hydroxypropyl)-2-[3-[4-amino-3-(4-phenoxyphenyl)-1H-  
pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]acetamide 330790-27-7P  
330790-28-8P, N-Benzyl-2-[3-[4-amino-3-(4-phenoxyphenyl)-1H-  
pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]acetamide 330790-30-2P,  
2-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-  
1-azetanyl]-1-morpholino-1-ethanone 330790-31-3P,  
N-(3-Methyl-5-isoxazolyl)-2-[3-[4-amino-3-(4-phenoxyphenyl)-1H-  
pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]acetamide 330790-34-6P,  
1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-  
1-azetanyl]-2-[(2-hydroxyethyl)amino]-1-ethanone 330790-35-7P,  
1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-

1-azetanyl]-2-[(2-methoxyethyl)amino]-1-ethanone 330790-36-8P,  
 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[(3-hydroxypropyl)amino]-1-ethanone 330790-37-9P,  
 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[(2,3-dihydroxypropyl)amino]-1-ethanone  
 330790-38-0P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[(tetrahydro-2-furanylmethyl)amino]-1-ethanone 330790-39-1P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[(2-piperidinoethyl)amino]-1-ethanone 330790-40-4P,  
 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[[2-(dimethylamino)ethyl](methyl)amino]-1-ethanone 330790-42-6P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[[2-(dimethylamino)ethyl]amino]-1-ethanone acetate 330790-43-7P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[methyl(1-methyl-4-piperidyl)amino]-1-ethanone 330790-44-8P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[(2-morpholinoethyl)amino]-1-ethanone  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (protein kinase inhibitor; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)  
 IT 330790-45-9P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[(3-morpholinopropyl)amino]-1-ethanone 330790-46-0P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[[3-(1H-1-imidazolyl)propyl]amino]-1-ethanone 330790-47-1P,  
 1-[3-[[2-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-oxoethyl]amino]propyl]-2-pyrrolidinone 330790-48-2P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-(4-hydroxypiperidino)-1-ethanone 330790-49-3P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[4-(hydroxymethyl)piperidino]-1-ethanone 330790-51-7P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-morpholino-1-ethanone 330790-52-8P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-(4-methylpiperazino)-1-ethanone 330790-53-9P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[4-(piperid-1-yl)piperidino]-1-ethanone 330790-54-0P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-(1H-4-imidazolyl)-1-ethanone 330790-56-2P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-(methylamino)-1-ethanone acetate 330790-58-4P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-(dimethylamino)-1-ethanone acetate 330790-59-5P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-3-(diethylamino)-1-propanone 330790-61-9P, 1-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-2-(methylamino)-1-ethanone acetate 330790-62-0P, 1-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-2-(dimethylamino)-1-ethanone 330790-64-2P, 1-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-3-(diethylamino)-1-propanone acetate 330790-66-4P, 1-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-2-morpholino-1-ethanone acetate 330790-68-6P, 1-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-2-(4-methylpiperazino)-1-ethanone acetate 330790-69-7P, Cis-2-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-



hydroxycyclohexyl]acetic acid 330790-71-1P, [3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-(hydroxymethyl)cyclobutyl]methanol 330790-72-2P 330790-73-3P 330790-75-5P 330790-76-6P 330790-77-7P 330790-79-9P, N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-5-chloro-2-thiophenesulfonamide maleate 330790-80-2P, 1-[4-[4-Amino-3-[4-(1,3-benzoxazol-2-ylamino)-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-2-(dimethylamino)-1-ethanone 330790-81-3P, 1-[4-[4-Amino-3-[4-(1,3-benzothiazol-2-ylamino)-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-2-(dimethylamino)-1-ethanone 330790-82-4P, N-[4-[4-Amino-1-(2-morpholino-2-oxoethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-2,3-dichloro-1-benzenesulfonamide 330790-83-5P, N-[4-[4-Amino-1-[2-(4-methylpiperazino)-2-oxoethyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-2,3-dichloro-1-benzenesulfonamide 330790-84-6P, N-((1R,2S)-2-Hydroxy-1-methyl-2-phenylethyl)-N-methyl-2-[4-amino-3-[4-[[2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]acetamide 330790-85-7P, N-((1S,2S)-2-Hydroxy-1-methyl-2-phenylethyl)-N-methyl-2-[4-amino-3-[4-[[2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]acetamide 330790-86-8P 330790-87-9P 330790-89-1P, 2-[4-Amino-3-[4-[[2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]acetic acid 330790-90-4P, N-[2-(Dimethylamino)ethyl]-2-[4-amino-3-[4-[[2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]acetamide 330790-91-5P, N-[2-(Diethylamino)ethyl]-2-[4-amino-3-[4-[[2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]acetamide 330790-92-6P, 2-(Dimethylamino)ethyl 2-[4-amino-3-[4-[[2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]acetate 330790-93-7P, N-[3-(Dimethylamino)propyl]-2-[4-amino-3-[4-[[2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]acetamide 330790-94-8P, 2-[4-Amino-3-[4-[[2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]acetamide 330790-96-0P, N-[4-[4-Amino-1-(2-morpholino-2-oxoethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methylphenyl)urea 330790-97-1P, N-[4-[4-Amino-1-[2-(4-methylpiperazino)-2-oxoethyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methylphenyl)urea 330791-00-9P, 2-[4-Amino-3-[4-[[2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]propanamide 330791-01-0P 330791-02-1P 330791-03-2P, Ethyl 4-[4-amino-3-[4-[[2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]butanoate 330791-05-4P, 4-[4-Amino-3-[4-[[2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]butanamide 330791-06-5P 330791-07-6P 330791-08-7P, 2-[4-Amino-3-[4-(1,3-benzoxazol-2-ylamino)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-5-(4-methylpiperazino)benzonitrile 330791-09-8P, Ethyl 2-[4-amino-3-[4-(1,3-benzothiazol-2-ylamino)-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]propanoate 330791-10-1P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-1,3-benzoxazol-2-amine 330791-11-2P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-1,3-benzothiazol-2-amine 330791-12-3P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-1,3-benzothiazol-2-amine 330791-13-4P, Trans-N-[4-[4-Amino-1-[4-(4-

methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-1,3-benzoxazol-2-amine 330791-14-5P,  
Trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-1,3-benzoxazol-2-amine 330791-15-6P, Trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-1,3-benzothiazol-2-amine 330791-16-7P,  
Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-4-methyl-1,3-benzoxazol-2-amine 330791-17-8P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-chloro-1,3-benzoxazol-2-amine 330791-18-9P,  
Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-methyl-1,3-benzoxazol-2-amine 330791-19-0P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 330791-20-3P  
330791-21-4P 330791-23-6P 330791-24-7P 330791-25-8P  
330791-26-9P, Trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]benzyl]-N'-(3-methylphenyl)urea 330791-27-0P 330791-28-1P,  
cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2,2-dimethyl-3-phenylpropanamide 330791-30-5P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2,2-dimethyl-3-phenylpropanamide trimaleate 330791-32-7P 330791-33-8P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]benzo[b]thiophene-2-carboxamide 330791-34-9P,  
cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-thiophenecarboxamide 330791-35-0P 330791-37-2P,  
trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-methyl-3-phenylbutanamide trimaleate 330791-38-3P 330791-39-4P  
330791-40-7P 330791-43-0P 330791-44-1P 330791-46-3P  
330791-48-5P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]benzo[b]furan-2-carboxamide trimaleate 330791-50-9P  
330791-52-1P, 3-[4-[(2-Furylmethyl)amino]-3-methoxyphenyl]-1-[1-(1-methyl-4-piperidinyl)-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330791-54-3P, N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-trans-2-phenylcyclopropane-1-carboxamide dimaleate 330791-58-7P 330791-59-8P 330791-60-1P 330791-61-2P  
330791-62-3P 330791-63-4P 330791-64-5P 330791-65-6P  
330791-66-7P 330791-67-8P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]benzyl]-5-methyl-1,3-thiazol-2-amine 330791-69-0P,  
Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dichloro-1,3-benzoxazol-2-amine 330791-70-3P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-7-methyl-1,3-benzoxazol-2-amine 330791-71-4P,  
Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-7-chloro-1,3-benzoxazol-2-amine 330791-72-5P 330791-73-6P, N-[2-(Dimethylamino)ethyl]-2-[4-amino-3-[4-[(5,7-dimethyl-1,3-benzoxazol-2-yl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]propanamide 330791-74-7P,  
N-[4-[4-Amino-1-[2-cyano-4-(4-methylpiperazino)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methylphenyl)urea 330791-75-8P, cis-N-[4-[4-Amino-1-[4-(4-

methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-6-chloro-1,3-benzothiazol-2-amine 330791-76-9P,  
cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-6-methoxy-1,3-benzothiazol-2-amine 330791-77-0P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-4-ethyl-1,3-thiazol-2-amine 330791-78-1P,  
cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-4,5-dimethyl-1,3-thiazol-2-amine 330791-79-2P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-4-phenyl-1,3-thiazol-2-amine 330791-80-5P,  
cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-4-(4-methylphenyl)-1,3-thiazol-2-amine 330791-81-6P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-methyl-4-phenyl-1,3-thiazol-2-amine 330791-83-8P,  
N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-(3R)-3-phenylbutanamide trimaleate 330791-85-0P, N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]benzo[b]furan-2-carboxamidetrimalate 330791-87-2P, N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-(3S)-3-phenylbutanamide trimaleate 330791-89-4P, 4-Amino-3-(4-amino-3-methoxyphenyl)-1-(4-nitrophenyl)-1H-pyrazolo[3,4-d]pyrimidine 330791-91-8P, N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide dimaleate 330791-93-0P, N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1H-2-indolecarboxamide dimaleate 330791-94-1P, 3-Phenyl-1-trityl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330791-95-2P, N-[4-[4-Amino-1-(4-oxocyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-(3R)-3-phenylbutanamide 330791-96-3P, [4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]phenyl]methanol 330791-97-4P,  
1-[4-[(4-Methylpiperazino)methyl]phenyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330792-00-2P,  
trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-5-fluoro-2-methoxyphenyl]-trans-2-phenyl-1-cyclopropanecarboxamide 330792-03-5P,  
Trans-3-[4-[(2-Chlorobenzyl)amino]-3-methoxyphenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330792-05-7P, Trans-3-[3-Methoxy-4-[(1,3-thiazol-2-ylmethyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330792-09-1P,  
Trans-3-[3-Methoxy-4-[(2-thienylmethyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine acetate 330792-11-5P, Trans-3-[3-Methoxy-4-[(5-methyl-2-thienyl)methyl]amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine acetate 330792-13-7P,  
Trans-3-[4-[(5-Chloro-2-thienyl)methyl]amino]-3-methoxyphenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine acetate 330792-15-9P, Trans-3-[3-Methoxy-4-[(2-methyl-1,3-thiazol-4-yl)methyl]amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330792-19-3P,  
Trans-3-[4-[(2-Chloro-6-fluorobenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330792-25-1P 330792-27-3P 330792-29-5P  
330792-31-9P, Trans-3-[4-(3-Methyl-5-phenyl-1H-1-pyrazolyl)phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330792-35-3P 330792-37-5P, 2-(2-Amino-1H-1-

imidazolyl)-1-[3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-1-ethanone acetate 330792-38-6P,  
1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-3-[(2-hydroxyethyl)amino]-1-propanone 330792-40-0P,  
2-(2-Amino-1H-1-imidazolyl)-1-[4-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-1-ethanone acetate  
330792-41-1P, 1-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-2-[(2-hydroxyethyl)amino]-1-ethanone  
330792-42-2P, 1-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-3-[(2-hydroxyethyl)amino]-1-propanone  
330792-46-6P, Trans-N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-phenyl-1-  
cyclopropanecarboxamide maleate 330792-48-8P, trans-N-[4-[4-Amino-1-[1-[(1-methyl-1H-imidazol-2-yl)methyl]-4-piperidyl]-1H-  
pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-phenyl-1-  
cyclopropanecarboxamide 330792-50-2P, 3-[3-Methoxy-4-[(5-methyl-2-furyl)methyl]amino]phenyl]-1-[1-[(1-methyl-1H-imidazol-2-yl)methyl]-  
4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330792-52-4P,  
trans-N-[4-[4-Amino-1-(4-oxocyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-phenylcyclopropane-1-carboxamide  
330792-54-6P 330792-55-7P 330792-56-8P, 1-(Aminomethyl)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-  
cyclobutanol 461697-05-2P, N-[4-[4-Amino-1-[4-(morpholinomethyl)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-  
methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461697-07-4P,  
N-[4-[4-Amino-1-[4-[(4-hydroxypiperidino)methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-  
(trifluoromethyl)benzamide monoacetate 461697-08-5P,  
N-[4-[4-Amino-1-[4-[(4-(2-hydroxyethyl)piperazino)methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-  
(trifluoromethyl)benzamide 461697-10-9P, N-[4-[4-Amino-1-[4-[(4-(2-hydroxyethyl)piperidino)methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-  
yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide diacetate  
461697-12-1P, N-[4-[4-Amino-1-[4-[(3-(hydroxymethyl)piperidino)methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-  
fluoro-4-(trifluoromethyl)benzamide monoacetate 461697-14-3P,  
N-[4-[4-Amino-1-[4-[(2-(hydroxymethyl)piperidino)methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-  
(trifluoromethyl)benzamide monoacetate 461697-15-4P,  
N-[4-[4-Amino-1-[4-[(2-morpholinoethyl)amino)methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-  
(trifluoromethyl)benzamide 461697-17-6P, N-[4-[4-Amino-1-[4-[(4-(hydroxymethyl)piperidino)methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-  
3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide  
diacetate 461697-18-7P, N-[4-[4-Amino-1-[4-[(4-(2-methoxyethyl)piperazino)methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-  
yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide  
461697-19-8P 461697-20-1P 461697-21-2P, N-[4-[4-Amino-1-[4-[(3-(1H-1-imidazolyl)propyl)amino)methyl]phenyl]-1H-pyrazolo[3,4-  
d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-  
(trifluoromethyl)benzamide 461697-22-3P, N-[4-[4-Amino-1-[4-[(4-(hydroxybutyl)amino)methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-  
2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide  
461697-23-4P, N-[4-[4-Amino-1-[4-[(3-methoxypropyl)amino)methyl]phe  
nyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-  
(trifluoromethyl)benzamide 461697-25-6P, N-[4-[4-Amino-1-[4-[(3-(dimethylamino)propyl)amino)methyl]phenyl]-1H-pyrazolo[3,4-  
d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-  
(trifluoromethyl)benzamide monoacetate 461697-26-7P, L-Histidine,  
N-[[4-[4-amino-3-[4-[(2-fluoro-4-(trifluoromethyl)benzoyl)amino]-3-  
methoxyphenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]phenyl]methyl]-,  
methyl ester 461697-27-8P, N-[4-[4-Amino-1-[4-[(2-



methoxyethyl)amino)methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461697-28-9P, N-[4-[4-Amino-1-[4-[[[2-(dimethylamino)ethyl]amino)methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461697-29-0P, N-[4-[4-Amino-1-(2-hydroxyethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461697-32-5P, N-[4-[4-Amino-1-[2-(4-methylpiperazino)ethyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide trimaleate 461697-35-8P, N-[4-[4-Amino-1-(2-morpholinoethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide dimaleate 461697-37-0P, N-[4-[4-Amino-1-[2-[(2-hydroxyethyl)amino]ethyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide monomaleate 461697-39-2P, N-[4-[4-Amino-1-[2-(dimethylamino)ethyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide monomaleate 461697-41-6P 461697-43-8P, Cis-N-[4-[4-Amino-1-(4-morpholinocyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-trifluoromethylbenzamide 461697-44-9P, Trans-N-[4-[4-Amino-1-(4-morpholinocyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-trifluoromethylbenzamide 461697-47-2P, Cis-3-[[4-[4-Amino-3-[4-[(2-fluoro-4-trifluoromethylbenzoyl)amino]-3-methoxyphenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]cyclohexyl]amino]propanoic acid 461697-48-3P, Trans-3-[[4-[4-Amino-3-[3-methoxy-4-[(2-methoxy-4-trifluoromethylbenzoyl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]cyclohexyl]amino]propanoic acid 461697-51-8P, N-[4-(4-Amino-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methoxyphenyl]-2-fluoro-4-trifluoromethylbenzamide 461697-54-1P, N-[4-[4-Amino-1-(3-hydroxycyclopentyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-trifluoromethylbenzamide 461697-56-3P, 1H-Indole-1-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate 461697-59-6P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-(trifluoromethoxy)-, monoacetate 461697-61-0P, Benzenebutanamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, monoacetate 461697-63-2P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-methyl-, monoacetate 461697-65-4P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-methoxy-, monoacetate 461697-67-6P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-, monoacetate 461697-69-8P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(trifluoromethyl)-, monoacetate 461697-71-2P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, monoacetate 461697-73-4P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-methoxy-, monoacetate 461697-75-6P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-fluoro-, monoacetate 461697-77-8P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-chloro-, monoacetate 461697-79-0P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-6-chloro-, monoacetate 461697-81-4P,

1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-6-methoxy-, monoacetate 461697-83-6P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-ethyl-, monoacetate 461697-85-8P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-7-methyl-, monoacetate 461697-87-0P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-7-nitro-, monoacetate 461697-89-2P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-phenyl-, monoacetate 461697-91-6P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-ethyl-, monoacetate 461697-93-8P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-(2-propenyl)-, monoacetate 461697-95-0P, 1H-Indole-1-acetic acid, 2-[[[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]amino]carbonyl]-, monoacetate 461697-97-2P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 1-(1-methyl-3-piperidinyl)-3-(4-phenoxyphenyl)-, acetate 461698-00-0P, 1-[1-(2-Methoxyethyl)-3-piperidyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine monoacetate 461698-03-3P, Trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-chlorophenyl]-4-(trifluoromethyl)benzamide dimaleate 461698-05-5P 461698-07-7P, Trans-3-[3-Chloro-4-[[5-methyl-2-furyl)methyl]amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine monoacetate 461698-09-9P 461698-11-3P, N-[4-[4-Amino-1-[1-(1H-2-imidazolylcarbonyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-trans-2-phenyl-1-cyclopropanecarboxamide monomaleate 461698-13-5P, Cyclopropanecarboxamide, N-[4-[4-amino-1-[cis-4-(2-aminoethyl)-4-hydroxycyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-phenyl-, (1R,2R)-rel-, acetate (salt) 461698-15-7P 461698-17-9P 461698-19-1P, 2-Pyrrolidinecarboxamide, N-[4-[4-amino-1-[trans-4-(4-methyl-1-piperazinyl)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, (2R)-, monoacetate 461698-22-6P, 3-(4-Phenoxyphenyl)-1-(4-pyridyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461698-23-7P, N-[4-[4-Amino-1-(4-pyridyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461698-25-9P, 1-(6-Amino-3-pyridyl)-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461698-26-0P, 3-(4-Phenoxyphenyl)-1-(2-pyridyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461698-30-6P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[4-[(1H-indol-2-ylmethyl)amino]phenyl]-1-[trans-4-(4-methyl-1-piperazinyl)cyclohexyl]-, acetate 461698-32-8P, Trans-3-[[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]anilino]methyl]-1,2-dihydro-2-pyridinone diacetate 461698-34-0P, Trans-5-[[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyanilino]methyl]-4-chloro-1,3-thiazol-2-amine diacetate 461698-36-2P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[3-methoxy-4-[[5-methyl-3-isoxazolyl)methyl]amino]phenyl]-1-[trans-4-(4-methyl-1-piperazinyl)cyclohexyl]-, acetate 461698-38-4P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[3-methoxy-4-[(4-thiazolylmethyl)amino]phenyl]-1-[trans-4-(4-methyl-1-piperazinyl)cyclohexyl]-, acetate 461698-40-8P, Trans-3-[4-[(4,6-Dichloro-2,3-dihydrobenzo[b]furan-3-yl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine acetate 461698-42-0P,

1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[4-[(4-chloro-2,3-dihydro-3-benzofuranyl)amino]phenyl]-1-[trans-4-(4-methyl-1-piperazinyl)cyclohexyl]-, acetate 461698-44-2P,  
 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[4-[(4,6-dichloro-2,3-dihydro-3-benzofuranyl)amino]-3-methoxyphenyl]-1-[trans-4-(4-methyl-1-piperazinyl)cyclohexyl]-, acetate 461698-48-6P,  
 3-[4-[[[(Benzo[b]furan-2-yl)methyl]amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461698-50-0P,  
 3-[4-[[[(2-Methoxy-3-pyridyl)methyl]amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461698-52-2P,  
 3-[4-[[[(5-Methyl-2-thienyl)methyl]amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461698-54-4P,  
 3-[4-[(2-Furylmethyl)amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461698-56-6P, 3-[4-(Benzylamino)phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461698-58-8P, 3-[4-[(2-Methoxybenzyl)amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461698-60-2P, 3-[4-[(3-Methoxybenzyl)amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461698-62-4P, 3-[4-[(4-Methoxybenzyl)amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461698-64-6P 461698-66-8P 461698-68-0P, 3-[4-[[[(2-Methyl-1,3-thiazol-4-yl)methyl]amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461698-70-4P, 3-[4-[(2-Chloro-6-fluorobenzyl)amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461698-72-6P 461698-74-8P, 3-[4-[[[(Benzo[b]furan-2-yl)methyl]amino]-3-methoxyphenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein kinase inhibitor; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT 461698-76-0P, 3-[4-[(2,3-Dihydrobenzo[b]furan-3-yl)amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine monoacetate 461698-78-2P, trans-3-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]anilino]-1H-benzo[d]isothiazole-1,1-dione monoacetate 461698-81-7P, Cis-3-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]anilino]-1H-benzo[d]isothiazole-1,1-dione diacetate 461698-83-9P, Trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]benzo[d]isoxazol-3-amine monoacetate 461698-89-5P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]benzo[d]isoxazol-3-amine diacetate 461698-91-9P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[4-(1,2-benzisoxazol-3-ylamino)phenyl]-1-(4-piperidinyl)-, acetate 461698-93-1P, Trans-3-[4-(1H-3-Indazolylamino)phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine monoacetate 461698-98-6P, Trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-6-(trifluoromethyl)benzo[d]isoxazol-3-amine monoacetate 461699-04-7P, N-[4-[4-Amino-1-[1-(2-methoxyethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461699-07-0P, N-[4-[4-Amino-1-(1-methyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461699-08-1P, N-[4-[4-Amino-1-(1-methyl-3-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461699-10-5P, N-[4-[4-Amino-1-[1-(2-methoxyethyl)-3-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461699-16-1P, Piperidine, 3-[4-amino-3-[4-[(5,7-

dimethyl-2-benzoxazolyl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-[(dimethylamino)acetyl]-, acetate 461699-17-2P,  
1-[3-[4-Amino-3-[4-[(5,7-dimethyl-1,3-benzoxazol-2-yl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-2-methyl-2-(methylamino)-1-propanone 461699-21-8P, N-4-[4-Amino-1-(3-azetanyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl-5,7-dimethyl-1,3-benzoxazol-2-amine 461699-24-1P, N-[4-[4-Amino-1-(1-methyl-3-azetanyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461699-29-6P, Cis-2-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]anilino]-1,3-benzoxazole-5-carbonitrile 461699-33-2P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-(trifluoromethoxy)-1,3-benzoxazol-2-amine 461699-37-6P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-ethyl-1,3-benzoxazol-2-amine 461699-40-1P, Cis-N-[4-[4-Amino-1-[4-(dimethylamino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461699-45-6P, trans-N-[4-[4-Amino-1-[4-(dimethylamino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461699-53-6P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[4-[(5,7-dimethyl-2-benzoxazolyl)amino]phenyl]-1-[cis-4-[(2-methoxyethyl)amino]cyclohexyl]- 461699-54-7P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[4-(2-benzoxazolylamino)phenyl]-1-[cis-4-[(2-methoxyethyl)amino]cyclohexyl]- 461699-55-8P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[4-[(5,7-dimethyl-2-benzoxazolyl)amino]phenyl]-1-[cis-4-(4-morpholinyl)cyclohexyl]- 461699-56-9P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[4-(2-benzoxazolylamino)phenyl]-1-[cis-4-(4-morpholinyl)cyclohexyl]- 461699-57-0P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[4-[(5-chloro-2-benzoxazolyl)amino]phenyl]-1-[cis-4-(4-morpholinyl)cyclohexyl]- 461699-58-1P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[4-(2-benzoxazolylamino)phenyl]-1-[cis-4-(methylamino)cyclohexyl]- 461699-59-2P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-4-(2-nitrophenyl)-1,3-thiazol-2-amine 461699-60-5P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzothiazol-2-amine 461699-62-7P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,6-dihydro-4H-cyclopenta[d][1,3]thiazol-2-amine 461699-63-8P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-ethyl-4-phenyl-1,3-thiazol-2-amine 461699-64-9P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-4,5,6,7-tetrahydro-1,3-benzothiazol-2-amine 461699-65-0P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-isopropyl-4-phenyl-1,3-thiazol-2-amine 461699-66-1P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-4-phenyl-5-propyl-1,3-thiazol-2-amine 461699-67-2P, 3-[4-(1,3-Benzoxazol-2-ylmethyl)phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461699-68-3P, N-[2-(Dimethylamino)ethyl]-2-[4-amino-3-[4-(1,3-benzoxazol-2-ylamino)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]propanamide 461699-69-4P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-ethyl-4-(4-methylphenyl)-1,3-thiazol-2-amine 461699-71-8P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-ethyl-4-(2-methylphenyl)-1,3-thiazol-2-amine 461699-72-9P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-



yl]phenyl]-5-ethyl-4-(3-methylphenyl)-1,3-thiazol-2-amine  
461699-73-0P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1H-2-indolecarboxamide bismaleate 461699-76-3P 461699-79-6P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461699-84-3P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-fluoro-4-(trifluoromethyl)-, acetate 461699-86-5P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate 461699-88-7P, Benzenepropanamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate 461699-90-1P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-cyclopentylpropanamide diacetate 461699-92-3P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1,3-dimethyl-1H-5-pyrazolecarboxamide diacetate 461699-94-5P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-(2-thienyl)acetamide diacetate 461699-95-6P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-phenylacetamide 461699-96-7P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-(3,4-dimethoxyphenyl)acetamide 461699-97-8P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-phenoxypropanamide 461699-99-0P, 5-Isioxazolecarboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate 461700-01-6P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-pyridinecarboxamide triacetate 461700-03-8P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2,4-difluorobenzamide diacetate 461700-05-0P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2,5-difluoro-, acetate 461700-07-2P, 2-Furancarboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate 461700-08-3P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2,2-dimethylpropanamide 461700-09-4P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-cyanobenzamide 461700-11-8P, Cyclopropanecarboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate 461700-13-0P, 3-Pyridinecarboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-methyl-, acetate 461700-14-1P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-fluoro-3-methylbenzamide 461700-15-2P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-(dimethylamino)benzamide 461700-16-3P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2,3-difluoro-4-methylbenzamide 461700-18-5P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]isonicotinamide diacetate 461700-20-9P, 3-Pyridinecarboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate 461700-22-1P, 1H-Pyrrole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-, acetate 461700-24-3P, 3-Pyridinecarboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-6-methyl-, acetate 461700-26-5P, Pyrazinecarboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate 461700-28-7P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-

methoxyphenyl]-4-iodobenzamide diacetate 461700-29-8P,  
N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-bromobenzamide 461700-30-1P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-phenoxybenzamide 461700-31-2P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-fluorobenzamide 461700-32-3P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-chlorobenzamide 461700-33-4P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-methoxybenzamide 461700-34-5P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(trifluoromethoxy)benzamide 461700-35-6P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-nitrobenzamide 461700-36-7P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]benzo[b]thiophene-2-carboxamide 461700-37-8P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]benzo[b]furan-2-carboxamide 461700-38-9P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-methylbenzamide 461700-40-3P, Benzamide, N-[4-[4-amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(1,1-dimethylethyl)-, acetate 461700-42-5P, Benzoic acid, 4-[[[4-[4-amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]amino]carbonyl]-, methyl ester, acetate 461700-43-6P, 4-[[[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyanilino]carbonyl]benzoic acid 461700-45-8P, Benzamide, N-[4-[4-amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-chloro-, acetate 461700-47-0P, Benzamide, N-[4-[4-amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-bromo-, acetate 461700-49-2P, Benzamide, N-[4-[4-amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-methoxy-, acetate 461700-50-5P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-phenylbenzamide 461700-52-7P, Benzamide, N-[4-[4-amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-(trifluoromethyl)-, acetate 461700-54-9P, Benzamide, N-[4-[4-amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-(trifluoromethoxy)-, acetate 461700-55-0P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-methoxybenzamide 461700-56-1P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-(trifluoromethyl)benzamide 461700-58-3P, Benzamide, N-[4-[4-amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-3-(trifluoromethyl)-, acetate 461700-60-7P, Benzamide, N-[4-[4-amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-6-(trifluoromethyl)-, acetate 461700-62-9P, Benzamide, N-[4-[4-amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-5-(trifluoromethyl)-, acetate 461700-63-0P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-5-methylbenzamide 461700-64-1P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-chloro-2-fluorobenzamide 461700-65-2P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-benzoylbenzamide 461700-66-3P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-acetylbenzamide 461700-67-4P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-isopropylbenzamide 461700-69-6P, Benzamide, N-[4-[4-amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-ethyl-, acetate 461700-71-0P, Benzamide, N-[4-[4-amino-1-(4-piperidyl)-1H-

pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-propyl-, acetate  
461700-73-2P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-  
pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-cyclohexyl-,  
acetate 461700-75-4P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-  
1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-ethoxy-,  
acetate 461700-77-6P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-  
1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-  
(methylsulfonyl)-, acetate 461700-79-8P, N-[4-[4-Amino-1-(4-  
piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-  
isopropoxybenzamide diacetate 461700-81-2P, Benzamide,  
N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-  
methoxyphenyl]-4-(1H-imidazol-1-yl)-, acetate 461700-83-4P,  
Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-  
d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-, acetate  
461700-84-5P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-  
d]pyrimidin-3-yl]-2-methoxyphenyl]-5-methoxybenzo[b]furan-2-  
carboxamide 461700-86-7P, 2-Benzofurancarboxamide,  
N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-  
methoxyphenyl]-5-bromo-, acetate 461700-87-8P,  
N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-  
methoxyphenyl]-5-methylbenzo[b]furan-2-carboxamide 461700-88-9P,  
N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-  
methoxyphenyl]-3-methylbenzo[b]furan-2-carboxamide 461700-89-0P,  
N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-  
methoxyphenyl]-5-nitrobenzo[b]furan-2-carboxamide 461700-91-4P,  
2-Benzofurancarboxamide, 5-amino-N-[4-[4-amino-1-(4-piperidinyl)-1H-  
pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate  
461700-93-6P, 2-Benzofurancarboxamide, 5-(acetylamino)-N-[4-[4-  
(acetylamino)-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-  
methoxyphenyl]-, acetate 461700-95-8P, 2-Benzofurancarboxamide,  
5-(acetylamino)-N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-  
d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate 461700-97-0P,  
2-Benzofurancarboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-  
pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-7-methyl-, acetate  
461700-99-2P, 2-Benzofurancarboxamide, N-[4-[4-amino-1-(4-  
piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-7-  
methoxy-, acetate 461701-00-8P, N-[4-[4-Amino-1-(1-  
methyltetrahydro-1H-pyrrol-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-  
yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461701-04-2P,  
N-[4-[4-Amino-1-[1-(2-methoxyethyl)tetrahydro-1H-pyrrol-3-yl]-1H-  
pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-  
amine 461701-06-4P, Cis-N-[4-[4-Amino-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-  
fluorophenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461701-09-7P,  
Cis-3-[4-(Imidazo[1,2-a]pyridin-2-yl)phenyl]-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
461701-11-1P, 1-[3-[4-Amino-3-[4-[(5,7-dimethyl-1,3-benzoxazol-2-  
yl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]tetrahydro-1H-  
pyrrol-1-yl]-2-(dimethylamino)-1-ethanone 461701-13-3P,  
1-[3-[4-Amino-3-[4-[(5,7-dimethyl-1,3-benzoxazol-2-yl)amino]phenyl]-  
1H-pyrazolo[3,4-d]pyrimidin-1-yl]tetrahydro-1H-pyrrol-1-yl]-2-methyl-  
2-(methylamino)-1-propanone 461701-16-6P, N-[4-[4-Amino-1-  
(tetrahydro-1H-pyrrol-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-  
5,7-dimethyl-1,3-benzoxazol-2-amine 461701-20-2P,  
Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-  
pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-7-isopropyl-1,3-benzoxazol-2-  
amine diacetate 461701-23-5P 461701-25-7P, N-[4-[4-Amino-1-[1-(2-  
methoxyethyl)tetrahydro-1H-pyrrol-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-  
3-yl]phenyl]-5-ethyl-1,3-benzoxazol-2-amine monoacetate  
461701-26-8P 461701-28-0P, N-[4-[4-Amino-1-[1-(2-  
methoxyethyl)tetrahydro-1H-pyrrol-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-  
3-yl]phenyl]-5-methyl-1,3-benzoxazol-2-amine monoacetate

461701-30-4P, N-[4-[4-Amino-1-[1-(2-methoxyethyl)tetrahydro-1H-pyrrol-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-chloro-1,3-benzoxazol-2-amine monoacetate 461701-32-6P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide dimesylate 461701-34-8P, N-[4-[4-Amino-1-(1-methyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]trans-2-phenyl-1-cyclopropanecarboxamide 461701-36-0P, N-[4-[4-Amino-1-(1-methyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(trifluoromethoxy)benzamide 461701-37-1P, cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-(1,3-oxazol-5-yl)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461701-39-3P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-5-fluoro-2-methoxyphenyl]-2,2-dimethyl-3-phenylpropanamide 461701-40-6P 461701-41-7P, 2-[[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]benzyl]amino]-1-ethanol 461701-42-8P, 2-[[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]benzyl]amino]-2-methyl-1-propanol 461701-43-9P, 4-[[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]benzyl]amino]-1-butanol 461701-44-0P, N-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]benzyl]-N',N'-dimethyl-1,2-ethanediamine 461701-45-1P, 1-[4-[[3-Methoxypropyl]amino]methyl]phenyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461701-46-2P, 1-[4-[[2-Methoxyethyl]amino]methyl]phenyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461701-47-3P, 3-(4-Phenoxyphenyl)-1-[4-(1,3-thiazolan-3-ylmethyl)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461701-48-4P, 2-[[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]benzyl](2-hydroxyethyl)amino]-1-ethanol 461701-49-5P, N-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]benzyl]-N,N',N'-trimethyl-1,2-ethanediamine 461701-50-8P, 1-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]benzyl]-4-piperidinol 461701-51-9P, N-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]benzyl]-N,N',N'-trimethyl-1,3-propanediamine 461701-52-0P, [1-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]benzyl]-4-piperidyl]methanol 461701-53-1P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide dimaleate 461701-55-3P, N-[4-[4-Amino-1-(1-ethyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-56-4P, N-[4-[4-Amino-1-[1-(cyclopropylmethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-58-6P, Benzamide, N-[4-[4-amino-1-[1-(1H-pyrrol-1-ylmethyl)-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461701-59-7P, N-[4-[4-Amino-1-[1-(1H-2-imidazolylmethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-61-1P, Benzamide, N-[4-[4-amino-1-[1-[(1-methyl-1H-imidazol-2-yl)methyl]-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461701-63-3P, Benzamide, N-[4-[4-amino-1-[1-[(2-methyl-1H-imidazol-4-yl)methyl]-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461701-65-5P, Benzamide, N-[4-[4-amino-1-[1-[(4-methyl-1H-imidazol-5-yl)methyl]-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461701-66-6P, N-[4-[4-Amino-1-[1-(1,3-thiazol-2-ylmethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-



(trifluoromethyl)benzamide 461701-67-7P, N-[4-[4-Amino-1-[1-[(5-(hydroxymethyl)-2-furyl)methyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-68-8P, N-[4-[4-Amino-1-(1-methyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-69-9P, N-[4-[4-Amino-1-(1-isopropyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-71-3P, Benzamide, N-[4-[4-amino-1-[1-(2-methylpropyl)-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461701-72-4P, N-[4-[4-Amino-1-[1-(2-furylmethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-73-5P, N-[4-[4-Amino-1-[1-(3-furylmethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-74-6P, Benzamide, N-[4-[4-amino-1-[1-(1H-imidazol-1-ylmethyl)-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461701-75-7P, N-[4-[4-Amino-1-[1-(tetrahydro-2H-pyran-4-yl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-76-8P, tert-Butyl 4-[4-[4-amino-3-[4-[[2-fluoro-4-(trifluoromethyl)benzoyl]amino]-3-methoxyphenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidyl]-1-piperidinecarboxylate 461701-77-9P, N-[4-[4-Amino-1-[1-(tetrahydrothiophen-3-yl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-78-0P, N-[4-[4-Amino-1-(1-benzyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-80-4P, Benzamide, N-[4-[4-amino-1-[1-(2-pyridinylmethyl)-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461701-81-5P 461701-82-6P 461701-84-8P, Benzamide, N-[4-[4-amino-1-[1-[(1-methyl-1H-pyrrol-2-yl)methyl]-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461701-86-0P, Benzamide, N-[4-[4-amino-1-[1-[(5-methyl-2-furanyl)methyl]-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461701-87-1P, N-[4-[4-Amino-1-[1-(2-thienylmethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-89-3P 461701-91-7P, N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide diacetate 461701-92-8P, N-[4-[4-Amino-1-[1-(tetrahydro-2H-thiopyran-4-yl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-93-9P, 4-[[4-[4-Amino-3-[4-[[2-fluoro-4-(trifluoromethyl)benzoyl]amino]-3-methoxyphenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]methyl]-1-pyridine-N-oxide 461701-94-0P, N-[4-[4-Amino-1-[1-(2-fluorobenzyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-95-1P, N-[4-[4-Amino-1-[1-(3-fluorobenzyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-96-2P, N-[4-[4-Amino-1-[1-(4-fluorobenzyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-97-3P, N-[4-[4-Amino-1-[1-[3-(methylsulfanyl)propyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-98-4P, N-[4-[4-Amino-1-[1-[(5-methyl-2-thienyl)methyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-

fluoro-4-(trifluoromethyl)benzamide 461701-99-5P,  
 N-[4-[4-Amino-1-[1-(3-cyanobenzyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461702-00-1P, N-[4-[4-Amino-1-[1-(4-cyanobenzyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461702-01-2P,  
 N-[4-[4-Amino-1-[1-(2-cyanobenzyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461702-02-3P, N-[4-[4-Amino-1-[1-(4-methoxybenzyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461702-03-4P,  
 N-[4-[4-Amino-1-[1-(1-acetylpiperidin-4-yl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461702-05-6P, Benzamide,  
 N-[4-[4-amino-1-[1-[(3-methyl-1H-pyrazol-1-yl)methyl]-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461702-06-7P, Methyl  
 2-[4-[4-amino-3-[4-[[2-fluoro-4-(trifluoromethyl)benzoyl]amino]-3-methoxyphenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]acetate 461702-07-8P 461702-10-3P, Benzamide, N-[4-[4-amino-1-[1-(2-methoxyethyl)-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate  
 461702-11-4P, N-[4-[4-Amino-1-[1-(cyanomethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461702-13-6P, 1-Piperidineacetamide,  
 4-[4-amino-3-[4-[[2-fluoro-4-(trifluoromethyl)benzoyl]amino]-3-methoxyphenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-, acetate 461702-15-8P 461702-17-0P, N-[4-[4-Amino-1-[1-[(2-methyl-1H-imidazol-4-yl)methyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide dimaleate  
 461702-20-5P 461702-23-8P, N-[4-[4-Amino-1-[1-(2-fluoroethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide dimaleate 461702-25-0P,  
 N-[4-[4-Amino-1-[1-(2,2-difluoroethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide dimaleate 461702-28-3P, N-[4-[4-Amino-1-(1-ethyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-31-8P, 1H-Indole-2-carboxamide,  
 N-[4-[4-amino-1-[1-[(3-methyl-1H-pyrazol-1-yl)methyl]-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-, acetate 461702-33-0P, N-[4-[4-Amino-1-[1-(3-furylmethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein kinase inhibitor; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT 461702-35-2P, N-[4-[4-Amino-1-[1-(tetrahydro-2H-pyran-4-yl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-36-3P, N-[4-[4-Amino-1-[1-(1-acetylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-indole-2-carboxamide 461702-37-4P 461702-38-5P, N-[4-[4-Amino-1-[3-(4-methylpiperazino)propyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-41-0P, N-[4-[4-Amino-1-(3-morpholinopropyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-43-2P, N-[4-[4-Amino-1-[3-(1H-1-imidazolyl)propyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-46-5P,  
 N-[4-[4-Amino-1-[1-[(1-methyl-1H-imidazol-2-yl)methyl]tetrahydro-1H-

pyrrol-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-47-6P, N-[4-[4-Amino-1-(1-isopropyltetrahydro-1H-pyrrol-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-48-7P, N-[4-[4-Amino-1-[1-(2-methoxyethyl)tetrahydro-1H-pyrrol-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-49-8P, N-[4-[4-Amino-1-[1-(1H-imidazol-4-ylmethyl)tetrahydro-1H-pyrrol-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-50-1P, N-[4-[4-Amino-1-[1-[(3-methyl-1H-pyrazol-4-yl)methyl]tetrahydro-1H-pyrrol-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-51-2P 461702-52-3P 461702-53-4P, N-[4-[4-Amino-1-[1-(2-methoxyethyl)tetrahydro-1H-pyrrol-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-7-isopropyl-1,3-benzoxazol-2-amine 461702-56-7P, cis-Methyl 4-[4-amino-3-[4-[(5,7-dimethyl-1,3-benzoxazol-2-yl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-cyclohexanecarboxylate 461702-57-8P, cis-4-[4-Amino-3-[4-[(5,7-dimethyl-1,3-benzoxazol-2-yl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-cyclohexanecarboxylic acid 461702-58-9P, cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-(2-pyrimidinylamino)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461702-61-4P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-[2-(4-methyl-1-piperazinyl)-4-pyridinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate 461702-64-7P 461702-65-8P, (S)-N-[4-[4-Amino-1-[1-(2-methoxyethyl)-3-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461702-72-7P, Cis-2-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]anilino]-1,3-benzoxazole-5-carboxamide triacetate 461702-75-0P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-(phenylmethoxy)-, monoacetate 461702-77-2P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-(methylsulfonyl)-, monoacetate 461702-79-4P, 1H-Indole-5-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, monoacetate 461702-81-8P, 1H-Indole-6-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, monoacetate 461702-83-0P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(phenylmethoxy)-, monoacetate 461702-85-2P,  $\beta$ -Alanine, N-[3-[4-[(1H-indol-2-ylcarbonyl)amino]-3-methoxyphenyl]-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, monoacetate 461702-87-4P, 1H-Indole-1-propanoic acid, 2-[[[4-[4-[(2-carboxyethyl)amino]-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]amino]carbonyl]-, monoacetate 461702-89-6P, 1H-Indole-1-acetamide, 2-[[[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]amino]carbonyl]-N,N-dimethyl-, monoacetate 461702-91-0P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-hydroxy-1H-2-indolecarboxamide monoacetate 461702-93-2P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-hydroxy-1H-2-indolecarboxamide monoacetate 461702-95-4P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-7-amino-1H-2-indolecarboxamide monoacetate 461702-97-6P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1H-3-indolecarboxamide monoacetate 461703-00-4P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1H-4-indolecarboxamide monoacetate 471925-60-7P, trans-1-[4-(4-Methylpiperazino)cyclohexyl]-3-(6-phenoxy-3-pyridyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine maleate 471925-63-0P,

Cis-3-[4-[(1H-4-Imidazolylmethyl)amino]-3-methoxyphenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine acetate 471925-65-2P, Cis-3-[4-[(1H-2-Indolylmethyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 471925-69-6P 471925-70-9P 471925-71-0P 471925-72-1P 471925-73-2P 471925-74-3P 471925-75-4P 471925-76-5P 471925-77-6P 471925-78-7P 471925-79-8P 471925-80-1P 471925-81-2P 471925-87-8P 471925-88-9P, N-[4-[4-Amino-1-(1-methyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(trifluoromethyl)benzamide trimaleate 471925-93-6P, N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-(2-methoxyphenyl)propanamide 471925-94-7P, N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-(4-methoxyphenyl)propanamide 471925-95-8P, N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-(3-methoxyphenyl)propanamide 471925-96-9P, N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-(4-methylphenyl)propanamide 471925-97-0P, N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-(4-fluorophenyl)propanamide 471925-98-1P, N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-(3,4-difluorophenyl)propanamide 471926-08-6P, Trans-3-[3-Methoxy-4-[(5-methyl-2-furyl)methyl]aminophenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine dimaleate 471926-09-7P 471926-14-4P, Cis-3-[3-[2-(1H-2-Imidazolyl)phenoxy]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 471926-16-6P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-anilinoacetamide 471926-23-5P, N,N-Methoxymethyl-2-[3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]acetamide 471926-25-7P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-3-(1H-4-imidazolyl)-1-propanone 471926-26-8P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[4-(2-methoxyethyl)piperidino]-1-ethanone 471926-61-1P 471926-74-6P 471926-76-8P 471926-82-6P 471927-20-5P, Trans-3-[3-Methoxy-4-[[3-methyl-1H-4-pyrazolyl)methyl]amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 471927-25-0P, Trans-3-[4-[(1H-7-Indolylmethyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 471927-28-3P, Trans-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-[(5-methyl-1H-4-pyrazolyl)methyl]amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 471927-44-3P, N-(1H-2-Imidazolyl)-2-[4-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]acetamide 471927-45-4P, trans-N-[4-[4-Amino-1-[1-(1H-2-imidazolylmethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-phenyl-1-cyclopropanecarboxamide 471927-46-5P, Trans-N-[4-[4-Amino-1-[(4-hydroxy-4-piperidyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-phenyl-1-cyclopropanecarboxamide  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (protein kinase inhibitor; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)




ACCESSION NUMBER: 2002:793426 HCAPLUS  
 DOCUMENT NUMBER: 137:310925  
 TITLE: Preparation of 3-(azahetero)aryl-1H-pyrazolo[3,4-d]pyrimidin-3-amines as protein kinase inhibitors with antiangiogenic properties  
 INVENTOR(S): Hirst, Gavin C.; Rafferty, Paul; Ritter, Kurt; Calderwood, David; Wishart, Neil; Arnold, Lee D.; Friedman, Michael M.  
 PATENT ASSIGNEE(S): Abbott G.m.b.H. & Co. K.-G., Germany  
 SOURCE: PCT Int. Appl., 867 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002080926	A1	20021017	WO 2002-US9104	20020322
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002156081	A1	20021024	US 2001-815310	20010322
US 6921763	B2	20050726		
CA 2440724	AA	20021017	CA 2002-2440724	20020322
EP 1385524	A1	20040204	EP 2002-746301	20020322
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004531513	T2	20041014	JP 2002-578965	20020322
BR 2002005889	A	20041109	BR 2002-5889	20020322
NO 2003004176	A	20031121	NO 2003-4176	20030919
PRIORITY APPLN. INFO.:				20010322
US 2001-815310				A
US 1999-154620P				P
				19990917

A2

W


OTHER SOURCE(S) : MARPAT 137:310925  
GI




AB Title compds. I [wherein G = (un)substituted 5-6 membered (azahetero)aryl; R2 = H or (un)substituted trityl, cycloalkenyl, azaheteroaryl, or C6H4-4-CH2E; E = (un)substituted alkyl-OR, alkyl-CO2R, alkylheteroaryl, alkylheterocycloalkyl, or alkyl-NR2; R = independently H or (un)substituted (cyclo)alkyl, or aryl(alkyl); R3 = independently H, OH, or (un)substituted alkyl, alkyl-CO, (hetero)aryl-CO, or alkoxy; or racemic diastereomeric mixts., optical isomers, pharmaceutically acceptable salts, prodrugs, and/or biol. active metabolites thereof] were prep'd. For example, 3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine was coupled with 4-fluorobenzaldehyde in the presence of NaH in DMF to give 4-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)benzaldehyde. **Treatment** of the 3-iodopyrazolopyrimidine with N-[2-methoxy-4-(4,4,5,5,-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2-fluoro-4-(trifluoromethyl)benzamide, Pd(PPh3)4, and Na2CO3 in H2O afforded the N-[4-(pyrazolopyrimidin-3-yl)phenyl]benzamide. Addn. of morpholine to the benzaldehyde in the presence of Na(AcO)3BH in dichloroethane produced II. All exemplified compds. significantly inhibited either FGFR, PDGFR, KDR, Tie-2, Lck, Fyn, Blk, Lyn, or Src at concn. of  $\leq 50 \mu\text{M}$ . Certain compds. of the invention also significantly inhibited cdc2 or cellular VEGF-induced KDR tyrosine kinase phosphorylation at concns. of  $\leq 50 \mu\text{M}$ . Thus, I are useful for the **treatment** of a wide variety of **disease** states ameliorated by the inhibition of protein tyrosine kinase activity essential for angiogenic processes (no

data).

IT 330793-97-0P, N-(4-Bromophenyl)-N-(4-ethyl-1,3-thiazol-2-yl)amine 330793-98-1P, N-(4-Ethyl-1,3-thiazol-2-yl)-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]amine  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (intermediate; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)  
 RN 330793-97-0 HCAPLUS  
 CN 2-Thiazolamine, N-(4-bromophenyl)-4-ethyl- (9CI) (CA INDEX NAME)



RN 330793-98-1 HCAPLUS  
 CN 2-Thiazolamine, 4-ethyl-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]- (9CI) (CA INDEX NAME)



IC ICM A61K031-519  
 ICS C07D487-04  
 CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))  
 Section cross-reference(s): 1  
 IT **Inflammation**  
 (Crohn's disease; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)  
 IT Tyrosine kinase receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (Tie, TIE-2; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)  
 IT Tyrosine kinase receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (Tie-1; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)  
 IT Vascular endothelial growth factor receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (VEGF, VEGF-B, VEGF-C, VEGF-D, or VEGF-E, combination therapy agent; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)  
 IT Antibodies and Immunoglobulins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (antiidotypic, combination therapy agent; prepn. of

[(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(c-fgr; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Angiogenic factors

Hepatocyte growth factor

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(combination therapy agent; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(fyn; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(gene hck; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(gene lyn; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Intestine, disease

(inflammatory; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(p62c-yes; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT Anemia (disease)

Angiogenesis

Angiogenesis inhibitors

Anti-inflammatory agents

Anti-ischemic agents

Antiarthritics

Antiasthmatics

Antibacterial agents

Antidiabetic agents

Antiglaucoma agents

Antirheumatic agents

Antitumor agents

Antiulcer agents

**Asthma**

Atherosclerosis

Cardiovascular agents

Cardiovascular system, disease

Cirrhosis

Contraceptives

Eye, disease

Fibrosis

Fungicides

Glaucoma (disease)

Hematopoiesis

Hodgkin's disease  
 Human  
 Human herpesvirus  
 Human immunodeficiency virus 1  
 Hypoxia  
 Ischemia  
 Leukemia  
 Lyme disease  
 Lymphoma  
 Melanoma  
 Multiple myeloma  
 Multiple sclerosis  
 Mycosis  
 Necrosis  
 Neoplasm  
 Osteoarthritis  
 Parapoxvirus  
 Preeclampsia  
 Protozoa  
 Protozoacides  
**Psoriasis**  
 Radiation  
 Rheumatoid arthritis  
 Sarcoidosis  
 Sarcoma  
 Sepsis  
 Sick cell anemia  
 Transplant rejection  
 Ulcer  
 Wound

- (prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as  
 protein kinase inhibitors with antiangiogenic properties)
- IT Hepatocyte growth factor receptors
- Insulin-like growth factor I receptors
- RL: BSU (Biological study, unclassified); BIOL
- (Biological study)
- (prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as  
 protein kinase inhibitors with antiangiogenic properties)
- IT Fibroblast growth factor receptors
- RL: BSU (Biological study, unclassified); BIOL
- (Biological study)
- (type 1; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines  
 as protein kinase inhibitors with antiangiogenic properties)
- IT Vascular endothelial growth factor receptors
- RL: BSU (Biological study, unclassified); BIOL
- (Biological study)
- (type VEGFR-1; prepn. of [(hetero)aryl]pyrazolo[3,4-  
 d]pyrimidinamines as protein kinase inhibitors with  
 antiangiogenic properties)
- IT Vascular endothelial growth factor receptors
- RL: BSU (Biological study, unclassified); BIOL
- (Biological study)
- (type VEGFR-2; prepn. of [(hetero)aryl]pyrazolo[3,4-  
 d]pyrimidinamines as protein kinase inhibitors with  
 antiangiogenic properties)
- IT Vascular endothelial growth factor receptors
- RL: BSU (Biological study, unclassified); BIOL
- (Biological study)
- (type VEGFR-3; prepn. of [(hetero)aryl]pyrazolo[3,4-  
 d]pyrimidinamines as protein kinase inhibitors with  
 antiangiogenic properties)
- IT Platelet-derived growth factor receptors

RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
( $\alpha$ ; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines  
as protein kinase inhibitors with antiangiogenic properties)

IT Platelet-derived growth factor receptors  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
( $\beta$ ; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines  
as protein kinase inhibitors with antiangiogenic properties)

IT 106096-92-8, FGF-1 106096-93-9, FGF-2  
RL: BSU (Biological study, unclassified); BIOL  
(Biological study)  
(combination therapy agent; prepn. of [(hetero)aryl]pyrazolo[3,4-  
d]pyrimidinamines as protein kinase inhibitors with  
antiangiogenic properties)

IT 330793-90-3P 330793-91-4P, cis-4-[4-Amino-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-  
yl]benzaldehyde 330793-95-8P, N-(6-Chloro-1,3-benzothiazol-2-yl)-N-  
[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]amine  
330793-96-9P 330793-97-0P, N-(4-Bromophenyl)-N-(4-ethyl-  
1,3-thiazol-2-yl)amine 330793-98-1P, N-(4-Ethyl-1,3-  
thiazol-2-yl)-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-  
yl)phenyl]amine 330793-99-2P, 4-Amino-1-(4-nitrophenyl)-3-iodo-1H-  
pyrazolo[3,4-d]pyrimidine 330794-00-8P, 3-Iodo-1-trityl-1H-  
pyrazolo[3,4-d]pyrimidin-4-amine 330794-01-9P,  
4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-  
yl]benzaldehyde 330794-02-0P, 1-Bromo-2-fluoro-5-methoxy-4-  
nitrobenzene 330794-03-1P, 4-Bromo-5-fluoro-2-methoxyaniline  
330794-04-2P, tert-Butyl N-(4-bromo-5-fluoro-2-  
methoxyphenyl)carbamate 330794-05-3P, tert-Butyl  
N-[5-fluoro-2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-  
yl)phenyl]carbamate 330794-06-4P, 3-Iodo-1-(1-methyl-4-piperidyl)-  
1H-pyrazolo[3,4-d]pyrimidin-4-amine 330794-08-6P, trans-tert-Butyl  
N-[2-[[[4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-  
pyrazolo[3,4-d]pyrimidin-3-yl]]anilino]methyl]phenyl]carbamate  
acetate 330794-09-7P, tert-Butyl N-(4-bromo-2-  
chlorophenyl)carbamate 330794-10-0P, tert-Butyl  
N-[2-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-  
yl)phenyl]carbamate 330794-11-1P, Trans-tert-Butyl  
N-[4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-  
d]pyrimidin-3-yl]-2-chlorophenyl]carbamate 330794-12-2P,  
Trans-3-(4-Amino-3-chlorophenyl)-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
330794-13-3P, 1-(4-Bromophenyl)-3-methyl-5-phenyl-4,5-dihydro-1H-  
pyrazole 330794-14-4P, 3-Methyl-5-phenyl-1-[4-(4,4,5,5-tetramethyl-  
1,3,2-dioxaborolan-2-yl)phenyl]-4,5-dihydro-1H-pyrazole  
330794-15-5P 330794-17-7P, tert-Butyl N-[3-[3-[4-amino-3-(4-  
phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-3-  
oxopropyl]-N-(2-hydroxyethyl)carbamate 330794-18-8P, tert-Butyl  
N-[3-[4-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-  
yl]piperidino]-3-oxopropyl]-N-(2-hydroxyethyl)carbamate  
330794-19-9P, tert-Butyl 2-[4-[4-amino-3-(4-phenoxyphenyl)-1H-  
pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]acetate 330794-20-2P,  
Benzyl 4-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-  
piperidinecarboxylate 330794-21-3P, Benzyl 4-[4-amino-3-[4-[(tert-  
butoxycarbonyl)amino]-3-methoxyphenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-  
yl]-1-piperidinecarboxylate 330794-22-4P, Benzyl  
4-[4-amino-3-(4-amino-3-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-  
yl]-1-piperidinecarboxylate 330794-23-5P, Trans-Benzyl  
4-[4-amino-3-[3-methoxy-4-[(2-phenylcyclopropyl)carbonyl]amino]phen-  
yl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinecarboxylate  
330794-24-6P, Benzyl 4-[4-amino-3-[3-methoxy-4-[(5-methyl-2-



furyl)methyl]amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinecarboxylate 330794-25-7P, tert-Butyl  
4-[(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl]-4-hydroxy-1-piperidinecarboxylate 330794-26-8P, tert-Butyl  
4-[[4-amino-3-[4-[(benzyloxy)carbonyl]amino]-3-methoxyphenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-4-hydroxy-1-piperidinecarboxylate 330794-27-9P, tert-Butyl  
4-[[4-amino-3-(4-amino-3-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-4-hydroxy-1-piperidinecarboxylate 330794-28-0P, Trans-tert-Butyl 4-[[4-amino-3-[3-methoxy-4-[(2-phenylcyclopropyl)carbonyl]amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-4-hydroxy-1-piperidinecarboxylate 330794-29-1P  
461696-99-1P, 4-(4-Amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)benzaldehyde 461697-00-7P 461697-02-9P, 2-(4-Amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-ethanol 461697-03-0P, [2-[4-Amino-3-[3-methoxy-4-[(1-methyl-1H-indol-2-yl)carbonyl]amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]methanesulfonate 461697-30-3P, N-[2-Methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1-methyl-1H-2-indolecarboxamide 461697-31-4P, N-[4-[4-Amino-1-[2-(4-methylpiperazino)ethyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461697-34-7P, N-[4-[4-Amino-1-(2-morpholinoethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461697-36-9P, N-[4-[4-Amino-1-[2-[(2-hydroxyethyl)amino]ethyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461697-38-1P, N-[4-[4-Amino-1-[2-(dimethylamino)ethyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461697-40-5P, N-[4-[4-Amino-1-[2-(1H-1-imidazolyl)ethyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461697-53-0P, 4-(4-Amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-2-cyclopenten-1-ol 461697-57-4P, tert-Butyl 4-[4-amino-3-(4-amino-3-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinecarboxylate 461697-66-5P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461697-98-3P, 3-Iodo-1-(1-methyl-3-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461698-01-1P, 3-Iodo-1-[1-(2-methoxyethyl)-3-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461698-02-2P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-chlorophenyl]-4-(trifluoromethyl)benzamide 461698-04-4P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-chlorophenyl]-4-(trifluoromethoxy)benzamide 461698-10-2P, N-[4-[4-Amino-1-[1-(1H-2-imidazolyl)carbonyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-trans-2-phenyl-1-cyclopropanecarboxamide 461698-14-6P 461698-21-5P 461698-24-8P 461698-45-3P, tert-Butyl 4-[4-amino-3-(4-aminophenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinecarboxylate 461698-46-4P, tert-Butyl 4-[4-amino-3-[4-[(benzyloxy)carbonyl]amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinecarboxylate 461698-79-3P, 3-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)anilino]-1H-benzo[d]isothiazole-1,1-dione 461698-84-0P, N-(4-Bromophenyl)-2-fluoro-1-benzenecarbothioamide 461698-85-1P 461698-86-2P, N-(Benzo[d]isoxazol-3-yl)-N-(4-bromophenyl)amine 461698-87-3P, N-(Benzo[d]isoxazol-3-yl)-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]amine 461698-94-2P, Benzenecarboximidic acid, N-(4-bromophenyl)-2-fluoro-, hydrazide 461698-95-3P, N-(4-Bromophenyl)-N-(1H-3-indazolyl)amine 461698-96-4P, N-(1H-3-Indazolyl)-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]amine 461698-99-7P, N-(4-Bromophenyl)-2-fluoro-4-(trifluoromethyl)benzamide 461699-00-3P, N-(4-Bromophenyl)-2-



fluoro-4-(trifluoromethyl)-1-benzenecarbothioamide 461699-01-4P,  
Benzenecarboximidic acid, N-(4-bromophenyl)-2-fluoro-4-  
(trifluoromethyl)-, hydrazide 461699-02-5P, N-(4-Bromophenyl)-N-[6-  
(trifluoromethyl)benzo[d]isoxazol-3-yl]amine 461699-03-6P,  
N-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-N-[6-  
(trifluoromethyl)benzo[d]isoxazol-3-yl]amine 461699-05-8P,  
3-Iodo-1-[1-(2-methoxyethyl)-4-piperidyl]-1H-pyrazolo[3,4-  
d]pyrimidin-4-amine 461699-06-9P 461699-09-2P,  
3-Iodo-1-(3-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine  
461699-13-8P, tert-Butyl 3-(4-amino-3-iodo-1H-pyrazolo[3,4-  
d]pyrimidin-1-yl)-1-piperidinecarboxylate 461699-14-9P, tert-Butyl  
3-[4-amino-3-[4-[(5,7-dimethyl-1,3-benzoxazol-2-yl)amino]phenyl]-1H-  
pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinecarboxylate  
461699-18-3P, 3-Iodo-1-(3-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-  
amine dihydrochloride 461699-19-4P, 9H-Fluoren-9-ylmethyl  
N-[2-[3-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidino]-  
1,1-dimethyl-2-oxoethyl]-N-methylcarbamate 461699-20-7P  
461699-22-9P, tert-Butyl 3-(4-amino-3-iodo-1H-pyrazolo[3,4-  
d]pyrimidin-1-yl)azetane-1-carboxylate 461699-23-0P, tert-Butyl  
3-[4-amino-3-[4-[(5,7-dimethyl-1,3-benzoxazol-2-yl)amino]phenyl]-1H-  
pyrazolo[3,4-d]pyrimidin-1-yl]azetane-1-carboxylate 461699-27-4P,  
1-(3-Azetanyl)-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate  
461699-28-5P, 3-Iodo-1-(1-methyl-3-azetanyl)-1H-pyrazolo[3,4-  
d]pyrimidin-4-amine 461699-30-9P, 2-(4-Bromoanilino)-1,3-  
benzoxazole-5-carbonitrile 461699-31-0P, 2-[4-(4,4,5,5-Tetramethyl-  
1,3,2-dioxaborolan-2-yl)anilino]-1,3-benzoxazole-5-carbonitrile  
461699-34-3P, 2-Amino-4-(trifluoromethoxy)phenol 461699-35-4P,  
N-(4-Bromophenyl)-5-(trifluoromethoxy)-1,3-benzoxazol-2-amine  
461699-36-5P, N-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-  
yl)phenyl]-5-(trifluoromethoxy)-1,3-benzoxazol-2-amine  
461699-38-7P, N-(4-Bromophenyl)-5-ethyl-1,3-benzoxazol-2-amine  
461699-39-8P, N-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-  
yl)phenyl]-5-ethyl-1,3-benzoxazol-2-amine 461699-41-2P,  
Cis-1-[4-(Dimethylamino)cyclohexyl]-3-iodo-1H-pyrazolo[3,4-  
d]pyrimidin-4-amine 461699-42-3P, trans-1-[4-  
(Dimethylamino)cyclohexyl]-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-  
amine 461699-46-7P, N-(4-Bromophenyl)-5-chloro-1,3-benzoxazol-2-  
amine 461699-47-8P, N-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-  
yl)phenyl]-5-chloro-1,3-benzoxazol-2-amine 461699-48-9P,  
N-(4-Bromophenyl)-5-methyl-1,3-benzoxazol-2-amine 461699-49-0P,  
N-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-methyl-  
1,3-benzoxazol-2-amine 461699-50-3P, 1H-Pyrazolo[3,4-d]pyrimidin-4-  
amine, 3-iodo-1-[cis-4-(4-morpholinyl)cyclohexyl]- 461699-51-4P,  
1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-iodo-1-[cis-4-[(2-  
methoxyethyl)amino]cyclohexyl]- 461699-52-5P, 1H-Pyrazolo[3,4-  
d]pyrimidin-4-amine, 3-iodo-1-[cis-4-(methylamino)cyclohexyl]-  
461699-61-6P, N-(4-Bromophenyl)-N-(5,7-dimethyl-1,3-benzothiazol-2-  
yl)amine 461699-78-5P, N-[4-[4-Amino-1-(4-piperidyl)-1H-  
pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-  
(trifluoromethyl)benzamide 461699-82-1P, 2-Methoxy-4-(4,4,5,5-  
tetramethyl-1,3,2-dioxaborolan-2-yl)aniline bismaleate  
461701-01-9P, 3-Iodo-1-(tetrahydro-1H-pyrrol-3-yl)-1H-pyrazolo[3,4-  
d]pyrimidin-4-amine monohydrochloride 461701-02-0P,  
3-Iodo-1-(1-methyltetrahydro-1H-pyrrol-3-yl)-1H-pyrazolo[3,4-  
d]pyrimidin-4-amine 461701-03-1P, N-(4-Bromophenyl)-5,7-dimethyl-  
1,3-benzoxazol-2-amine 461701-05-3P, 3-Iodo-1-[1-(2-  
methoxyethyl)tetrahydro-1H-pyrrol-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-  
4-amine 461701-07-5P, N-(4-Bromo-2-fluorophenyl)-5,7-dimethyl-1,3-  
benzoxazol-2-amine 461701-08-6P, N-[2-Fluoro-4-(4,4,5,5-  
tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5,7-dimethyl-1,3-  
benzoxazol-2-amine 461701-10-0P, 2-[4-(4,4,5,5-Tetramethyl-1,3,2-  
dioxaborolan-2-yl)phenyl]imidazo[1,2-a]pyridine 461701-12-2P,

1-[3-(4-Amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)tetrahydro-1H-pyrrol-1-yl]-2-(dimethylamino)-1-ethanone 461701-14-4P,  
 9H-Fluoren-9-ylmethyl N-[2-[3-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)tetrahydro-1H-pyrrol-1-yl]-1,1-dimethyl-2-oxoethyl]-N-methylcarbamate 461701-15-5P 461701-17-7P, tert-Butyl  
 3-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-pyrrolidinecarboxylate 461701-18-8P, tert-Butyl  
 3-[4-amino-3-[4-[(5,7-dimethyl-1,3-benzoxazol-2-yl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-pyrrolidinecarboxylate  
 461701-21-3P, N-(4-Bromophenyl)-7-isopropyl-1,3-benzoxazol-2-amine  
 461701-22-4P, N-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-7-isopropyl-1,3-benzoxazol-2-amine 461701-38-2P,  
 4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]benzaldehyde 461701-54-2P 461702-08-9P,  
 1-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]-1H-benzo[d]imidazole 461702-16-9P, N-[4-[4-Amino-1-[1-[(2-methyl-1H-imidazol-4-yl)methyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-21-6P  
 461702-22-7P, N-[4-[4-Amino-1-[1-(2-fluoroethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-24-9P, N-[4-[4-Amino-1-[1-(2,2-difluoroethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-39-6P,  
 1-(3-Bromopropyl)-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
 461702-40-9P, 3-Iodo-1-[3-(4-methylpiperazino)propyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461702-42-1P,  
 3-Iodo-1-(3-morpholinopropyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
 461702-44-3P, 1-[3-(1H-1-Imidazolyl)propyl]-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461702-55-6P, Cyclohexanecarboxylic acid,  
 4-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-, ethyl ester,  
 cis- 461702-59-0P, N-(4-Bromophenyl)-N-(2-pyrimidinyl)amine  
 461702-62-5P, 1-(2-Chloro-4-pyridyl)-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461702-63-6P 461702-66-9P, (S)-tert-Butyl  
 3-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-piperidinecarboxylate 461702-68-1P 461702-69-2P,  
 (S)-3-Iodo-1-[1-(2-methoxyethyl)-3-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461702-98-7P, N-[2-Methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1H-3-indolecarboxamide  
 471925-68-5P, 3-(4-Phenoxyphenyl)-1-(3-propylidenecyclobutyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 471925-82-3P 471925-83-4P,  
 N-[4-[4-Amino-1-[1-(1-methyl-4-piperidyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]aniline  
 471925-90-3P, 1-[1-(1H-2-Imidazolylmethyl)-4-piperidyl]-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine 471925-91-4P, tert-Butyl  
 N-[4-[4-amino-1-[1-(1H-2-imidazolylmethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]carbamate  
 471925-92-5P, 3-(4-Amino-3-methoxyphenyl)-1-[1-(1H-2-imidazolylmethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
 471925-99-2P, 2-Fluoro-6-[(2-methoxyethyl)amino]benzonitrile  
 471927-37-4P, 5-Ethoxy-3-methyl-1-[4-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)phenyl]-1H-pyrazole  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);  
 RACT (Reactant or reagent)

(intermediate; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT 144697-17-6 144941-35-5, Blk protein kinase  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)

(prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT 330785-88-1P, 1-(1-Benzyl-4-piperidiny)-3-(4-phenoxyphenyl)-1H-

pyrazolo[3,4-d]pyrimidin-4-amine

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(protein kinase inhibitor.; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT 330788-71-1P 330788-72-2P 330788-73-3P 330788-74-4P  
330788-75-5P 330788-76-6P 330788-77-7P 330788-78-8P  
330788-79-9P 330788-80-2P 330788-81-3P 330788-82-4P  
330788-83-5P 330788-84-6P 330788-85-7P 330788-86-8P  
330788-87-9P 330788-88-0P 471925-84-5P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(protein kinase inhibitor; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT 330785-90-5P, 3-(4-Phenoxyphenyl)-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330786-11-3P 330786-13-5P,  
4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-cyclohexanone 330786-15-7P, tert-Butyl cis-4-[4-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]cyclohexyl]-1-piperazinecarboxylate 330786-16-8P, tert-Butyl trans-4-[4-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]cyclohexyl]-1-piperazinecarboxylate 330786-24-8P,  
3-(4-Phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330786-58-8P, Cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-(2-phenoxy-5-pyrimidinyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330786-63-5P, Cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-(2-pyrimidinyl)oxy]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330786-67-9P 330787-59-2P 330787-63-8P 330787-67-2P,  
3-[4-(Benzyloxy)phenyl]-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-88-7P, Cis-2-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]benzonitrile 330787-91-2P, Cis-3-[4-[2-(Aminomethyl)phenoxy]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330788-01-7P 330788-03-9P,  
1-(3-Azetanyl)-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330788-11-9P, Cis-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-cyclobutanol 330788-15-3P, Trans-1-[3-[(Benzyloxy)methyl]cyclobutyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330788-68-6P,  
trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(dimethylamino)benzamide 330788-92-6P, Ethyl 2-[4-amino-3-[4-[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]acetate 330789-03-2P,  
trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 330789-23-6P, cis-3-[4-(Benzyloxy)phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330789-29-2P, trans-3-[4-(Benzyloxy)phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330789-32-7P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-phenylpropanamide 330789-75-8P,  
Cis-2-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]anilino]-1-phenyl-1-ethanone diacetate 330790-07-3P, Methyl 5-[4-(4-amino-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)phenoxy]-2-furoate 330790-15-3P,

Cis-2-[3-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]benzaldehyde 330790-20-0P  
330790-21-1P 330790-70-0P, Trans-2-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-hydroxycyclohexyl]acetic acid  
330790-74-4P 330790-88-0P, Methyl 2-[4-amino-3-[4-[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]acetate 330790-98-2P, Ethyl 2-[4-amino-3-[4-[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]propanoate 330790-99-3P, Methyl 2-[4-amino-3-[4-[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]propanoate 330791-04-3P, Methyl 4-[4-amino-3-[4-[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]butanoate 330791-51-0P, tert-Butyl N-[4-[4-amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]carbamate 330791-57-6P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine dihydrochloride 330791-68-9P 330791-88-3P, tert-Butyl N-[4-[4-amino-1-(4-nitrophenyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]carbamate 330791-99-6P, trans-3-(4-Amino-2-fluoro-5-methoxyphenyl)-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330792-01-3P, tert-Butyl N-[4-[4-amino-1-(1-methyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]carbamate 330792-23-9P, Trans-3-[4-[(2-Aminobenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330792-33-1P, Trans-3-[4-(5-Ethoxy-1H-1-pyrazolyl)phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine acetate 330792-43-3P, 2-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]acetic acid 330792-49-9P, 3-[3-Methoxy-4-[(5-methyl-2-furyl)methyl]amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461697-04-1P, N-[4-[4-Amino-1-(2-hydroxyethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461697-42-7P, N-[4-[4-Amino-1-(4-oxocyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-trifluoromethylbenzamide 461697-45-0P, Cis-Ethyl 3-[4-[4-amino-3-[4-[(2-fluoro-4-trifluoromethylbenzoyl)amino]-3-methoxyphenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]cyclohexyl]amino]propanoate 461697-46-1P, Trans-Ethyl 3-[4-[4-amino-3-[4-[(2-fluoro-4-trifluoromethylbenzoyl)amino]-3-methoxyphenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]cyclohexyl]amino]propanoate 461697-49-4P, N-[4-(4-Amino-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methoxyphenyl]-2-fluoro-4-trifluoromethylbenzamide 461697-50-7P, N-[4-(4-Amino-1-trityl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methoxyphenyl]-2-fluoro-4-trifluoromethylbenzamide 461697-52-9P, N-[4-[4-Amino-1-(4-hydroxy-2-cyclopentenyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-trifluoromethylbenzamide 461698-20-4P 461698-28-2P, trans-3-[4-[(2-Methoxy-3-pyridyl)methyl]amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461699-12-7P 461701-33-7P, 3-(4-Amino-3-methoxyphenyl)-1-(1-methyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461701-35-9P, N-[4-[4-Amino-1-(1-methyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(trifluoromethyl)benzamide 461702-45-4P, N-[4-[4-Amino-1-(tetrahydro-1H-pyrrol-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-54-5P, cis-Ethyl 4-[4-amino-3-[4-[(5,7-dimethyl-1,3-benzoxazol-2-yl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-cyclohexanecarboxylate 471926-42-8P 471927-18-1P, trans-tert-Butyl N-[4-[4-amino-1-[4-(4-



methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-5-fluoro-2-methoxyphenyl]carbamate

RL: PAC (Pharmacological activity); RCT (Reactant); SPN

(Synthetic preparation); THU (Therapeutic use); BIOL

(Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(protein kinase inhibitor; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT 330785-92-7P, 1-[1-(1-Methyl-4-piperidinyl)-4-piperidinyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine trimaleate  
 330785-96-1P, 1-[1-(1-Isopropyl-4-piperidinyl)-4-piperidinyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine trimaleate  
 330785-98-3P, 1-[1-(4-Piperidinyl)-4-piperidinyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine trimaleate  
 330786-02-2P, 1-[trans-4-(4-Methylpiperazino)cyclohexyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine dimaleate  
 330786-06-6P, 1-[4-(4-Methylpiperazino)cyclohexyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine trimaleate  
 330786-08-8P, N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-4-fluoro-1-benzenesulfonamide dimaleate 330786-18-0P, Cis-3-(4-Phenoxyphenyl)-1-(4-piperazinocyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine trimaleate 330786-20-4P, Trans-3-(4-Phenoxyphenyl)-1-(4-piperazinocyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine trimaleate 330786-25-9P, 4-Amino-1-cyclopentyl-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidine 330786-27-1P, 3-(4-Phenoxyphenyl)-1-(tetrahydropyran-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine  
 330786-29-3P 330786-30-6P 330786-33-9P 330786-36-2P, Cis-3-(4-Anilinophenyl)-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine trimaleate 330786-40-8P, Cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-(6-phenoxy-3-pyridyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine dimaleate 330786-45-3P, Trans-Benzyl N-[4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]carbamate dimaleate  
 330786-47-5P, Trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]benzamide dimaleate 330786-49-7P, N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-N'-phenylsulfamide dimaleate  
 330786-51-1P 330786-53-3P 330786-55-5P 330786-57-7P  
 330786-59-9P, Cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-(2-phenoxy-5-pyrimidinyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine dimaleate  
 330786-61-3P, Trans-1-[4-(4-Methylpiperazino)cyclohexyl]-3-(2-phenoxy-5-pyrimidinyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine dimaleate  
 330786-64-6P, Cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-(2-pyrimidinylloxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine trimaleate 330786-66-8P, trans-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-(2-pyrimidinylloxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine dimaleate 330786-69-1P  
 330786-71-5P 330786-72-6P 330786-73-7P 330786-75-9P  
 330786-77-1P 330786-78-2P, Cis-4-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]benzamide 330786-79-3P, Cis-4-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]benzoic acid 330786-81-7P 330786-83-9P  
 330786-85-1P, cis-3-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]benzamide diacetate  
 330786-86-2P, Cis-3-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]benzoic acid 330786-88-4P  
 330786-89-5P, Cis-N-[3-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-

yl]phenoxy]benzyl]benzamide 330786-91-9P 330786-93-1P,  
Cis-Benzyl N-[4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-  
pyrazolo-[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]carbamate dimaleate  
330786-95-3P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-  
1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-N'-benzylurea  
acetate 330786-97-5P, Cis-3-[4-(Benzylamino)-3-methoxyphenyl]-1-[4-  
(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
acetate 330786-99-7P 330787-03-6P, Trans-3-[4-(Benzylamino)-3-  
methoxyphenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-  
d]pyrimidin-4-amine dimaleate 330787-05-8P, Trans-3-[4-[(2,6-  
Dimethoxybenzyl)amino]-3-methoxyphenyl]-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
diacetate 330787-07-0P, Trans-3-[4-[(2-Chloro-6-  
fluorobenzyl)amino]-3-methoxyphenyl]-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
diacetate 330787-09-2P, Cis-3-[4-(Benzylamino)phenyl]-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
diacetate 330787-11-6P, Cis-3-[4-[(2-Methylbenzyl)amino]phenyl]-1-  
[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-  
amine diacetate 330787-13-8P 330787-14-9P, Cis-3-[4-[(2-  
Chlorobenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-  
pyrazolo[3,4-d]pyrimidin-4-amine 330787-15-0P,  
Cis-3-[4-[(2-Bromobenzyl)amino]phenyl]-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
330787-16-1P, Cis-3-[4-[(2-Ethoxybenzyl)amino]phenyl]-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
330787-17-2P, Cis-3-[4-[(2-(Difluoromethoxy)benzyl)amino]phenyl]-1-  
[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-  
amine 330787-19-4P 330787-21-8P 330787-23-0P,  
Cis-2-[[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-  
pyrazolo[3,4-d]pyrimidin-3-yl]anilino]methyl]benzonitrile diacetate  
330787-24-1P, Cis-3-[4-[(2,6-Difluorobenzyl)amino]phenyl]-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
330787-26-3P, Cis-3-[4-[(2-Chloro-6-fluorobenzyl)amino]phenyl]-1-[4-  
(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
acetate 330787-27-4P, Cis-3-[4-[[2-Fluoro-6-  
(trifluoromethyl)benzyl]amino]phenyl]-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
330787-29-6P, Cis-3-[4-[(2-Fluoro-6-methoxybenzyl)amino]phenyl]-1-[4-  
(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
diacetate 330787-30-9P, Cis-3-[4-[(2,6-  
Dichlorobenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-  
pyrazolo[3,4-d]pyrimidin-4-amine 330787-32-1P,  
Cis-3-[4-[(2,6-Dimethoxybenzyl)amino]phenyl]-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
diacetate 330787-34-3P, Cis-3-[4-[(2-Fluoro-4-  
methylbenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-  
pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-38-7P,  
Cis-3-[4-[[1-Methyl-1H-indol-2-yl)methyl]amino]phenyl]-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
diacetate 330787-40-1P, Trans-3-[4-(Benzylamino)phenyl]-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
trimaleate 330787-42-3P, Trans-3-[4-[(2-Methylbenzyl)amino]phenyl]-  
1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-  
amine diacetate 330787-44-5P, Trans-3-[4-[(2,6-  
Dimethoxybenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-  
1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-46-7P,  
Trans-3-[4-[(2-Chlorobenzyl)amino]phenyl]-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
diacetate 330787-48-9P, Trans-3-[4-[(2-Bromobenzyl)amino]phenyl]-1-  
[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-  
amine acetate 330787-50-3P 330787-52-5P 330787-53-6P

330787-55-8P, Cis-3-[4-[Benzyl(methyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-57-0P, Cis-3-[4-[Benzyl(ethyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-61-6P, Cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-(phenethylamino)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-65-0P, Cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-[(3-phenylpropyl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-66-1P, 1-Cyclopentyl-3-[4-(3-methoxyphenoxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-68-3P, 1-Cyclopentyl-3-[4-(4-fluorophenoxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-69-4P, 1-Cyclopentyl-3-[4-[3-(trifluoromethyl)phenoxy]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-70-7P, 1-Cyclopentyl-3-[4-(3-nitrophenoxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-71-8P, 1-Cyclopentyl-3-[4-[4-(trifluoromethoxy)phenoxy]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-72-9P, 1-Cyclopentyl-3-[4-[4-(trifluoromethyl)phenoxy]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-73-0P, 3-[3-(Benzyloxy)phenyl]-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-75-2P, Cis-3-[4-[(3-Fluorobenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine triacetate 330787-77-4P, Cis-3-[4-[(2-Fluorobenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine triacetate 330787-79-6P, Cis-3-[4-[(4-Methoxybenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-81-0P, Cis-3-[4-[(3-Methoxybenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine triacetate 330787-83-2P, Cis-3-[4-[(4-Fluorobenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine triacetate 330787-84-3P, Cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-[(3-pyridylmethyl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-85-4P, Cis-3-[4-[(2-Methoxybenzyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-87-6P, Cis-3-[3-(Benzylamino)phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine triacetate 330787-90-1P, Cis-2-[3-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]benzamide triacetate 330787-93-4P, Cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenoxy]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-95-6P, Cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-(2-nitrophenoxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330787-96-7P, Cis-3-[4-(2-Aminophenoxy)phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330787-97-8P, [2-(4-Amino-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-5-phenoxyphenyl]methanol 330787-99-0P 330788-02-8P 330788-04-0P, 2-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-1-ethanol 330788-06-2P, 1-[1-(2-Methoxyethyl)-3-azetanyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine acetate 330788-07-3P, 1-[1-[2-(2-Methoxyethoxy)ethyl]-3-azetanyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330788-08-4P, 1-[1-(1-Methyl-4-piperidyl)-3-azetanyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330788-09-5P, 1-[1-[(1-Methyl-1H-imidazol-2-yl)methyl]-3-azetanyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330788-10-8P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-1-ethanone 330788-12-0P, Trans-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-cyclobutanol



330788-14-2P 330788-16-4P, trans-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]cyclobutanemethanol 330788-18-6P  
330788-19-7P 330788-20-0P 330788-21-1P 330788-23-3P  
330788-24-4P 330788-25-5P 330788-26-6P 330788-27-7P  
330788-28-8P 330788-29-9P 330788-30-2P 330788-31-3P  
330788-32-4P 330788-34-6P, cis-3-[4-[(4-Bromobenzyl)amino]-3-fluorophenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine trimaleate 330788-46-0P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(2,4-difluorophenyl)urea 330788-47-1P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methoxyphenyl)urea 330788-48-2P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methoxyphenyl)urea monoacetate 330788-50-6P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methylphenyl)urea monoacetate 330788-51-7P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methylphenyl)urea 330788-52-8P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N-ethyl-N'-(3-methylphenyl)urea 330788-53-9P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N-benzyl-N'-(2,4-difluorophenyl)urea 330788-54-0P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-N'-(3-methylphenyl)urea 330788-55-1P, N-[4-[4-Amino-1-[1-[2-(dimethylamino)acetyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methylphenyl)urea 330788-57-3P, N-[4-[4-Amino-1-[1-[3-(diethylamino)propanoyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methylphenyl)urea monoacetate 330788-58-4P, N-[4-[4-Amino-1-[1-[2-(methylamino)acetyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methylphenyl)urea 330788-60-8P, N-[4-[4-Amino-1-[1-[3-[(2-hydroxyethyl)amino]propanoyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methylphenyl)urea monoacetate 330788-61-9P 330788-62-0P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1H-indole-2-carboxamide 330788-63-1P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-methyl-1H-indene-2-carboxamide 330788-64-2P 330788-65-3P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-indole-2-carboxamide 330788-66-4P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1H-indole-3-carboxamide 330788-67-5P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-phenylpropanamide 330788-69-7P, Trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(dimethylamino)benzamide trimaleate 330788-70-0P 330788-89-1P 330788-90-4P, 1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-[(phenethylamino)(phenyl)methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330788-91-5P, N-[4-[4-Amino-1-(4-oxocyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methylphenyl)urea 330788-93-7P, N-[4-[4-Amino-1-(2-hydroxyethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-2,3-dichloro-1-benzenesulfonamide 330788-94-8P, N-[4-[4-Amino-1-[2-cyano-4-(4-methylpiperazino)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-2,3-dichloro-1-benzenesulfonamide 330788-95-9P,

cis-N-Phenyl-4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxybenzamide 330788-96-0P,  
trans-N-Phenyl-4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxybenzamide 330788-97-1P,  
cis-N-Benzyl-4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxybenzamide 330788-98-2P,  
cis-N-Phenethyl-4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxybenzamide 330788-99-3P,  
cis-N-Phenyl-4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]benzamide 330789-00-9P,  
cis-N-Phenethyl-4-[4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]benzamide 330789-02-1P,  
trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1H-2-indolecarboxamide trimaleate 330789-04-3P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide trimaleate 330789-06-5P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(trifluoromethyl)benzamide trimaleate 330789-08-7P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(trifluoromethoxy)benzamide trimaleate 330789-09-8P, N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-phenylpropanamide 330789-13-4P, 1-[1-(1H-Imidazol-2-ylmethyl)tetrahydro-1H-pyrrol-3-yl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330789-15-6P, 1-[1-(1-Methyl-4-piperidyl)tetrahydro-1H-pyrrol-3-yl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine trimaleate 330789-16-7P, N-[4-[4-Amino-1-[1-(1H-imidazol-2-ylmethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-phenylpropanamide 330789-24-7P, cis-2-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]-6-[(3-methoxypropyl)amino]benzonitrile 330789-26-9P, cis-2-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]-6-[(4-methylphenyl)sulfanyl]benzonitrile trimaleate 330789-28-1P, cis-2-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]-6-(2-pyridylsulfanyl)benzonitrile dimaleate 330789-31-6P, trans-2-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]-6-[(3-methoxypropyl)amino]benzonitrile trimaleate 330789-33-8P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-phenylpropanamide trimaleate 330789-34-9P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-N-methyl-3-phenylpropanamide 330789-35-0P, N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(trifluoromethoxy)benzamide trimaleate 330789-37-2P, [4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino][4-methylpiperazino]methanone dimaleate 330789-39-4P, N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(dimethylamino)benzamide trimaleate 330789-40-7P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-(trifluoromethyl)benzamide 330789-41-8P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-(trifluoromethoxy)benzamide 330789-42-9P,

cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-(trifluoromethoxy)benzamide 330789-43-0P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 330789-44-1P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-(trifluoromethyl)benzamide 330789-46-3P 330789-48-5P, Cis-3-[4-[(2-Furylmethyl)amino]-3-methoxyphenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine acetate 330789-50-9P 330789-52-1P, Trans-3-[4-[(2-Furylmethyl)amino]-3-methoxyphenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine dimaleate 330789-56-5P, Cis-2-[2-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]anilino]methyl]phenoxy]acetic acid diacetate 330789-58-7P, Cis-3-[4-[(2-Furylmethyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330789-60-1P, Cis-3-[4-[(5-Methyl-2-furyl)methyl]amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330789-62-3P, Cis-3-[4-[(3-Furylmethyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330789-64-5P 330789-66-7P, Trans-3-[4-[(2-Furylmethyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330789-68-9P, 3-[4-[(5-Methyl-2-furyl)methyl]amino]phenyl]-1-[1-(1-methyl-4-piperidyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine acetate 330789-70-3P 330789-71-4P 330789-77-0P 330789-79-2P 330789-81-6P 330789-83-8P 330789-85-0P 330789-86-1P 330789-88-3P 330789-90-7P 330789-92-9P 330789-93-0P 330789-96-3P 330789-98-5P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-2-methyl-2-phenylpropanamide diacetate 330790-00-6P 330790-02-8P 330790-03-9P 330790-05-1P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-1,3-benzoxazol-2-amine diacetate 330790-06-2P, 2-[4-(4-Amino-1-cyclopentyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]acetamide 330790-08-4P, 5-[4-(4-Amino-1-cyclopentyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenoxy]-2-furoic acid 330790-09-5P, 1-Cyclopentyl-3-[4-(3-thienyloxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330790-11-9P 330790-12-0P, Cis-3-[3-[Di(2-furylmethyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330790-14-2P 330790-18-6P, (2S)-3-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]propane-1,2-diol 330790-19-7P, (2R)-3-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]propane-1,2-diol 330790-22-2P 330790-23-3P, N-Methyl-2-[3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]acetamide 330790-24-4P, N,N-Dimethyl-2-[3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]acetamide 330790-25-5P, N-Isopropyl-2-[3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]acetamide 330790-26-6P, N-(3-Hydroxypropyl)-2-[3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]acetamide 330790-27-7P 330790-28-8P, N-Benzyl-2-[3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]acetamide 330790-30-2P, 2-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-1-morpholino-1-ethanone 330790-31-3P, N-(3-Methyl-5-isoxazolyl)-2-[3-[4-amino-3-(4-phenoxyphenyl)-1H-

pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]acetamide 330790-34-6P,  
 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-  
 1-azetanyl]-2-[(2-hydroxyethyl)amino]-1-ethanone 330790-35-7P,  
 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-  
 1-azetanyl]-2-[(2-methoxyethyl)amino]-1-ethanone 330790-36-8P,  
 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-  
 1-azetanyl]-2-[(3-hydroxypropyl)amino]-1-ethanone 330790-37-9P,  
 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-  
 1-azetanyl]-2-[(2,3-dihydroxypropyl)amino]-1-ethanone  
 330790-38-0P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-  
 d]pyrimidin-1-yl]-1-azetanyl]-2-[(tetrahydro-2-furanylmethyl)amino]-  
 1-ethanone 330790-39-1P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-  
 pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[(2-  
 piperidinoethyl)amino]-1-ethanone 330790-40-4P,  
 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-  
 1-azetanyl]-2-[(2-(dimethylamino)ethyl)(methyl)amino]-1-ethanone  
 330790-42-6P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-  
 d]pyrimidin-1-yl]-1-azetanyl]-2-[(2-(dimethylamino)ethyl)amino]-1-  
 ethanone acetate 330790-43-7P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-  
 1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[methyl(1-methyl-4-  
 piperidyl)amino]-1-ethanone 330790-44-8P, 1-[3-[4-Amino-3-(4-  
 phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[(2-  
 morpholinoethyl)amino]-1-ethanone

RL: PAC (Pharmacological activity); SPN (Synthetic  
 preparation); THU (Therapeutic use); BIOL (Biological  
 study); PREP (Preparation); USES (Uses)

(protein kinase inhibitor; prepn. of [(hetero)aryl]pyrazolo[3,4-  
 d]pyrimidinamines as protein kinase inhibitors with  
 antiangiogenic properties)

IT 330790-45-9P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-  
 d]pyrimidin-1-yl]-1-azetanyl]-2-[(3-morpholinopropyl)amino]-1-  
 ethanone 330790-46-0P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-  
 pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[[3-(1H-1-  
 imidazolyl)propyl]amino]-1-ethanone 330790-47-1P,  
 1-[3-[[2-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-  
 1-yl]-1-azetanyl]-2-oxoethyl]amino]propyl]-2-pyrrolidinone  
 330790-48-2P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-  
 d]pyrimidin-1-yl]-1-azetanyl]-2-(4-hydroxypiperidino)-1-ethanone  
 330790-49-3P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-  
 d]pyrimidin-1-yl]-1-azetanyl]-2-[4-(hydroxymethyl)piperidino]-1-  
 ethanone 330790-51-7P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-  
 pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-morpholino-1-ethanone  
 330790-52-8P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-  
 d]pyrimidin-1-yl]-1-azetanyl]-2-(4-methylpiperazino)-1-ethanone  
 330790-53-9P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-  
 d]pyrimidin-1-yl]-1-azetanyl]-2-[4-(piperid-1-yl)piperidino]-1-  
 ethanone 330790-54-0P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-  
 pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-(1H-4-imidazolyl)-1-  
 ethanone 330790-56-2P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-  
 pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-(methylamino)-1-  
 ethanone acetate 330790-58-4P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-  
 1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-(dimethylamino)-1-  
 ethanone acetate 330790-59-5P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-  
 1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-3-(diethylamino)-1-  
 propanone 330790-61-9P, 1-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-  
 pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-2-(methylamino)-1-ethanone  
 acetate 330790-62-0P, 1-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-  
 pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-2-(dimethylamino)-1-  
 ethanone 330790-64-2P, 1-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-  
 pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-3-(diethylamino)-1-  
 propanone acetate 330790-66-4P, 1-[4-[4-Amino-3-(4-phenoxyphenyl)-  
 1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-2-morpholino-1-ethanone



acetate 330790-68-6P, 1-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-2-(4-methylpiperazino)-1-ethanone acetate 330790-69-7P, Cis-2-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-hydroxycyclohexyl]acetic acid 330790-71-1P, [3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-(hydroxymethyl)cyclobutyl]methanol 330790-72-2P 330790-73-3P 330790-75-5P 330790-76-6P 330790-77-7P 330790-79-9P, N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-5-chloro-2-thiophenesulfonamide maleate 330790-80-2P, 1-[4-[4-Amino-3-[4-(1,3-benzoxazol-2-ylamino)-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-2-(dimethylamino)-1-ethanone 330790-81-3P, 1-[4-[4-Amino-3-[4-(1,3-benzothiazol-2-ylamino)-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-2-(dimethylamino)-1-ethanone 330790-82-4P, N-[4-[4-Amino-1-(2-morpholino-2-oxoethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-2,3-dichloro-1-benzenesulfonamide 330790-83-5P, N-[4-[4-Amino-1-[2-(4-methylpiperazino)-2-oxoethyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-2,3-dichloro-1-benzenesulfonamide 330790-84-6P, N-((1R,2S)-2-Hydroxy-1-methyl-2-phenylethyl)-N-methyl-2-[4-amino-3-[4-[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]acetamide 330790-85-7P, N-((1S,2S)-2-Hydroxy-1-methyl-2-phenylethyl)-N-methyl-2-[4-amino-3-[4-[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]acetamide 330790-86-8P 330790-87-9P 330790-89-1P, 2-[4-Amino-3-[4-[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]acetic acid 330790-90-4P, N-[2-(Dimethylamino)ethyl]-2-[4-amino-3-[4-[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]acetamide 330790-91-5P, N-[2-(Diethylamino)ethyl]-2-[4-amino-3-[4-[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]acetamide 330790-92-6P, 2-(Dimethylamino)ethyl 2-[4-amino-3-[4-[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]acetate 330790-93-7P, N-[3-(Dimethylamino)propyl]-2-[4-amino-3-[4-[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]acetamide 330790-94-8P, 2-[4-Amino-3-[4-[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]acetamide 330790-96-0P, N-[4-[4-Amino-1-(2-morpholino-2-oxoethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methylphenyl)urea 330790-97-1P, N-[4-[4-Amino-1-[2-(4-methylpiperazino)-2-oxoethyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-methylphenyl)urea 330791-00-9P, 2-[4-Amino-3-[4-[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]propanamide 330791-01-0P 330791-02-1P 330791-03-2P, Ethyl 4-[4-amino-3-[4-[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]butanoate 330791-05-4P, 4-[4-Amino-3-[4-[(2,3-dichlorophenyl)sulfonyl]amino]-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]butanamide 330791-06-5P 330791-07-6P 330791-08-7P, 2-[4-Amino-3-[4-(1,3-benzoxazol-2-ylamino)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-5-(4-methylpiperazino)benzonitrile 330791-09-8P, Ethyl 2-[4-amino-3-[4-(1,3-benzothiazol-2-ylamino)-3-fluorophenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]propanoate 330791-10-1P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-1,3-benzoxazol-2-amine 330791-11-2P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-

fluorophenyl]-1,3-benzothiazol-2-amine 330791-12-3P,  
Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-  
pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-1,3-benzothiazol-2-amine  
330791-13-4P, Trans-N-[4-[4-Amino-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-  
yl]phenyl]-1,3-benzoxazol-2-amine 330791-14-5P,  
Trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-  
pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-1,3-benzoxazol-2-  
amine 330791-15-6P, Trans-N-[4-[4-Amino-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-  
fluorophenyl]-1,3-benzothiazol-2-amine 330791-16-7P,  
Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-  
pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-4-methyl-1,3-benzoxazol-2-  
amine 330791-17-8P, Cis-N-[4-[4-Amino-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-  
yl]phenyl]-5-chloro-1,3-benzoxazol-2-amine 330791-18-9P,  
Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-  
pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-methyl-1,3-benzoxazol-2-  
amine 330791-19-0P, Cis-N-[4-[4-Amino-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-  
yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 330791-20-3P  
330791-21-4P 330791-23-6P 330791-24-7P 330791-25-8P  
330791-26-9P, Trans-N-[4-[4-Amino-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-  
yl]benzyl]-N'-(3-methylphenyl)urea 330791-27-0P 330791-28-1P,  
cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-  
pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2,2-dimethyl-3-  
phenylpropanamide 330791-30-5P, trans-N-[4-[4-Amino-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-  
methoxyphenyl]-2,2-dimethyl-3-phenylpropanamide trimaleate  
330791-32-7P 330791-33-8P, cis-N-[4-[4-Amino-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-  
methoxyphenyl]benzo[b]thiophene-2-carboxamide 330791-34-9P,  
cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-  
pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-  
thiophenecarboxamide 330791-35-0P 330791-37-2P,  
trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-  
pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-methyl-3-  
phenylbutanamide trimaleate 330791-38-3P 330791-39-4P  
330791-40-7P 330791-43-0P 330791-44-1P 330791-46-3P  
330791-48-5P, trans-N-[4-[4-Amino-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-  
methoxyphenyl]benzo[b]furan-2-carboxamide trimaleate 330791-50-9P  
330791-52-1P, 3-[4-[(2-Furylmethyl)amino]-3-methoxyphenyl]-1-[1-(1-  
methyl-4-piperidinyl)-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-4-  
amine 330791-54-3P, N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-  
yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-  
methoxyphenyl]-trans-2-phenylcyclopropane-1-carboxamide dimaleate  
330791-58-7P 330791-59-8P 330791-60-1P 330791-61-2P  
330791-62-3P 330791-63-4P 330791-64-5P 330791-65-6P  
330791-66-7P 330791-67-8P, cis-N-[4-[4-Amino-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-  
yl]benzyl]-5-methyl-1,3-thiazol-2-amine 330791-69-0P,  
Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-  
pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dichloro-1,3-benzoxazol-2-  
amine 330791-70-3P, Cis-N-[4-[4-Amino-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-  
yl]phenyl]-7-methyl-1,3-benzoxazol-2-amine 330791-71-4P,  
Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-  
pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-7-chloro-1,3-benzoxazol-2-  
amine 330791-72-5P 330791-73-6P, N-[2-(Dimethylamino)ethyl]-2-[4-  
amino-3-[4-[(5,7-dimethyl-1,3-benzoxazol-2-yl)amino]phenyl]-1H-

pyrazolo[3,4-d]pyrimidin-1-yl]propanamide 330791-74-7P,  
N-[4-[4-Amino-1-[2-cyano-4-(4-methylpiperazino)phenyl]-1H-  
pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-N'-(3-  
methylphenyl)urea 330791-75-8P, cis-N-[4-[4-Amino-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-  
yl]phenyl]-6-chloro-1,3-benzothiazol-2-amine 330791-76-9P,  
cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-  
pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-6-methoxy-1,3-benzothiazol-2-  
amine 330791-77-0P, cis-N-[4-[4-Amino-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-  
yl]phenyl]-4-ethyl-1,3-thiazol-2-amine 330791-78-1P,  
cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-  
pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-4,5-dimethyl-1,3-thiazol-2-  
amine 330791-79-2P, cis-N-[4-[4-Amino-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-  
yl]phenyl]-4-phenyl-1,3-thiazol-2-amine 330791-80-5P,  
cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-  
pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-4-(4-methylphenyl)-1,3-thiazol-  
2-amine 330791-81-6P, cis-N-[4-[4-Amino-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-  
yl]phenyl]-5-methyl-4-phenyl-1,3-thiazol-2-amine 330791-83-8P,  
N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-  
pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-(3R)-3-  
phenylbutanamide trimaleate 330791-85-0P, N-[4-[4-Amino-1-[1-(1-  
methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-  
yl]-2-methoxyphenyl]benzo[b]furan-2-carboxamide trimaleate  
330791-87-2P, N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-  
yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-(3S)-3-  
phenylbutanamide trimaleate 330791-89-4P, 4-Amino-3-(4-amino-3-  
methoxyphenyl)-1-(4-nitrophenyl)-1H-pyrazolo[3,4-d]pyrimidine  
330791-91-8P, N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-  
yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-  
indolecarboxamide dimaleate 330791-93-0P, N-[4-[4-Amino-1-[1-(1-  
methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-  
yl]-2-methoxyphenyl]-1H-2-indolecarboxamide dimaleate  
330791-94-1P, 3-Phenyl-1-trityl-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
330791-95-2P, N-[4-[4-Amino-1-(4-oxocyclohexyl)-1H-pyrazolo[3,4-  
d]pyrimidin-3-yl]-2-methoxyphenyl]-(3R)-3-phenylbutanamide  
330791-96-3P, [4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-  
d]pyrimidin-1-yl]phenyl]methanol 330791-97-4P,  
1-[4-[(4-Methylpiperazino)methyl]phenyl]-3-(4-phenoxyphenyl)-1H-  
pyrazolo[3,4-d]pyrimidin-4-amine 330792-00-2P,  
trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-  
pyrazolo[3,4-d]pyrimidin-3-yl]-5-fluoro-2-methoxyphenyl]-trans-2-  
phenyl-1-cyclopropanecarboxamide 330792-03-5P,  
Trans-3-[4-[(2-Chlorobenzyl)amino]-3-methoxyphenyl]-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
diacetate 330792-05-7P, Trans-3-[3-Methoxy-4-[(1,3-thiazol-2-  
ylmethyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-  
pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330792-09-1P,  
Trans-3-[3-Methoxy-4-[(2-thienylmethyl)amino]phenyl]-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
acetate 330792-11-5P, Trans-3-[3-Methoxy-4-[(5-methyl-2-  
thienyl)methyl]amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-  
pyrazolo[3,4-d]pyrimidin-4-amine acetate 330792-13-7P,  
Trans-3-[4-[(5-Chloro-2-thienyl)methyl]amino]-3-methoxyphenyl]-1-[4-  
(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
acetate 330792-15-9P, Trans-3-[3-Methoxy-4-[(2-methyl-1,3-thiazol-  
4-yl)methyl]amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-  
pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330792-19-3P,  
Trans-3-[4-[(2-Chloro-6-fluorobenzyl)amino]phenyl]-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine



diacetate 330792-25-1P 330792-27-3P 330792-29-5P  
330792-31-9P, Trans-3-[4-(3-Methyl-5-phenyl-1H-1-pyrazolyl)phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 330792-35-3P 330792-37-5P, 2-(2-Amino-1H-1-imidazolyl)-1-[3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-1-ethanone acetate 330792-38-6P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-3-[(2-hydroxyethyl)amino]-1-propanone 330792-40-0P, 2-(2-Amino-1H-1-imidazolyl)-1-[4-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-1-ethanone acetate 330792-41-1P, 1-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-2-[(2-hydroxyethyl)amino]-1-ethanone 330792-42-2P, 1-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-3-[(2-hydroxyethyl)amino]-1-propanone 330792-46-6P, Trans-N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-phenyl-1-cyclopropanecarboxamide maleate 330792-48-8P, trans-N-[4-[4-Amino-1-[1-[(1-methyl-1H-imidazol-2-yl)methyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-phenyl-1-cyclopropanecarboxamide 330792-50-2P, 3-[3-Methoxy-4-[(5-methyl-2-furyl)methyl]amino]phenyl]-1-[1-[(1-methyl-1H-imidazol-2-yl)methyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 330792-52-4P, trans-N-[4-[4-Amino-1-(4-oxocyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-phenylcyclopropane-1-carboxamide 330792-54-6P 330792-55-7P 330792-56-8P, 1-(Aminomethyl)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-cyclobutanol 461697-05-2P, N-[4-[4-Amino-1-[4-(morpholinomethyl)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461697-07-4P, N-[4-[4-Amino-1-[4-[(4-hydroxypiperidino)methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide monoacetate 461697-08-5P, N-[4-[4-Amino-1-[4-[[4-(2-hydroxyethyl)piperazino]methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461697-10-9P, N-[4-[4-Amino-1-[4-[[4-(2-hydroxyethyl)piperidino]methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide diacetate 461697-12-1P, N-[4-[4-Amino-1-[4-[[3-(hydroxymethyl)piperidino]methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide monoacetate 461697-14-3P, N-[4-[4-Amino-1-[4-[[2-(hydroxymethyl)piperidino]methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide monoacetate 461697-15-4P, N-[4-[4-Amino-1-[4-[[2-morpholinoethyl]amino]methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461697-17-6P, N-[4-[4-Amino-1-[4-[[4-(hydroxymethyl)piperidino]methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide diacetate 461697-18-7P, N-[4-[4-Amino-1-[4-[[4-(2-methoxyethyl)piperazino]methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461697-19-8P 461697-20-1P 461697-21-2P, N-[4-[4-Amino-1-[4-[[3-(1H-1-imidazolyl)propyl]amino]methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461697-22-3P, N-[4-[4-Amino-1-[4-[[4-(4-hydroxybutyl)amino]methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461697-23-4P, N-[4-[4-Amino-1-[4-[[3-(3-methoxypropyl)amino]methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461697-25-6P, N-[4-[4-Amino-1-[4-[[3-(dimethylamino)propyl]amino]methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-

(trifluoromethyl)benzamide monoacetate 461697-26-7P, L-Histidine, N-[[4-[4-amino-3-[4-[[2-fluoro-4-(trifluoromethyl)benzoyl]amino]-3-methoxyphenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]phenyl]methyl]-, methyl ester 461697-27-8P, N-[4-[4-Amino-1-[4-[[2-methoxyethyl]amino]methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461697-28-9P, N-[4-[4-Amino-1-[4-[[2-(dimethylamino)ethyl]amino]methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461697-29-0P, N-[4-[4-Amino-1-(2-hydroxyethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461697-32-5P, N-[4-[4-Amino-1-[2-(4-methylpiperazino)ethyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide trimaleate 461697-35-8P, N-[4-[4-Amino-1-(2-morpholinoethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide dimaleate 461697-37-0P, N-[4-[4-Amino-1-[2-[(2-hydroxyethyl)amino]ethyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide monomaleate 461697-39-2P, N-[4-[4-Amino-1-[2-(dimethylamino)ethyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide monomaleate 461697-41-6P 461697-43-8P, Cis-N-[4-[4-Amino-1-(4-morpholinocyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-trifluoromethylbenzamide 461697-44-9P, Trans-N-[4-[4-Amino-1-(4-morpholinocyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-trifluoromethylbenzamide 461697-47-2P, Cis-3-[[4-[4-Amino-3-[4-[(2-fluoro-4-trifluoromethylbenzoyl)amino]-3-methoxyphenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]cyclohexyl]amino]propanoic acid 461697-48-3P, Trans-3-[[4-[4-Amino-3-[3-methoxy-4-[(2-methoxy-4-trifluoromethylbenzoyl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]cyclohexyl]amino]propanoic acid 461697-51-8P, N-[4-(4-Amino-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methoxyphenyl]-2-fluoro-4-trifluoromethylbenzamide 461697-54-1P, N-[4-[4-Amino-1-(3-hydroxycyclopentyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-trifluoromethylbenzamide 461697-56-3P, 1H-Indole-1-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate 461697-59-6P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-(trifluoromethoxy)-, monoacetate 461697-61-0P, Benzenebutanamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, monoacetate 461697-63-2P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-methyl-, monoacetate 461697-65-4P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-methoxy-, monoacetate 461697-67-6P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-, monoacetate 461697-69-8P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(trifluoromethyl)-, monoacetate 461697-71-2P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, monoacetate 461697-73-4P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-methoxy-, monoacetate 461697-75-6P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-fluoro-, monoacetate 461697-77-8P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-

pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-chloro-,  
monoacetate 461697-79-0P, 1H-Indole-2-carboxamide,  
N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-  
methoxyphenyl]-6-chloro-, monoacetate 461697-81-4P,  
1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-  
pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-6-methoxy-,  
monoacetate 461697-83-6P, 1H-Indole-2-carboxamide,  
N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-  
methoxyphenyl]-5-ethyl-, monoacetate 461697-85-8P,  
1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-  
pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-7-methyl-,  
monoacetate 461697-87-0P, 1H-Indole-2-carboxamide,  
N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-  
methoxyphenyl]-7-nitro-, monoacetate 461697-89-2P,  
1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-  
pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-phenyl-,  
monoacetate 461697-91-6P, 1H-Indole-2-carboxamide,  
N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-  
methoxyphenyl]-1-ethyl-, monoacetate 461697-93-8P,  
1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-  
pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-(2-propenyl)-,  
monoacetate 461697-95-0P, 1H-Indole-1-acetic acid,  
2-[[[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-  
2-methoxyphenyl]amino]carbonyl]-, monoacetate 461697-97-2P,  
1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 1-(1-methyl-3-piperidinyl)-3-(4-  
phenoxyphenyl)-, acetate 461698-00-0P, 1-[1-(2-Methoxyethyl)-3-  
piperidyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
monoacetate 461698-03-3P, Trans-N-[4-[4-Amino-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-  
chlorophenyl]-4-(trifluoromethyl)benzamide dimaleate 461698-05-5P  
461698-07-7P, Trans-3-[3-Chloro-4-[[5-methyl-2-  
furyl)methyl]amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-  
pyrazolo[3,4-d]pyrimidin-4-amine monoacetate 461698-09-9P  
461698-11-3P, N-[4-[4-Amino-1-[1-(1H-2-imidazolylcarbonyl)-4-  
piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-trans-  
2-phenyl-1-cyclopropanecarboxamide monomaleate 461698-13-5P,  
Cyclopropanecarboxamide, N-[4-[4-amino-1-[cis-4-(2-aminoethyl)-4-  
hydroxycyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-  
methoxyphenyl]-2-phenyl-, (1R,2R)-rel-, acetate (salt)  
461698-15-7P 461698-17-9P 461698-19-1P, 2-  
Pyrrolidinecarboxamide, N-[4-[4-amino-1-[trans-4-(4-methyl-1-  
piperazinyl)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-  
methoxyphenyl]-, (2R)-, monoacetate 461698-22-6P,  
3-(4-Phenoxyphenyl)-1-(4-pyridyl)-1H-pyrazolo[3,4-d]pyrimidin-4-  
amine 461698-23-7P, N-[4-[4-Amino-1-(4-pyridyl)-1H-pyrazolo[3,4-  
d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide  
461698-25-9P, 1-(6-Amino-3-pyridyl)-3-(4-phenoxyphenyl)-1H-  
pyrazolo[3,4-d]pyrimidin-4-amine 461698-26-0P,  
3-(4-Phenoxyphenyl)-1-(2-pyridyl)-1H-pyrazolo[3,4-d]pyrimidin-4-  
amine 461698-30-6P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine,  
3-[4-[(1H-indol-2-ylmethyl)amino]phenyl]-1-[trans-4-(4-methyl-1-  
piperazinyl)cyclohexyl]-, acetate 461698-32-8P,  
Trans-3-[[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-  
pyrazolo[3,4-d]pyrimidin-3-yl]anilino]methyl]-1,2-dihydro-2-  
pyridinone diacetate 461698-34-0P, Trans-5-[[4-[4-Amino-1-[4-(4-  
methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-  
methoxyanilino]methyl]-4-chloro-1,3-thiazol-2-amine diacetate  
461698-36-2P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine,  
3-[3-methoxy-4-[[5-methyl-3-isoxazolyl)methyl]amino]phenyl]-1-  
[trans-4-(4-methyl-1-piperazinyl)cyclohexyl]-, acetate  
461698-38-4P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine,  
3-[3-methoxy-4-[(4-thiazolylmethyl)amino]phenyl]-1-[trans-4-(4-

methyl-1-piperazinyl)cyclohexyl]-, acetate 461698-40-8P,  
 Trans-3-[4-[(4,6-Dichloro-2,3-dihydrobenzo[b]furan-3-yl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine acetate 461698-42-0P,  
 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[4-[(4-chloro-2,3-dihydro-3-benzofuranyl)amino]phenyl]-1-[trans-4-(4-methyl-1-piperazinyl)cyclohexyl]-, acetate 461698-44-2P,  
 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[4-[(4,6-dichloro-2,3-dihydro-3-benzofuranyl)amino]-3-methoxyphenyl]-1-[trans-4-(4-methyl-1-piperazinyl)cyclohexyl]-, acetate 461698-48-6P,  
 3-[4-[[[Benzo[b]furan-2-yl)methyl]amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461698-50-0P,  
 3-[4-[[[2-Methoxy-3-pyridyl)methyl]amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461698-52-2P,  
 3-[4-[[[5-Methyl-2-thienyl)methyl]amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461698-54-4P,  
 3-[4-[(2-Furylmethyl)amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461698-56-6P, 3-[4-(Benzylamino)phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461698-58-8P, 3-[4-[(2-Methoxybenzyl)amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461698-60-2P, 3-[4-[(3-Methoxybenzyl)amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461698-62-4P, 3-[4-[(4-Methoxybenzyl)amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461698-64-6P 461698-66-8P 461698-68-0P, 3-[4-[[[2-Methyl-1,3-thiazol-4-yl)methyl]amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461698-70-4P, 3-[4-[(2-Chloro-6-fluorobenzyl)amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 461698-72-6P 461698-74-8P, 3-[4-[[[Benzo[b]furan-2-yl)methyl]amino]-3-methoxyphenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein kinase inhibitor; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT 461698-76-0P, 3-[4-[(2,3-Dihydrobenzo[b]furan-3-yl)amino]phenyl]-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine monoacetate 461698-78-2P, trans-3-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]anilino]-1H-benzo[d]isothiazole-1,1-dione monoacetate 461698-81-7P, Cis-3-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]anilino]-1H-benzo[d]isothiazole-1,1-dione diacetate 461698-83-9P, Trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]benzo[d]isoxazol-3-amine monoacetate 461698-89-5P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]benzo[d]isoxazol-3-amine diacetate 461698-91-9P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[4-(1,2-benzisoxazol-3-ylamino)phenyl]-1-(4-piperidinyl)-, acetate 461698-93-1P, Trans-3-[4-(1H-3-Indazolylamino)phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine monoacetate 461698-98-6P, Trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-6-(trifluoromethyl)benzo[d]isoxazol-3-amine monoacetate 461699-04-7P, N-[4-[4-Amino-1-[1-(2-methoxyethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461699-07-0P, N-[4-[4-Amino-1-(1-methyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461699-08-1P, N-[4-[4-Amino-1-(1-methyl-3-piperidyl)-1H-



pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461699-10-5P, N-[4-[4-Amino-1-[1-(2-methoxyethyl)-3-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461699-16-1P, Piperidine, 3-[4-amino-3-[4-[(5,7-dimethyl-2-benzoxazolyl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-[(dimethylamino)acetyl]-, acetate 461699-17-2P, 1-[3-[4-Amino-3-[4-[(5,7-dimethyl-1,3-benzoxazol-2-yl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]-2-methyl-2-(methylamino)-1-propanone 461699-21-8P, N-4-[4-Amino-1-(3-azetanyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl-5,7-dimethyl-1,3-benzoxazol-2-amine 461699-24-1P, N-[4-[4-Amino-1-(1-methyl-3-azetanyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461699-29-6P, Cis-2-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]anilino]-1,3-benzoxazole-5-carbonitrile 461699-33-2P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-(trifluoromethoxy)-1,3-benzoxazol-2-amine 461699-37-6P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-ethyl-1,3-benzoxazol-2-amine 461699-40-1P, Cis-N-[4-[4-Amino-1-[4-(dimethylamino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461699-45-6P, trans-N-[4-[4-Amino-1-[4-(dimethylamino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461699-53-6P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[4-[(5,7-dimethyl-2-benzoxazolyl)amino]phenyl]-1-[cis-4-[(2-methoxyethyl)amino]cyclohexyl]- 461699-54-7P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[4-(2-benzoxazolylamino)phenyl]-1-[cis-4-[(2-methoxyethyl)amino]cyclohexyl]- 461699-55-8P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[4-[(5,7-dimethyl-2-benzoxazolyl)amino]phenyl]-1-[cis-4-(4-morpholinyl)cyclohexyl]- 461699-56-9P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[4-(2-benzoxazolylamino)phenyl]-1-[cis-4-(4-morpholinyl)cyclohexyl]- 461699-57-0P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[4-[(5-chloro-2-benzoxazolyl)amino]phenyl]-1-[cis-4-(4-morpholinyl)cyclohexyl]- 461699-58-1P, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[4-(2-benzoxazolylamino)phenyl]-1-[cis-4-(methylamino)cyclohexyl]- 461699-59-2P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-4-(2-nitrophenyl)-1,3-thiazol-2-amine 461699-60-5P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzothiazol-2-amine 461699-62-7P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,6-dihydro-4H-cyclopenta[d][1,3]thiazol-2-amine 461699-63-8P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-ethyl-4-phenyl-1,3-thiazol-2-amine 461699-64-9P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-4,5,6,7-tetrahydro-1,3-benzothiazol-2-amine 461699-65-0P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-isopropyl-4-phenyl-1,3-thiazol-2-amine 461699-66-1P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-4-phenyl-5-propyl-1,3-thiazol-2-amine 461699-67-2P, 3-[4-(1,3-Benzoxazol-2-ylmethyl)phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461699-68-3P, N-[2-(Dimethylamino)ethyl]-2-[4-amino-3-[4-(1,3-benzoxazol-2-ylamino)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]propanamide 461699-69-4P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-ethyl-4-(4-methylphenyl)-1,3-thiazol-2-amine

461699-71-8P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-ethyl-4-(2-methylphenyl)-1,3-thiazol-2-amine 461699-72-9P, cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-ethyl-4-(3-methylphenyl)-1,3-thiazol-2-amine 461699-73-0P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1H-2-indolecarboxamide bismaleate 461699-76-3P 461699-79-6P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461699-84-3P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-fluoro-4-(trifluoromethyl)-, acetate 461699-86-5P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate 461699-88-7P, Benzenepropanamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate 461699-90-1P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-cyclopentylpropanamide diacetate 461699-92-3P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1,3-dimethyl-1H-5-pyrazolecarboxamide diacetate 461699-94-5P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-(2-thienyl)acetamide diacetate 461699-95-6P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-phenylacetamide 461699-96-7P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-(3,4-dimethoxyphenyl)acetamide 461699-97-8P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-phenoxypropanamide 461699-99-0P, 5-Isioxazolecarboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate 461700-01-6P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-pyridinecarboxamide triacetate 461700-03-8P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2,4-difluorobenzamide diacetate 461700-05-0P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2,5-difluoro-, acetate 461700-07-2P, 2-Furancarboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate 461700-08-3P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2,2-dimethylpropanamide 461700-09-4P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-cyanobenzamide 461700-11-8P, Cyclopropanecarboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate 461700-13-0P, 3-Pyridinecarboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-methyl-, acetate 461700-14-1P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-fluoro-3-methylbenzamide 461700-15-2P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-(dimethylamino)benzamide 461700-16-3P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2,3-difluoro-4-methylbenzamide 461700-18-5P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]isonicotinamide diacetate 461700-20-9P, 3-Pyridinecarboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate 461700-22-1P, 1H-Pyrrole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-, acetate 461700-24-3P, 3-Pyridinecarboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-

methoxyphenyl]-6-methyl-, acetate 461700-26-5P,  
Pyrazinecarboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate 461700-28-7P,  
N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-iodobenzamide diacetate 461700-29-8P,  
N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-bromobenzamide 461700-30-1P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-phenoxybenzamide 461700-31-2P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-fluorobenzamide 461700-32-3P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-chlorobenzamide 461700-33-4P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-methoxybenzamide 461700-34-5P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(trifluoromethoxy)benzamide 461700-35-6P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-nitrobenzamide 461700-36-7P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]benzo[b]thiophene-2-carboxamide 461700-37-8P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]benzo[b]furan-2-carboxamide 461700-38-9P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-methylbenzamide 461700-40-3P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(1,1-dimethylethyl)-, acetate 461700-42-5P, Benzoic acid, 4-[[[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]amino]carbonyl]-, methyl ester, acetate 461700-43-6P, 4-[[[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyanilino]carbonyl]benzoic acid 461700-45-8P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-chloro-, acetate 461700-47-0P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-bromo-, acetate 461700-49-2P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-methoxy-, acetate 461700-50-5P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-phenylbenzamide 461700-52-7P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-(trifluoromethyl)-, acetate 461700-54-9P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-(trifluoromethoxy)-, acetate 461700-55-0P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-methoxybenzamide 461700-56-1P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-(trifluoromethyl)benzamide 461700-58-3P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-3-(trifluoromethyl)-, acetate 461700-60-7P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-6-(trifluoromethyl)-, acetate 461700-62-9P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-5-(trifluoromethyl)-, acetate 461700-63-0P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-5-methylbenzamide 461700-64-1P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-chloro-2-fluorobenzamide 461700-65-2P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-benzoylbenzamide 461700-66-3P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-acetylbenzamide 461700-67-4P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-



d]pyrimidin-3-yl]-2-methoxyphenyl]-4-isopropylbenzamide  
461700-69-6P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-ethyl-, acetate  
461700-71-0P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-propyl-, acetate  
461700-73-2P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-cyclohexyl-, acetate  
461700-75-4P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-ethoxy-, acetate  
461700-77-6P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(methylsulfonyl)-, acetate  
461700-79-8P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-isopropoxybenzamide diacetate  
461700-81-2P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(1H-imidazol-1-yl)-, acetate  
461700-83-4P, Benzamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-, acetate  
461700-84-5P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-methoxybenzo[b]furan-2-carboxamide  
461700-86-7P, 2-Benzofurancarboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-bromo-, acetate  
461700-87-8P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-methylbenzo[b]furan-2-carboxamide  
461700-88-9P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-methylbenzo[b]furan-2-carboxamide  
461700-89-0P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-nitrobenzo[b]furan-2-carboxamide  
461700-91-4P, 2-Benzofurancarboxamide, 5-amino-N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate  
461700-93-6P, 2-Benzofurancarboxamide, 5-(acetylamino)-N-[4-[4-(acetylamino)-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate  
461700-95-8P, 2-Benzofurancarboxamide, 5-(acetylamino)-N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate  
461700-97-0P, 2-Benzofurancarboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-7-methyl-, acetate  
461700-99-2P, 2-Benzofurancarboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-7-methoxy-, acetate  
461701-00-8P, N-[4-[4-Amino-1-(1-methyltetrahydro-1H-pyrrol-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine  
461701-04-2P, N-[4-[4-Amino-1-[1-(2-methoxyethyl)tetrahydro-1H-pyrrol-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine  
461701-06-4P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-fluorophenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine  
461701-09-7P, Cis-3-[4-(Imidazo[1,2-a]pyridin-2-yl)phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine  
461701-11-1P, 1-[3-[4-Amino-3-[4-[(5,7-dimethyl-1,3-benzoxazol-2-yl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]tetrahydro-1H-pyrrol-1-yl]-2-(dimethylamino)-1-ethanone  
461701-13-3P, 1-[3-[4-Amino-3-[4-[(5,7-dimethyl-1,3-benzoxazol-2-yl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]tetrahydro-1H-pyrrol-1-yl]-2-methyl-2-(methylamino)-1-propanone  
461701-16-6P, N-[4-[4-Amino-1-(tetrahydro-1H-pyrrol-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine  
461701-20-2P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-7-isopropyl-1,3-benzoxazol-2-amine diacetate  
461701-23-5P 461701-25-7P, N-[4-[4-Amino-1-[1-(2-methoxyethyl)tetrahydro-1H-pyrrol-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-

3-yl]phenyl]-5-ethyl-1,3-benzoxazol-2-amine monoacetate  
461701-26-8P 461701-28-0P, N-[4-[4-Amino-1-[1-(2-methoxyethyl)tetrahydro-1H-pyrrol-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-methyl-1,3-benzoxazol-2-amine monoacetate  
461701-30-4P, N-[4-[4-Amino-1-[1-(2-methoxyethyl)tetrahydro-1H-pyrrol-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5-chloro-1,3-benzoxazol-2-amine monoacetate 461701-32-6P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide dimesylate  
461701-34-8P, N-[4-[4-Amino-1-(1-methyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]trans-2-phenyl-1-cyclopropanecarboxamide 461701-36-0P, N-[4-[4-Amino-1-(1-methyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(trifluoromethoxy)benzamide 461701-37-1P, cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-(1,3-oxazol-5-yl)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461701-39-3P, trans-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-5-fluoro-2-methoxyphenyl]-2,2-dimethyl-3-phenylpropanamide 461701-40-6P 461701-41-7P, 2-[[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]benzyl]amino]-1-ethanol 461701-42-8P  
2-[[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]benzyl]amino]-2-methyl-1-propanol 461701-43-9P, 4-[[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]benzyl]amino]-1-butanol 461701-44-0P, N-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]benzyl]-N',N'-dimethyl-1,2-ethanediamine 461701-45-1P, 1-[4-[[3-Methoxypropyl]amino]methyl]phenyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461701-46-2P, 1-[4-[[2-Methoxyethyl]amino]methyl]phenyl]-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461701-47-3P, 3-(4-Phenoxyphenyl)-1-[4-(1,3-thiazolan-3-ylmethyl)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461701-48-4P, 2-[[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]benzyl](2-hydroxyethyl)amino]-1-ethanol 461701-49-5P, N-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]benzyl]-N,N',N'-trimethyl-1,2-ethanediamine 461701-50-8P, 1-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]benzyl]-4-piperidinol 461701-51-9P, N-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]benzyl]-N,N',N'-trimethyl-1,3-propanediamine 461701-52-0P, [1-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]benzyl]-4-piperidyl]methanol 461701-53-1P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide dimaleate 461701-55-3P, N-[4-[4-Amino-1-(1-ethyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-56-4P, N-[4-[4-Amino-1-[1-(cyclopropylmethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-58-6P, Benzamide, N-[4-[4-amino-1-[1-(1H-pyrrol-1-ylmethyl)-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461701-59-7P, N-[4-[4-Amino-1-[1-(1H-2-imidazolylmethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-61-1P, Benzamide, N-[4-[4-amino-1-[1-[(1-methyl-1H-imidazol-2-yl)methyl]-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461701-63-3P, Benzamide, N-[4-[4-amino-1-[1-[(2-methyl-1H-imidazol-4-yl)methyl]-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461701-65-5P, Benzamide, N-[4-[4-amino-1-[1-[(4-methyl-1H-imidazol-5-yl)methyl]-4-

piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461701-66-6P,  
N-[4-[4-Amino-1-[1-(1,3-thiazol-2-ylmethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-67-7P, N-[4-[4-Amino-1-[1-[(5-hydroxymethyl)-2-furyl]methyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-68-8P, N-[4-[4-Amino-1-(1-methyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-69-9P,  
N-[4-[4-Amino-1-(1-isopropyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-71-3P, Benzamide,  
N-[4-[4-amino-1-[1-(2-methylpropyl)-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461701-72-4P, N-[4-[4-Amino-1-[1-(2-furylmethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-73-5P,  
N-[4-[4-Amino-1-[1-(3-furylmethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-74-6P, Benzamide,  
N-[4-[4-amino-1-[1-(1H-imidazol-1-ylmethyl)-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461701-75-7P, N-[4-[4-Amino-1-[1-(tetrahydro-2H-pyran-4-yl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-76-8P, tert-Butyl 4-[4-[4-amino-3-[4-[[2-fluoro-4-(trifluoromethyl)benzoyl]amino]-3-methoxyphenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidyl]-1-piperidinecarboxylate 461701-77-9P, N-[4-[4-Amino-1-[1-(tetrahydrothiophen-3-yl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-78-0P,  
N-[4-[4-Amino-1-(1-benzyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-80-4P, Benzamide, N-[4-[4-amino-1-[1-(2-pyridinylmethyl)-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461701-81-5P 461701-82-6P 461701-84-8P, Benzamide, N-[4-[4-amino-1-[1-[(1-methyl-1H-pyrrol-2-yl)methyl]-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461701-86-0P, Benzamide, N-[4-[4-amino-1-[1-[(5-methyl-2-furanyl)methyl]-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461701-87-1P,  
N-[4-[4-Amino-1-[1-(2-thienylmethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-89-3P 461701-91-7P,  
N-[4-[4-Amino-1-[1-(1-methylpiperidin-4-yl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide diacetate 461701-92-8P,  
N-[4-[4-Amino-1-[1-(tetrahydro-2H-thiopyran-4-yl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-93-9P, 4-[[4-[4-Amino-3-[4-[[2-fluoro-4-(trifluoromethyl)benzoyl]amino]-3-methoxyphenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]methyl]-1-pyridine-N-oxide 461701-94-0P, N-[4-[4-Amino-1-[1-(2-fluorobenzyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-95-1P, N-[4-[4-Amino-1-[1-(3-fluorobenzyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-96-2P,  
N-[4-[4-Amino-1-[1-(4-fluorobenzyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-97-3P, N-[4-[4-Amino-1-[1-[3-

(methylsulfanyl)propyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide  
 461701-98-4P, N-[4-[4-Amino-1-[1-[(5-methyl-2-thienyl)methyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461701-99-5P,  
 N-[4-[4-Amino-1-[1-(3-cyanobenzyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461702-00-1P, N-[4-[4-Amino-1-[1-(4-cyanobenzyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461702-01-2P,  
 N-[4-[4-Amino-1-[1-(2-cyanobenzyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461702-02-3P, N-[4-[4-Amino-1-[1-(4-methoxybenzyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461702-03-4P,  
 N-[4-[4-Amino-1-[1-(1-acetylpiperidin-4-yl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461702-05-6P, Benzamide,  
 N-[4-[4-amino-1-[1-[(3-methyl-1H-pyrazol-1-yl)methyl]-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate 461702-06-7P, Methyl  
 2-[4-[4-amino-3-[4-[[2-fluoro-4-(trifluoromethyl)benzoyl]amino]-3-methoxyphenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]acetate 461702-07-8P 461702-10-3P, Benzamide, N-[4-[4-amino-1-[1-(2-methoxyethyl)-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)-, acetate  
 461702-11-4P, N-[4-[4-Amino-1-[1-(cyanomethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-fluoro-4-(trifluoromethyl)benzamide 461702-13-6P, 1-Piperidineacetamide,  
 4-[4-amino-3-[4-[[2-fluoro-4-(trifluoromethyl)benzoyl]amino]-3-methoxyphenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-, acetate 461702-15-8P 461702-17-0P, N-[4-[4-Amino-1-[1-[(2-methyl-1H-imidazol-4-yl)methyl]-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide dimaleate  
 461702-20-5P 461702-23-8P, N-[4-[4-Amino-1-[1-(2-fluoroethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide dimaleate 461702-25-0P,  
 N-[4-[4-Amino-1-[1-(2,2-difluoroethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide dimaleate 461702-28-3P, N-[4-[4-Amino-1-(1-ethyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-31-8P, 1H-Indole-2-carboxamide,  
 N-[4-[4-amino-1-[1-[(3-methyl-1H-pyrazol-1-yl)methyl]-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-, acetate 461702-33-0P, N-[4-[4-Amino-1-[1-(3-furylmethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein kinase inhibitor; prepn. of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)

IT 461702-35-2P, N-[4-[4-Amino-1-[1-(tetrahydro-2H-pyran-4-yl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-36-3P, N-[4-[4-Amino-1-[1-(1-acetylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-indole-2-carboxamide 461702-37-4P  
 461702-38-5P, N-[4-[4-Amino-1-[3-(4-methylpiperazino)propyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-41-0P, N-[4-[4-Amino-1-(3-morpholinopropyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-



1-methyl-1H-2-indolecarboxamide 461702-43-2P, N-[4-[4-Amino-1-[3-(1H-1-imidazolyl)propyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-46-5P, N-[4-[4-Amino-1-[1-[(1-methyl-1H-imidazol-2-yl)methyl]tetrahydro-1H-pyrrol-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-47-6P, N-[4-[4-Amino-1-(1-isopropyltetrahydro-1H-pyrrol-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-48-7P, N-[4-[4-Amino-1-[1-(2-methoxyethyl)tetrahydro-1H-pyrrol-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-49-8P, N-[4-[4-Amino-1-[1-(1H-imidazol-4-ylmethyl)tetrahydro-1H-pyrrol-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-50-1P, N-[4-[4-Amino-1-[1-[(3-methyl-1H-pyrazol-4-yl)methyl]tetrahydro-1H-pyrrol-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methyl-1H-2-indolecarboxamide 461702-51-2P 461702-52-3P 461702-53-4P, N-[4-[4-Amino-1-[1-(2-methoxyethyl)tetrahydro-1H-pyrrol-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-7-isopropyl-1,3-benzoxazol-2-amine 461702-56-7P, cis-Methyl 4-[4-amino-3-[4-[(5,7-dimethyl-1,3-benzoxazol-2-yl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-cyclohexanecarboxylate 461702-57-8P, cis-4-[4-Amino-3-[4-[(5,7-dimethyl-1,3-benzoxazol-2-yl)amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-cyclohexanecarboxylic acid 461702-58-9P, cis-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-(2-pyrimidinylamino)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 461702-61-4P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-[2-(4-methyl-1-piperazinyl)-4-pyridinyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, acetate 461702-64-7P 461702-65-8P, (S)-N-[4-[4-Amino-1-[1-(2-methoxyethyl)-3-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-5,7-dimethyl-1,3-benzoxazol-2-amine 461702-72-7P, Cis-2-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]anilino]-1,3-benzoxazole-5-carboxamide triacetate 461702-75-0P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-(phenylmethoxy)-, monoacetate 461702-77-2P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-(methylsulfonyl)-, monoacetate 461702-79-4P, 1H-Indole-5-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, monoacetate 461702-81-8P, 1H-Indole-6-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-, monoacetate 461702-83-0P, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(phenylmethoxy)-, monoacetate 461702-85-2P,  $\beta$ -Alanine, N-[3-[4-[(1H-indol-2-ylcarbonyl)amino]-3-methoxyphenyl]-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, monoacetate 461702-87-4P, 1H-Indole-1-propanoic acid, 2-[[[4-[4-[(2-carboxyethyl)amino]-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]amino]carbonyl]-, monoacetate 461702-89-6P, 1H-Indole-1-acetamide, 2-[[[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]amino]carbonyl]-N,N-dimethyl-, monoacetate 461702-91-0P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-hydroxy-1H-2-indolecarboxamide monoacetate 461702-93-2P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-hydroxy-1H-2-indolecarboxamide monoacetate 461702-95-4P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-7-amino-1H-2-indolecarboxamide monoacetate 461702-97-6P, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1H-3-indolecarboxamide monoacetate 461703-00-4P,

N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1H-4-indolecarboxamide monoacetate 471925-60-7P,  
 trans-1-[4-(4-Methylpiperazino)cyclohexyl]-3-(6-phenoxy-3-pyridyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine maleate 471925-63-0P,  
 Cis-3-[4-[(1H-4-Imidazolylmethyl)amino]-3-methoxyphenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine acetate 471925-65-2P, Cis-3-[4-[(1H-2-Indolylmethyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 471925-69-6P 471925-70-9P 471925-71-0P  
 471925-72-1P 471925-73-2P 471925-74-3P 471925-75-4P  
 471925-76-5P 471925-77-6P 471925-78-7P 471925-79-8P  
 471925-80-1P 471925-81-2P 471925-87-8P 471925-88-9P,  
 N-[4-[4-Amino-1-(1-methyl-4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(trifluoromethyl)benzamide trimaleate 471925-93-6P, N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-(2-methoxyphenyl)propanamide 471925-94-7P, N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-(4-methoxyphenyl)propanamide 471925-95-8P,  
 N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-(3-methoxyphenyl)propanamide 471925-96-9P, N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-(4-methylphenyl)propanamide 471925-97-0P, N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-(4-fluorophenyl)propanamide 471925-98-1P,  
 N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-3-(3,4-difluorophenyl)propanamide 471926-08-6P, Trans-3-[3-Methoxy-4-[(5-methyl-2-furyl)methyl]aminophenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine dimaleate 471926-09-7P  
 471926-14-4P, Cis-3-[3-[2-(1H-2-Imidazolyl)phenoxy]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 471926-16-6P, Cis-N-[4-[4-Amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-anilinoacetamide 471926-23-5P, N,N-Methoxymethyl-2-[3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]acetamide 471926-25-7P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-3-(1H-4-imidazolyl)-1-propanone 471926-26-8P, 1-[3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-azetanyl]-2-[4-(2-methoxyethyl)piperidino]-1-ethanone 471926-61-1P 471926-74-6P  
 471926-76-8P 471926-82-6P 471927-20-5P, Trans-3-[3-Methoxy-4-[[3-methyl-1H-4-pyrazolyl)methyl]amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 471927-25-0P, Trans-3-[4-[(1H-2-Indolylmethyl)amino]phenyl]-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 471927-28-3P,  
 Trans-1-[4-(4-Methylpiperazino)cyclohexyl]-3-[4-[[5-methyl-1H-4-pyrazolyl)methyl]amino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine diacetate 471927-44-3P, N-(1H-2-Imidazolyl)-2-[4-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidino]acetamide 471927-45-4P, trans-N-[4-[4-Amino-1-[1-(1H-2-imidazolylmethyl)-4-piperidyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-phenyl-1-cyclopropanecarboxamide 471927-46-5P,  
 Trans-N-[4-[4-Amino-1-[(4-hydroxy-4-piperidyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-2-phenyl-1-cyclopropanecarboxamide  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (protein kinase inhibitor; prepn. of [(hetero)aryl]pyrazolo[3,4-

d]pyrimidinamines as protein kinase inhibitors with  
antiangiogenic properties)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR  
THIS RECORD. ALL CITATIONS AVAILABLE IN  
THE RE FORMAT

L32 ANSWER 18 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:658109 HCAPLUS

DOCUMENT NUMBER: 137:201312

TITLE: Preparation of N-(piperidin-4-yl) amides for  
treating a chemokine mediated  
diseases

INVENTOR(S): Brough, Stephen; McInally, Thomas; Perry,  
Matthew; Springthorpe, Brian

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.

SOURCE: PCT Int. Appl., 53 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002066460	A1	20020829	WO 2002-SE269	20020218
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1363902	A1	20031126	EP 2002-711619	20020218
EP 1363902	B1	20040915		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004518742	T2	20040624	JP 2002-565975	20020218
AT 276246	E	20041015	AT 2002-711619	20020218
US 2004102483	A1	20040527	US 2003-468179	20030818
US 6958350	B2	20051025		
PRIORITY APPLN. INFO.:				
			GB 2001-4050	A
				20010219
			WO 2002-SE269	W
				20020218



OTHER SOURCE(S): MARPAT 137:201312  
GI




AB The title compds. [I; R1 = (un)substituted Ph; R2-R4 = H, alkyl; R5 = alkyl, aryl, heteroaryl, etc.; X = (CH<sub>2</sub>)<sub>n</sub>; n = 1-4; Y = 2,4-, 2,5- or 3,5-linking 5-membered heteroaryl comprising 2-3 heteroatoms selected from N, O, and S], useful in therapy, esp. for the **treatment of chemokine receptor related diseases and conditions**, were prepd. Thus, a 2-step synthesis of the propionamide II, starting with 1-(3,4-dichlorobenzyl)piperidin-4-ylamine and Me 3-chlorocarbonylpropionate, was given. The exemplified compds. I were found to be antagonists of the eotaxin mediated [Ca<sup>2+</sup>]<sub>i</sub> in human eosinophils and/or antagonists of the MIP-1 $\alpha$  mediated [Ca<sup>2+</sup>]<sub>i</sub> in human monocytes (no data). Certain exemplified compds. I were found to be antagonists of the eotaxin mediated human eosinophil chemotaxis (no data).

IT 453524-35-1P 453524-38-4P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of N-(piperidin-4-yl) amides for **treating a chemokine mediated diseases**)


RN 453524-35-1 HCAPLUS

CN 4-Thiazoleacetamide, N-[1-[(3,4-dichlorophenyl)methyl]-4-piperidinyl]-2-(phenylamino)- (9CI) (CA INDEX NAME)




RN 453524-38-4 HCAPLUS


CN 4-Thiazoleacetamide, N-[1-[(3,4-dichlorophenyl)methyl]-4-piperidinyl]-5-methyl-2-(phenylamino)- (9CI) (CA INDEX NAME)



IT 259654-76-7 453524-57-7  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (prepn. of N-(piperidin-4-yl) amides for **treating a**  
**chemokine mediated diseases**)  
 RN 259654-76-7 HCAPLUS  
 CN 4-Thiazoleacetic acid, 5-methyl-2-(phenylamino)-, methyl ester (9CI)  
 (CA INDEX NAME)



RN 453524-57-7 HCAPLUS  
 CN 4-Thiazoleacetic acid, 2-(phenylamino)-, ethyl ester (9CI) (CA  
 INDEX NAME)



IC ICM C07D401-12  
 ICS C07D401-14; C07D405-12; C07D405-14; C07D411-12; C07D411-14;  
 C07D413-12; C07D413-14; C07D417-12; C07D417-14; C07D419-12;  
 C07D419-14; A61K031-4525; A61K031-4535; A61K031-4545;  
 A61P011-00; A61P017-00; A61P029-00; A61P037-00  
 CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))  
 Section cross-reference(s): 1  
 IT Eotaxin  
 Macrophage inflammatory protein 1 $\alpha$   
 RL: BSU (Biological study, unclassified); BIOL  
 (Biological study)  
 (prepn. of N-(piperidin-4-yl) amides as antagonists of the  
 eotaxin mediated [Ca<sup>2+</sup>]<sub>i</sub> in human eosinophils and/or antagonists  
 of the MIP-1 $\alpha$  mediated [Ca<sup>2+</sup>]<sub>i</sub> in human monocytes)  
 IT Human  
 (prepn. of N-(piperidin-4-yl) amides for **treating a**  
**chemokine mediated diseases**)  
 IT Chemokine receptors  
 RL: BSU (Biological study, unclassified); BIOL  
 (Biological study)  
 (prepn. of N-(piperidin-4-yl) amides for **treating a**  
**chemokine mediated diseases**)  
 IT 453524-44-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of N-(piperidin-4-yl) amides for treating a chemokine mediated diseases)

IT 453523-76-7P 453523-78-9P 453523-80-3P 453523-82-5P  
453523-84-7P 453523-86-9P 453523-88-1P 453523-90-5P  
453523-92-7P 453523-94-9P 453523-96-1P 453523-98-3P  
453523-99-4P 453524-00-0P 453524-01-1P 453524-02-2P  
453524-03-3P 453524-04-4P 453524-05-5P 453524-06-6P  
453524-07-7P 453524-08-8P 453524-09-9P 453524-10-2P  
453524-11-3P 453524-12-4P 453524-13-5P 453524-14-6P  
453524-15-7P 453524-16-8P 453524-17-9P 453524-18-0P  
453524-19-1P 453524-20-4P 453524-21-5P 453524-22-6P  
453524-23-7P 453524-24-8P 453524-25-9P 453524-26-0P  
453524-27-1P 453524-28-2P 453524-29-3P 453524-32-8P  
453524-35-1P 453524-38-4P 453524-41-9P  
453524-45-3P 453524-46-4P 453524-47-5P 453524-48-6P  
453524-49-7P 453524-50-0P 453524-51-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of N-(piperidin-4-yl) amides for treating a chemokine mediated diseases)

IT 100-52-7, Benzaldehyde, reactions 103-72-0, Isothiocyanatobenzene  
1490-25-1, Methyl 3-chlorocarbonylpropionate 2740-81-0,  
1-Chloro-2-isothiocyanatobenzene 36239-09-5, Ethyl malonyl  
chloride 50541-93-0, 1-(Phenylmethyl)-4-piperidinamine  
92539-28-1 160358-08-7 259654-76-7 453524-57-7

RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of N-(piperidin-4-yl) amides for treating a chemokine mediated diseases)

IT 453524-52-2P 453524-53-3P 453524-54-4P 453524-55-5P  
453524-56-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of N-(piperidin-4-yl) amides for treating a chemokine mediated diseases)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR  
THIS RECORD. ALL CITATIONS AVAILABLE IN  
THE RE FORMAT

L32 ANSWER 19 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:504649 HCAPLUS

DOCUMENT NUMBER: 137:83638

TITLE: Concomitant drugs of p38MAP kinase inhibitors  
and/or TNF- $\alpha$  prodn. inhibitors with other  
specified agents

INVENTOR(S): Ohkawa, Shigenori; Naruo, Kenichi; Miwatashi,  
Seiji

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan

SOURCE: PCT Int. Appl., 278 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
-----				

Ross Shipe EIC 1700 Remsen 4B31 571/272-6018

WO 2002051442 A1 20020704 WO 2001-JP11353 200112  
25

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD,  
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO,  
NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ,  
BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,  
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,  
SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
SN, TD, TG

CA 2436739 AA 20020704 CA 2001-2436739 200112  
25

JP 2002302458 A2 20021018 JP 2001-392778 200112  
25

EP 1354603 A1 20031022 EP 2001-271876 200112  
25

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,  
PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

US 2004097555 A1 20040520 US 2003-451839 200306  
25

PRIORITY APPLN. INFO.: JP 2000-396220 A 200012  
26

JP 2001-27572 A 200102  
02

WO 2001-JP11353 W 200112  
25

## OTHER SOURCE(S): MARPAT 137:83638


AB Drugs comprising a combination of one or more p38MAP kinase inhibitors and/or TNF- $\alpha$  prodn. inhibitors with one or more agents selected from the group consisting of: (1) nonsteroidal anti-inflammatory agents; (2) disease-modification antirheumatics; (3) anti-cytokine drugs; (4) immunomodulators; (5) steroidal drugs; and (6) c-JUN N-terminal kinase inhibitors. These concomitant drugs are useful as preventives and remedies for diseases such as rheumatism and arthritis and other diseases. For example, tablets contg. [4-(3,5-dimethylphenyl)-5-(2-phenylmethoxy-4-pyridyl)-1,3-thiazol-2-yl]amine 50 mg/tablet are administered with tablets contg. rofecoxib 5 mg/tablet.

IT 97422-54-3P 97422-55-4P 97422-56-5P  
224038-79-3P 224038-87-3P


RL: SPN (Synthetic preparation); THU (Therapeutic use);  
BIOL (Biological study); PREP (Preparation); USES (Uses)  
(combination drugs contg. p38MAP kinase inhibitors and/or  
TNF- $\alpha$  prodn. inhibitors with other specified agents)

RN 97422-54-3 HCAPLUS


CN 2-Thiazolamine, 4-(4-methoxyphenyl)-N-phenyl-5-(3-pyridinyl)- (9CI)  
(CA INDEX NAME)




RN 97422-55-4 HCAPLUS

CN 2-Thiazolamine, N-phenyl-5-(3-pyridinyl)-4-(3,4,5-trimethoxyphenyl)-  
(9CI) (CA INDEX NAME)

RN 97422-56-5 HCAPLUS


CN Phenol, 4-[2-(phenylamino)-5-(3-pyridinyl)-4-thiazolyl]- (9CI) (CA  
INDEX NAME)

RN 224038-79-3 HCAPLUS

CN 2-Thiazolamine, 4-(4-methoxyphenyl)-N-phenyl-5-(4-pyridinyl)- (9CI)  
(CA INDEX NAME)

RN 224038-87-3 HCAPLUS

CN Acetamide, N-[4-(4-methoxyphenyl)-5-(4-pyridinyl)-2-thiazolyl]-N-  
phenyl- (9CI) (CA INDEX NAME)



IC ICM A61K045-06  
 ICS A61K031-4439; A61K031-4545; A61K031-497; A61K031-506;  
 A61K031-5377; A61P001-04; A61P001-16; A61P003-10; A61P007-06;  
 A61P009-02; A61P009-04; A61P009-10; A61P011-00; A61P011-06;  
 A61P013-12; A61P017-04; A61P017-06; A61P019-02; A61P019-10

CC 63-6 (Pharmaceuticals)  
 Section cross-reference(s): 1

IT **Inflammation**  
 (Crohn's disease; combination drugs contg. p38MAP  
 kinase inhibitors and/or TNF- $\alpha$  prodn. inhibitors with other  
 specified agents)

IT Addison's disease  
 Allergy  
 Allergy inhibitors  
 Alzheimer's disease  
 Anti-Alzheimer's agents  
 Anti-inflammatory agents  
 Antianginal agents  
 Antiarteriosclerotics  
 Antiarthritics  
 Antiasthmatics  
 Antidiabetic agents  
 Antihypertensives  
 Antihypotensives  
 Antiparkinsonian agents  
 Antitumor agents  
 Antiviral agents  
 Arteriosclerosis  
 Arthritis  
**Asthma**  
 Cachexia  
 Cardiovascular agents  
 Diabetes mellitus  
 Hypertension  
 Immunomodulators  
 Meningitis  
 Multiple sclerosis  
 Neoplasm  
 Osteoarthritis  
 Osteoporosis  
 Parkinson's disease  
**Psoriasis**  
 Rheumatic diseases  
 Silicosis  
 Transplant rejection  
 Tuberculosis  
 (combination drugs contg. p38MAP kinase inhibitors and/or  
 TNF- $\alpha$  prodn. inhibitors with other specified agents)

IT Tumor necrosis factors  
 RL: BSU (Biological study, unclassified); BIOL

(Biological study)  
 (combination drugs contg. p38MAP kinase inhibitors and/or  
 TNF- $\alpha$  prodn. inhibitors with other specified agents)

IT Steroids, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study)  
 ; USES (Uses)  
 (combination drugs contg. p38MAP kinase inhibitors and/or  
 TNF- $\alpha$  prodn. inhibitors with other specified agents)

IT Cytokines  
 RL: THU (Therapeutic use); BIOL (Biological study)  
 ; USES (Uses)  
 (inhibitors; combination drugs contg. p38MAP kinase inhibitors  
 and/or TNF- $\alpha$  prodn. inhibitors with other specified agents)

IT 165245-96-5, p38 Kinase  
 RL: BSU (Biological study, unclassified); BIOL  
 (Biological study)  
 (combination drugs contg. p38MAP kinase inhibitors and/or  
 TNF- $\alpha$  prodn. inhibitors with other specified agents)

IT 97422-32-7P 97422-44-1P 97422-45-2P 99478-69-0P 99478-80-5P  
 224038-59-9P  
 RL: PAC (Pharmacological activity); SPN (Synthetic  
 preparation); THU (Therapeutic use); BIOL (Biological  
 study); PREP (Preparation); USES (Uses)  
 (combination drugs contg. p38MAP kinase inhibitors and/or  
 TNF- $\alpha$  prodn. inhibitors with other specified agents)

IT 303162-57-4 303162-58-5 303162-59-6 303162-60-9 303162-61-0  
 303162-62-1  
 RL: PAC (Pharmacological activity); THU (Therapeutic  
 use); BIOL (Biological study); USES (Uses)  
 (combination drugs contg. p38MAP kinase inhibitors and/or  
 TNF- $\alpha$  prodn. inhibitors with other specified agents)

IT 97422-27-0P 97422-28-1P 97422-29-2P 97422-30-5P 97422-31-6P  
 97422-33-8P 97422-34-9P 97422-35-0P 97422-36-1P 97422-37-2P  
 97422-38-3P 97422-39-4P 97422-41-8P 97422-42-9P 97422-43-0P  
 97422-46-3P 97422-47-4P 97422-48-5P 97422-49-6P 97422-50-9P  
 97422-51-0P 97422-52-1P 97422-53-2P 97422-54-3P  
 97422-55-4P 97422-56-5P 97422-57-6P  
 97422-58-7P 97422-59-8P 97422-60-1P 97422-61-2P 97422-62-3P  
 97422-63-4P 97422-64-5P 97422-65-6P 97422-66-7P 97422-67-8P  
 97422-68-9P 97422-69-0P 97422-70-3P 97422-71-4P 97422-72-5P  
 97422-73-6P 97422-74-7P 97422-75-8P 97422-76-9P 97422-77-0P  
 97422-78-1P 97422-79-2P 97422-80-5P 97422-81-6P 97422-82-7P  
 97422-83-8P 97422-84-9P 97422-85-0P 97422-86-1P 97422-87-2P  
 97422-88-3P 97422-89-4P 97443-15-7P 97443-16-8P 97443-17-9P  
 99478-71-4P 99478-73-6P 99478-74-7P 99478-75-8P 99478-76-9P  
 99478-78-1P 99478-79-2P 99478-81-6P 99478-82-7P 99478-83-8P  
 99478-84-9P 99478-85-0P 99478-86-1P 99478-87-2P 99478-88-3P  
 99478-89-4P 99496-91-0P 99496-92-1P 99496-93-2P 223914-57-6P  
 223914-58-7P 223914-59-8P 223914-63-4P 224037-86-9P  
 224037-87-0P 224037-88-1P 224037-89-2P 224037-90-5P  
 224037-91-6P 224037-92-7P 224037-93-8P 224037-94-9P  
 224037-95-0P 224037-96-1P 224037-98-3P 224037-99-4P  
 224038-00-0P 224038-01-1P 224038-02-2P 224038-03-3P  
 224038-04-4P 224038-05-5P 224038-06-6P 224038-07-7P  
 224038-08-8P 224038-09-9P 224038-11-3P 224038-13-5P 224038-1  
 4-6P 224038-15-7P 224038-16-8P 224038-17-9P 224038-18-0P  
 224038-19-1P 224038-20-4P 224038-21-5P 224038-22-6P  
 224038-23-7P 224038-24-8P 224038-25-9P 224038-26-0P  
 224038-27-1P 224038-28-2P 224038-29-3P 224038-30-6P  
 224038-31-7P 224038-32-8P 224038-33-9P 224038-34-0P  
 224038-35-1P 224038-36-2P 224038-38-4P 224038-39-5P  
 224038-40-8P 224038-41-9P 224038-42-0P 224038-43-1P



224038-44-2P	224038-45-3P	224038-46-4P	224038-47-5P
224038-48-6P	224038-49-7P	224038-50-0P	224038-51-1P
224038-52-2P	224038-53-3P	224038-54-4P	224038-55-5P
224038-56-6P	224038-57-7P	224038-58-8P	224038-60-2P
224038-61-3P	224038-62-4P	224038-63-5P	224038-64-6P
224038-65-7P	224038-66-8P	224038-67-9P	224038-68-0P
224038-69-1P	224038-70-4P	224038-71-5P	224038-72-6P
224038-73-7P	224038-74-8P	224038-75-9P	224038-76-0P
224038-77-1P	224038-78-2P	224038-79-3P	224038-80-6P
224038-81-7P	224038-82-8P	224038-83-9P	224038-84-0P
224038-85-1P	224038-86-2P	224038-87-3P	224038-88-4P
224038-89-5P	224038-90-8P	224038-91-9P	224038-92-0P
224038-93-1P	224038-94-2P	224038-95-3P	224038-96-4P
224038-97-5P	224038-98-6P	224038-99-7P	224039-00-3P
224039-01-4P	224039-02-5P	224039-03-6P	224039-04-7P
224039-05-8P	224039-06-9P	224039-07-0P	224039-08-1P
224039-09-2P	224039-10-5P	224039-11-6P	224039-12-7P
224039-13-8P	224039-14-9P	224039-15-0P	224039-16-1P
224039-18-3P	224039-19-4P	224039-20-7P	224039-21-8P
224039-22-9P	224039-23-0P	224039-24-1P	224039-25-2P
224039-26-3P	224039-27-4P	224039-28-5P	224039-30-9P
224039-31-0P	224039-32-1P	224039-33-2P	224039-34-3P
224039-36-5P	224039-37-6P	224039-38-7P	224039-39-8P
224039-40-1P	224039-42-3P	224039-44-5P	224039-46-7P

RL: SPN (Synthetic preparation); THU (Therapeutic use);  
 BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (combination drugs contg. p38MAP kinase inhibitors and/or  
 TNF- $\alpha$  prodn. inhibitors with other specified agents)

IT 224039-49-0P	224039-51-4P	224039-54-7P	224039-55-8P
224039-56-9P	224039-57-0P	224039-58-1P	224039-59-2P
224039-60-5P	224039-61-6P	224039-63-8P	224039-64-9P
224039-65-0P	224039-66-1P	224039-67-2P	224039-68-3P
224039-70-7P	224039-72-9P	224039-73-0P	224039-74-1P
224039-76-3P	224039-77-4P	224039-78-5P	224039-79-6P
224039-81-0P	224039-82-1P	224039-83-2P	224039-85-4P
224039-86-5P	224039-87-6P	224039-88-7P	224039-90-1P
224039-91-2P	224039-92-3P	224039-93-4P	224039-95-6P
224039-96-7P	224039-97-8P	224039-99-0P	224040-00-0P
224040-01-1P	224040-02-2P	224040-03-3P	224040-04-4P
224040-06-6P	224040-07-7P	224040-08-8P	224040-10-2P
224040-11-3P	224040-12-4P	224040-13-5P	224040-14-6P
224040-16-8P	224040-17-9P	224040-18-0P	224040-19-1P
224040-21-5P	224040-22-6P	224040-23-7P	224040-24-8P
224040-26-0P	224040-27-1P	224040-28-2P	224040-30-6P
224040-31-7P	224040-33-9P	224040-34-0P	224040-36-2P
224040-37-3P	224040-38-4P	224040-40-8P	224040-41-9P
224040-42-0P	224040-43-1P	224040-44-2P	224040-45-3P
224040-46-4P	224040-47-5P	224040-57-7P	252198-63-3P
252198-66-6P	252198-74-6P	252198-75-7P	252198-97-3P
284486-00-6P	303162-67-6P	303162-68-7P	303162-69-8P
303162-70-1P	303162-71-2P	303162-72-3P	303162-73-4P
303162-74-5P	303162-75-6P	303162-76-7P	303162-77-8P
303162-78-9P	303162-79-0P	303162-80-3P	303162-81-4P
303162-82-5P	303162-84-7P	303162-85-8P	303162-86-9P
303162-87-0P	303162-88-1P	303162-89-2P	303162-90-5P
303162-91-6P	303162-92-7P	303162-93-8P	303162-94-9P
303162-95-0P	303162-96-1P	303162-97-2P	303162-98-3P
303162-99-4P	303163-00-0P	303163-01-1P	303163-02-2P
303163-03-3P	303163-04-4P	303163-05-5P	303163-06-6P
303163-07-7P	303163-08-8P	303163-09-9P	303163-10-2P
303163-11-3P	303163-12-4P	303163-13-5P	303163-14-6P
303163-15-7P	303163-16-8P	303163-17-9P	303163-18-0P

303163-19-1P	303163-20-4P	303163-21-5P	303163-22-6P
303163-23-7P	303163-24-8P	303163-25-9P	303163-26-0P
303163-27-1P	303163-28-2P	303163-29-3P	303163-30-6P
303163-31-7P	303163-32-8P	303163-33-9P	303163-34-0P
303163-35-1P	303163-36-2P	303163-37-3P	303163-38-4P
303163-39-5P	303163-40-8P	303163-41-9P	303163-42-0P
303163-43-1P	303163-44-2P	303787-77-1P	303787-98-6P
325767-68-8P	325767-69-9P	325767-71-3P	325767-72-4P
325767-73-5P	325767-74-6P	325767-75-7P	325767-76-8P
325767-77-9P	325767-79-1P	325767-80-4P	325767-81-5P
325767-82-6P	325767-83-7P	325767-84-8P	325767-85-9P
325767-86-0P	325767-87-1P	325767-88-2P	325767-89-3P
325767-90-6P	325767-91-7P	325767-92-8P	325767-93-9P
325767-94-0P	325767-95-1P	325767-96-2P	325767-97-3P
325767-99-5P	325768-00-1P	325768-02-3P	325768-03-4P
325768-04-5P	325768-05-6P	325768-06-7P	325768-07-8P
325768-08-9P	325768-09-0P	325768-10-3P	325768-11-4P
325768-12-5P	325768-13-6P	325768-14-7P	325768-15-8P
325768-16-9P	325768-17-0P	325768-18-1P	325768-19-2P
325768-20-5P	325768-21-6P	325768-22-7P	325768-23-8P
325768-24-9P	325768-25-0P	325768-27-2P	325768-28-3P
325768-29-4P	325768-30-7P	325768-31-8P	325768-32-9P
325768-33-0P	325768-34-1P	325768-35-2P	325768-36-3P
325768-37-4P	325768-38-5P	325768-40-9P	325768-41-0P
325768-42-1P	325768-43-2P	325768-44-3P	

RL: SPN (Synthetic preparation); THU (Therapeutic use);  
 BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (combination drugs contg. p38MAP kinase inhibitors and/or  
 TNF- $\alpha$  prodn. inhibitors with other specified agents)

IT	325768-45-4P	325768-46-5P	325768-47-6P	325768-48-7P
	325768-49-8P	325768-50-1P	325768-51-2P	325768-52-3P
	325768-53-4P	325768-54-5P	325768-55-6P	325768-56-7P
	325768-57-8P	325768-58-9P	325768-59-0P	325768-60-3P
	325768-61-4P	325768-62-5P	325768-63-6P	325768-64-7P
	325768-65-8P	325768-66-9P	325768-67-0P	325768-68-1P
	325768-69-2P	325768-70-5P	325768-71-6P	325768-72-7P
	325768-73-8P	325768-75-0P	325768-76-1P	325768-77-2P
	325768-78-3P	325768-79-4P	325768-80-7P	325768-81-8P
	325768-82-9P	325768-83-0P	325768-84-1P	325768-85-2P
	325768-86-3P	325768-87-4P	325768-88-5P	325768-89-6P
	325768-90-9P	325768-91-0P	325768-92-1P	325768-93-2P
	325768-94-3P	325768-95-4P	325768-96-5P	325768-97-6P
	325768-98-7P	325768-99-8P	325769-00-4P	325769-01-5P
	325769-02-6P	325769-03-7P	325769-04-8P	325769-05-9P
	325769-06-0P	325769-07-1P	325769-08-2P	325769-09-3P
	325769-10-6P	325769-11-7P	325769-12-8P	325769-13-9P
	325769-14-0P	325769-15-1P	325769-16-2P	325769-17-3P
	325769-18-4P	325769-19-5P	325769-20-8P	325769-21-9P
	325769-22-0P	325769-23-1P	325769-25-3P	325769-26-4P
	325769-27-5P	325769-28-6P	325769-29-7P	325769-30-0P
	325769-31-1P	325769-32-2P	325769-33-3P	325769-34-4P
	325769-35-5P	325769-36-6P	325769-37-7P	325769-38-8P
	325769-39-9P	325769-40-2P	325769-41-3P	325769-42-4P
	325769-43-5P	325769-44-6P	325769-45-7P	325769-46-8P
	325769-47-9P	325769-48-0P	325769-49-1P	325769-50-4P
	325769-51-5P	325769-52-6P	325769-53-7P	325769-54-8P
	325769-55-9P	325769-56-0P	325769-57-1P	325769-58-2P
	325769-59-3P	325769-60-6P	325769-61-7P	325769-62-8P
	325769-63-9P	325769-64-0P	325769-65-1P	325769-66-2P
	325769-67-3P	325769-68-4P	325769-69-5P	325769-70-8P
	325769-71-9P	325769-73-1P	325769-74-2P	325769-75-3P
	325769-76-4P	325769-77-5P	325769-78-6P	325769-79-7P

325769-80-0P 325769-81-1P 325769-82-2P 325769-83-3P  
 325769-84-4P 325769-85-5P 325769-86-6P 325769-87-7P  
 325769-88-8P 325769-89-9P 325769-91-3P 325769-92-4P  
 325769-93-5P 325769-95-7P 325769-96-8P 325769-97-9P  
 325769-98-0P 325769-99-1P 325770-00-1P 325770-01-2P  
 325770-02-3P 325770-03-4P 325770-09-0P 325770-10-3P  
 325770-11-4P 325770-12-5P 325770-13-6P 325770-14-7P  
 325770-15-8P 325770-16-9P 325770-18-1P 325770-19-2P  
 325770-20-5P 325770-21-6P 325770-22-7P 325770-23-8P  
 325770-24-9P 325770-25-0P 325770-26-1P 325770-27-2P  
 325770-28-3P 325770-29-4P 325770-30-7P 439914-34-8P  
 439914-35-9P 439914-36-0P 439914-37-1P 439914-40-6P  
 439914-41-7P 439914-43-9P

RL: SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)

(combination drugs contg. p38MAP kinase inhibitors and/or

TNF- $\alpha$  prodn. inhibitors with other specified agents)

IT 162011-90-7, Rofecoxib 303162-64-3 439914-42-8 439914-44-0  
 439914-45-1 439914-46-2 439914-47-3 439914-49-5 439914-51-9  
 439914-53-1 439914-55-3 439914-58-6 439914-60-0 439914-61-1  
 439914-62-2 439914-64-4 439914-66-6 439914-68-8 439914-69-9  
 439914-70-2 439914-72-4 439914-74-6 439914-76-8 439914-78-0  
 439914-80-4 439914-81-5 439914-83-7 439914-84-8 439914-85-9  
 439914-86-0

RL: THU (Therapeutic use); BIOL (Biological study)

; USES (Uses)

(combination drugs contg. p38MAP kinase inhibitors and/or

TNF- $\alpha$  prodn. inhibitors with other specified agents)

IT 289898-51-7, c-JUN N-terminal kinase

RL: BSU (Biological study, unclassified); BIOL

(Biological study)

(inhibitors; combination drugs contg. p38MAP kinase inhibitors

and/or TNF- $\alpha$  prodn. inhibitors with other specified agents)

REFERENCE COUNT: 58 THERE ARE 58 CITED REFERENCES AVAILABLE  
 FOR THIS RECORD. ALL CITATIONS AVAILABLE  
 IN THE RE FORMAT

L32 ANSWER 20 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:293390 HCAPLUS

DOCUMENT NUMBER: 136:304071

TITLE: Modulation of CCR4 function for  
 disease therapy

INVENTOR(S): Collins, Tassie; Dairaghi, Daniel J.; Mahmud,  
 Hoosen; McMaster, Brian E.; Medina, Julio C.;  
 Schall, Thomas J.; Xu, Feng; Wang, Xuemei

PATENT ASSIGNEE(S): Tularik Inc., USA; Chemocentryx, Inc.

SOURCE: PCT Int. Appl., 78 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	
WO 2002030358	A2	20020418	WO 2001-US42625	200110 11

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,  
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD,  
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,

LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,  
 NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,  
 TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG,  
 KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH,  
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE,  
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,  
 TD, TG

CA 2425259 AA 20020418 CA 2001-2425259 200110  
 11  
 AU 2002013467 A5 20020422 AU 2002-13467 200110  
 11  
 US 2002173524 A1 20021121 US 2001-975566 200110  
 11  
 EP 1578341 A2 20050928 EP 2001-981850 200110  
 11  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,  
 PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR  
 WO 2002094264 A1 20021128 WO 2002-US16393 200205  
 22

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,  
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD,  
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,  
 LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,  
 NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,  
 TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM,  
 AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,  
 CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,  
 SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
 SN, TD, TG


US 2003018022 A1 20030123 US 2002-155605 200205  
 22  
 US 2004039035 A1 20040226 US 2003-654112 200309  
 02  
 PRIORITY APPLN. INFO.: US 2000-240022P P 200010  
 11  
 US 2001-293781P P 200105  
 23  
 US 2001-975566 B3 200110  
 11  
 WO 2001-US42625 W 200110  
 11

OTHER SOURCE(S): MARPAT 136:304071


AB The present invention is directed to compds. which are modulators of  
 CCR4 chemokine receptor function and are  
 useful in the prevention or treatment of inflammatory

conditions and diseases such as allergic diseases, psoriasis, atopic dermatitis and asthma. The invention is also directed to pharmaceutical compns. comprising these compds. and the use of these compds. and compns. in the prevention or treatment of diseases in which CCR4 chemokine receptors are involved. Compds. and compns. are provided that bind to the CCR4 chemokine receptor and which are useful for treating diseases assocd. with CCR4 activity, such as contact hypersensitivity.

IT 1619-51-8P 219314-97-3P 284668-45-7P  
 301236-29-3P 339201-47-7P 339204-07-8P  
 339204-08-9P 412008-20-9P 412008-21-0P  
 412008-22-1P 412008-23-2P 412008-24-3P  
 412008-25-4P 412008-27-6P 412008-28-7P  
 412008-30-1P 412008-31-2P 412008-32-3P  
 412008-33-4P 412008-34-5P 412008-36-7P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (modulators of CCR4 chemokine receptor function for prevention and treatment of inflammatory conditions and diseases such as allergic diseases, psoriasis, atopic dermatitis, and asthma)  
 RN 1619-51-8 HCAPLUS  
 CN 2-Thiazolamine, 4-[4-(1,1-dimethylethyl)phenyl]-N-1-naphthalenyl-(9CI) (CA INDEX NAME)




RN 219314-97-3 HCAPLUS  
 CN 2-Thiazolamine, N-(3-chloro-2-methylphenyl)-4-(1,1-dimethylethyl)-(9CI) (CA INDEX NAME)




RN 284668-45-7 HCAPLUS

CN 2-Thiazolamine, 4-(4-chlorophenyl)-N-1-naphthalenyl- (9CI) (CA INDEX NAME)




RN 301236-29-3 HCAPLUS

CN 2-Thiazolamine, 4-(4-methylphenyl)-N-1-naphthalenyl- (9CI) (CA INDEX NAME)



RN 339201-47-7 HCAPLUS


CN 2-Thiazolamine, N-2-naphthalenyl-4-phenyl-5-propyl- (9CI) (CA INDEX NAME)



RN 339204-07-8 HCAPLUS


CN 2-Thiazolamine, N-(4-methylphenyl)-4-phenyl-5-propyl- (9CI) (CA INDEX NAME)






RN 339204-08-9 HCAPLUS

CN 2-Thiazolamine, N-(4-chlorophenyl)-4-phenyl-5-propyl- (9CI) (CA INDEX NAME)




RN 412008-20-9 HCAPLUS

CN 2-Thiazolamine, 4-(1-methylethyl)-N-1-naphthalenyl- (9CI) (CA INDEX NAME)




RN 412008-21-0 HCAPLUS

CN 2-Thiazolamine, 4-(1,1-dimethylethyl)-N-(2,3-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 412008-22-1 HCAPLUS


CN 2-Thiazolamine, N-(4-chloro-1-naphthalenyl)-4-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 412008-23-2 HCAPLUS  
CN 2-Thiazolamine, 4-(1,1-dimethylethyl)-N-1-naphthalenyl-5-propyl-  
(9CI) (CA INDEX NAME)




RN 412008-24-3 HCAPLUS  
CN 2-Thiazolamine, 4-(1,1-dimethylethyl)-5-methyl-N-1-naphthalenyl-  
(9CI) (CA INDEX NAME)




RN 412008-25-4 HCAPLUS  
CN 2-Thiazolamine, 4-(1,1-dimethylethyl)-N-[2-(4-morpholinyl)phenyl]-  
(9CI) (CA INDEX NAME)




RN 412008-27-6 HCAPLUS  
CN 4-Thiazolepropanoic acid,  $\beta,\beta$ -dimethyl-2-(1-naphthalenylamino)-, ethyl ester (9CI) (CA INDEX NAME)




RN 412008-28-7 HCAPLUS  
CN 2-Thiazolamine, 4-(1,1-dimethylethyl)-N-(5,6,7,8-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 412008-30-1 HCAPLUS  
CN 2-Thiazolamine, 4-(2,2-dimethylpropyl)-N-1-naphthalenyl- (9CI) (CA  
INDEX NAME)




RN 412008-31-2 HCAPLUS  
CN 4-Thiazolemethanamine, N,N-bis(2-methylpropyl)-2-(1-naphthalenylamino)- (9CI) (CA INDEX NAME)



RN 412008-32-3 HCAPLUS  
CN 2-Thiazolamine, N-(3-bromo-2-methylphenyl)-4-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 412008-33-4 HCAPLUS  
CN 4-Thiazolemethanamine,  $\alpha$ -methyl-N,N-bis(2-methylpropyl)-2-(1-naphthalenylamino)- (9CI) (CA INDEX NAME)




RN 412008-34-5 HCAPLUS

CN 5-Quinolinamine, N-[4-(1,1-dimethylethyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 412008-36-7 HCAPLUS

CN 2-Thiazolamine, 4-(4-ethylphenyl)-N-1-naphthalenyl- (9CI) (CA INDEX NAME)




IT 412008-18-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(modulators of CCR4 chemokine)

receptor function for prevention and treatment  
of inflammatory conditions and diseases such  
as allergic diseases, psoriasis, atopic  
dermatitis, and asthma)

RN 412008-18-5 HCAPLUS

CN 2-Thiazolamine, 5-methyl-N-1-naphthalenyl- (9CI) (CA INDEX NAME)




IT 21917-60-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);  
RACT (Reactant or reagent)

(modulators of CCR4 chemokine  
receptor function for prevention and treatment  
of inflammatory conditions and diseases such  
as allergic diseases, psoriasis, atopic  
dermatitis, and asthma)

RN 21917-60-2 HCAPLUS

CN 2-Thiazolamine, 4-(chloromethyl)-N-1-naphthalenyl- (9CI) (CA INDEX NAME)



IC ICM A61K

CC 1-7 (Pharmacology)

ST chemokine receptor CCR4 modulator  
disease therapy

IT Chemokine receptors

RL: BSU (Biological study, unclassified); BIOL  
(Biological study)

(CCR4; modulators of CCR4 chemokine  
receptor function for prevention and treatment  
of inflammatory conditions and diseases such  
as allergic diseases, psoriasis, atopic  
dermatitis, and asthma)

IT Dermatitis

(atopic; modulators of CCR4 chemokine  
receptor function for prevention and treatment



of inflammatory conditions and diseases such as allergic diseases, psoriasis, atopic dermatitis, and asthma)

IT Dermatitis  
(contact; modulators of CCR4 chemokine receptor function for prevention and treatment of inflammatory conditions and diseases such as allergic diseases, psoriasis, atopic dermatitis, and asthma)

IT Intestine, disease  
(inflammatory; modulators of CCR4 chemokine receptor function for prevention and treatment of inflammatory conditions and diseases such as allergic diseases, psoriasis, atopic dermatitis, and asthma)

IT Anti-AIDS agents  
Anti-inflammatory agents  
Antiasthmatics  
Antirheumatic agents  
Antitumor agents  
Chemotaxis  
Human  
Human immunodeficiency virus 1  
Lupus erythematosus  
Psoriasis  
T cell (lymphocyte)  
(modulators of CCR4 chemokine receptor function for prevention and treatment of inflammatory conditions and diseases such as allergic diseases, psoriasis, atopic dermatitis, and asthma)

IT Shock (circulatory collapse)  
(septic; modulators of CCR4 chemokine receptor function for prevention and treatment of inflammatory conditions and diseases such as allergic diseases, psoriasis, atopic dermatitis, and asthma)

IT Antidiabetic agents  
(type I diabetes; modulators of CCR4 chemokine receptor function for prevention and treatment of inflammatory conditions and diseases such as allergic diseases, psoriasis, atopic dermatitis, and asthma)

IT 1619-51-8P 219314-97-3P 284668-45-7P  
301236-29-3P 339201-47-7P 339204-07-8P  
339204-08-9P 412008-20-9P 412008-21-0P  
412008-22-1P 412008-23-2P 412008-24-3P  
412008-25-4P 412008-26-5P 412008-27-6P  
412008-28-7P 412008-29-8P 412008-30-1P  
412008-31-2P 412008-32-3P 412008-33-4P  
412008-34-5P 412008-35-6P 412008-36-7P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(modulators of CCR4 chemokine receptor function for prevention and treatment of inflammatory conditions and diseases such as allergic diseases, psoriasis, atopic dermatitis, and asthma)

IT 81191-20-0 411207-58-4 411207-59-5 411207-60-8 411207-61-9  
412008-18-5 412008-19-6  
RL: PAC (Pharmacological activity); THU (Therapeutic

use); BIOL (Biological study); USES (Uses)  
 (modulators of CCR4 chemokine  
 receptor function for prevention and treatment  
 of inflammatory conditions and diseases such  
 as allergic diseases, psoriasis, atopic  
 dermatitis, and asthma)

IT 78-81-9, Isobutylamine 78-84-2 108-18-9, Diisopropylamine  
 134-32-7, 1-Aminonaphthalene 3622-23-9 104860-16-4  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (modulators of CCR4 chemokine  
 receptor function for prevention and treatment  
 of inflammatory conditions and diseases such  
 as allergic diseases, psoriasis, atopic  
 dermatitis, and asthma)

IT 21917-60-2P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);  
 RACT (Reactant or reagent)  
 (modulators of CCR4 chemokine  
 receptor function for prevention and treatment  
 of inflammatory conditions and diseases such  
 as allergic diseases, psoriasis, atopic  
 dermatitis, and asthma)

L32 ANSWER 21 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:293389 HCAPLUS

DOCUMENT NUMBER: 136:304070

TITLE: Compounds and methods for modulating  
 CCR4 function for prevention and  
 treatment of inflammatory and  
 immunoregulatory disorders and diseases

INVENTOR(S): Dairaghi, Daniel J.; McMaster, Brian E.; Schall,  
 Thomas J.

PATENT ASSIGNEE(S): Chemocentryx, Inc., USA

SOURCE: PCT Int. Appl., 44 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002030357	A2	20020418	WO 2001-US42624	20011011
WO 2002030357	A3	20030515		
WO 2002030357	C2	20031009		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002013466	A5	20020422	AU 2002-13466	20011011
US 2002132836	A1	20020919	US 2001-975567	

US 2004039035	A1	20040226	US 2003-654112	200110 11
				200309 02
PRIORITY APPLN. INFO.:			US 2000-240022P	P 200010 11
			US 2001-293781P	P 200105 23
			US 2001-975566	B3 200110 11
			WO 2001-US42624	W 200110 11

OTHER SOURCE(S): MARPAT 136:304070


AB The present invention is directed to compns. and methods useful in modulating **CCR4 chemokine receptor** activity. The compds., compns. and methods described herein are useful in the prevention or **treatment** of certain inflammatory and immunoregulatory disorders and **diseases**, including **asthma** and allergic **diseases**, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis.

IT 1957-01-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(modulators of **CCR4** functions for prevention and **treatment** of inflammatory and immunoregulatory disorders and **diseases**)

RN 1957-01-3 HCAPLUS

CN 2-Thiazolamine, 4-methyl-N-1-naphthalenyl- (9CI) (CA INDEX NAME)



IC ICM A61K

CC 1-7 (Pharmacology)

Section cross-reference(s): 15

ST autoimmune disease **chemokine receptor****CCR4** modulatorIT **Chemokine receptors**

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(CCR4; modulators of CCR4 functions for

prevention and **treatment** of inflammatory and immunoregulatory disorders and **diseases**)

IT Allergy  
(allergic contact dermatitis; modulators of CCR4 functions for prevention and **treatment** of inflammatory and immunoregulatory disorders and **diseases**)

IT Dermatitis  
(allergic contact; modulators of CCR4 functions for prevention and **treatment** of inflammatory and immunoregulatory disorders and **diseases**)

IT Allergy  
Inflammation  
Nose, **disease**  
(allergic rhinitis; modulators of CCR4 functions for prevention and **treatment** of inflammatory and immunoregulatory disorders and **diseases**)

IT Antiarteriosclerotics  
(antiatherosclerotics; modulators of CCR4 functions for prevention and **treatment** of inflammatory and immunoregulatory disorders and **diseases**)

IT Dermatitis  
(atopic; modulators of CCR4 functions for prevention and **treatment** of inflammatory and immunoregulatory disorders and **diseases**)

IT Ischemia  
(cardiac; modulators of CCR4 functions for prevention and **treatment** of inflammatory and immunoregulatory disorders and **diseases**)

IT Respiratory system, **disease**  
(hyperresponsiveness, allergic; modulators of CCR4 functions for prevention and **treatment** of inflammatory and immunoregulatory disorders and **diseases**)

IT Heart, **disease**  
(infarction; modulators of CCR4 functions for prevention and **treatment** of inflammatory and immunoregulatory disorders and **diseases**)

IT Intestine, **disease**  
(inflammatory; modulators of CCR4 functions for prevention and **treatment** of inflammatory and immunoregulatory disorders and **diseases**)

IT Drug delivery systems  
(injections, i.v.; modulators of CCR4 functions for prevention and **treatment** of inflammatory and immunoregulatory disorders and **diseases**)

IT Reperfusion  
(injury; modulators of CCR4 functions for prevention and **treatment** of inflammatory and immunoregulatory disorders and **diseases**)

IT Autoimmune **disease**  
(insulin-dependent diabetes mellitus; modulators of CCR4 functions for prevention and **treatment** of inflammatory and immunoregulatory disorders and **diseases**)

IT Diabetes mellitus  
(insulin-dependent; modulators of CCR4 functions for prevention and **treatment** of inflammatory and immunoregulatory disorders and **diseases**)

IT Heart, **disease**  
(ischemia; modulators of CCR4 functions for prevention and **treatment** of inflammatory and immunoregulatory disorders and **diseases**)

IT Keratosis  
(keratolytic agent; modulators of CCR4 functions for


- prevention and **treatment** of inflammatory and immunoregulatory disorders and **diseases**)
- IT Anti-AIDS agents  
 Anti-ischemic agents  
 Antianginal agents  
 Antiasthmatics  
 Antihistamines  
 Antirheumatic agents  
 Antitumor agents  
 Atherosclerosis  
 Autoimmune **disease**  
 Human  
 Human immunodeficiency virus 1  
 Lupus erythematosus  
 Photodynamic therapy  
**Psoriasis**  
 UV A radiation  
 (modulators of **CCR4** functions for prevention and **treatment** of inflammatory and immunoregulatory disorders and **diseases**)
- IT Corticosteroids, biological studies  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (modulators of **CCR4** functions for prevention and **treatment** of inflammatory and immunoregulatory disorders and **diseases**)
- IT Cosmetics  
 (moisturizers; modulators of **CCR4** functions for prevention and **treatment** of inflammatory and immunoregulatory disorders and **diseases**)
- IT Drug delivery systems  
 (oral; modulators of **CCR4** functions for prevention and **treatment** of inflammatory and immunoregulatory disorders and **diseases**)
- IT Injury  
 (reperfusion; modulators of **CCR4** functions for prevention and **treatment** of inflammatory and immunoregulatory disorders and **diseases**)
- IT Artery, **disease**  
 (restenosis; modulators of **CCR4** functions for prevention and **treatment** of inflammatory and immunoregulatory disorders and **diseases**)
- IT Shock (circulatory collapse)  
 (septic; modulators of **CCR4** functions for prevention and **treatment** of inflammatory and immunoregulatory disorders and **diseases**)
- IT Multiple sclerosis  
 (therapeutic agents; modulators of **CCR4** functions for prevention and **treatment** of inflammatory and immunoregulatory disorders and **diseases**)
- IT 66-97-7, Psoralen 67-97-0, Vitamin D3 1143-38-0, Anthralin  
 1957-01-3 81191-20-0 411207-58-4 411207-59-5  
 411207-60-8 411207-61-9  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (modulators of **CCR4** functions for prevention and **treatment** of inflammatory and immunoregulatory disorders and **diseases**)

L32 ANSWER 22 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2001:232516 HCAPLUS  
 DOCUMENT NUMBER: 134:275760

TITLE: Medicine compositions for **treatment** of  
 integrin  $\alpha$ 4-mediated cell  
 adhesion-associated **diseases**  
 INVENTOR(S): Sircar, Ila; Gudmundsson, Kristjan S.; Martin,  
 Richard  
 PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 88 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001089368	A2	20010403	JP 2000-216898	20000718
PRIORITY APPLN. INFO.:			JP 1999-204581	A 19990719

OTHER SOURCE(S): MARPAT 134:275760  
 GI



I

AB The medicine compns. (I; A = arom. hydrocarbon ring; Q = binding linkage; N = 0, 1, 2; W = O, S, -CH=CH-, -N=CH-; Z = O, S; R1, R2, R3 = H, halogen, (substituted)low alkyl; R4 = tetrazolyl, carboxyl, etc.; R5 = H, nitro, (substituted)amino, OH low alkanoyl, etc.; R6 = (substituted)phenyl, etc.) and their pharmacol. acceptable salts are claimed for **treatment** of integrin 4-mediated cell adhesion-assocd. **diseases**, including **asthma**, diabetes, rheumatoid arthritis, **inflammatory** bowel **disease**, and digestive tract and other **diseases** assocd. with leukocyte infiltration in the epithelium (e.g. skin, urethra, bronchiole, synovial membrane and transplanted kidney, liver, heart, blood vessel, and nerve tissues, and pancreas and other **diseases** including **psoriasis**, atopic dermatitis, contact dermatitis, systemic lupus erythematosus, etc.). I were prepd., and their inhibitory effects on cell adhesion were tested in vitro.


IT 232274-66-7P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (phenylalanine analogs as medicine compns. for **treatment** of integrin  $\alpha$ 4-mediated cell adhesion-assocd.

**diseases)**

RN 232274-66-7 HCAPLUS

CN [1,1'-Biphenyl]-4-propanoic acid,  $\alpha$ -[[2-chloro-4-[(4,5-dihydro-2-thiazolyl)amino]benzoyl]amino]-2'-methoxy-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 232275-57-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(phenylalanine analogs as medicine compns. for **treatment** of integrin  $\alpha$ 4-mediated cell adhesion-assocd.**diseases)**

RN 232275-57-9 HCAPLUS

CN Benzoic acid, 2-chloro-4-[(4,5-dihydro-2-thiazolyl)amino]- (9CI) (CA INDEX NAME)



IC ICM A61K031-198

ICS A61K031-27; A61K031-275; A61K031-343; A61K031-381; A61K031-40; A61K031-426; A61K031-44; A61K031-445; A61K031-495; A61K031-4965; A61K031-5375; A61K031-54; A61P001-04; A61P003-10; A61P011-06; A61P017-02; A61P017-06; A61P029-00; A61P037-00

CC 1-7 (Pharmacology)

Section cross-reference(s): 25, 26

IT Dermatitis

(atopic; phenylalanine analogs as medicine compns. for **treatment** of integrin  $\alpha$ 4-mediated cell adhesion-assocd. **diseases**)

IT Transplant and Transplantation

(blood vessel; phenylalanine analogs as medicine compns. for **treatment** of integrin  $\alpha$ 4-mediated cell adhesion-assocd. **diseases**)

IT Dermatitis

(contact; phenylalanine analogs as medicine compns. for **treatment** of integrin  $\alpha$ 4-mediated cell adhesion-assocd. **diseases**)

IT Transplant and Transplantation

(heart; phenylalanine analogs as medicine compns. for



treatment of integrin  $\alpha$ 4-mediated cell  
adhesion-assocd. diseases)

IT Intestine, disease  
(inflammatory; phenylalanine analogs as medicine  
compns. for treatment of integrin  $\alpha$ 4-mediated  
cell adhesion-assocd. diseases)

IT Transplant and Transplantation  
(kidney; phenylalanine analogs as medicine compns. for  
treatment of integrin  $\alpha$ 4-mediated cell  
adhesion-assocd. diseases)

IT Transplant and Transplantation  
(liver; phenylalanine analogs as medicine compns. for  
treatment of integrin  $\alpha$ 4-mediated cell  
adhesion-assocd. diseases)

IT Transplant and Transplantation  
(neural; phenylalanine analogs as medicine compns. for  
treatment of integrin  $\alpha$ 4-mediated cell  
adhesion-assocd. diseases)

IT Transplant and Transplantation  
(pancreas; phenylalanine analogs as medicine compns. for  
treatment of integrin  $\alpha$ 4-mediated cell  
adhesion-assocd. diseases)

IT Adhesion, biological  
Antiasthmatics  
Antidiabetic agents  
Antirheumatic agents  
Psoriasis  
Transplant and Transplantation  
(phenylalanine analogs as medicine compns. for treatment  
of integrin  $\alpha$ 4-mediated cell adhesion-assocd.  
diseases)

IT Lupus erythematosus  
(systemic; phenylalanine analogs as medicine compns. for  
treatment of integrin  $\alpha$ 4-mediated cell  
adhesion-assocd. diseases)

IT Blood vessel  
Heart  
Kidney  
Liver  
Nerve  
Pancreas  
(transplant; phenylalanine analogs as medicine compns. for  
treatment of integrin  $\alpha$ 4-mediated cell  
adhesion-assocd. diseases)

IT Integrins  
RL: BAC (Biological activity or effector, except adverse); BPR  
(Biological process); BSU (Biological study, unclassified)  
; BIOL (Biological study); PROC (Process)  
( $\alpha$ 4; phenylalanine analogs as medicine compns. for  
treatment of integrin  $\alpha$ 4-mediated cell  
adhesion-assocd. diseases)

IT 232274-04-3P  
RL: BAC (Biological activity or effector, except adverse); BSU  
(Biological study, unclassified); SPN (Synthetic preparation);  
THU (Therapeutic use); BIOL (Biological study);  
PREP (Preparation); USES (Uses)  
(delphenylalanine analogs as medicine compns. for  
treatment of integrin  $\alpha$ 4-mediated cell  
adhesion-assocd. diseases)

IT 232271-13-5P 232271-15-7P 232271-17-9P, N-(2,6-Dichlorobenzoyl)-  
4-(2-methoxyphenyl)-D-phenylalanine 232271-20-4P 232271-21-5P  
232271-22-6P 232271-23-7P 232271-24-8P 232271-25-9P

232271-26-0P 232271-27-1P, N-(2,6-Dichlorobenzoyl)-4-[2-[N-(tert-butyl)sulfamoyl]phenyl]-L-phenylalanine 232271-28-2P  
 232271-29-3P 232271-30-6P 232271-31-7P 232271-32-8P  
 232271-33-9P 232271-34-0P 232271-35-1P 232271-36-2P  
 232271-37-3P 232271-38-4P 232271-39-5P 232271-40-8P  
 232271-41-9P 232271-42-0P 232271-43-1P 232271-44-2P  
 232271-45-3P 232271-46-4P 232271-47-5P 232271-48-6P  
 232271-49-7P 232271-50-0P 232271-51-1P 232271-52-2P  
 232271-53-3P 232271-54-4P 232271-55-5P 232271-56-6P  
 232271-57-7P 232271-58-8P 232271-59-9P 232271-61-3P  
 232271-62-4P 232271-63-5P 232271-64-6P 232271-65-7P  
 232271-66-8P 232271-67-9P 232271-68-0P 232271-69-1P  
 232271-70-4P 232271-71-5P 232271-72-6P 232271-73-7P  
 232271-74-8P 232271-75-9P 232271-76-0P 232271-77-1P  
 232271-78-2P 232271-79-3P 232271-80-6P 232271-81-7P  
 232271-82-8P 232271-83-9P 232271-84-0P 232271-85-1P  
 232271-86-2P 232271-87-3P 232271-88-4P 232271-89-5P  
 232271-90-8P 232271-91-9P 232271-92-0P 232271-93-1P  
 232271-94-2P 232271-95-3P 232271-96-4P 232271-97-5P  
 232271-98-6P 232271-99-7P 232272-01-4P 232272-02-5P  
 232272-04-7P 232272-06-9P 232272-08-1P 232272-10-5P  
 232272-11-6P 232272-12-7P 232272-14-9P 232272-16-1P  
 232272-17-2P 232272-18-3P 232272-19-4P 232272-21-8P  
 232272-22-9P 232272-24-1P 232272-25-2P 232272-26-3P  
 232272-27-4P 232272-28-5P 232272-30-9P 232272-32-1P  
 232272-34-3P 232272-36-5P 232272-38-7P 232272-39-8P  
 232272-41-2P 232272-43-4P 232272-45-6P 232272-47-8P  
 232272-49-0P 232272-50-3P 232272-51-4P 232272-52-5P  
 232272-53-6P 232272-54-7P 232272-56-9P 232272-58-1P  
 232272-60-5P 232272-62-7P 232272-64-9P 232272-65-0P  
 232272-67-2P 232272-68-3P 232272-70-7P 232272-72-9P  
 232272-74-1P 232272-76-3P 232272-78-5P 232272-81-0P  
 232272-83-2P 232272-85-4P 232272-87-6P 232272-89-8P  
 232272-91-2P 232272-92-3P 232272-93-4P 232272-94-5P  
 232272-95-6P 232272-96-7P 232272-98-9P 232272-99-0P  
 232273-00-6P 232273-01-7P 232273-02-8P 232273-03-9P  
 232273-04-0P 232273-05-1P 232273-06-2P 232273-07-3P  
 232273-08-4P 232273-09-5P 232273-10-8P 232273-11-9P  
 232273-12-0P 232273-13-1P 232273-14-2P 232273-15-3P  
 232273-16-4P 232273-17-5P 232273-18-6P 232273-21-1P  
 232273-22-2P 232273-23-3P 232273-24-4P 232273-25-5P  
 232273-26-6P 232273-27-7P 232273-28-8P 232273-29-9P  
 232273-30-2P 232273-31-3P 232273-32-4P 232273-33-5P  
 232273-34-6P 232273-35-7P 232273-36-8P 232273-37-9P  
 232273-38-0P 232273-39-1P 232273-40-4P 232273-41-5P  
 232273-42-6P 232273-43-7P 232273-44-8P 232273-45-9P  
 232273-46-0P 232273-47-1P 232273-48-2P 232273-49-3P  
 232273-50-6P 232273-51-7P 232273-52-8P 232273-53-9P  
 232273-54-0P 232273-55-1P 232273-56-2P 232273-57-3P  
 232273-59-5P 232273-60-8P 232273-61-9P 232273-63-1P  
 232273-64-2P 232273-65-3P 232273-66-4P 232273-68-6P  
 232273-70-0P 232273-72-2P 232273-74-4P 232273-76-6P,  
 [1,1'-Biphenyl]-4-propanoic acid,  $\alpha$ -[(2,6-dichlorobenzoyl)amino]-2'-(1-methylethoxy)-, ( $\alpha$ S)-  
 232273-78-8P 232273-80-2P 232273-81-3P 232273-82-4P  
 232273-84-6P 232273-86-8P 232273-88-0P 232274-02-1P  
 232274-03-2P 232274-05-4P 232274-06-5P 232274-07-6P  
 232274-08-7P 232274-09-8P 232274-10-1P 232274-11-2P  
 232274-13-4P 232274-17-8P 232274-20-3P 232274-24-7P  
 232274-27-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation);

**THU (Therapeutic use); BIOL (Biological study);**  
**PREP (Preparation); USES (Uses)**  
 (phenylalanine analogs as medicine compns. for treatment  
 of integrin  $\alpha$ 4-mediated cell adhesion-assocd.  
 diseases)

IT	232274-28-1P	232274-31-6P	232274-37-2P	232274-38-3P
	232274-39-4P	232274-40-7P	232274-41-8P	232274-42-9P
	232274-43-0P	232274-44-1P	232274-45-2P	232274-46-3P
	232274-47-4P	232274-48-5P	232274-49-6P	232274-50-9P
	232274-51-0P	232274-52-1P	232274-53-2P	232274-54-3P
	232274-55-4P	232274-56-5P	232274-57-6P	232274-58-7P
	232274-59-8P	232274-60-1P	232274-61-2P	232274-62-3P
	232274-63-4P	232274-64-5P	232274-65-6P	232274-66-7P
	232274-67-8P	232274-68-9P	232274-69-0P	232274-70-3P
	232274-71-4P	232274-72-5P	232274-73-6P	232274-74-7P
	232274-75-8P	232274-76-9P	232274-77-0P	232274-80-5P
	232274-81-6P	232274-82-7P	232274-83-8P	232274-84-9P
	232274-85-0P	232274-88-3P	232274-90-7P	232274-91-8P
	232274-92-9P	232274-93-0P	232274-94-1P	232274-95-2P
	232274-96-3P	232274-97-4P	232274-99-6P	232275-00-2P
	232275-01-3P	232275-02-4P	232275-03-5P	232275-04-6P
	232275-05-7P	232275-06-8P	232275-07-9P	232275-08-0P
	232275-09-1P	232275-10-4P	232275-11-5P	232275-12-6P
	232275-13-7P	232275-14-8P	232275-15-9P	232275-16-0P
	232275-17-1P	232275-18-2P	232275-19-3P	232275-20-6P
	232275-21-7P	232275-22-8P	232275-23-9P	232275-24-0P
	232275-25-1P	232275-26-2P	232275-27-3P	232275-28-4P
	232275-29-5P	232275-30-8P	232275-31-9P	232275-91-1P
	232275-99-9P	332391-52-3P	332391-77-2P	332391-92-1P
	332392-28-6P	332392-88-8P	332392-90-2P	332393-45-0P
	332393-47-2P	332393-49-4P	332393-52-9P	332393-55-2P
	332393-57-4P	332393-60-9P	332393-62-1P	332393-65-4P
	332393-77-8P	332394-03-3P		

**RL: BAC (Biological activity or effector, except adverse); BSU**  
**(Biological study, unclassified); SPN (Synthetic preparation);**  
**THU (Therapeutic use); BIOL (Biological study);**  
**PREP (Preparation); USES (Uses)**

(phenylalanine analogs as medicine compns. for treatment  
 of integrin  $\alpha$ 4-mediated cell adhesion-assocd.  
 diseases)

IT	121-43-7	349-55-3, 3-Methoxy-5-trifluoromethylaniline	626-17-5,
	1.3-Dicyanobenzene	1530-32-1, Ethyl triphenylphosphonium bromide	
	10272-07-8, 3,5-Dimethoxyaniline	13330-65-9, 2,4-Dimethoxyphenol	
	18791-98-5, 3-Bromothiophene-2-carbonitrile	19393-92-1,	
	1-Bromo-2,6-dichlorobenzene	22509-50-8	29668-44-8
	4-Bromo-3,5-dimethoxybenzaldehyde	31558-40-4,	

**RL: RCT (Reactant); RACT (Reactant or reagent)**  
 (phenylalanine analogs as medicine compns. for treatment  
 of integrin  $\alpha$ 4-mediated cell adhesion-assocd.  
 diseases)

IT	4641-38-7P	5204-46-6P, 4-Amino-2,6-dichlorobenzoic acid	
	73852-17-2P,	2,6-Dichlorobenzeneboronic acid	80257-12-1P
	158580-15-5P	232275-35-3P	232275-36-4P
	232275-39-7P	232275-40-0P	232275-41-1P
	232275-44-4P	232275-45-5P	232275-46-6P
	232275-52-4P	232275-55-7P	232275-57-9P
	232275-65-9P	232275-67-1P	232275-69-3P
	232275-75-1P	232275-77-3P	232275-83-1P
	232275-88-6P	232276-76-5P	332394-13-5P
	332394-20-4P	332394-23-7P	332394-26-0P
	332394-32-8P	332394-34-0P	332394-37-3P
	332394-46-4P	332394-52-2P	

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);  
RACT (Reactant or reagent)  
(phenylalanine analogs as medicine compns. for treatment  
of integrin  $\alpha$ 4-mediated cell adhesion-assocd.  
diseases)

L32 ANSWER 23 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2001:115147 HCAPLUS  
DOCUMENT NUMBER: 134:163031  
TITLE: Preparation of thiazole derivatives as p38MAP  
kinase inhibitors and inhibitors of TNF- $\alpha$   
production  
INVENTOR(S): Ohkawa, Shigenori; Naruo, Kenichi; Kimura,  
Hiroyuki; Miwatashi, Seiji  
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan  
SOURCE: PCT Int. Appl., 166 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	
WO 2001010865	A1	20010215	WO 2000-JP5198	200008 03
W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2381215	AA	20010215	CA 2000-2381215	200008 03
EP 1205478	A1	20020515	EP 2000-951874	200008 03
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2001114690	A2	20010424	JP 2000-242761	200008 04
US 6962933	B1	20051108	US 2002-48937	200202 06
PRIORITY APPLN. INFO.:				JP 1999-224651 A 199908 06
				WO 2000-JP5198 W 200008 03

OTHER SOURCE(S): MARPAT 134:163031  
AB Claimed are p38MAP kinase inhibitors contg. 1,3-thiazole compds.  
(substituted by optionally substituted pyridyl at the 5-position),  
or salts or prodrugs thereof. Compds. of this invention in vitro


showed IC50 values of 0.086  $\mu$ M to 0.63  $\mu$ M against p38MAP kinase. Formulations are given.

IT 97422-54-3P 97422-55-4P 97422-56-5P  
224038-79-3P 224038-87-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of thiazole derivs. as p38MAP kinase inhibitors and inhibitors of TNF- $\alpha$  prodn.)


RN 97422-54-3 HCAPLUS

CN 2-Thiazolamine, 4-(4-methoxyphenyl)-N-phenyl-5-(3-pyridinyl)- (9CI)  
(CA INDEX NAME)




RN 97422-55-4 HCAPLUS

CN 2-Thiazolamine, N-phenyl-5-(3-pyridinyl)-4-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 97422-56-5 HCAPLUS

CN Phenol, 4-[2-(phenylamino)-5-(3-pyridinyl)-4-thiazolyl]- (9CI) (CA INDEX NAME)




RN 224038-79-3 HCAPLUS

CN 2-Thiazolamine, 4-(4-methoxyphenyl)-N-phenyl-5-(4-pyridinyl)- (9CI)  
(CA INDEX NAME)



RN 224038-87-3 HCAPLUS

CN Acetamide, N-[4-(4-methoxyphenyl)-5-(4-pyridinyl)-2-thiazolyl]-N-phenyl- (9CI) (CA INDEX NAME)



IC ICM C07D417-04

ICS C07D417-14; A61K031-4439; A61K031-5377; A61P043-00; A61P011-06;  
A61P011-00; A61P037-08; A61P029-00; A61P007-06; A61P009-10;  
A61P025-28; A61P025-16; A61P021-00; A61P003-10; A61P019-02;  
A61P019-10; A61P039-02; A61P001-04; A61P031-06CC 28-7 (Heterocyclic Compounds (More Than One Hetero Atom))  
Section cross-reference(s): 1, 63IT Lung, **disease**  
(inflammation; prepn. and effect of thiazole derivs.  
with activity against p38MAP kinase and TNF prodn.)IT Addison's disease  
Alzheimer's disease  
Atherosclerosis  
Cachexia  
Diabetes mellitus  
Hepatitis  
Hypotension  
Lung, disease  
Lupus erythematosus  
Multiple sclerosis  
Osteoarthritis  
Osteoporosis  
Parkinson's disease  
**Psoriasis**  
Rheumatoid arthritis  
Sarcoidosis  
Septicemia  
Silicosis  
Thrombosis  
Transplant and Transplantation  
Tuberculosis  
(prepn. and effect of thiazole derivs. with activity against  
p38MAP kinase and TNF prodn.)

IT Tumor necrosis factors

RL: BPR (Biological process); BSU (Biological study,  
unclassified); BIOL (Biological study); PROC  
(Process)

(thiazole derivs. with activity against p38MAP kinase and TNF  
prodn.)

IT	97422-27-0P	97422-28-1P	97422-29-2P	97422-30-5P	97422-31-6P
	97422-32-7P	97422-33-8P	97422-34-9P	97422-35-0P	97422-36-1P
	97422-37-2P	97422-38-3P	97422-39-4P	97422-40-7P	97422-41-8P
	97422-42-9P	97422-43-0P	97422-44-1P	97422-45-2P	97422-46-3P
	97422-47-4P	97422-48-5P	97422-49-6P	97422-50-9P	97422-51-0P
	97422-52-1P	97422-53-2P	97422-54-3P	97422-55-4P	
	97422-56-5P	97422-57-6P	97422-58-7P	97422-59-8P	
	97422-60-1P	97422-61-2P	97422-62-3P	97422-63-4P	97422-64-5P
	97422-65-6P	97422-66-7P	97422-67-8P	97422-68-9P	97422-69-0P
	97422-70-3P	97422-71-4P	97422-72-5P	97422-73-6P	97422-74-7P
	97422-75-8P	97422-76-9P	97422-77-0P	97422-78-1P	97422-79-2P
	97422-80-5P	97422-81-6P	97422-82-7P	97422-83-8P	97422-84-9P
	97422-85-0P	97422-86-1P	97422-87-2P	97422-88-3P	97422-89-4P
	97443-15-7P	97443-16-8P	97443-17-9P	99478-69-0P	99478-71-4P
	99478-73-6P	99478-74-7P	99478-75-8P	99478-76-9P	99478-77-0P
	99478-78-1P	99478-79-2P	99478-80-5P	99478-81-6P	99478-82-7P
	99478-83-8P	99478-84-9P	99478-85-0P	99478-86-1P	99478-87-2P
	99478-88-3P	99478-89-4P	99496-91-0P	99496-92-1P	99496-93-2P
	223914-57-6P	223914-58-7P	223914-59-8P	223914-63-4P	
	224037-86-9P	224037-87-0P	224037-88-1P	224037-89-2P	
	224037-90-5P	224037-91-6P	224037-92-7P	224037-93-8P	
	224037-94-9P	224037-95-0P	224037-96-1P	224037-98-3P	
	224037-99-4P	224038-00-0P	224038-01-1P	224038-02-2P	
	224038-03-3P	224038-04-4P	224038-05-5P	224038-06-6P	
	224038-07-7P	224038-08-8P	224038-09-9P	224038-11-3P	
	224038-13-5P	224038-14-6P	224038-15-7P	224038-16-8P	
	224038-17-9P	224038-18-0P	224038-19-1P	224038-20-4P	
	224038-21-5P	224038-22-6P	224038-23-7P	224038-24-8P	
	224038-25-9P	224038-26-0P	224038-27-1P	224038-28-2P	
	224038-29-3P	224038-30-6P	224038-31-7P	224038-32-8P	
	224038-33-9P	224038-34-0P	224038-35-1P	224038-36-2P	
	224038-37-3P	224038-38-4P	224038-39-5P	224038-40-8P	
	224038-41-9P	224038-42-0P	224038-43-1P	224038-44-2P	
	224038-45-3P	224038-46-4P	224038-47-5P	224038-48-6P	
	224038-49-7P	224038-50-0P	224038-51-1P	224038-52-2P	
	224038-53-3P	224038-54-4P	224038-55-5P	224038-56-6P	
	224038-57-7P	224038-58-8P	224038-59-9P	224038-60-2P	
	224038-61-3P	224038-62-4P	224038-63-5P	224038-64-6P	
	224038-65-7P	224038-66-8P	224038-67-9P	224038-68-0P	
	224038-69-1P	224038-70-4P	224038-71-5P	224038-72-6P	
	224038-73-7P	224038-74-8P	224038-75-9P	224038-76-0P	
	224038-77-1P	224038-78-2P	224038-79-3P	224038-80-6P	
	224038-81-7P	224038-82-8P	224038-83-9P	224038-84-0P	
	224038-85-1P	224038-86-2P	224038-87-3P	224038-88-4P	
	224038-89-5P	224038-90-8P	224038-91-9P	224038-92-0P	
	224038-93-1P	224038-94-2P	224038-95-3P	224038-96-4P	
	224038-97-5P	224038-98-6P	224038-99-7P	224039-00-3P	
	224039-01-4P	224039-02-5P	224039-03-6P	224039-04-7P	
	224039-05-8P	224039-06-9P	224039-07-0P	224039-08-1P	
	224039-09-2P	224039-10-5P	224039-11-6P	224039-12-7P	
	224039-13-8P	224039-14-9P	224039-15-0P	224039-16-1P	
	224039-17-2P	224039-18-3P	224039-19-4P	224039-20-7P	
	224039-21-8P	224039-22-9P	224039-23-0P	224039-24-1P	
	224039-25-2P	224039-26-3P	224039-27-4P	224039-28-5P	
	224039-30-9P				

RL: BAC (Biological activity or effector, except adverse); BSU  
(Biological study, unclassified); SPN (Synthetic preparation);



THU (Therapeutic use); BIOL (Biological study);  
 PREP (Preparation); USES (Uses)  
 (prepn. of thiazole derivs. as p38MAP kinase inhibitors and  
 inhibitors of TNF- $\alpha$  prodn.)

IT	224039-31-0P	224039-32-1P	224039-33-2P	224039-34-3P
	224039-36-5P	224039-37-6P	224039-38-7P	224039-39-8P
	224039-40-1P	224039-42-3P	224039-44-5P	224039-46-7P
	224039-49-0P	224039-51-4P	224039-54-7P	224039-55-8P
	224039-56-9P	224039-57-0P	224039-58-1P	224039-59-2P
	224039-60-5P	224039-61-6P	224039-63-8P	224039-64-9P
	224039-65-0P	224039-66-1P	224039-67-2P	224039-68-3P
	224039-70-7P	224039-71-8P	224039-72-9P	224039-73-0P
	224039-74-1P	224039-76-3P	224039-77-4P	224039-78-5P
	224039-79-6P	224039-81-0P	224039-82-1P	224039-83-2P
	224039-85-4P	224039-86-5P	224039-87-6P	224039-88-7P
	224039-90-1P	224039-91-2P	224039-92-3P	224039-93-4P
	224039-95-6P	224039-96-7P	224039-97-8P	224039-99-0P
	224040-00-0P	224040-01-1P	224040-02-2P	224040-03-3P
	224040-04-4P	224040-06-6P	224040-07-7P	224040-08-8P
	224040-10-2P	224040-11-3P	224040-12-4P	224040-13-5P
	224040-14-6P	224040-16-8P	224040-17-9P	224040-18-0P
	224040-19-1P	224040-21-5P	224040-22-6P	224040-23-7P
	224040-24-8P	224040-26-0P	224040-27-1P	224040-28-2P
	224040-30-6P	224040-31-7P	224040-33-9P	224040-34-0P
	224040-36-2P	224040-37-3P	224040-38-4P	224040-39-5P
	224040-40-8P	224040-41-9P	224040-42-0P	224040-43-1P
	224040-44-2P	224040-45-3P	224040-46-4P	224040-47-5P
	224040-57-7P	252198-66-6P	252198-74-6P	252198-75-7P
	252198-97-3P	284486-00-6P	303787-77-1P	303787-98-6P
	325767-68-8P	325767-69-9P	325767-70-2P	325767-71-3P
	325767-72-4P	325767-73-5P	325767-74-6P	325767-75-7P
	325767-76-8P	325767-77-9P	325767-79-1P	325767-80-4P
	325767-81-5P	325767-82-6P	325767-83-7P	325767-84-8P
	325767-85-9P	325767-86-0P	325767-87-1P	325767-88-2P
	325767-89-3P	325767-90-6P	325767-91-7P	325767-92-8P
	325767-93-9P	325767-94-0P	325767-95-1P	325767-96-2P
	325767-97-3P	325767-98-4P	325767-99-5P	325768-00-1P
	325768-02-3P	325768-03-4P	325768-04-5P	325768-05-6P
	325768-06-7P	325768-07-8P	325768-08-9P	325768-09-0P
	325768-10-3P	325768-11-4P	325768-12-5P	325768-13-6P
	325768-14-7P	325768-15-8P	325768-16-9P	325768-17-0P
	325768-18-1P	325768-19-2P	325768-20-5P	325768-21-6P
	325768-22-7P	325768-23-8P	325768-24-9P	325768-25-0P
	325768-27-2P	325768-28-3P	325768-29-4P	325768-30-7P
	325768-31-8P	325768-32-9P	325768-33-0P	325768-34-1P
	325768-35-2P	325768-36-3P	325768-37-4P	325768-38-5P
	325768-39-6P	325768-40-9P	325768-41-0P	325768-42-1P
	325768-43-2P	325768-44-3P	325768-45-4P	325768-46-5P
	325768-47-6P	325768-48-7P	325768-49-8P	325768-50-1P
	325768-51-2P	325768-52-3P	325768-53-4P	325768-54-5P
	325768-55-6P	325768-56-7P	325768-57-8P	325768-58-9P
	325768-59-0P	325768-60-3P	325768-61-4P	325768-62-5P
	325768-63-6P	325768-64-7P	325768-65-8P	325768-66-9P
	325768-67-0P	325768-68-1P	325768-69-2P	325768-70-5P
	325768-71-6P	325768-72-7P	325768-73-8P	325768-75-0P
	325768-76-1P	325768-77-2P	325768-78-3P	325768-79-4P
	325768-80-7P	325768-81-8P	325768-82-9P	325768-83-0P
	325768-84-1P	325768-85-2P	325768-86-3P	325768-87-4P
	325768-88-5P	325768-89-6P	325768-90-9P	325768-91-0P
	325768-92-1P	325768-93-2P	325768-94-3P	325768-95-4P
	325768-96-5P	325768-97-6P	325768-98-7P	325768-99-8P
	325769-00-4P	325769-01-5P	325769-02-6P	325769-03-7P

325769-04-8P

RL: BAC (Biological activity or effector, except adverse); **BSU** (Biological study, unclassified); SPN (Synthetic preparation); **THU** (Therapeutic use); **BIOL** (Biological study); PREP (Preparation); USES (Uses)

(prepn. of thiazole derivs. as p38MAP kinase inhibitors and inhibitors of TNF- $\alpha$  prodn.)

IT	325769-05-9P	325769-06-0P	325769-07-1P	325769-08-2P
	325769-09-3P	325769-10-6P	325769-11-7P	325769-12-8P
	325769-13-9P	325769-14-0P	325769-15-1P	325769-16-2P
	325769-17-3P	325769-18-4P	325769-19-5P	325769-20-8P
	325769-21-9P	325769-22-0P	325769-23-1P	325769-25-3P
	325769-26-4P	325769-27-5P	325769-28-6P	325769-29-7P
	325769-30-0P	325769-31-1P	325769-32-2P	325769-33-3P
	325769-34-4P	325769-35-5P	325769-36-6P	325769-37-7P
	325769-38-8P	325769-39-9P	325769-40-2P	325769-41-3P
	325769-42-4P	325769-43-5P	325769-44-6P	325769-45-7P
	325769-46-8P	325769-47-9P	325769-48-0P	325769-49-1P
	325769-50-4P	325769-51-5P	325769-52-6P	325769-53-7P
	325769-54-8P	325769-55-9P	325769-56-0P	325769-57-1P
	325769-58-2P	325769-59-3P	325769-60-6P	325769-61-7P
	325769-62-8P	325769-63-9P	325769-64-0P	325769-65-1P
	325769-66-2P	325769-67-3P	325769-68-4P	325769-69-5P
	325769-70-8P	325769-71-9P	325769-73-1P	325769-74-2P
	325769-75-3P	325769-76-4P	325769-77-5P	325769-78-6P
	325769-79-7P	325769-80-0P	325769-81-1P	325769-82-2P
	325769-83-3P	325769-84-4P	325769-85-5P	325769-86-6P
	325769-87-7P	325769-88-8P	325769-89-9P	325769-91-3P
	325769-92-4P	325769-93-5P	325769-94-6P	325769-95-7P
	325769-96-8P	325769-97-9P	325769-98-0P	325769-99-1P
	325770-00-1P	325770-01-2P	325770-02-3P	325770-03-4P
	325770-04-5P	325770-05-6P	325770-06-7P	325770-07-8P
	325770-08-9P	325770-09-0P	325770-10-3P	325770-11-4P
	325770-12-5P	325770-13-6P	325770-14-7P	325770-15-8P
	325770-16-9P	325770-18-1P	325770-19-2P	325770-20-5P
	325770-21-6P	325770-22-7P	325770-23-8P	325770-24-9P
	325770-25-0P	325770-26-1P	325770-27-2P	325770-28-3P
	325770-29-4P	325770-30-7P		

RL: BAC (Biological activity or effector, except adverse); **BSU** (Biological study, unclassified); SPN (Synthetic preparation); **THU** (Therapeutic use); **BIOL** (Biological study); PREP (Preparation); USES (Uses)

(prepn. of thiazole derivs. as p38MAP kinase inhibitors and inhibitors of TNF- $\alpha$  prodn.)

IT 165245-96-5, p38 Mitogen-activated protein kinase  
RL: BPR (Biological process); **BSU** (Biological study, unclassified); **BIOL** (Biological study); PROC (Process)

(prepn. of thiazole derivs. as p38MAP kinase inhibitors and inhibitors of TNF- $\alpha$  prodn.)

IT 9036-21-9, Phosphodiesterase IV  
RL: BPR (Biological process); **BSU** (Biological study, unclassified); **BIOL** (Biological study); PROC (Process)

(prepn. of thiazole derivs. as p38MAP kinase inhibitors and inhibitors of TNF- $\alpha$  prodn. and phosphodiesterase IV inhibitors)

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L32 ANSWER 24 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN

Ross Shipe EIC 1700 Remsen 4B31 571/272-6018

ACCESSION NUMBER: 1999:464267 HCAPLUS  
 DOCUMENT NUMBER: 131:116517  
 TITLE: Preparation of N-acyl-phenylalanine derivatives  
 as inhibitors of  $\alpha$ 4-mediated cell adhesion  
 INVENTOR(S): Sircar, Ila; Gudmundsson, Kristjan S.; Martin,  
 Richard  
 PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 243 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9936393	A1	19990722	WO 1999-US993	19990119
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2318527	AA	19990722	CA 1999-2318527	19990119
AU 9924584	A1	19990802	AU 1999-24584	19990119
AU 749568	B2	20020627		19990119
BR 9907040	A	20001017	BR 1999-7040	19990119
EP 1049662	A1	20001108	EP 1999-904115	19990119
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002509131	T2	20020326	JP 2000-540111	19990119
JP 3634749	B2	20050330		19990119
NZ 506081	A	20030228	NZ 1999-506081	19990119
TW 591007	B	20040611	TW 1999-88100776	19990119
US 6521666	B1	20030218	US 2000-619712	20000719
US 2003191118	A1	20031009	US 2002-286777	20021104
US 6855843	B2	20050215		
JP 2005002116	A2	20050106	JP 2004-202046	

PRIORITY APPLN. INFO.:	US 1998-71840P	P	200407 08
			199801 20
	JP 2000-540111	A3	199901 19
	WO 1999-US993	W	199901 19
	US 2000-619712	A3	200007 19

OTHER SOURCE(S): MARPAT 131:116517

GI For diagram(s), see printed CA Issue.

AB The present invention relates to a pharmaceutical compn. comprising as an active ingredient a compd. of formula [I; wherein ring A is an arom. or a heterocyclic ring; Q is a bond, carbonyl, lower alkylene optionally substituted by HO or Ph, lower alkenylene, or -O-(lower alkylene)-; n is 0, 1 or 2; Z is oxygen or sulfur; W is oxygen, sulfur, -CH:CH-, -NH- or -N:CH-; R1, R2 and R3 are the same or different and are hydrogen, halogen, hydroxyl, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted lower alkoxy group, a substituted or unsubstituted amino group, CO2H or an amide or an ester thereof, cyano, lower alkylthio, lower alkanesulfonyl, substituted or unsubstituted SO2NH2, etc.; R4 is tetrazolyl, carboxyl group, amide or ester; R5 is hydrogen, nitro, amino, hydroxyl, lower alkanoyl, lower alkyl, etc.; R6 is selected from (a) a substituted or unsubstituted Ph group, (b) a substituted or unsubstituted pyridyl group, (c) a substituted or unsubstituted thienyl group, (d) a substituted or unsubstituted benzofuranyl group, etc.; or a pharmaceutically acceptable salt thereof]. These phenylalanine derivs. are useful for **treating** or **preventing conditions** caused by  $\alpha 4$ -mediated cell adhesion such as rheumatoid arthritis, **asthma**, **psoriasis**, eczema, contact dermatitis and other skin **inflammatory diseases**, diabetes, multiple sclerosis, systemic lupus erythematosus (SLE), **inflammatory bowel disease** including ulcerative colitis and Crohn's **disease**, and other **diseases** involving leukocyte infiltration of the gastrointestinal tract, or other epithelial lined tissues, such as skin, urinary tract, respiratory airway, and joint synovium. N-(tert-butoxycarbonyl)-O-(trifluoromethanesulfonyl)-L-tyrosine Me ester (prepn. given) was coupled with 2-methoxybenzene boronic acid in toluene/DMF in the presence of K2CO3 and Pd(PPh3)4 at 80 °C for 24 h to give N-(tert-butoxycarbonyl)-4-(2-methoxyphenyl)-L-phenylalanine Me ester. The latter compd. was **treated** with CF3CO2H in CH2Cl2 for 1.5 h to remove the Boc group and then condensed with 2,6-dichlorobenzoyl chloride in the presence of diisopropylethylamine at room temp. for 24 h to give N-(2,6-dichlorobenzoyl)-4-(2-methoxyphenyl)-L-phenylalanine Me ester (II) which was sapond. with LiOH in THF/MeOH at room temp. for 3 h, evapd., **treated** with H2O, adjusted Ph 2, and extd. with EtOAc to give N-(2,6-dichlorobenzoyl)-4-(2-methoxyphenyl)-L-phenylalanine (III). II and III in vitro inhibited at IC50 of 1 $\geq$  and 0.3 $\geq$   $\mu$ M, resp.,  $\beta 7$ -mediated cell

adhesion which measured the adhesive interactions of a B-cell line, RPMI, known to express  $\alpha 4\beta 7$ , to the alternatively spliced region of fibronectin referred to as CS-1, in the presence of test compds.

IT 232274-66-7P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of N-acyl-phenylalanine derivs. as inhibitors of  $\alpha 4$ -mediated cell adhesion for prevention and treatment of diseases caused by  $\alpha 4$ -mediated cell adhesion)

RN 232274-66-7 HCAPLUS

CN [1,1'-Biphenyl]-4-propanoic acid,  $\alpha$ -[[2-chloro-4-[(4,5-dihydro-2-thiazolyl)amino]benzoyl]amino]-2'-methoxy-, ( $\alpha S$ )- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 232275-57-9P 232275-58-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of N-acyl-phenylalanine derivs. as inhibitors of  $\alpha 4$ -mediated cell adhesion for prevention and treatment of diseases caused by  $\alpha 4$ -mediated cell adhesion)


RN 232275-57-9 HCAPLUS

CN Benzoic acid, 2-chloro-4-[(4,5-dihydro-2-thiazolyl)amino]- (9CI) (CA INDEX NAME)



RN 232275-58-0 HCAPLUS

CN Benzoic acid, 2-chloro-4-[(4,5-dihydro-2-thiazolyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



IC ICM C07C233-87  
 ICS C07C237-30; C07C271-28; C07C311-09; C07D295-14; C07D333-34;  
 A61K031-245; A61K031-33

CC 34-2 (Amino Acids, Peptides, and Proteins)  
 Section cross-reference(s): 1

ST acylphenylalanine deriv prepn inhibitor 4 mediated cell adhesion;  
 rheumatoid arthritis **treatment** prevention  
 acylphenylalanine; **asthma treatment** prevention  
 acylphenylalanine; **psoriasis treatment**  
 prevention acylphenylalanine; eczema **treatment** prevention  
 acylphenylalanine; contact dermatitis **treatment** prevention  
 acylphenylalanine; skin **inflammatory disease**  
**treatment** prevention acylphenylalanine; diabetes  
**treatment** prevention acylphenylalanine; multiple sclerosis  
 prevention **treatment** acylphenylalanine; systemic lupus  
 erythematosus **treatment** prevention acylphenylalanine;  
**inflammatory bowel disease treatment**  
 prevention acylphenylalanine; ulcerative colitis **treatment**  
 prevention acylphenylalanine; Crohn **disease**  
**treatment** prevention acylphenylalanine; leukocyte  
 infiltration prevention **treatment** acylphenylalanine

IT Intestine, **disease**  
 (Crohn's; prepn. of N-acyl-phenylalanine derivs. as inhibitors of  
 $\alpha$ 4-mediated cell adhesion for prevention and  
**treatment of diseases** caused by  
 $\alpha$ 4-mediated cell adhesion)

IT Dermatitis  
 (contact; prepn. of N-acyl-phenylalanine derivs. as inhibitors of  
 $\alpha$ 4-mediated cell adhesion for prevention and  
**treatment of diseases** caused by  
 $\alpha$ 4-mediated cell adhesion)

IT Intestine, **disease**  
 (**inflammatory**; prepn. of N-acyl-phenylalanine derivs.  
 as inhibitors of  $\alpha$ 4-mediated cell adhesion for prevention  
 and **treatment of diseases** caused by  
 $\alpha$ 4-mediated cell adhesion)

IT Cell migration  
 (leukocyte infiltration, **diseases** caused by; prepn. of  
 N-acyl-phenylalanine derivs. as inhibitors of  $\alpha$ 4-mediated  
 cell adhesion for prevention and **treatment of**  
**diseases** caused by  $\alpha$ 4-mediated cell adhesion)

IT Antiasthmatics  
 Antidiabetic agents  
 Cell adhesion  
 Dermatitis  
 Eczema  
 Multiple sclerosis  
**Psoriasis**  
 Rheumatoid arthritis  
 (prepn. of N-acyl-phenylalanine derivs. as inhibitors of  
 $\alpha$ 4-mediated cell adhesion for prevention and  
**treatment of diseases** caused by



α4-mediated cell adhesion)

IT Amino acids, preparation  
 RL: BAC (Biological activity or effector, except adverse); **BSU**  
**(Biological study, unclassified)**; SPN (Synthetic preparation);  
**THU (Therapeutic use)**; **BIOL (Biological study)**;  
 PREP (Preparation); USES (Uses)  
 (prepn. of N-acyl-phenylalanine derivs. as inhibitors of  
 α4-mediated cell adhesion for prevention and  
**treatment of diseases** caused by  
 α4-mediated cell adhesion)

IT Lupus erythematosus  
 (systemic; prepn. of N-acyl-phenylalanine derivs. as inhibitors  
 of α4-mediated cell adhesion for prevention and  
**treatment of diseases** caused by  
 α4-mediated cell adhesion)

IT Intestine, **disease**  
 (ulcerative colitis; prepn. of N-acyl-phenylalanine derivs. as  
 inhibitors of α4-mediated cell adhesion for prevention and  
**treatment of diseases** caused by  
 α4-mediated cell adhesion)

IT 232275-30-8P 232275-31-9P 232275-99-9P 232277-16-6P  
 RL: BAC (Biological activity or effector, except adverse); **BSU**  
**(Biological study, unclassified)**; RCT (Reactant); SPN  
 (Synthetic preparation); **THU (Therapeutic use)**; **BIOL**  
**(Biological study)**; PREP (Preparation); RACT (Reactant or  
 reagent); USES (Uses)  
 (prepn. of N-acyl-phenylalanine derivs. as inhibitors of  
 α4-mediated cell adhesion for prevention and  
**treatment of diseases** caused by  
 α4-mediated cell adhesion)

IT 232271-13-5P 232271-14-6P 232271-15-7P 232271-16-8P  
 232271-17-9P 232271-18-0P 232271-19-1P 232271-20-4P  
 232271-21-5P 232271-22-6P 232271-23-7P 232271-24-8P  
 232271-25-9P 232271-26-0P 232271-27-1P 232271-28-2P  
 232271-29-3P 232271-30-6P 232271-31-7P 232271-32-8P  
 232271-33-9P 232271-34-0P 232271-35-1P 232271-36-2P  
 232271-37-3P 232271-38-4P 232271-39-5P 232271-40-8P  
 232271-41-9P 232271-42-0P 232271-43-1P 232271-44-2P  
 232271-45-3P 232271-46-4P 232271-47-5P 232271-48-6P  
 232271-49-7P 232271-50-0P 232271-51-1P 232271-52-2P  
 232271-53-3P 232271-54-4P 232271-55-5P 232271-56-6P  
 232271-57-7P 232271-58-8P 232271-59-9P 232271-60-2P  
 232271-61-3P 232271-62-4P 232271-63-5P 232271-64-6P  
 232271-65-7P 232271-66-8P 232271-67-9P 232271-68-0P  
 232271-69-1P 232271-70-4P 232271-71-5P 232271-72-6P  
 232271-73-7P 232271-74-8P 232271-75-9P 232271-76-0P  
 232271-77-1P 232271-78-2P 232271-79-3P 232271-80-6P  
 232271-81-7P 232271-82-8P 232271-83-9P 232271-84-0P  
 232271-85-1P 232271-86-2P 232271-87-3P 232271-88-4P  
 232271-89-5P 232271-90-8P 232271-91-9P 232271-92-0P  
 232271-93-1P 232271-94-2P 232271-95-3P 232271-96-4P  
 232271-97-5P 232271-98-6P 232271-99-7P 232272-00-3P  
 232272-01-4P 232272-02-5P 232272-04-7P 232272-06-9P  
 232272-08-1P 232272-10-5P 232272-11-6P 232272-12-7P  
 232272-14-9P 232272-16-1P 232272-17-2P 232272-18-3P  
 232272-19-4P 232272-21-8P 232272-22-9P 232272-24-1P  
 232272-25-2P 232272-26-3P 232272-27-4P 232272-28-5P  
 232272-30-9P 232272-32-1P 232272-34-3P 232272-36-5P  
 232272-38-7P 232272-39-8P 232272-41-2P 232272-43-4P  
 232272-45-6P 232272-47-8P 232272-49-0P 232272-50-3P  
 232272-51-4P 232272-52-5P 232272-53-6P 232272-54-7P  
 232272-56-9P 232272-58-1P 232272-60-5P 232272-62-7P



232272-64-9P	232272-65-0P	232272-67-2P	232272-68-3P
232272-70-7P	232272-72-9P	232272-74-1P	232272-76-3P
232272-78-5P	232272-81-0P	232272-83-2P	232272-85-4P
232272-87-6P	232272-89-8P	232272-91-2P	232272-92-3P
232272-93-4P	232272-94-5P	232272-95-6P	232272-96-7P
232272-97-8P	232272-98-9P	232272-99-0P	232273-00-6P
232273-01-7P	232273-02-8P	232273-03-9P	232273-04-0P
232273-05-1P	232273-06-2P	232273-07-3P	232273-08-4P
232273-09-5P	232273-10-8P	232273-11-9P	232273-12-0P
232273-13-1P	232273-14-2P	232273-15-3P	232273-16-4P
232273-17-5P	232273-18-6P	232273-19-7P	232273-20-0P
232273-21-1P	232273-22-2P	232273-23-3P	232273-24-4P
232273-25-5P	232273-26-6P	232273-27-7P	232273-28-8P
232273-29-9P	232273-30-2P	232273-31-3P	232273-32-4P
232273-33-5P	232273-34-6P	232273-35-7P	232273-36-8P
232273-37-9P	232273-38-0P	232273-39-1P	232273-40-4P
232273-41-5P	232273-42-6P	232273-43-7P	232273-44-8P
232273-45-9P	232273-46-0P	232273-47-1P	232273-48-2P
232273-49-3P	232273-50-6P	232273-51-7P	232273-52-8P
232273-53-9P	232273-54-0P	232273-55-1P	232273-56-2P
232273-57-3P	232273-59-5P	232273-60-8P	232273-61-9P
232273-62-0P	232273-63-1P	232273-64-2P	232273-65-3P
232273-66-4P	232273-68-6P	232273-70-0P	232273-72-2P
232273-74-4P	232273-76-6P	232273-78-8P	232273-80-2P
232273-81-3P	232273-82-4P	232273-84-6P	232273-86-8P
232273-88-0P	232273-90-4P	232273-92-6P	232273-94-8P
232273-96-0P			

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of N-acyl-phenylalanine derivs. as inhibitors of  $\alpha$ 4-mediated cell adhesion for prevention and treatment of diseases caused by  $\alpha$ 4-mediated cell adhesion)

IT	232273-97-1P	232273-98-2P	232273-99-3P	232274-00-9P
	232274-01-0P	232274-02-1P	232274-03-2P	232274-04-3P
	232274-05-4P	232274-06-5P	232274-07-6P	232274-08-7P
	232274-09-8P	232274-10-1P	232274-11-2P	232274-13-4P
	232274-17-8P	232274-20-3P	232274-24-7P	232274-27-0P
	232274-28-1P	232274-31-6P	232274-34-9P	232274-37-2P
	232274-38-3P	232274-39-4P	232274-40-7P	232274-41-8P
	232274-42-9P	232274-43-0P	232274-44-1P	232274-45-2P
	232274-46-3P	232274-47-4P	232274-48-5P	232274-49-6P
	232274-50-9P	232274-51-0P	232274-52-1P	232274-53-2P
	232274-54-3P	232274-55-4P	232274-56-5P	232274-57-6P
	232274-58-7P	232274-59-8P	232274-60-1P	232274-61-2P
	232274-62-3P	232274-63-4P	232274-64-5P	232274-65-6P
	232274-66-7P	232274-67-8P	232274-68-9P	232274-69-0P
	232274-70-3P	232274-71-4P	232274-72-5P	232274-73-6P
	232274-74-7P	232274-75-8P	232274-76-9P	232274-77-0P
	232274-78-1P	232274-79-2P	232274-80-5P	232274-81-6P
	232274-82-7P	232274-83-8P	232274-84-9P	232274-85-0P
	232274-86-1P	232274-87-2P	232274-88-3P	232274-89-4P
	232274-90-7P	232274-91-8P	232274-92-9P	232274-93-0P
	232274-94-1P	232274-95-2P	232274-96-3P	232274-97-4P
	232274-99-6P	232275-00-2P	232275-01-3P	232275-02-4P
	232275-03-5P	232275-04-6P	232275-05-7P	232275-06-8P
	232275-07-9P	232275-08-0P	232275-09-1P	232275-10-4P
	232275-11-5P	232275-12-6P	232275-13-7P	232275-14-8P
	232275-15-9P	232275-16-0P	232275-17-1P	232275-18-2P
	232275-19-3P	232275-20-6P	232275-21-7P	232275-22-8P

232275-23-9P 232275-24-0P 232275-25-1P 232275-26-2P  
 232275-27-3P 232275-28-4P 232275-29-5P 232275-32-0P  
 232275-33-1P 232275-34-2P 232277-14-4P

RL: BAC (Biological activity or effector, except adverse); BSU  
 (Biological study, unclassified); SPN (Synthetic preparation);

THU (Therapeutic use); BIOL (Biological study);

PREP (Preparation); USES (Uses)

(prep. of N-acyl-phenylalanine derivs. as inhibitors of  
 $\alpha$ 4-mediated cell adhesion for prevention and  
 treatment of diseases caused by  
 $\alpha$ 4-mediated cell adhesion)

IT 50-00-0, Formaldehyde, reactions 59-92-7, 3,4-Dihydroxy-L-  
 phenylalanine, reactions 62-53-3, Benzenamine, reactions  
 67-63-0, 2-Propanol, reactions 68-12-2, reactions 74-88-4,  
 reactions 74-89-5, Methylamine, reactions 75-36-5, Acetyl  
 chloride 75-65-0, reactions 79-22-1, Methyl chloroformate  
 96-32-2, Methyl bromoacetate 98-80-6, Benzeneboronic acid  
 98-88-4, Benzoyl chloride 100-46-9, Benzyl amine, reactions  
 106-95-6, Allyl bromide, reactions 107-21-1, 1,2-Ethanediol,  
 reactions 107-30-2, Chloromethyl methyl ether 108-24-7, Acetic  
 anhydride 108-46-3, Resorcinol, reactions 108-93-0,  
 Cyclohexanol, reactions 109-01-3, N-Methylpiperazine 110-89-4,  
 Piperidine, reactions 110-91-8, Morpholine, reactions 121-43-7,  
 Trimethyl borate 123-56-8, Succinimide 123-90-0, Thiomorpholine  
 124-63-0, Mesyl chloride 151-10-0, 1,3-Dimethoxybenzene  
 151-18-8, 2-Cyanoethylamine 349-55-3, 3-Methoxy-5-  
 (trifluoromethyl)aniline 358-23-6, Triflic anhydride 407-25-0,  
 Trifluoroacetic anhydride 421-83-0, Trifluoromethanesulfonyl  
 chloride 541-41-3, Ethyl chloroformate 556-61-6, Methyl  
 isothiocyanate 590-17-0, Bromoacetonitrile 593-56-6,  
 Methoxyamine hydrochloride 614-68-6, 2-Methylphenyl isocyanate  
 616-04-6, 1-Methylhydantoin 624-83-9, Methyl isocyanate  
 626-17-5, 1,3-Dicyanobenzene 661-69-8, Hexamethylditin 696-59-3,  
 2,5-Dimethoxytetrahydrofuran 705-76-0, 3,5-Dimethoxybenzyl alcohol  
 927-68-4, 2-Bromoethyl acetate 1189-71-5, Chlorosulfonyl  
 isocyanate 1530-32-1, Ethyltriphenylphosphonium bromide  
 1762-95-4, Ammonium thiocyanate 1943-83-5, 2-Chloroethyl  
 isocyanate 2148-56-3, 2-Amino-6-chlorobenzoic acid 2457-76-3,  
 4-Amino-2-chlorobenzoic acid 2605-67-6,  
 (Triphenylphosphoranylidene)acetic acid methyl ester 3144-09-0,  
 Methanesulfonamide 3722-78-9 3728-20-9, D-Tyrosine methyl ester  
 hydrochloride 4326-36-7 4635-59-0, 4-Chlorobutyryl chloride  
 4659-45-4, 2,6-Dichlorobenzoyl chloride 4670-10-4,  
 (3,5-Dimethoxy)phenylacetic acid 5191-60-6 5470-11-1,  
 Hydroxylamine hydrochloride 5720-06-9, 2-Methoxybenzene boronic  
 acid 6099-88-3, 2-Chloroethyl isothiocyanate 6160-65-2,  
 1,1'-Thiocarbonyldiimidazole 6165-68-0, 2-Thienylboronic acid  
 6575-24-2, (2,6-Dichlorophenyl)acetic acid 6652-32-0,  
 3,5-Dimethoxybenzyl chloride 7073-36-1, 2-Chloro-4-nitrobenzoyl  
 chloride 7311-34-4, 3,5-Dimethoxybenzaldehyde 7782-24-3,  
 (S)-2-Phenylpropionic acid 10272-07-8, 3,5-Dimethoxyaniline  
 13330-65-9, 2,4-Dimethoxyphenol 13360-57-1, N,N-Dimethylsulfamoyl  
 chloride 16649-50-6, tert-Butylhydroxylamine 18063-02-0,  
 2,6-Difluorobenzoyl chloride 18791-98-5 19179-31-8,  
 3,5-Dimethoxybenzonitrile 19393-92-1, 1-Bromo-2,6-dichlorobenzene  
 22509-50-8 24424-99-5, Di-tert-butyl dicarbonate 25784-91-2,  
 2-Chloro-5-nitrobenzoyl chloride 29668-44-8 31558-40-4,  
 4-Bromo-3,5-dimethoxybenzaldehyde 32483-30-0 34128-16-0,  
 2-Chloro-3-nitrobenzoyl chloride 40138-16-7, 2-  
 Formylbenzeneboronic acid 46004-37-9, Methyl 4-amino-2-  
 chlorobenzoate 55737-77-4 57260-71-6, N-(tert-  
 Butoxycarbonyl)piperazine 58479-61-1, tert-Butyl-diphenylsilyl

chloride 62129-39-9 64248-56-2, 1-Bromo-2,6-difluorobenzene  
 107264-06-2 115377-94-1 121359-48-6 135884-31-0 150587-19-2  
 150691-04-6 173979-01-6 188978-71-4 206347-30-0,  
 7-Bromo-2,3-dihydrobenzo[b]furan 220497-50-7 220848-45-3  
 232277-15-5 232277-17-7 232277-19-9 232277-20-2 232277-21-3  
 232277-22-4 232277-23-5 232277-24-6 232277-25-7 232277-26-8  
 232277-27-9 232277-28-0

RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of N-acyl-phenylalanine derivs. as inhibitors of  
 $\alpha$ 4-mediated cell adhesion for prevention and  
 treatment of diseases caused by  
 $\alpha$ 4-mediated cell adhesion)

IT 349-56-4P 532-55-8P, Benzoyl isothiocyanate 2012-78-4P  
 4641-38-7P, 2,6-Dichloro-4-hydroxybenzoic acid 7101-51-1P  
 7417-20-1P 10288-72-9P, 6-Hydroxy-1,4-benzodioxan 23112-96-1P  
 29668-45-9P, 6-Methoxy-1,4-benzodioxan 37169-36-1P 41395-10-2P  
 54551-83-6P 57234-29-4P 73852-17-2P, 2,6-Dichlorobenzeneboronic  
 acid 80257-12-1P 104202-36-0P 112766-18-4P 115130-81-9P  
 123796-61-2P 139887-64-2P 153037-34-4P 153037-35-5P  
 158152-56-8P 158580-15-5P 158580-33-7P 192211-90-8P  
 193420-30-3P 193420-35-8P 204972-82-7P 232275-35-3P  
 232275-36-4P 232275-37-5P 232275-38-6P 232275-39-7P 232275-4  
 0-0P 232275-41-1P 232275-42-2P 232275-43-3P 232275-44-4P  
 232275-45-5P 232275-46-6P 232275-47-7P 232275-48-8P  
 232275-49-9P 232275-50-2P 232275-51-3P 232275-52-4P  
 232275-53-5P 232275-54-6P 232275-55-7P 232275-56-8P  
 232275-57-9P 232275-58-0P 232275-59-1P  
 232275-60-4P 232275-61-5P 232275-62-6P 232275-63-7P  
 232275-64-8P 232275-65-9P 232275-66-0P 232275-67-1P  
 232275-68-2P 232275-69-3P 232275-70-6P 232275-71-7P  
 232275-72-8P 232275-73-9P 232275-74-0P 232275-75-1P  
 232275-76-2P 232275-77-3P 232275-78-4P 232275-79-5P  
 232275-80-8P 232275-81-9P 232275-82-0P 232275-83-1P  
 232275-84-2P 232275-85-3P 232275-86-4P 232275-87-5P  
 232275-88-6P 232275-89-7P 232275-90-0P 232275-91-1P  
 232275-92-2P 232275-93-3P 232275-94-4P 232275-95-5P  
 232275-96-6P 232275-97-7P 232275-98-8P 232276-00-5P  
 232276-01-6P 232276-02-7P 232276-03-8P 232276-04-9P  
 232276-06-1P 232276-07-2P 232276-08-3P 232276-09-4P  
 232276-10-7P 232276-11-8P 232276-12-9P 232276-13-0P  
 232276-14-1P 232276-15-2P 232276-16-3P 232276-17-4P  
 232276-18-5P 232276-19-6P 232276-20-9P 232276-21-0P  
 232276-22-1P 232276-23-2P 232276-24-3P 232276-25-4P  
 232276-26-5P 232276-27-6P 232276-28-7P 232276-29-8P  
 232276-30-1P 232276-31-2P 232276-33-4P 232276-34-5P  
 232276-35-6P 232276-36-7P 232276-37-8P 232276-38-9P  
 232276-39-0P 232276-40-3P 232276-42-5P 232276-43-6P  
 232276-44-7P 232276-45-8P 232276-46-9P 232276-47-0P  
 232276-48-1P 232276-49-2P 232276-50-5P 232276-51-6P  
 232276-52-7P 232276-53-8P 232276-54-9P 232276-55-0P  
 232276-56-1P 232276-57-2P 232276-58-3P 232276-59-4P  
 232276-60-7P 232276-61-8P 232276-62-9P 232276-63-0P  
 232276-64-1P 232276-65-2P 232276-66-3P 232276-67-4P  
 232276-68-5P 232276-69-6P 232276-70-9P 232276-71-0P  
 232276-72-1P 232276-73-2P 232276-74-3P 232276-75-4P  
 232276-76-5P 232276-77-6P 232276-78-7P 232276-79-8P  
 232276-80-1P 232276-81-2P 232276-82-3P 232276-83-4P  
 232276-84-5P 232276-85-6P 232276-86-7P 232276-87-8P  
 232276-88-9P 232276-89-0P 232276-90-3P 232276-91-4P  
 232276-92-5P 232276-93-6P 232276-94-7P 232276-95-8P  
 232276-96-9P 232276-97-0P 232276-98-1P 232276-99-2P  
 232277-00-8P 232277-01-9P 232277-02-0P 232277-03-1P

232277-04-2P 232277-05-3P 232277-06-4P 232277-07-5P  
232277-08-6P 232277-09-7P 232277-10-0P 232277-11-1P  
232277-12-2P 232277-13-3P 232277-18-8P 232277-29-1P  
232277-30-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);  
RACT (Reactant or reagent)

(prepn. of N-acyl-phenylalanine derivs. as inhibitors of  
 $\alpha$ 4-mediated cell adhesion for prevention and  
**treatment of diseases** caused by  
 $\alpha$ 4-mediated cell adhesion)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR  
THIS RECORD. ALL CITATIONS AVAILABLE IN  
THE RE FORMAT

=>